

Finnish statistics on medicines 2020

Kela[®] fimea

Finnish Medicines Agency Fimea

Mannerheimintie 166
P.O. Box 55
FI-00034 Fimea
Finland
salesstatistics@fimea.fi
Tel. +358 29 522 3341

Social Insurance Institution

Nordenskiöldinkatu 12
P.O. Box 450
FI-00056 Kela
Finland
tilastot@kela.fi
Tel. +358 20 634 11


ISSN 2737-3592

Key figures for medicine sales and their reimbursement in 2020

Total sales of pharmaceuticals

Sales to hospitals and other health care institutions (at wholesale prices)
820 million euros,
-0.4% change from 2019

OTC medicines
(at pharmacy prices with VAT)
367 million euros,
-2.8% change from 2019




Prescription medicines
(at pharmacy prices with VAT)
2,331 million euros,
2.1% change from 2019

Reimbursement of medicine costs

Additional Refunds
217 million euros,
6.0% change from 2019

Basic Refunds
308 million euros,
-2.5% change from 2019



Special Refunds
1,109 million euros,
7.7% change from 2019



Contents

List of figures.....	5	7. Tables: Sales statistics according to medicine group	84
List of tables.....	6	A Alimentary tract and metabolism	85
1. Basic information about the compilation of statistics on medicines	9	B Blood and blood forming organs	105
Concepts in Finnish statistics on medicines	10	C Cardiovascular system	114
Material used for the statistics	13	D Dermatologicals	129
Abbreviations and symbols	13	G Genito urinary system and sex hormones	139
Calculating drug consumption	14	H Systemic hormonal preparations, excl. sex hormones and insulins	148
Structure of the ATC system	15	J Antiinfectives for systemic use	154
2. Current issues in pharmacy	16	L Antineoplastic and immunomodulating agents	167
Key events in the pharmaceutical field in 2020	17	M Musculo-skeletal system	183
Pharmaceutical year 2020	18	N Nervous system	191
Impacts of the COVID-19 pandemic on purchases of medications at community pharmacies	26	P Antiparasitic products, insecticides and repellents	207
Pharmaceutical policies	28	R Respiratory system	210
3. Finnish population and hospital districts	30	S Sensory organs	222
4. Drug control and pharmaceutical services	33	V Various	230
Distribution of medicine sales	34	Nicotine replacement therapy	238
Pharmacies and hospital pharmacies	35	OTC medicines in outpatient care	240
5. National health insurance and reimbursement of medicine expenses	38	Figures on sales statistics	263
Medicine reimbursement system and approval of medicine prices	40	Appendices	285
Reimbursable medicines, confirming wholesale prices and the reference price system	48	Appendix 1. Alterations to ATC classification, valid as of January 2021	286
6. Tables: Reimbursement of medicine costs	55	Appendix 2. Alterations to defined daily doses (DDD), valid as of January 2021	288
Medicine costs and their reimbursement annually and according to hospital district	56	Appendix 3. Deflators for converting expenditure items to 2020 money, 2000–2020	289
Medicine costs and their reimbursement in diseases entitling patients to special refund	59		
Medicinal products eligible for restricted basic refund	75		
Clinical nutritional preparations	78		
Medicine costs and their reimbursement according to prescriber	79		



List of figures

1. Basic information about the compilation of statistics on medicines	9		
2. Current issues in pharmacy	16		
Figure 2.1. Trends in sales of prescription medicines in outpatient care (at retail prices), in the costs forming the basis for reimbursement of prescription medicines in outpatient care, and in reimbursements paid out for prescription medicines in outpatient care, 2010–2020	18		
Figure 2.2. Purchases of antibiotics (ATC category J01) from community pharmacies reimbursed by the National Health Insurance, by age group, in 2019 and 2020	27		
3. Finnish population and hospital districts	30		
Figure 3.1. Age structure of the Finnish population at the end of 2020	31		
Figure 3.2. University hospital regions and hospital districts in 2020	31		
4. Drug control and pharmaceutical services	33		
Figure 4.1. Distribution of medicine sales between pharmacies and hospitals according to the ATC code, at wholesales prices, in 2020, EUR 1,000	34		
Figure 4.2. Number of pharmacies and prescriptions dispensed in 1990–2020	36		
Figure 4.3. Number of pharmacies per 10,000 inhabitants by hospital district in 2020	37		
5. National health insurance and reimbursement of medicine expenses	38		
The medicine supply chain and the role of various organisations in oversight and reimbursement	39		
Reimbursements for medicine expenses in 2020	46		
Figure 5.1. Reimbursement of medicine costs in 2000–2020 according to Refund Category	47		
6. Tables: Reimbursement of medicine costs	55		
Figure 6.1. Percentages of medicine prescribers, 2020	79		
7. Tables: Sales statistics according to medicine group	84		
Figure 7.1. Consumption and sales of proton pump inhibitors (A02BC) in 2006–2020	263		
Figure 7.2. Consumption of drugs for acid related disorders (A02) by hospital district in 2020	264		
Figure 7.3. Consumption and sales of insulins and analogues (A10A) in 2006–2020	265		
Figure 7.4. Consumption and sales of Blood glucose lowering drugs (A10B) in 2006–2020	266		
Figure 7.5. Consumption and sales of most common antihypertensives in 2006–2020	267		
Figure 7.6. Consumption and sales of agents acting on renin-angiotensin system (C09) in 2006–2020	268		
		Figure 7.7. Consumption of agents acting on renin-angiotensin system (C09) by hospital district in 2020	269
		Figure 7.8. Consumption and sales of statins (C10AA) in 2006–2020	270
		Figure 7.9. Consumption of lipid modifying agents reducers (C10) by hospital district in 2020	271
		Figure 7.10. Consumption of hormonal contraceptives in 2006–2020	272
		Figure 7.11. Consumption of hormone replacement therapy drugs (G03C, G03F) among women aged over 45 by hospital district in 2020	273
		Figure 7.12. Consumption of antibacterials (J01) in 2006–2020	274
		Figure 7.13. Consumption of antibacterials (J01) by hospital district in 2020	274
		Figure 7.14. Consumption of analgesics (M01A, N02A and N02B) in 2006–2020	275
		Figure 7.15. Consumption of most common OTC analgesics in 2006–2020	276
		Figure 7.16. Consumption of opioids (N02A, N07BC) in 2006–2020	277
		Figure 7.17. Consumption of most common hypnotics (N05C) in 2006–2020	278
		Figure 7.18. Consumption of hypnotics (N05C) in outpatient care by hospital district in 2020	279
		Figure 7.19. Consumption of antidepressants (N06A) in 2006–2020	280
		Figure 7.20. Consumption of most common antidepressants (N06A) in 2006–2020	281
		Figure 7.21. Consumption of antidepressants (N06A) in outpatient care by hospital district in 2020.....	282
		Figure 7.22. Consumption of inhaled drugs for obstructive airway diseases in 2006–2020	283
		Figure 7.23. Consumption of drugs for obstructive airway diseases (R03) by hospital district in 2020	284
		Appendices	285



List of tables

1. Basic information about the compilation of statistics on medicines	9	6. Tables: Reimbursement of medicine costs	55
2. Current issues in pharmacy	16	Table 6.1. Medicine costs and their reimbursement in 2005–2020	56
Table 2.1. Top 10 medicines sold in 2020 (wholesale)	20	Table 6.2. Medicine costs and their reimbursement according to hospital district, in 2020	58
Table 2.2. Top 10 medicines by consumption in 2020	21	Table 6.3. Patients entitled to reimbursement under the Special Refund Categories, and cost of the diseases per recipient in 2020	59
3. Finnish population and hospital districts	30	Table 6.4. Patients receiving reimbursement payments under the Special Refund Categories and total cost and reimbursement payments in the Special Refund Categories in 2020	65
Table 3.1. Population according to hospital district, the proportion of elderly people and the proportion of the population in receipt of Special Refunds of medicines of the total population, at the end of 2020	32	Table 6.5. Drug treatment statistics of the most common diseases entitling the patients to reimbursement under the Special Refund Categories, in 2020	69
Table 3.2. Population according to university hospital regions by age groups, 31 December 2020.....	32	Table 6.6. Medicines eligible for restricted basic refund: Number of purchasers and the cost of reimbursed drugs in 2020	75
4. Drug control and pharmaceutical services	33	Table 6.7. Clinical nutritional preparations reimbursable under the Health Insurance Scheme: Number of purchasers and the cost of reimbursed preparations in 2020	78
Table 4.1. Medicine sales to pharmacies and hospitals at wholesale prices according to the ATC code in 2020	34	Table 6.8. Medicine prescribers, 2015 – 2020	79
Table 4.2. Statistics for pharmacies in 2020	35	Table 6.9. Average number and cost (before reimbursement is deducted) of dispensations per doctor, according to speciality, in 2020 (only those dispensations entitled to reimbursement are included)	80
Table 4.3. Dispensations dispensed by pharmacies in 2005–2020	36	Table 6.10. Data relating to purchases of reimbursable medicines eligible for generic substitution and savings generated through substitution, in 2016–2020	82
5. National health insurance and reimbursement of medicine expenses	38		
Table 5.1. Reimbursement numbers adopted in 2020, basic reimbursement	43		
Table 5.2. Reimbursement numbers discontinued in 2020, basic reimbursement	43		
Table 5.3. Reimbursement numbers adopted in 2020, special reimbursement	44		
Table 5.4. Reimbursement numbers discontinued in 2020, special reimbursement	44		
Table 5.5. Medicines added to existing reimbursement numbers in 2020, basic reimbursement	45		
Table 5.6. Medicines added to existing reimbursement numbers in 2020, special reimbursement	45		
Table 5.7. Medicine costs and their reimbursement in 2020	47		
Table 5.8. Calculation formula for retail prices, without VAT, of medicinal products in 2020	53		
Table 5.9. New active substances in 2020	53		
Table 5.10. Number of applications for reasonable wholesale prices and reimbursement status processed by the Pharmaceuticals Pricing Board in 2020	54		
Table 5.11. Median process times of applications (number of days) approved or rejected by the Pharmaceuticals Pricing Board, according to the type of application, in 2020	54		



7. Tables: Sales statistics according to medicine group 84

A01 Stomatological preparations 86

A02 Drugs for acid related disorders 87

A03 Drugs for functional gastrointestinal disorders 89

A04 Antiemetics and antinauseants 91

A05 Bile and liver therapy 91

A06 Drugs for constipation 92

A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents 94

A08 Antiobesity preparations, excl. diet products 96

A09 Digestives, incl. enzymes 96

A10 Drugs used in diabetes 97

A11 Vitamins 100

A12 Mineral supplements 102

A14 Anabolic agents for systemic use 103

A16 Other alimentary tract and metabolism products 103

B01 Antithrombotic agents 106

B02 Antihemorrhagics 108

B03 Antianemic preparations 110

B05 Blood substitutes and perfusion solutions 111

B06 Other hematological agents 113

C01 Cardiac therapy 115

C02 Antihypertensives 117

C03 Diuretics 118

C04 Peripheral vasodilators..... 119

C05 Vasoprotectives 120

C07 Beta blocking agents 121

C08 Calcium channel blockers 123

C09 Agents acting on the renin-angiotensin system 124

C10 Lipid modifying agents 127

D01 Antifungals for dermatological use 130

D02 Emollients and protectives 131

D03 Preparations for treatment of wounds and ulcers 131

D04 Antipruritics, incl. antihistamines, anesthetics, etc. 132

D05 Antipsoriatics 132

D06 Antibiotics and chemotherapeutics for dermatological use 133

D07 Corticosteroids, dermatological preparations 134

D08 Antiseptics and disinfectants 136

D09 Medicated dressings 136

D10 Anti-acne preparations 137

D11 Other dermatological preparations 138

G01 Gynecological antiinfectives and antiseptics 140

G02 Other gynecologicals 141

G03 Sex hormones and modulators of the genital system 142

G04 Urologicals 146

H01 Pituitary, hypothalamic hormones and analogues 149

H02 Corticosteroids for systemic use 151

H03 Thyroid therapy 152

H04 Pancreatic hormones 152

H05 Calcium homeostasis 153

J01 Antibacterials for systemic use 155

J02 Antimycotics for systemic use 159

J04 Antimycobacterials 160

J05 Antivirals for systemic use 161

J06 Immune sera and immunoglobulins 165



J07 Vaccines	166	R07 Other respiratory system products	221
L01 Antineoplastic agents	168	S01 Ophthalmologicals	223
L02 Endocrine therapy	177	S02 Otologicals	228
L03 Immunostimulants	179	S03 Ophthalmological and otological preparations	229
L04 Immunosuppressants	180	V01 Allergens	231
M01 Antiinflammatory and antirheumatic products	184	V03 All other therapeutic products	232
M02 Topical products for joint and muscular pain	186	V04 Diagnostic agents	234
M03 Muscle relaxants	187	V06 General nutrients	235
M04 Antigout preparations	188	V07 All other non-therapeutic products	235
M05 Drugs for treatment of bone diseases	189	V08 Contrast media	236
M09 Other drugs for disorders of the musculo-skeletal system	190	Appendices	285
N01 Anesthetics	192		
N02 Analgesics	194		
N03 Antiepileptics	196		
N04 Anti-parkinson drugs	198		
N05 Psycholeptics	199		
N06 Psychoanaleptics	202		
N07 Other nervous system drugs	205		
P01 Antiprotozoals	208		
P02 Anthelmintics	209		
P03 Ectoparasiticides, incl. scabicides, insecticides and repellents	209		
R01 Nasal preparations	211		
R02 Throat preparations	213		
R03 Drugs for obstructive airway diseases	214		
R05 Cough and cold preparations	218		
R06 Antihistamines for systemic use	220		

1. Basic information
about the compilation
of statistics on
medicines



Concepts in Finnish statistics on medicines

Active substance

The effective ingredient contained in a medicinal product. This is the most detailed (5th) level of ATC classification.

Additional Refund

A patient becomes eligible for Additional Refund payments if his/her personal payments for the non-reimbursed part of his/her medicines, clinical nutritional preparations and basic topical ointments exceed a certain limit during a calendar year. In such a case, the patient pays a fixed deductible of EUR 2.50 per reimbursable medicine purchased, and the rest is refunded in full under the National Health Insurance Scheme.

Annual deductible (ceiling)

This is the upper limit for annual out-of-pocket-cost. If this is exceeded, the customer is entitled to an additional refund. The purpose of the additional refund is to ensure that no individual faces unreasonably high medicine costs.

Annual fee

The holder of the marketing authorisation has to pay an annual fee for each authorised year following the year in which the marketing authorisation was granted.

ATC classification

A pharmaceutical classification system developed and maintained by the World Health Organization (WHO). In this anatomic-therapeutic-chemical (ATC) classification, medicinal agents are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. The Finnish statistics on medicines follows the most recent version of ATC classification, which is commonly used for statistics on the consumption of medicines.

Please also see the section on the structure of the ATC system.

Basic Rrefund

The National Health Insurance Scheme reimburses 40% of the cost of medicines in the Basic Refund Category.

Biosimilar

A biological medicine containing the same active substance as the corresponding original biological medicine and designed to be identical and comparable to the original.

Conditional reimbursement

A risk sharing method used in Finland which aims to control the introduction of new pharmaceuticals at the beginning of their life cycle. Conditional reimbursement hinges on confidential agreements between the Pharmaceuticals Pricing Board and pharmaceutical companies. So far, the agreements concluded have been financial agreements concerning a payback payment to Kela.

Cost/Medicine costs

The total cost of a medicine before the deduction of the reimbursement paid under the National Health Insurance Scheme. The costs listed in the register 'Dispensations reimbursable under the National Health Insurance Scheme' from Kela include the costs of medicines purchased at pharmacies, at retail price inclusive of tax, i.e. including the pharmacy markup, delivery fees and VAT. Please also see the figures for wholesale sales of medicines.

Defined Daily Dose (DDD)

The DDD is a unit of measurement of pharmaceutical consumption. Please also see Calculation of consumption of pharmaceuticals.

Direct refundreimbursement

Generally, customers are credited refunds on their medicines at the pharmacy once their initial deductible limit has been met. The pharmacy deducts the refund from the price of the medicine, and the customer pays the rest. Pharmacies verify eligibility for refunds using the Kela's direct reimbursement inquiry service for every purchase of medicines. The query service also informs pharmacies about customers' entitlement to refunds. Pharmacies have access to up-to-date information on the accrual of initial and annual deductibles. As of the beginning of 2020, direct reimbursements also apply to additional refunds. Additional refunds are applied at pharmacies to purchases that exceed the predetermined ceiling.



Dispensation (filled prescriptions)

The batch of a medicinal product dispensed by a pharmacy at any one time. A medicine prescribed for a period of one or two years is recorded as several dispensations, because the National Health Insurance Scheme only permits refunds for purchases of a three-month supply of medicines.

Generic medicine

A medicinal product that entered the market after the expiry of the patent on the original preparation, containing the same active agent as the original and having the same dosage and form. Also referred to as generic preparation.

Generic Substitution

Generic substitution places the pharmacy under an obligation to substitute a prescribed medicinal product with a less expensive alternative containing the same active substance. However, a medicinal product cannot be substituted if the prescriber has forbidden substitution on medical or therapeutic grounds by marking the prescription accordingly or if the customer forbids substitution. The list of substitutable medicinal products is approved by the Finnish Medicines Agency Fimea.

Initial deductible

Customers will be reimbursed for medicines after their combined purchases have exceeded the initial deductible. The initial deductible is EUR 50 per calendar year. It is applicable from the beginning of the year of the customer's 19th birthday.

Marketing authorisation

A new medicinal product can only be sold or otherwise released for consumption with marketing authorisation granted by the Finnish Medicines Agency Fimea or the European Commission.

Medicinal product

The term refers to a medicine released for consumption in the manufacturer's package. A medicinal product may contain one or more chemical entities.

Medicinal Products Eligible for Restricted Basic Refund / Medicinal Products Eligible for Restricted Special Refund

Certain restrictions apply to the Basic and Special Refunds available for a number of particularly expensive medicines. These costly but clinically valuable medicines are reimbursed only when used to treat specified medical conditions where reimbursement is considered medically justifiable. To qualify the patient must provide a doctor's certificate. In certain cases, an addendum to the prescription sheet will suffice.

Medicine

A substance or preparation, the purpose of which is to treat, alleviate or prevent a disease of its symptoms, or which is used in the diagnosis of a health condition or disease.

Out-of-pocket-cost

The amount of a medicine cost payable by the patient. Please also see Initial deductible and Annual deductible.

Prescription

An order, issued by a doctor or dentist, for a pharmacy to supply a medicinal product to a patient. Some licensed nurses also have a limited right to prescribe medicines to a patient. Previously, the term 'prescription' was also used to refer to the batch of a medicine given out by a pharmacy at any one time, but the current term for this is 'dispensation'.

Purchase

A purchase usually refers to the medicines, clinical nutritional preparations and basic topical ointments prescribed for the treatment of chronic skin ailments that are bought from a pharmacy for one person during one transaction. The statistics describing the number of purchases according to refund category, however, consider one purchase being the medicines, clinical nutritional preparations or basic topical ointments in the same refund

category that are bought from a pharmacy for one person during one transaction.

Rational pharmacotherapy

Pharmacotherapy that is effective, safe, of high quality, cost-effective and equal.

Reference price system

Under the reference price system the reimbursement payment for a medicinal product is calculated from its reference price. Under the reference price system, substitutable medicinal products containing the same active substance in an equal composition, and being sold in comparable package sizes, are grouped together in the same reference price group. The reference price groups are based on the list for substitutable medicinal products compiled by the Finnish Medicines Agency Fimea. A reference price constitutes of the price of the most inexpensive product within the group and an additional EUR 0.50. Reference prices are determined on a quarterly basis by the Pharmaceuticals Pricing Board. The cost in excess of the reference price is payable by the customer should one/he/she forbid substitution. If the substitution is forbidden by the prescribing doctor, or a product at the reference price is not available nationwide, the customer's reimbursement is calculated from the full purchase price.



Refund/Reimbursement of medicine costs

A reimbursement of medicine costs refers to the proportion of the price of a medicine which is reimbursed by the National Health Insurance Scheme. Prescription-only medicines, deemed necessary for the treatment of an illness, are reimbursed under the National Health Insurance Scheme provided that their reimbursability and reasonable wholesale price have been approved. Some over-the-counter (OTC) medicines are also reimbursable when prescribed by a doctor. In addition to medicines, reimbursement is also paid for clinical nutritional preparations used in some serious illnesses, basic topical ointments used for the treatment of chronic skin ailments as well as for dosage service charges.

Special permit

The Finnish Medicines Agency Fimea may allow drugs without marketing authorisation to be released for consumption in individual cases on special medical grounds. For outpatient care the special permit is issued on a named-patient basis. For inpatient care the permit is issued separately for each institution, and it may cover several patients. The special permit is valid for one year from the day of issue.

Special Refund

Special refunds apply to certain serious and chronic diseases. The diseases qualifying customers for special refunds are divided into a higher special refund category and a lower special refund category. In the lower special refund category, the National Health Insurance Scheme covers 65% of the cost of medications. In the higher special refund category, the patient only pays a deductible of EUR 4.50 per medication, the remainder being reimbursed in full (100%). Patients must apply for eligibility from Kela and provide a doctor's statement.

Wholesale sales of medicines

Wholesale sales means the sales of medicines by pharmaceutical wholesale suppliers to pharmacies and institutions. In this publication, wholesale sales of medicines are presented at recommended wholesale prices exclusive of VAT. See also Cost/Medicine costs.



Material used for the statistics

Drug sales register maintained by the Finnish Medicines Agency (Fimea)

The consumption figures in Finnish statistics on medicines are based on the sales of human medicines with marketing authorisation to pharmacies and hospitals by the three largest medicine wholesalers in Finland, Oriola, Tamro and Magnum Medical. Inpatient care institutions also buy medicines from other wholesalers or directly from pharmaceutical companies. Furthermore, they may import medicines themselves. The recommended wholesale figures of medicines do not include value added tax. Changes in ATC classification and DDD values are considered in the reference data as well as images. The figures in this year's publication are not fully comparable to earlier editions of the Finnish Statistics on Medicines. Because of a technical error, some data were missing in the previous editions. Also, the current figures no longer include medicines supplied to veterinarians.

Special Refund Entitlement Register of Medicines

The register maintained by Kela includes data both about the patients and the medicine refund entitlements granted by Kela.

Dispensations reimbursable under the National Health Insurance Scheme register (previously Kela's Prescription Register)

A register created from pharmacy accounts, comprising all purchases of medicines directly reimbursed upon purchase at the pharmacy, as well as all purchases of medicines within the reimbursement system made before the initial deductible limit has been met. The register includes information, derived from the prescription, relating to the patient, the medicine, the prescribing doctor as well as the cost and reimbursement paid for the medicine.

Register of Statistical Information on National Health Insurance General Benefit Payments

These statistics comprise data about all reimbursement payments paid during the year and are maintained by Kela. The database includes reimbursements applied for retroactively and not included on the 'Dispensations reimbursable under the NHI scheme' register.

Abbreviations and symbols

Abbreviations

ATC	Anatomical Therapeutic Chemical classification
DDD	Defined Daily Dose
UD	Unit dose (for example one tablet or 5 ml of mixture)
U	Unit
TU	Thousand units
MU	Million units
mcg	Microgram
I	Inhalative
N	Nasal
O	Oral
P	Parenteral
SL	Sublingual
TD	Transdermal
V	Vaginal

Symbols

-	Magnitude nil
.	Category not applicable
..	Data no available or too uncertain for presentation, or subject to secrecy



Calculating drug consumption

In Finnish Statistics on Medicines, drug consumption is expressed using the unit Defined Daily Dose (DDD). The calculations are based on the volume of wholesale sales, in other words, the amount of medicine in units of weight or volume as well as an internationally agreed medicine-specific theoretic daily dose. The recommended wholesale figures of medicines do not include value added tax.

The following example shows how simvastatin consumption is calculated:

DDD of simvastatin	0.03
Sales	2,031,716 g/year
Population	5,540.767 x 1,000

1. Total consumption of simvastatin in grams is first converted into DDDs using the following equation:

$$2,031,716 \text{ g} / 0.03 \text{ g} = 67,723,867 \text{ DDD}$$

2. The number of DDDs is then adjusted to the population and the number of days per year.

$$\frac{67,723,867 \text{ DDD}}{5,540.767 \times 366} = 33.4 \text{ DDD}/1,000 \text{ inhabitants}/\text{day}$$

The figure of 33.4 DDD/1,000 inh/day indicates how many people (in this case 33.4) per 1,000 of the population may, in theory, have received that standard dose (30 mg) of simvastatin.

When interpreting the figures, it should be remembered that the DDD is only a technical expedient and is not necessarily equal to the real dose. The DDD of a drug can be very difficult to establish, as the drug dose depends on indications, individuals and therapeutic practices. When using sales figures provided by wholesalers, it is worth noting that some drugs sold may still be unused, either in dealer stores or in patient homes. The DDD figure is generally calculated in relation to the total population, although drug use may be concentrated in certain age groups or a particular sex.

In retrospective studies, changes in DDD units and the ATC classification should always be considered. Changes made in each year are listed in Appendices of Finnish Statistics on Medicines. In case the DDD of an active substance has changed, the consumption figures of different years should be altered so that they are comparable. This is done by converting the consumption expressed as DDD back to its initial value, in other words the consumption in units of weight or volume, after which it is possible to calculate the new figure by using the new DDD.



Structure of the ATC system

In the Anatomical Therapeutic Chemical (ATC) classification system, the drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutic properties.


In the ATC system drugs are classified in groups at five different levels. The drugs are divided into fourteen main groups (1st level), with one pharmacological/therapeutic subgroup (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups.

The complete classification of simvastatin (C10AA01) illustrates the structure of the code:

ATC code	ATC name
C	Cardiovascular system (1st level, anatomical main group)
C10	Lipid modifying agents (2nd level, pharmacological subgroup)
C10A	Lipid modifying agents, plain (3rd level, pharmacological subgroup)
C10AA	HMG CoA reductase inhibitors (4th level, pharmacological subgroup)
C10AA01	Simvastatin (5th level, chemical substance)


Source: Guidelines for ATC classification and DDD assignment, WHO Collaborating Centre for Drug Statistics Methodology, Oslo 2021.

2. Current issues in pharmacy





Key events in the pharmaceutical field in 2020





Pharmaceutical year 2020

Leena K. Saastamoinen, PhD (Pharm.), Adjunct professor, Research Manager, Kela

Kati Sarnola, PhD (Pharm.), M.Sc. (Econ.), Senior Researcher, Kela

Tinna Voipio, B.Sc. (Pharm.), Researcher, Fimea


Päivi Rastas, M.Sc. (Pol.), Statistics Specialist, Kela

In the pharmaceutical year 2020, the coronavirus pandemic caused a temporary increase in medicine consumption in March, when people began to stockpile medicines. However, the pandemic seems not to have affected the overall consumption of medicines in 2020. Both medicine sales and refunds for medicines paid out by the National Health Insurance Scheme continued to grow in 2020 at a rate similar to that of previous years. The pandemic did have a measurable impact in the consumption of systemic antibacterials, which decreased by nearly 20%. The consumption of certain symptomatic medicines for infectious diseases also decreased. This was probably due to the coronavirus restriction measures having an impact on the incidence of infections more generally.

Medicine sales increased

Medicine sales totalled EUR 3,518 million in 2020, an increase of 1.0% on the previous year. The majority of these sales, EUR 2,331 million (66%), were sales of prescription medicines in outpatient care, which showed an increase of 2.1% on the previous year. Sales of over-the-counter medicines in outpatient care, at EUR 367 million or 10% of all medicine sales, decreased by 2.8%. The remaining medicine sales, EUR 820 million (24%), went to hospitals and other institutions. Hospital sales are reported at wholesale prices not subject to competitive tendering, so sales at tendered prices are lower than the reported figures. Currently, no statistics are compiled at actual competitive prices.

Figure 2.1. Trends in sales of prescription medicines in outpatient care (at retail prices), in the costs forming the basis for reimbursement of prescription medicines in outpatient care, and in reimbursements paid out for prescription medicines in outpatient care, 2010–2020





The costs forming the basis for reimbursement, EUR 2,168 million, amounted to 93% of the total retail-price costs for prescription medicines in outpatient care in 2020 (Figure 2.1). These costs consisted of medicine refunds (EUR 1,635 million) and patient deductibles (EUR 533 million). The total deductibles paid by patients decreased by about EUR 5 million (1%) on the previous year.

Medicine refunds increased by 5.4%

Kela paid out a total of EUR 1,635 million in medicine refunds, an increase of 5% on the previous year. The increase in refunds remained roughly the same as in the two previous years. At the same time, pharmaceutical companies paid Kela EUR 33 million in conditional reimbursability refunds on medicines subject to a financial agreement on price and reimbursability. These refunds were not deducted from the reimbursement figures given in this publication. The medicine costs underlying reimbursements totalled EUR 2,168 million.

In all, 3,730,000 Finns purchased reimbursable medicines. For a number of Finns, their medicine costs remained under the initial deductible of EUR 50, and they thus received no refunds. More than half of all Finns (53%) did receive medicine refunds. The number of refund recipients, 2,953,500 individuals, decreased by 3% on the previous year. As in previous years, special refunds constituted a significant portion of all medicine refunds: EUR 1,109 million was paid out in special refunds to 1,251,800 individuals. EUR 308 million was paid out in basic refunds to 2,839,800 individuals. The amount of special refunds paid increased by 8% on the previous year, though the number of individuals receiving them only increased by 1%. Both the sum of basic refunds and the number of their recipients decreased by 3% on the previous year. In summary, the overall increase in medicine refunds is driven by the increase in special refunds, although these refunds are being paid out to a smaller group of people.

With the introduction of extraordinary circumstances due to the coronavirus pandemic in week 12, medicine purchases increased substantially in all main groups of pharmaceuticals due to a stockpiling spree. The number of medicine shortage notifications also increased during the first two quarters of 2020, but as the year went on, the incidence of notifications decreased to a normal level. This means that the aforementioned stockpiling did not have an impact on consumption at the annual level: the growth in medicine sales and the growth in medicine purchases reimbursed by the National Health Insurance Scheme both matched the growth trends of recent years.

The annual deductible for medicines in 2020 was EUR 577.66. For those whose medicine costs exceeded this ceiling, additional refunds were paid to a total of EUR 217 million, an increase of 6% on the previous year. The number of individuals who were paid additional refunds was 294,600, an increase of 14% on the previous year. In the previous reporting period (2018–2019), the growth in the number of individuals who were paid additional refunds was only 2%. It would seem that an increasing number of Finns are using increasingly expensive pharmacotherapies that exceed the annual deductible for medicines.

One of the main drivers of the growing pharmaceutical expenditure is the introduction of new, expensive medicines. Despite cost-cutting measures undertaken in 2017, medicine costs continue to grow at an annual rate of 5% to 7%. According to decisions made at the Government's spending limits sessions in 2020, pharmaceutical supply costs are to be cut by EUR 60 million in 2023 and 2024.

**Breast and stomach cancer medicine trastuzumab now in the top 10 of sales**

After a hiatus of a couple of years, nicotine re-entered the top 10 list of medicines sold, with an increase of 17% in sales. Otherwise, the list remained largely unaltered. The only new entrant in 2020 was trastuzumab, a medicine used to treat breast and stomach cancer. There are now three cancer medicines on the top 10 list: trastuzumab, enzalutamide (used for prostate cancer) and lenalidomide (mainly used for myeloma and lymphomas). The anticoagulants apixaban and rivaroxaban, which entered the top 10 list in the previous year, maintained their position, with sales increasing by 29% and 14%, respectively, on the previous year. Infliximab, a TNF- α inhibitor, yielded its top spot to nicotine and dropped to 2nd place while the sofosbuvir and velpatasvir compound used to treat hepatitis C took in 3rd place. Adalimumab, another TNF- α inhibitor, fell to 5th place. Normal human immunoglobulin for intravascular use rose up two spots in the top 10 list, taking 6th place.

Only three of the top 10 medicines sold showed a decrease in sales compared to the previous year. The decrease in the sales of the TNF- α inhibitors infliximab and adalimumab may have been due to biosimilars entering the market, while the decline in sales of medication for hepatitis C may have been due to the one-off nature of the course of treatment. Significant growth compared to the previous year, as with apixaban or rivaroxaban, may have been influenced by changes and expansions to medicine reimbursability. Nearly 90% of nicotine products are sold outside pharmacies, and these sales increased substantially more than sales at pharmacies in 2020.

Table 2.1. Top 10 medicines sold in 2020 (wholesale)

Medicine	ATC code	Wholesale sales, EUR 1,000	Change from 2019, %
Nicotine	N07BA01	71,691	+17
Infliximab	L04AB02	63,663	-16
Sofosbuvir and velpatasvir	J05AP55	58,351	-8
Apixaban	B01AF02	47,651	+29
Adalimumab	L04AB04	47,071	-6
Normal human immunoglobulin for intravascular use	J06BA02	39,974	+22
Rivaroxaban	B01AF01	37,647	+14
Enzalutamide	L02BB04	32,729	+5
Lenalidomide	L04AX04	31,671	+5
Trastuzumab	L01XC03	30,979	+11



The top 10 medicines by consumption are used almost exclusively to treat cardiovascular diseases

Eight out of the top 10 medicines in terms of consumption are used to treat cardiovascular diseases. The angiotensin II inhibitor ramipril continues to occupy the top spot. The consumption of acetylsalicylic acid continued to decline as in the previous

year, pushing it down from 2nd to 4th place. Rosuvastatin, a cholesterol-lowering medicine whose consumption has been growing robustly for several years and now showed an increase of 27% on the previous year, is a new addition to the top 10 list. The only medicines on the list not used to treat cardiovascular diseases were the analgesics ibuprofen and paracetamol.

Table 2.2. Top 10 medicines by consumption in 2020

Medicine	ATC code	Consumption, DDD/1,000 inhabitants/day	Change from 2019, %
Ramipril	C09AA05	73.8	0
Amlodipine	C08CA01	69.8	5
Atorvastatin	C10AA05	63.1	12
Acetylsalicylic acid	B01AC06	62.3	-2
Ibuprofen	M01AE01	50.1	-5
Losartan	C09CA01	49.4	5
Candesartan	C09CA06	49.0	14
Bisoprolol	C07AB07	42.2	7
Paracetamol	N02BE01	41.1	6
Rosuvastatin	A02BC02	38.1	27

Proton pump inhibitor consumption is on the rise

Sales in the group of medicines for gastrointestinal diseases and metabolic disorders totalled EUR 321 million. This represented an increase of 4% on the previous year. The consumption of medicines in this group amounted to 326.1 DDD/1,000 inhabitants/day, also representing an increase of 4% on the previous year.

Medicines for gastric hyperacidity-related disorders were sold for EUR 31 million, and their consumption was 72.9 DDD/1,000 inhabitants/day. Of this, proton pump inhibitors accounted for 95% (69.2 DDD/1,000 inhabitants/day). The consumption of these has grown steadily over the past 5 years, while their wholesale sales in euros have decreased (EUR 23 million). All proton pump inhibitors are in the reference price system. The most frequently used proton pump inhibitor was pantoprazole, with a consumption of 37.9 DDD/1,000 inhabitants/day. It would seem that the price of proton pump inhibitors goes down as their consumption goes up.

Both laxatives and diarrhoea medicines were sold for almost as much as medicines for gastric hyperacidity-related disorders (EUR 29 million each). The consumption of laxatives amounted to 51.3 DDD/1,000 inhabitants/day. The consumption of diarrhoea and bowel infection medicines was substantially less, at 13.6 DDD/1,000 inhabitants/day. Both sales and consumption of laxatives increased by 7% on the previous year. The majority of the consumption (31.5 DDD/1,000 inhabitants/day) was in osmotic laxatives. The most used laxative was macrogol, followed by lactulose. Macrogol consumption (17.2 DDD/1,000 inhabitants/day) has been growing robustly in recent years, now showing an increase of 16% on the previous year. Macrogol is not eligible for reimbursement under the National Health Insurance Scheme. Lactulose is reimbursable, but its consumption is gradually decreasing (now 13.2 DDD/1,000 inhabitants/day). Most of the diarrhoea medicines consumed and sold are sulfasalazine and mesalazine, used for bowel inflammations.



Diabetes medicine sales continue to grow

Sales of diabetes medicines are on a prolonged growth trend and continued to grow by 6% on the previous year, to EUR 171 million, while consumption increased by 2% to 101.8 DDD/1,000 inhabitants/day. The number of individuals purchasing diabetes medicines eligible for reimbursement under the National Health Insurance Scheme increased by 2% on the previous year, with the number of individuals receiving refunds exceeding 400,000.

Insulin sales decreased again, as in the three previous years, to EUR 58 million (-5%).

Insulin consumption also decreased, to 31.2 DDD/1,000 inhabitants/day (-3%). Insulin consumption breaks down into 63% long-acting insulin (19.8 DDD/1,000 inhabitants/day) and 34% fast-acting insulin (10.66 DDD/1,000 inhabitants/day). The most commonly used long-acting insulin by far is insulin glargine. Consumption of both insulin glargine and insulin detemir has decreased in recent years (being now 12.3 and 4.4 DDD/1,000 inhabitants/day, respectively), while that of insulin degludec has increased.

In 2020, the consumption of insulin degludec (3.1 DDD/1,000 inhabitants/day) increased by 55%, accounting for 16% of the consumption of all long-acting insulins. Sales (EUR 8 million, +54%) grew at the same pace. Restrictions on the

reimbursability of insulin degludec and insulin glargine were removed in March 2020.

Sales of other blood glucose lowering agents also increased, as in previous years, now by 12% to EUR 113 million. Their consumption increased by 4%, to 70.5 DDD/1,000 inhabitants/day. A significant portion (48%) of this consumption was accounted for by metformin (33.6 DDD/1,000 inhabitants/day). Furthermore, about 9% of the consumption consisted of metformin combinations. The next most popular medicine groups were DPP4 inhibitors or gliptins (12.7 DDD/1,000 inhabitants/day) and SGLT2 inhibitors (11.0 DDD/1,000 inhabitants/day). However, the most significant group of blood glucose lowering agents excluding insulins is the GLP1 analogues, with sales of EUR 33 million and consumption of 5.4 DDD/1,000 inhabitants/day. Consumption of GLP1 analogues increased by 42% on the previous year.

Speedy increase of antithrombotics sales

Sales of blood disorder medicines grew by 6% on the previous year, to EUR 284 million, while consumption increased by 3% to 140.9 DDD per 1,000 inhabitants per day. Sales growth was more moderate than in the previous year. The number of individuals purchasing reimbursable medicines increased by 1%, but the total amount in EUR of refunds paid under the National Health Insurance Scheme increased by more than 10%.

The total sales of antithrombotics (EUR 155 million) increased by 12% on the previous year, while consumption remained almost unchanged at 116.1 DDD/1,000 inhabitants/day. Both sales and consumption of direct factor Xa inhibitors – rivaroxaban, apixaban and edoxaban – increased again, both by 24%, to EUR 91 million and 21.0 DDD/1,000 inhabitants/day. Warfarin consumption and sales continued to decrease at the same rate as in the previous year, both by 19% (8.2 DDD/1,000 inhabitants/day). New and more expensive treatments continue to replace old and more affordable treatments for blood disorders. In 2020, there were more than 400,000 individuals purchasing antithrombotics that were eligible for reimbursement.

Sales of cardiovascular medicines decrease for the fourth year running

Sales of cardiovascular medicines decreased for the fourth year running, now by 8% to EUR 138 million. Consumption was 655.3 DDD/1,000 inhabitants/day, up 4% on the previous year. There were more than 1.6 million individuals purchasing cardiovascular medicines eligible for reimbursement, and the number of those receiving refunds increased by 2% on the previous year.

Among cardiovascular medicines, sales of diuretics grew by 6% on the previous year, to EUR 9 million, while consumption decreased by 2% to 50.5 DDD per 1,000 inhabitants per day. The greatest reduction (24%) was in the sales of lipid-modifying medicines (EUR 24 million), while their consumption actually increased by 11% to 147.7 DDD/1,000 inhabitants/day. Among these, consumption of rosuvastatin increased the most, by 27% to EUR 38.1 DDD/1,000 inhabitants/day, passing simvastatin, the consumption of which decreased by 6% to 33.4 DDD/1,000 inhabitants/day. Rosuvastatin consumption also increased at a rate of 20% to 24% between 2017 and 2019. Atorvastatin remains the most used statin, though. Its consumption increased by 12.1% to 63.1 DDD/1,000 inhabitants/day, the growth trend having remained stable in recent years. Price competition appears to be still ongoing in cardiovascular medicines, because sales in all the most frequently used categories except for diuretics – i.e. beta blockers, calcium channel inhibitors, agents acting on the renin-angiotensin system and lipid-modifying agents – decreased even though consumption increased.



The consumption of anti-infectives collapsed in the first year of the COVID19 pandemic

The consumption of systemic anti-infectives went in a different direction from all other medicines in the first year of the COVID19 pandemic. Consumption decreased by 17% to 13.9 DDD/1,000 inhabitants/day, and sales decreased by 4% to EUR 257 million. The reduction in the use of medicines in this group was particularly due to a drop of nearly 20% in consumption of systemic antibacterials, to 11.9 DDD/1,000 inhabitants/day. In systemic antibacterials, the greatest decrease was in medicines mostly used in outpatient care: amoxicillin (1.2 DDD/1,000 inhabitants/day, -38.3%), doxycycline (1.3 DDD/1,000 inhabitants/day, -32.8%) and amoxicillin - beta lactamase inhibitor compound (0.5 DDD/1,000 inhabitants/day, -32.1%). The consumption of macrolids mostly used in outpatient care also decreased (0.3 DDD/1,000 inhabitants/day, -36%).

In systemic antivirals, which had shown robust growth in earlier years, sales decreased by 9% to EUR 128 million and consumption decreased by 5% to 1.55 DDD/1,000 inhabitants/day. The sales and consumption of the top selling-compound in the category, sofosbuvir - velpatasvir used to treat hepatitis C, both decreased by 8%. Consumption was very low, at only 0.05 DDD/1,000 inhabitants/day. The costs of hepatitis C medicines are covered

by the patient's home municipality. Cost information at actual competitive prices is not currently available.

Sales of antineoplastic and immunomodulating agents increased less robustly than before

Sales of antineoplastic and immunomodulating agents increased by 4% on the previous year to EUR 814 million. This was a less robust growth rate compared to 13% in 2019 and 22% in 2018. In euros, the increase this time was EUR 31 million. The increase in refunds also slowed down on the two previous years, to 7% (EUR 573 million), even if the increase was substantial at EUR 39 million. By comparison, reimbursement costs increased by 14% in 2019 and by 25% in 2018. The number of individuals purchasing medicines eligible for reimbursement medicines increased by 3% to 157,000.

Sales of antineoplastic medicines increased significantly less than in the previous year, now by 7% to EUR 328 million. In this group, the largest sellers were monoclonal antibodies (EUR 163 million, +6%) and protein kinase inhibitors (EUR 91 million, +10%). Among monoclonal antibodies, the largest sellers were trastuzumab, used to treat breast and stomach cancer (EUR 31 million), rituximab, used to treat lymphomas, leukaemia and arthritis (EUR 28 million), and bevacizumab, used to treat a variety of cancers (EUR 25 million). Sales of rituximab

decreased by EUR 7 million from the more than EUR 35 million in the previous year, which is when trastuzumab surpassed it to become the best selling monoclonal antibody. There was no clear leader in the group of protein kinase inhibitors, the top sellers being the same as in the previous year: palbociclib, used to treat breast cancer (EUR 14 million), ibrutinib, used to treat blood cancers (EUR 13 million) and cabozantinib, used to treat kidney and liver cancer (EUR 9 million).

Sales of endocrine therapy grew by 8% on the previous year, to EUR 70 million, while consumption decreased by 2% to 7.8 DDD per 1,000 inhabitants per day. As in previous years, the largest seller among endocrine therapy medicines was enzalutamide, a prostate cancer medicine whose sales increased by 5% to EUR 33 million.

Sales in the immunostimulant group decreased by 2% to EUR 31 million. This decrease was largely due to a decline in the use of interferons in the year under review.

Immunosuppressants constituted the largest group in antineoplastic and immunomodulating agents in terms of sales, at EUR 384 million. Sales growth was considerably slower than in the previous year at 2%, an increase of EUR 7 million. Consumption of medicines in this group increased more than sales, by 6% to 15.8 DDD/1,000 inhabitants/day.

Sales in the subgroup showing the most significant growth, tumour necrosis factor alpha (TNF- α) inhibitors (EUR 163 million, -8%), decreased for the first time in three years, even though consumption was up 9% (4.2 DDD/1,000 inhabitants/day). Sales of infliximab and adalimumab decreased the most (EUR 64 million, -16% and EUR 47 million, -6%, respectively), even though consumption of both was up (13% and 7%, respectively). Sales of the third most sold TNF- α inhibitor, etanercept (EUR 24 million, +3%), also increased by less than its consumption at +4%. There are biosimilars available on the market for all the three aforementioned agents, so their pricing must have affected the general price level here. Sales of interleukin inhibitors grew by 20% on the previous year, to EUR 48 million, while consumption increased by 28% to 1.0 DDD/1,000 inhabitants/day. The largest seller among interleukin inhibitors was ustekinumab, the sales and consumption of which both increased (EUR 18 million, 31% and 0.5 DDD/1,000 inhabitants/day, +40%).



New migraine medicines are increasing their market share

Sales (EUR 98 million) and consumption of medicines for musculoskeletal disorders decreased by 5%, and consumption fell by 3% (98.7 DDD/1,000 inhabitants/day). The number of individuals purchasing medicines eligible for reimbursement decreased by 4% to 1.3 million in the year under review. The amount of refunds paid out decreased by 2% on the previous year to EUR 27 million.

Sales of anti-inflammatory analgesics decreased by 7% on the previous year, to EUR 43 million, while consumption decreased by 4% to 77.5 DDD/1,000 inhabitants/day. The most used analgesic is ibuprofen, which is the fifth most used medical agent of any kind in Finland, at 50.1 DDD/1,000 inhabitants/day. Ibuprofen sales and consumption both decreased by 5% (EUR 29 million). Coxib consumption increased (11.4 DDD/1,000 inhabitants/day, +7%), but sales decreased by 14%, probably because of price competition on etoricoxib. Paracetamol sales and consumption grew, both by 6% to EUR 27 million and 41.1 DDD/1,000 inhabitants/day, as they had done in several consecutive previous years. Paracetamol is the second most used analgesic in Finland.

The combined sales (EUR 25 million) and consumption (13.3 DDD/1,000 inhabitants/day) of opioids

used to treat pain continued to decrease. Sales fell by 4% and consumption by -3%. More than half of opioid consumption is made up of mild opioids – codeine and tramadol – and their combinations; this has decreased in recent years. In the year under review, the consumption of mild opioids decreased by 4% to 8.8 DDD/1,000 inhabitants/day. The combined consumption of strong and moderate opioids used to treat pain (4.5 DDD/1,000 inhabitants/day) has increased in recent years but now decreased by 1%.

Sales and consumption of migraine medicines increased more moderately than in the previous year, but growth was still robust. Sales increased by 27% to EUR 26 million, and consumption increased by 11% to 3.1 DDD/1,000 inhabitants/day. Calcitonin gene-related peptide (CGRP) receptor agonists – erenumab, fremanezumab and galcanezumab – now account for more than 1/4 of all migraine medicine consumption and 70% of sales, with a combined consumption of 0.8 DDD/1,000 inhabitants/day (+94%) and sales of EUR 18 million. Consumption of selective 5HT1 receptor agonists decreased by 3% to 2.3 DDD/1,000 inhabitants/day, and sales decreased by 2% to EUR 8 million. The most used 5HT1 receptor agonist is sumatriptan, the consumption of which decreased by 6% to 1.46 DDD/1,000 inhabitants/day. The growth that emerged in 2019 due to an increase in the reference prices of sumatriptan peaked in the year

under review, and sales decreased by 2% to EUR 5 million.

COVID19 pandemic did not increase the overall consumption of psychotropics

Sales of central nervous system medicines again grew by 7% on the previous year, to EUR 384 million, while consumption increased by 4% to 304.0 DDD per 1,000 inhabitants per day. More than 1.7 million individuals purchased medicines eligible for reimbursement medicines; the number of people receiving refunds thus remained almost unchanged. The amount of refunds paid out, however, increased by 4.8% to more than EUR 225 million.

The total consumption of psychotropics increased by 12% to 141.5 DDD/1,000 inhabitants/day, while melatonin consumption increased by 15% to 27.44 DDD/1,000 inhabitants/day. It must be noted that a significant percentage of all melatonin sold is sold in nutritional supplements, which are not included in these figures. Excluding melatonin consumption, the overall consumption of psychotropics increased by 1%. The coronavirus pandemic does not seem to have increased the consumption of psychotropics.

Consumption of the most used psychotropics, antidepressants, increased by 4% to 81.5 DDD/1,000 inhabitants/day, which is similar to the previous year's growth of 5%. Sales of

antidepressants, on the other hand, increased by 8%. The consumption of other psychotropics, principally serotonin and noradrenaline reuptake inhibitors, increased by more than that of the most used group of antidepressants, selective serotonin reuptake inhibitors (32.7 DDD/1,000 inhabitants/day, +7% vs. 44.6 DDD/1,000 inhabitants/day, +3%).

The consumption of hypnotics increased by 5% to 49.0 DDD/1,000 inhabitants/day, mainly due to the increased consumption of melatonin (27.4 DDD/1,000 inhabitants/day, +15%). The combined consumption of benzodiazepine derivatives and benzodiazepine-related medicines in the hypnotics group decreased by 6% to 21.3 DDD/1,000 inhabitants/day. Sales of hypnotics grew by just 3%, to EUR 14 million. The consumption of anxiolytics decreased by 5% to 15.5 DDD/1,000 inhabitants/day in the year under review, but their sales increased by 16% to EUR 7 million. Most of the growth in sales was due to increased sales of lorazepam. Lorazepam sales more than tripled from the previous year, evidently related to the tripling of the percentage of sales to hospitals out of all lorazepam sales. This growth was probably fuelled by the entry to market in late 2019 of an injection product whose price is dozens of times higher than that of the tablet products.



Consumption and sales of antipsychotics increased to 23.0 DDD/1,000 inhabitants/day (+4%) and EUR 52 million (+3%), respectively. The growth was moderate, even if it was greater than in the previous year, when both consumption and sales increased by 1%.

Sales of epilepsy medicines decreased by 9% on the previous year, to EUR 48 million, although consumption increased by 4% to 24.3 DDD/1,000 inhabitants/day. The greatest drop was in pregabalin sales, which decreased by almost half to EUR 6 million. Nevertheless, pregabalin consumption increased by 3% to 5.6 DDD/1,000 inhabitants/day. The decline in sales was probably due to a reduction in pregabalin prices. For instance, the reference price for a package of 56 pregabalin 300mg tablets decreased from EUR 45.05 at the beginning of 2020 to EUR 26.37 at the end of the year.

Consumption and sales of centrally acting sympathomimetics continued to grow at about the same rate as in the previous year, to 6.7 DDD/1,000 inhabitants/day and EUR 16 million, an increase of 21% and 17%, respectively. This group mainly comprises ADHD medicines. The consumption and sales of the most used of these, methylphenidate, both increased (5.0 DDD/1,000 inhabitants/day, +16% and EUR 8 million, +13%). The fastest growth continues to

be recorded in lisdexamphetamine consumption (1.2 DDD/1,000 inhabitants/day, +51%). Consumption of the newest ADHD medicine, guanfacine, is following a similar trend but is still at a low level (0.1 DDD/1,000 inhabitants/day).

Consumption of medicines for controlling the symptoms of infections decreased in the year of the coronavirus

Combined sales of medicines for pulmonary diseases decreased for the third year running, now by 3% to EUR 149 million. Their consumption increased by 3%, to 194.2 DDD/1,000 inhabitants/day. About one million individuals purchased medicines eligible for reimbursement in this group, and about EUR 89 million was paid out in refunds. The number of individuals receiving refunds decreased by 7%, but the amount of refunds paid out increased by 6%.

Consumption and sales of medicines for obstructive pulmonary diseases increased to 83.8 DDD/1,000 inhabitants/day (+5%) and EUR 94 million (+3%), respectively. The slight decline in sales seen in the previous year did not continue. Consumption and sales of adrenergic agents and anticholinergic compounds increased (3.4 DDD/1,000 inhabitants/day, +19% and EUR 10 million, +25%). Consumption involves a number of compounds, the most used of which is the fenoterol and ipratropium bromide combination.

Consumption and sales of inhaled glucocorticoids increased (20.1 DDD/1,000 inhabitants/day, +5% and EUR 17 million, +1%).

Consumption and sales of products for treating nasal mucous membranes decreased (33.3 DDD/1,000 inhabitants/day, -10% and EUR 24 million, -12%). The majority of medicines for treating nasal mucous membranes are intranasal corticosteroids. Their consumption decreased by 4% to 21.6 DDD/1,000 inhabitants/day. The decrease in consumption was the most pronounced in systemic products for alleviating congestion and in locally applied sympathomimetic agents. Consumption of medicines for disorders of the larynx and of cough medicines decreased substantially, probably due to the general decline in infections achieved through COVID19 prevention measures.

The consumption of systemic antihistamines has been growing for years. In the year under review, consumption increased by 11% to 71.5 DDD/1,000 inhabitants/day, and sales increased by 8% to EUR 17 million. The most used products were cetirizine (33.0 DDD/1,000 inhabitants/day) and desloratadine (15.9 DDD/1,000 inhabitants/day).

Sources: Finnish Medicines Agency Fimea, Drug Sales Register, Fimea shortage notification data, Kela's register of dispensations reimbursable under the National Health Insurance Scheme (including purchases not exceeding the initial deductible), Register of Statistical Information on National Health Insurance General Benefit Payments.



Impacts of the COVID-19 pandemic on purchases of medications at community pharmacies

Heini Kari, M.Sc. (Pharm.), M.Sc. (Tech.),
Senior Researcher, Kela

Hanna Rättö, M.Soc.Sc. (Econ), Researcher, Kela

In 2020, the impacts of the COVID-19 pandemic permeated all areas of society, in Finland as elsewhere. The pharmaceutical industry and national authorities faced a novel situation in March 2020, as the number of COVID-19 cases soared and people began to panic buy medications at pharmacies. The volume of pharmacy purchases of prescription medicines reimbursed under the National Health Insurance (NHI) scheme began to increase substantially in week 11, and in week 12 the volume of purchases of these medications was 36% higher than in the corresponding period in 2019. Costs and reimbursements of medications reimbursed by the NHI also increased.

At the beginning of week 12, the Government in cooperation with the President of the Republic declared that Finland was in state of emergency due to the COVID-19 pandemic. During the same week, the Finnish Medicines Agency (Fimea) published guidelines for pharmacies and pharmaceutical wholesalers concerning the storage and dispensing of medications, and Kela also notified community pharmacies that during the COVID-19

pandemic pharmacies may, for special reasons, be flexible with the dispensing intervals given in the NHI guidelines, in the interests of reducing the number of visits to the pharmacy. Also, restrictions on people's movement were tightened for instance by partly shutting down schools and by instructing people aged over 70 to maintain quarantine-like conditions.

Panic buying of medications for respiratory disorders, painkillers and antipyretics in Finland

Purchases of all drug groups (ATC level 1) except systemic anti-infectives increased during the early stages of the COVID-19 pandemic as compared with the previous year, but growth was not equally strong in all groups. Purchases of medications for respiratory disorders, blood disorders, and alimentary tract and metabolic disorders increased the most.

In particular, purchases of medications for respiratory disorders increased at the beginning of the COVID-19 pandemic: in week 12, the increase was 89% on the corresponding period in 2019. Medications in this group are used to treat asthma, chronic obstructive pulmonary disease (COPD), allergy symptoms, etc. The massive growth in purchases


raised concerns about the availability of medications for respiratory disorders in Finland, and in week 15 the Ministry of Social Affairs and Health, pursuant to the Emergency Powers Act that had entered into force when state of emergency had been declared, ordered pharmacies to restrict dispensing of salbutamol treatments in order to ensure availability of these medicines (VN/8524/2020).

Among painkillers, prescription purchases of paracetamol and ibuprofen increased substantially. During weeks 11–12, 67% more paracetamol and 54% more ibuprofen were bought on prescription than in the corresponding period in the previous year. These medications are also sold over the counter at community pharmacies, and these sales likewise increased.

Purchase volumes of regularly used medications such as diabetes medicines also increased at the beginning of the COVID-19 pandemic, compared with the corresponding period in the previous year. However, during 2020 the spike in for example diabetes drugs evened out and no significant changes in yearly cost or purchase volume trends were evident.

By contrast, purchases of systemic antibacterials (antibiotics) decreased significantly in early 2020 compared to 2019. The decrease was particularly notable during weeks 12–15, following which their purchase volume remained lower than in the previous year for the remainder of 2020. Purchases decreased in all age groups (Figure 2.1), but decrease was most evident in children under the age of 13 and least evident among people aged 75 and older. Lockdown measures, restrictions on social contacts and paying particular attention to hand hygiene, etc., probably contributed to this trend, as the incidence of bacterial respiratory infections was lower than in previous years.

Figure 2.2. Purchases of antibiotics (ATC category J01) from community pharmacies reimbursed by the National Health Insurance, by age group, in 2019 and 2020



Source: Dispensations reimbursable under the National Health Insurance Scheme register

Pharmaceutical authorities took rapid and timely action

The coronavirus pandemic was an unexpected shock in early 2020, forcing both individuals and societies to react very rapidly. There were probably multiple reasons for the panic buying of prescription medicines from community pharmacies in weeks 11 and 12, one of them being wanting to ensure the sufficiency of medications by buying unusually large amounts of them. The societal measures taken to curb the impact of pandemic and the public debate around those measures may likewise have contributed to changes in behaviour in purchasing medications, e.g. the desire to minimise visits to the pharmacy to safeguard one's health, leading to larger purchases per visit.

Very early in the pandemic, the authorities took action to safeguard the sufficiency and availability of medications. Cooperation among the various authorities and a new information collection system rapidly set up by Fimea were used to monitor the pharmaceutical sector, keeping an eye on medication consumption and availability of medicines, besides generating situation updates for the central government. Kela, meanwhile, quickly developed and introduced a new, freely available online application for monitoring the costs and volume of purchases of medications reimbursed by NHI and the number of buyers. Although the pandemic came as a surprise to the pharmaceutical sector

as well, looking back at 2020 it does seem that cooperation among the various authorities in the crisis situation worked well in Finland, and that the measures taken were timely and secured the availability of medications as well as the continuity of patient care under the extraordinary circumstances.

Exceptionally large purchase volumes quickly subsided

The spikes in outpatient pharmaceutical purchases caused by panic buying quickly subsided during the spring; by week 14, the total volume of purchases of medications reimbursed by the NHI was at or below the previous year's level. The cumulative amount of purchases of medications in outpatient care was higher in early 2020 than in the corresponding period in 2019, but this too evened out over the course of the year. Considering the year 2020 as a whole, the costs of medications reimbursed by the NHI and the reimbursements followed trends very similar to those of the previous years.



Pharmaceutical policies

Ulla Närhi, Ministerial Advisor, Ministry of Social Affairs and Health / Biotechnology and Medicines
Elina Asola, Senior Specialist, Ministry of Social Affairs and Health / Biotechnology and Medicines

Basic policy from Government Programmes

As with all policy, pharmaceutical policy is implemented by goals set in Government Programmes. Entries in the Government Programme are implemented, for example, through legislation and strategies. These, along with other guidelines and regulations related to the pharmaceutical industry, may be considered as part of pharmaceutical policy. Purpose in this article is not to discuss individual regulatory proposals or actions but pharmaceutical policy as a whole.

Development of pharmacotherapy or pharmaceutical services have been included in the latest Government Programmes. The Government Programme of the Government of Prime Minister Sipilä's (29 May 2015 – 6 June 2019) recorded a need to strengthen the overall evaluation of pharmacotherapy¹. Another goal was to devise a rational pharmacotherapy action plan to improve comprehensive care for patients, to improve functional capacity and create preconditions for cost-effective

pharmacotherapy advantageous both for patients and for society.

Rational pharmacotherapy is also mentioned as an ongoing practice in the Government Programmes of the Governments of Prime Minister Rinne (6 June – 10 December 2019)² and Prime Minister Marin (10 December 2019 –)³ Long-term reform of the pharmaceutical services system is also considered important, in accordance with the roadmap included in a report published by the Ministry of Social Affairs and Health (2019:5). The goal is to improve the cost-efficiency of pharmaceutical services while ensuring the safety of medicinal products, advisory services and smoothly running, available and accessible services.

Pharmaceutical policies

Pharmaceutical policies were discussed in co-operation between pharmaceutical sector in the early 2010s. The policy document *Lääkepolitiikka 2020 – Kohti tehokasta, turvallista, tarkoituksenmukaista ja taloudellista lääkkeiden käyttöä* [Pharmaceutical policy 2020 – Towards an efficient, safe, purposeful and economic use of medications]⁴ was published in 2011. The policy work involved representatives from various stages of the life cycle of pharmaceutical products, from research to clinical use.

The principal goals for pharmaceutical policy to be attained by 2020 were:

- Pharmaceutical service constitutes part of the social welfare and health care system.
- Pharmaceutical service are of a high quality, effective, and cost-efficient.
- Rational pharmacotherapy and good medication safety improve people's well-being and public health, decreasing health care expenditure.
- Pharmaceutical research improves health, well-being, and employment rates.
- Veterinary service safeguards public health and promotes well-being of humans and animals.
- The pharmaceutical policy points were devised from a practical perspective, and goals were jointly agreed that pointed the way to further developments in the sector going forward. Attainment of the goals has not yet been evaluated.

Rational Pharmacotherapy Action Plan

Preparation of the Rational Pharmacotherapy Action Plan was launched actively in January 2016, and an interim report was published at the beginning of 2017.

The Rational Pharmacotherapy Action Plan was published in early 2018.⁵ According to this

document, rational pharmacotherapy is effective, safe, high-quality, cost-effective and equitable.

The following objectives were set to be achieved by 2022:

- Pharmacotherapy and pharmaceutical services will be managed by knowledge at national and regional levels and in service units.
- Service organisers will be in charge of pharmacotherapy and pharmaceutical services as a whole.
- Pharmacotherapy will be managed as a whole.
- Health care and social welfare professionals will implement rational pharmacotherapy, and medicine users will use pharmaceuticals rationally and as agreed.
- Medicine users will use pharmaceuticals rationally and as agreed

The Action Plan includes several publications, such as separate final reports by each subgroup, where the topics were addressed in more detail. Also, a Research Strategy for Rational Pharmacotherapy 2018–2022 was prepared, and separate reports were published. A publicity campaign titled *Sopiva lääke* [Suitable Medicine] was run in support of the Action Plan to stimulate public debate and a new approach to pharmacotherapy. All these



publications can be found on the rational pharmacotherapy website of the Ministry of Social Affairs and Health.⁶

The attainment of the goals of the Rational Pharmacotherapy Action Plan has not yet been assessed. Success in attaining the goals has been impacted inter alia by the delay of the health and social services reform and by the COVID-19 pandemic.

Pharmaceutical services reform

As part of the health and social services reform, a memo by officials on the needs for change in pharmacotherapy and dispensing of medications was published in early 2019.⁷ In the preparation of this memo, factors were identified due to which pharmacotherapy is not always effective, safe, high-quality, cost-effective and equitable. The memo discussed changes to the responsibility for funding pharmacotherapy and also pharmacotherapy steering, the knowledge base and tools required for that steering, and the sustainability of pharmacotherapy funding. The memo was not intended as a comprehensive evaluation of all development needs at various points in the pharmacotherapy value chain; it was more of a conversation starter.

This civil service memo (pharmaceutical roadmap) laid the outline for the pharmaceutical reform entered in the Government Programme. A cross-sectoral coordination group was appointed to monitor and support the reform work in autumn 2020.

Implementation of the roadmap comprises three modules.⁸ The objective for development of pharmacotherapy steering and funding is the rational use of medications and cost control. Another objective is to strengthen national steering and support the evolution of regional steering in pharmaceutical services. The development efforts are closely linked to other ongoing projects, such as the health and social services reform and the dismantling of multichannel funding.

The purpose of improving knowledge management and digital tools is to make information better available, to have it used in a timely manner, and to ensure information safety. Another objective is to introduce better digital tools and services for the needs of social welfare and health care professionals on the one hand and of medication users on the other. These objectives are conducive to achieving safe and successful pharmacotherapy. Setting up an up-to-date national medication list in the Kanta online system will avoid the proliferation of system-specific medication lists and thus an improved control of pharmacotherapy for professionals and users.

The goal in further development of the pharmacy economy and the dispensing of medications is to reduce the share of the pharmacy system in the costs of pharmacotherapy, though without compromising the availability of medicines, the accessibility

of services or the delivery of rational pharmacotherapy. The intention is to determine the goals and duties of the retail distribution of medicines and to explore development needs once this is done.

Pharmaceutical reform is a comprehensive process that will continue to be prepared and implemented over the next terms of government.

Sources

1. Programme of Prime Minister Juha Sipilä's Government 29 May 2015. Finland, a land of solutions: Government Action Plan 2018–2019. <http://urn.fi/URN:ISBN:978-952-287-584-6>, accessed 30 August 2021
2. Programme of Prime Minister Antti Rinne's Government 6 June 2019: Inclusive and competent Finland – A socially, economically and ecologically sustainable society <http://urn.fi/URN:ISBN:978-952-287-760-4>, accessed 30 August 2021
3. Programme of Prime Minister Sanna Marin's Government 10 December 2019. Inclusive and competent Finland - a socially, economically and ecologically sustainable society <http://urn.fi/URN:ISBN:978-952-287-811-3>, accessed 30 August 2021

4. Pharmaceutical policy 2020 – Towards an efficient, safe, purposeful and economic use of medications. Publications of the Ministry of Social Affairs and Health 2011:2. <http://urn.fi/URN:ISBN:978-952-00-3165-7>, accessed 30 August 2021

5. Rational Pharmacotherapy Action Plan Ministry of Social Affairs and Health Reports and Memorandums 19/2018. <http://urn.fi/URN:ISBN:978-952-00-3930-1>, accessed 30 August 2021

6. Rational pharmacotherapy <https://stm.fi/en/rational-pharmacotherapy>, accessed 31 August 2021

7. Aspects of needs for change in pharmacotherapy and dispensing of medications. Ministry of Social Affairs and Health Reports and Memorandums 2019:5., accessed 31 August 2021

8. Reform of pharmaceutical matters <https://stm.fi/en/reform-of-pharmaceutical-matters>, accessed 31 August 2021

3. Finnish population and hospital districts





Figure 3.1. Age structure of the Finnish population at the end of 2020



Source: Kela's population data.


Figure 3.2. University hospital regions and hospital districts in 2020

University hospital regions

- A. Helsinki University Central Hospital region (HYKS)
- B. Turku University Central Hospital region (TYKS)
- C. Tampere University Hospital region (TaYS)
- D. Kuopio University Hospital region (KYS)
- E. Oulu University Hospital region (OYS)

Hospital districts

- | | |
|----------------------|--------------------------|
| 0. Åland | 15. South Ostrobothnia |
| 3. Southwest Finland | 16. Vaasa |
| 4. Satakunta | 17. Central Ostrobothnia |
| 5. Kanta-Häme | 18. North Ostrobothnia |
| 6. Pirkanmaa | 19. Kainuu |
| 7. Päijät-Häme | 20. Länsi-Pohja |
| 8. Kymenlaakso | 21. Lapland |
| 9. South Karelia | 25. Helsinki and Uusimaa |
| 10. South Savo | |
| 11. Itä-Savo | |
| 12. North Karelia | |
| 13. North Savo | |
| 14. Central Finland | |



Source: Kela. Suomen karttatiedosto - Map file of Finland.

**Table 3.1. Population according to hospital district, the proportion of elderly people and the proportion of the population in receipt of Special Refunds of medicines of the total population, at the end of 2020**

Hospital district	Total	Male	Female	Population % aged 65 or over	The proportion % of population in receipt of Special Refunds of medicines
Whole country	5,540,767	2,738,108	2,802,659	22.7	22.6
Helsinki and Uusimaa	1,702,260	832,425	869,835	17.8	17.9
Southwest Finland	484,634	237,556	247,078	23.8	21.7
Satakunta	215,465	106,795	108,670	27.7	25.1
Kanta-Häme	170,879	84,572	86,307	25.8	24.9
Pirkanmaa	540,846	266,654	274,192	22.4	22.6
Päijät-Häme	209,601	102,422	107,179	27.3	24.6
Kymenlaakso	163,293	80,823	82,470	28.6	26.9
South Karelia	126,979	63,226	63,753	28.0	24.6
South Savo	97,592	48,282	49,310	30.9	29.2
Itä-Savo	39,892	19,694	20,198	33.7	31.0
North Karelia	163,697	81,512	82,185	27.2	28.7
North Savo	243,722	120,512	123,210	25.8	28.6
Central Finland	252,899	125,882	127,017	23.0	24.0
South Ostrobothnia	192,241	96,049	96,192	26.0	26.3
Vaasa	169,479	85,672	83,807	23.3	21.6
Central Ostrobothnia	77,169	38,559	38,610	24.1	24.1
North Ostrobothnia	411,426	207,688	203,738	20.1	23.8
Kainuu	71,729	36,263	35,466	29.2	30.6
Länsi-Pohja	59,681	30,048	29,633	27.6	26.7
Lapland	117,164	58,489	58,675	25.1	26.9
Åland	30,119	14,985	15,134	23.0	16.3


Source: Kela's population data, Register of Statistical Information on National Health Insurance General Benefit Payments.

Table 3.2. Population according to university hospital regions by age groups, 31 December 2020

Hospital region	Gender	Total	0-15 years	16-64 years	65 or over
A HYKS	Male	1,078,896	188,460	701,597	188,839
	Female	1,123,237	179,597	689,816	253,824
B TYKS	Male	395,882	62,444	238,792	94,646
	Female	401,920	60,067	227,365	114,488
C TaYS	Male	371,047	69,731	223,977	77,339
	Female	366,122	67,180	208,126	90,816
D KYS	Male	447,275	76,544	275,735	94,996
	Female	456,691	73,034	263,629	120,028
E OYS	Male	445,008	73,973	272,582	98,453
	Female	454,689	70,648	261,389	122,652
Total		5,540,767	921,678	3,363,008	1,256,081
Proportion of total population, %		100.0	16.6	60.7	22.7

Source: Kela's population data.

4. Drug control and pharmaceutical services






Distribution of medicine sales

Table 4.1. Medicine sales to pharmacies and hospitals at wholesale prices according to the ATC code in 2020¹

ATC code	Sales at wholesale prices, EUR 1,000	Pharmacies, %	Hospitals, %	Total
A Alimentary tract and metabolism	320,864	11.1 (92.9)	0.8 (7.1)	11.9 (100.0)
B Blood and blood forming organs	284,227	7.8 (73.5)	2.8 (26.5)	10.6 (100.0)
C Cardiovascular system	138,177	4.4 (86.6)	0.7 (13.4)	5.1 (100.0)
D Dermatologicals	43,110	1.5 (95.6)	0.1 (4.4)	1.6 (100.0)
G Genito-urinary system and sex hormones	104,274	3.6 (93.5)	0.3 (6.5)	3.9 (100.0)
H Systemic hormonal preparations, excl. sex hormones and insulines	49,489	1.5 (82.3)	0.3 (17.7)	1.8 (100.0)
J Antiinfectives for systemic use	256,591	2.2 (22.7)	7.4 (77.3)	9.5 (100.0)
L Antineoplastic and immunomodulating agents	813,258	17.4 (57.6)	12.8 (42.4)	30.2 (100.0)
M Musculo-skeletal system	97,706	2.9 (79.9)	0.7 (20.1)	3.6 (100.0)
N Nervous system	319,715	10.0 (84.4)	1.9 (15.6)	11.9 (100.0)
P Antiparasitic products, insecticides and repellents	5,749	0.2 (96.8)	0.0 (3.2)	0.2 (100.0)
R Respiratory system	148,602	5.2 (94.2)	0.3 (5.8)	5.5 (100.0)
S Sensory organs	67,883	1.4 (55.7)	1.1 (44.3)	2.5 (100.0)
V Various	39,679	0.2 (13.9)	1.3 (86.1)	1.5 (100.0)
Total	2,689,325	(69.5)	(30.5)	(100.0)

1 The percentages given in brackets indicate the sales distribution within the group.
Source: Finnish Medicines Agency Fimea, Drug Sales Register.

Figure 4.1. Distribution of medicine sales between pharmacies and hospitals according to the ATC code, at wholesales prices, in 2020, EUR 1,000



Source: Finnish Medicines Agency Fimea, Drug Sales Register.



Pharmacies and hospital pharmacies

In Finland, medicines may be sold to the public by pharmacies, subsidiary pharmacies, pharmacy service points and pharmacies' online services. OTC nicotine products can also be sold from outlets other than pharmacies, e.g. grocery shops and kiosks, under a permit issued by the municipal authorities. A pharmacy will dispense prescription-only medicines against a prescription issued by a doctor, dentist, veterinary surgeon or (in certain cases) nurse.

Pharmacies are privately owned and licensed. After announcing a vacancy the Finnish Medicines Agency grants a licence to own and operate a pharmacy to an applicant of its choice. Proprietary pharmacists are required to hold the qualification of a Master of Science (Pharmacy) and be a citizen of any state belonging to the European Economic Area. In addition to the privately owned pharmacies, the University of Helsinki has the statutory right to operate one pharmacy in the city of Helsinki, and up to 16 subsidiary pharmacies with permission granted by the Finnish Medicines Agency. The University of Eastern Finland also has the statutory right to operate one pharmacy in the city of Kuopio.

A turnover-based pharmacy tax was introduced at the beginning of 2017. It is a state tax payable by proprietary pharmacists and replaces the pharmacy fee. The purpose of the pharmacy tax is to guarantee nationwide access to pharmacy services and to reduce differences in revenue among pharmacies.

The Finnish Medicines Agency may permit hospitals and other health care institutions to operate a hospital pharmacy or a medicine dispensary. The director of a hospital pharmacy is required to hold the qualification of a Master of Science (Pharmacy) and the director of a medicine dispensary is required to hold the qualification of a Master of Science (Pharmacy) or a Bachelor of Science (Pharmacy).

Hospital pharmacies and medicine dispensaries issue medicines only to their own wards and other departments; they are not allowed to sell medicines to patients or directly to the public. Only on special occasions may patients, who are being discharged or temporarily transferred to outpatient care, be issued medicines from the hospital to ensure the continuation of their medication. These medicines are supplied without charge and normally for one or two days only

Table 4.2. Statistics for pharmacies in 2020

	Private pharmacies	University pharmacies
Number of pharmacy outlets	800	18
Pharmacies	624	2
Subsidiary pharmacies	176	16
Number of prescriptions in thousands	60,867	6,252

Source: Finnish Medicines Agency Fimea.




Table 4.3. Dispensations dispensed by pharmacies in 2005–2020

Year	Number of pharmacies	Dispensations		
		Number in thousands	Per capita	Per doctor
2005	606	42,161	8.0	1,686
2006	608	43,468	8.2	1,676
2007	610	45,747	8.6	1,721
2008	613	48,252	9.1	1,774
2009	617	48,725	9.1	1,666
2010	618	50,364	9.4	1,668
2011	620	48,498	9.0	1,556
2012	620	51,698	9.5	1,615
2013	618	51,724	9.5	1,586
2014	615	53,381	9.8	1,616
2015	615	55,791	10.2	1,665
2016	613	58,812	10.7	1,560
2017	616	61,250	11.1	1,824
2018	618	63,300	11.4	1,874
2019	621	65,668	11.7	1,857
2020	626	67,120	12.1	1,893

Source: Finnish Medicines Agency Fimea.


Figure 4.2. Number of pharmacies and prescriptions dispensed in 1990–2020



Source: Finnish Medicines Agency Fimea.




Figure 4.3. Number of pharmacies per 10,000 inhabitants by hospital district in 2020



Hospital pharmacies and medicine dispensaries have not been taken into account.


Source: Finnish Medicines Agency Fimea.

5. National health insurance and reimbursement of medicine expenses



The medicine supply chain and the role of various organisations in oversight and reimbursement

- How medicines reach customers
- Government authority, oversight and marketing authorisations
- Government authority, reimbursement process
- Oversight and marketing authorisations
- Reimbursement process



The chart only includes the organisations relevant in the context of the Finnish Statistics on Medicines.



Medicine reimbursement system and approval of medicine prices

Jaana Kruuti, Chief Pharmaceutical Officer, M.Sc. (Pharm.), Kela

Jaana Harsia-Alatalo, Pharmaceutical Officer, M.Sc. (Pharm.), Kela

Miia Djerf, Pharmaceutical Officer, M.Sc. (Pharm.), Kela

General information

The medicine reimbursement system was first implemented in Finland in 1964 pursuant to the Health Insurance Act (sairausvakuutuslaki 1224/2004). The system covers all residents of Finland, regardless of age, wealth or address. The Health Insurance Scheme is administered by the Social Insurance Institution of Finland (Kela).

The Health Insurance Scheme reimburses some of the necessary costs of prescription-only medicines which are used for the treatment of an illness. An over-the-counter product may also be granted reimbursement status if the product is prescribed by a physician and considered, on medical grounds, to be an indispensable medicinal product. Basic topical ointments prescribed for the treatment of chronic skin ailments are also reimbursable, as are clinical nutritional preparations used in the treatment of a serious illness. Reimbursement is also

paid to a limited group of patients for the dosage service fee charged by pharmacies.

The payment of reimbursement is possible only after the Pharmaceuticals Pricing Board has approved the reimbursement status of the medicine, basic topical ointment or clinical nutritional preparation and confirmed its reasonable wholesale price. The Pharmaceuticals Pricing Board operates under the auspices of the Ministry of Social Affairs and Health.

The Finnish medicine reimbursement system consists of three categories: the Basic Refund Category, and the Lower and Higher Special Refund Categories. The categories are graded according to medical criteria based on the severity of the disease and the necessity of the drug treatment. Up to three months' supply of medicines can be reimbursed at any one transaction. However, a maximum of one month's supply of the medicine is reimbursed at any one time if there is a pack size available on the market whose retail price exceeds EUR 1,000 (inclusive of VAT). The customers usually have their medicine costs refunded directly at the pharmacy, after the pharmacy has verified their

eligibility for the reimbursement with Kela's direct reimbursement inquiry service.

In 2015, all pharmacies adopted a real-time data transmission procedure, which applies to medicine purchases. Real-time transmission of data relating to medicine purchases between pharmacies and Kela was a prerequisite for the adoption of the initial deductible limit at the beginning of 2016. The exceptional medicine-specific copayment for Higher Special Refund and Additional Refund categories, charged for each new week of treatment, was adopted at the same time. This also enabled real-time transmission of purchasing data on dose-dispensed medicines from pharmacies to Kela. In addition to dose-dispensed medicines, the exceptional medicine-specific copayment also applies to purchases of medicines containing clozapine, peritoneal dialysis solutions and medicinal oxygen. As of 1 January 2017, the exceptional medicine-specific copayment is also applicable to a supply of a maximum of one month's treatment in case of an expensive medicine, or if a medicinal product is prescribed by a physician, on therapeutic grounds, to be purchased in several batches. The exceptional medicine-specific copayment amounts

to 1/12 of the medicine-specific deductible for three months of treatment.

Determining the price of medicines

The Government Decree on the Price List of Drugs regulates the sale prices of medicines and the pharmacy margin for the sale of medicines. The purpose of the price list is to keep the prices of medicines on a reasonable level. In addition, the price list ensures that the prices of medicines are the same in every pharmacy.

The retail price of a medicine is determined on the basis of the price list of drugs and the nationwide wholesale price of the medicine in question. The price list uses separate formulas for calculating the prices of prescription-only medicines and over-the-counter medicines.

A new Government Decree on the Price List of Drugs was issued in 2014. This decree adjusted the principles of calculating the retail prices of prescription-only medicines, reducing the prices of the most expensive prescription-only medicines and increasing the prices at the lower end of the price range. In addition, the processing fee charged by pharmacies increased from EUR 0.43 to EUR 2.39



(inclusive of VAT). The goal of this reform was, for example, to guarantee the continued availability of medicines throughout the country and ensure that pharmacies have sufficient resources for expert tasks and statutory medication counselling. The changes made to the price list of drugs were anticipated to cut the cost of reimbursement payments made under the Health Insurance Scheme. The savings generated in this way made it possible to reduce the patients' annual deductible, i.e. the maximum limit on annual out-of-pocket medicine expenses, in 2014.

The price list of drugs was adjusted in 2015 in connection with the implementation of real-time transmission of data relating to dose-dispensed medicines. To prevent the total costs of the dosage service fees from exceeding the amount the customer needs to pay for each three-month supply of dose-dispensed medicines, the Government Decree on the Price List of Drugs was amended to include a processing fee for each transaction involving dose-dispensed medicines. The fee is EUR 0.20 (inclusive of VAT) for each new week of treatment. This amounts to 1/12 of the processing fee for a three-month supply of medicine.

Reference Price System

A reference price system was introduced in Finland in 2009 to complement generic substitution, which had started in 2003. Under the reference price system, substitutable medicinal products that contain the same active ingredient and are biologically equivalent are grouped together in the same reference price group. The reference price groups are based on the list of substitutable medicinal products compiled by the Finnish Medicines Agency Fimea. The reference price groups, and the reference price for each group, must be confirmed by the Pharmaceuticals Pricing Board. As of 1 January 2017, the reference price is calculated by adding EUR 0.50 to the price of the most inexpensive product within the group. The reference price is the maximum price used as the basis for calculating reimbursement payments. If the medicine purchased is less expensive than the reference price, reimbursement is calculated from the medicine's purchase price. If a customer does not wish to change the prescribed medicine to an alternative at or below the reference price, the cost in excess of the reference price, in addition to the non-reimbursable portion of the medicine cost, is paid by the customer. The cost in excess of the reference price will not count towards the annual deductible (see Annual deductible). The prescribing physician may only forbid substitution on medical and therapeutic grounds. In that event, the reimbursement to the customer is calculated from the retail price of the medicine.

Drugs in the Basic Refund Category

Forty per cent of the purchase price or reference price (including the pharmacy's processing fee charged for each transaction) of a medicinal product belonging to the Basic Refund Category is reimbursed to the patient. As a general rule, reimbursement for a medicinal product in the Basic Refund Category is paid to all individuals covered by the Finnish Health Insurance Scheme. Decisions relating to medicinal products eligible for reimbursement under the Basic Refund Category are made by the Pharmaceuticals Pricing Board. A medicinal product for the treatment of a disease can only be granted basic reimbursement status to the extent defined in its Summary of Product Characteristics and for the therapeutic indications listed therein. The Pharmaceuticals Pricing Board also has the authority to restrict the basic reimbursement status of certain medicinal products to clearly defined indications. These products form a group known as Medicinal Products Eligible for Restricted Basic Refund, and they will only generate the Basic Refund if the need for such medication can be proved by providing a separate statement, as specified by Kela. The separate statement can either be in the form of a Medical Certificate B or an addendum to the prescription sheet. The reason for creating the sub-group was to target and limit the payment of the Basic Refund to patients who, based on existing knowledge and scientific evidence, are likely to gain most from these costly treatments.

Drugs in the Special Refund Categories

The provisions on diseases that entitle medicinal products used in their treatment to be included in the Special Refund Categories are given by Government decree. The Higher Special Refund Category consists of diseases that are, according to medical criteria, considered to be serious and chronic and where drug treatment is necessary for the patient and where the drug restores or replaces normal bodily functions. Insulin treatment for diabetes mellitus and drugs used to treat malignant diseases are examples of drugs belonging to the Higher Special Refund Category. The purchase price or reference price of a medicinal product is reimbursed to the patient in full (100%), including the pharmacy's processing fee charged for each transaction. The patient pays a non-reimbursable sum of EUR 4.50 per transaction for each medicinal product in the Higher Special Refund Category. In addition, the patient will also pay any part of the medicine price exceeding the reference price.

The Lower Special Refund Category consists of diseases that are, according to medical criteria, considered to be serious and chronic. The most common diseases in this group are hypertension, asthma, coronary heart disease and, since 1 January 2017, also diabetes (other than insulin treatment). Sixty-five per cent of the purchase price or reference price (including the pharmacy's processing fee charged for each transaction) of a medicinal



product belonging to the Lower Special Refund Category is reimbursed to the patient.

Decisions relating to medicinal products eligible for reimbursement under the Special Refund Categories are made by the Pharmaceuticals Pricing Board. Special reimbursement status may be granted for a medicinal product that is indicated for the treatment of serious or chronic diseases, which are defined by Government decree. The Pharmaceuticals Pricing Board may also restrict the special reimbursement status of a medicinal product to certain forms or grades of the disease. In such a case the product is eligible for Restricted Special Refund.

Drugs in the Special Refund Categories are only reimbursed if the need for medication can be proved by providing a separate statement, as specified by Kela. The separate statement shall always be in the form of a Medical Certificate B. For certain medicinal products, an addendum to the prescription sheet is also needed.

Clinical nutritional preparations

Either 40% or 65% of the cost of a clinical nutritional preparation, prescribed for the treatment of a serious disease, is reimbursed to the patient, provided that the preparation is used to replace or augment, either fully or partially, the patient's diet. Decisions relating to the reimbursement status of clinical nutritional preparations are made by the

Pharmaceuticals Pricing Board. The reimbursement status may be granted for a nutritional preparation used for the treatment of serious or chronic diseases, which are defined by Government decree. Clinical nutritional preparations are only reimbursed if the need for medication can be proved by providing a separate statement, as specified by Kela. In the case of clinical nutritional preparations, the required statement is in the form of a Medical Certificate B.

Initial deductible

A calendar year-specific initial deductible was introduced at the start of 2016. Reimbursement under the medicine reimbursement system is not paid until the sum paid by the customer exceeds the initial deductible, which is EUR 50. Reimbursable medicines, clinical nutritional preparations and basic topical ointments purchased on prescription count towards the initial deductible. The initial deductible is not applicable to children and youth. It is applicable from the beginning of the year during which one turns 19.

Both pharmacies and Kela have real-time data on the amount of each customer's initial deductible. Once the initial deductible is met, the reimbursement is refunded to the customer directly at the pharmacy. The initial deductible counts towards the annual deductible (maximum limit on annual out-of-pocket medicine expenses).

Annual deductible (maximum annual limit on out-of-pocket medicine expenses)

If the total amount spent by the customer on reimbursable medicines, basic topical ointments and clinical nutritional preparations exceeds the annual deductible (the maximum annual limit on out-of-pocket medicine expenses), the customer is entitled to an additional reimbursement. In 2020 the annual deductible was set at EUR 577,66. The cost-of-living index is used to review the limit annually. After the annual deductible is exceeded, the customer pays a fixed non-reimbursable sum of EUR 2.50 per transaction for each reimbursable medicinal product, basic topical ointment and clinical nutritional preparation purchased as well as any portion of the medicine's price exceeding the reference price. Additional Refunds are usually paid to the customers directly at the pharmacy, after the pharmacy has verified their eligibility for Additional Refunds with Kela's direct reimbursement inquiry service. Until 2019, customers claimed additional reimbursement from Kela for the part of the purchase exceeding the annual maximum. Since the beginning of 2020, customers have received the additional reimbursement in real time at the pharmacy also for purchases exceeding the annual maximum.

Dosage service

Dosage service, or dose dispensing service, refers to a service whereby patients receive up to a fortnight's supply of tablets or capsules from a pharmacy pre-packed into individual single doses. Pharmacies charge from the customer a dose-dispensing fee for the service, which is partially reimbursed by Kela to a specific group of customers in accordance with the Health Insurance Act (sairausvakuutuslaki 1224/2004). The customer is reimbursed 40% of the pharmacy's service fee. However, the maximum fee eligible for reimbursement per week is EUR 3.15. Patients over 75 years of age are entitled to this reimbursement provided that at the start of the service they use at least six reimbursable medicinal products suitable for the dosage service. Moreover, the patient's medication needs to be reviewed in order to eliminate any unnecessary or overlapping medication. The treating physician must also consider the dosage service to be medically justified for the patient.

**Table 5.1. Reimbursement numbers adopted in 2020, basic reimbursement**

Number and name	Disease	Valid from
3020. Patiomer	Hyperkalemia	01/01/2020
3021. Ketoconazole	Cushing's syndrome	01/01/2020
3022. Liraglutide (children and adolescents)	Type 2 diabetes	01/02/2020
3023. Birch allergen extract (adults)	Allergic rhinitis and conjunctivitis	01/02/2020
3024. Dabrafenib and trametinib	Melanoma	01/02/2020 ¹
3025. Calcium carbonate	Chronic vitamin D metabolism disorder and hypoparathyroidism	01/03/2020
3026. Lorlatinib	Lung cancer	01/04/2020
3027. Benralizumab	Asthma	01/05/2020
3028. Mepolizumab	Asthma	01/06/2020
3029. Upadacitinib	Rheumatoid arthritis	01/07/2020
3030. Abemaciclib	Breast cancer	01/07/2020
3031. Apalutamide	Prostate cancer	01/08/2020
3032. Budesonide tablet, orodispersible	Eosinophilic esophagitis	01/11/2020
3033. Gilteritinib	Acute myeloid leukaemia	01/11/2020
3034. Larotrectinib	Solid tumours	01/11/2020
3035. Pitolisant	Narcolepsy	01/11/2020
3036. Darolutamide	Prostate cancer	01/12/2020
3037. Neratinib	Breast cancer	01/12/2020
3038. Romiplostim	Immune thrombocytopenic purpura (ITP)	01/12/2020
3039. Eltrombopag	Immune thrombocytopenic purpura (ITP) and aplastic anaemia	01/12/2020
Letemovir (Addendum to the prescription)	Prevention of cytomegalovirus (CMV) reactivation and infection	01/08/2020

¹ Until 31/01/2020, dabrafenib and trametinib were eligible for the basic reimbursement under reimbursement number 362, but as of 01/02/2020 they were assigned a new number. Vemurafenib is still eligible for the basic reimbursement under reimbursement number 362.

Table 5.2. Reimbursement numbers discontinued in 2020, basic reimbursement

Number and name	Disease	Valid from
371. Insulin degludec	Type 1 diabetes	01/03/2020
382. Insulin glargine 300 U/ml	Type 1 and type 2 diabetes	01/03/2020

Eligibility for reimbursements was discontinued as redundant. Preparations for which reimbursement numbers 371 and 383 were created are eligible for basic reimbursement when prescribed for the treatment of a disease.

**Table 5.3. Reimbursement numbers adopted in 2020, special reimbursement**

Number and name	Disease	Valid from
1507. Pomalidomide	Multiple myeloma	01/02/2020
1508. Lenvatinib	Thyroid and liver cancer	01/02/2020
1509. Dabrafenib and trametinib	Melanoma	01/02/2020 ¹
1510. Niraparib	Ovarian cancer, fallopian tube cancer and peritoneal cancer	01/03/2020
1511. Olaparib	Ovarian cancer, fallopian tube cancer and peritoneal cancer	01/03/2020
1512. Ibrutinib	Chronic lymphocytic leukaemia, mantle cell lymphoma and waldenström macroglobulinaemia	01/03/2020
1513. Binimetinib and encorafenib	Melanoma	01/07/2020
1514. Ribociclib	Breast cancer	01/10/2020
1515. Abemaciclib	Breast cancer	01/12/2020
1516. Romiplostim	Immune thrombocytopenic purpura (ITP)	01/12/2020
1517. Eltrombopag	Immune thrombocytopenic purpura (ITP) and aplastic anaemia	01/12/2020
1518. Venetoclax	Chronic lymphatic leukaemia	01/12/2020
294. Alirocumab and evolocumab in the treatment of hypercholesterolaemia and mixed dyslipidaemia	Hypercholesterolaemia and mixed dyslipidaemia associated with chronic coronary artery disease	01/03/2020
295. Liraglutide (children and adolescents)	Type 2 diabetes	01/02/2020
296. Rivaroxaban in the treatment of coronary artery disease	Chronic coronary artery disease	01/08/2020
Rivaroxaban in acute coronary syndrome (Addendum to the prescription)	Chronic coronary artery disease	01/08/2020

¹ Until 31/01/2020, dabrafenib and trametinib were eligible for special reimbursement under reimbursement number 167, but as of 01/02/2020 they were assigned a new number. Vemurafenib is still eligible for special reimbursement under reimbursement number 167.

Table 5.4. Reimbursement numbers discontinued in 2020, special reimbursement

Number and name	Disease	Valid from
171. Insulin degludec	Type 1 diabetes	01/03/2020
177. Insulin glargine 300 U/ml	Type 1 and type 2 diabetes	01/03/2020
127. + Addendum to the prescription Tacrolimus ointment	Sequelae of organ or tissue transplantation	01/07/2020

Eligibility for reimbursements was discontinued as redundant. Preparations for which reimbursement numbers 171 and 177 were created are eligible for special reimbursement under reimbursement number 103.

Tacrolimus ointment is eligible for special reimbursement under reimbursement number 127.

In addition, as of 01/11/2020, growth hormone has been eligible for special reimbursement for growth disorders in children with anterior hypopituitarism and renal failure under reimbursement number 186. Growth hormone (somatropin) used in the treatment of growth disorder due to anterior hypopituitarism, was eligible for reimbursement under reimbursement number 101.

**Table 5.5. Medicines added to existing reimbursement numbers in 2020, basic reimbursement**

Number	Medicinal agent	Disease	Added as of
319.	Risankizumab	Skin psoriasis	01/01/2020
3007.	Fremanezumab	Prevention of migraine	01/02/2020
3007.	Galcanezumab	Prevention of migraine	01/10/2020



Table 5.6. Medicines added to existing reimbursement numbers in 2020, special reimbursement

Number	Medicinal agent	Disease	Added as of
164.	Cladribine	Multiple sclerosis	01/10/2020
190.	Sucroferric oxyhydroxide	Chronic vitamin d metabolism disorder	01/03/2020
285.	Semaglutide	Type 2 diabetes	01/02/2020
292.	Alirocumab	Familial hypercholesterolaemia	01/03/2020

As of 1 July 2020, Modafinil has been eligible for special reimbursement under reimbursement number 214. Previously it was eligible for special reimbursement under reimbursement number 282. Sodium oxybate is still eligible for special reimbursement under reimbursement number 282.



Reimbursements for medicine expenses in 2020

EUR 0 Initial deductible	EUR 50 Reimbursement for medicine expenses			EUR 577.66 Additional reimbursement						
<p>Customers pay full price for medicines covered by the reimbursement system up to 50 euros. Persons under 19 are exempt from the initial deductible.</p> 	<p>Once the customer has reached the initial deductible limit, the pharmacy will deduct the reimbursement from the price of purchased medicines. The rate of reimbursement depends on the specific medicine and illness.</p> <table border="0"> <tr> <td data-bbox="822 628 1162 686">Basic rate of reimbursement</td> <td data-bbox="1167 628 1507 686">Lower special rate of reimbursement</td> <td data-bbox="1512 628 1841 686">Higher special rate of reimbursement</td> </tr> <tr> <td data-bbox="822 708 1162 782"></td> <td data-bbox="1167 708 1507 782"></td> <td data-bbox="1512 708 1841 782"></td> </tr> </table>			Basic rate of reimbursement	Lower special rate of reimbursement	Higher special rate of reimbursement				<p>Customers' out-of-pocket payments and the initial deductible count towards an annual maximum limit on medicine expenses. Once customers exceed the annual maximum limit, they are entitled to an additional reimbursement.</p> 
Basic rate of reimbursement	Lower special rate of reimbursement	Higher special rate of reimbursement								
<p>Rate of reimbursement per medicine and per purchase 0%</p> <p>Customer's out-of-pocket share per medicine and per purchase 100%</p>	<p>40%</p> <p>60%</p>	<p>65%</p> <p>35%</p>	<p>100%</p> <p>EUR 4.50 (copayment)</p>	<p>100%</p> <p>EUR 2.50 (copayment)</p>						

Calendar year



Table 5.7. Medicine costs and their reimbursement in 2020

Costs of reimbursed medicines¹

	EUR 1,000
Total cost	2,168,295
Basic Refund Category (40%) ²	631,453
Restricted Basic Refund Category (40%)	170,820
Higher Special Refund Category (100%)	720,306
Lower Special Refund Category (65%)	644,233

Reimbursement of medicine costs

	EUR 1,000
Total reimbursements ³	1,634,903
Basic Refund Category (40%) ²	240,644
Restricted Basic Refund Category (40%)	67,810
Higher Special Refund Category (100%)	700,049
Lower Special Refund Category (65%)	408,750

Number of recipients of reimbursement

	Recipients
Total	2,953,465
Basic Refund Category (40%) ²	2,830,793
Restricted Basic Refund Category (40%)	88,891
Higher Special Refund Category (100%)	498,400
Lower Special Refund Category (65%)	988,705


1 The figures do not include purchases that did not clear the initial deductible limit.

2 Purchases of medicines eligible for restricted basic refund not included.

3 Includes reimbursements for dosage service charges and Additional Refunds.

Source: Register of Statistical Information on National Health Insurance General Benefit Payments.

Figure 5.1. Reimbursement of medicine costs in 2000–2020 according to Refund Category



Source: Register of Statistical Information on National Health Insurance General Benefit Payments.



Reimbursable medicines, confirming wholesale prices and the reference price system

Kaarina Koskela, Lawyer, Pharmaceuticals Pricing Board

Ulla Kurkijärvi, Principal Pharmaceutical Officer, Pharmaceuticals Pricing Board

A pharmaceutical company can introduce a medicinal product onto the market and make it available to consumers after marketing authorisation has been granted. The inclusion of a medicinal product into the system of medicine reimbursement under the Health Insurance Scheme requires a decision by the Pharmaceuticals Pricing Board, which operates under the auspices of the Ministry of Social Affairs and Health. The product is included in the reimbursement system after its reimbursement status and wholesale price have been approved.

The role of the Pharmaceuticals Pricing Board as a decision-maker

The task of the Pharmaceuticals Pricing Board is to decide which medicinal products are to be included in the reimbursement system and confirm their wholesale prices and refund categories. The Pricing Board also makes decisions regarding wholesale price increases of reimbursable medicines. The decisions are based on applications submitted by Marketing Authorisation Holders. Moreover, the

Pricing Board makes decisions relating to the reference price system, including decisions regarding the reference price groups, reference prices and the products to be included in the reference price groups.

The Pharmaceuticals Pricing Board consists of seven members and their deputies nominated by the Ministry of Social Affairs and Health. The Board members represent the Ministry of Social Affairs and Health, the Social Insurance Institution of Finland (Kela), the Finnish Medicines Agency Fimea, the National Institute for Health and Welfare and the Ministry of Finance. The Board members must cover medical, pharmaceutical, legal and economic expertise. The Pharmaceuticals Pricing Board works closely with a group of experts and the Board's Secretariat. Cases are presented at the Board meetings by the Chief Pharmaceutical Officers and Pharmaceutical Officers of the Board's Secretariat. The group of experts linked to the Pricing Board consists of seven members and their personal deputies, and it comprises experts from the fields of medicine, pharmacology and health insurance. The presenting official of the group of experts is the Senior Medical Officer of the Board's Secretariat.

The decision is based on the application process, and the decision must be issued within a set time period. The application process is based on the provisions laid down in the Health Insurance Act (sairausvakuutuslaki 1224/2004) and the Administrative Procedure Act (hallintolaki 434/2003). In certain circumstances, as provided in the Health Insurance Act, the Pricing Board may decide to review both the reimbursability and wholesale price of a medicinal product on their own initiative.

A decision issued by the Pharmaceuticals Pricing Board regarding the reimbursement status and reasonable wholesale price of a medicinal product containing a new active substance is valid for up to three years. Decisions regarding all other products are valid for up to five years. Decisions regarding the reimbursement status and maximum wholesale price of products to be included in the reference price system are valid for an indefinite period. The applicant retains the right to appeal against the decisions to the Supreme Administrative Court.

Inclusion of a medicinal product into the reimbursement system

Medicinal products included in the reimbursement system are subject to price regulation. The inclusion of a product into the reimbursement system requires a decision which approves both the reimbursement status of the product and its wholesale price. A medicinal product with a valid marketing authorisation may be marketed in Finland without its wholesale price having been confirmed by the authorities. However, reimbursement for the cost of the medicinal product can only be paid under the Health Insurance Act if the Pharmaceuticals Pricing Board has approved the product for reimbursement and confirmed its wholesale price. A confirmed wholesale price refers to the maximum price at which the product may be sold to pharmacies. The actual reimbursement payment is based on the retail price (inclusive of VAT), which cannot be higher than the confirmed wholesale price plus the pharmacy's profit margin (Table 5.8.) at the rate prescribed by the Government Decree on the Price List of Drugs (713/2013) and VAT (10%).



The medicine cost will remain fully payable by the patient if the Marketing Authorisation Holder fails to apply for reimbursement status and wholesale price for the product, or if the product's reimbursement status and wholesale price proposed by the Marketing Authorisation Holder have not been approved. Likewise, the cost remains payable by the patient if the Marketing Authorisation Holder has removed the product from the list of reimbursable medicines, or if its reimbursement status and wholesale price have been removed. The removal of a medicine from the reimbursement system by the Marketing Authorisation Holder is possible on a quarterly basis.

Basic reimbursement status and reasonable wholesale price

An application for basic reimbursement status and wholesale price is submitted by the Marketing Authorisation Holder. The application must include, in addition to the proposed wholesale prices, a well-grounded evaluation of the benefits and costs incurred should the product be included in the reimbursement system with the proposed prices. Applications for reimbursement status and wholesale price are processed simultaneously by the Pharmaceuticals Pricing Board.

The application must include a statement on the intended use and therapeutic value of the medicinal product and the benefits expected to be gained with reimbursement status as compared with other medicinal products used to treat the same illness. The application must also include a detailed and well-grounded statement regarding the average daily dose and the cost of the drug treatment based on this dose. Moreover, the application must include the validity period of the pharmaceutical patent or the supplementary protection certificate, an estimate of the sales volume and number of users of the product as well as the approved prices and grounds for reimbursement of the product in other EEA countries. The application is also to include any other trade names under which the product is marketed in other EEA countries, and the respective prices. Applications must contain a health economic evaluation, if the medicinal product contains a new active substance or the reimbursement status is going to be significantly extended.

A renewal application submitted by the Marketing Authorisation Holder shall contain a description of the changes to the aspects affecting the reasonableness of the wholesale price if a higher wholesale price than the previously confirmed wholesale price is being proposed for the product.

Before reaching decisions regarding basic reimbursement status and a reasonable wholesale price, the Pricing Board may request that Kela submit a statement, if necessary. In the statement, Kela will assess whether the criteria for granting reimbursement status are fulfilled and evaluate the reasonableness of the proposed price in terms of the Health Insurance Scheme. The statement will also include an estimate of the cost effect of the product on the Health Insurance Scheme. The Pricing Board may also request an opinion from the expert group before making a decision, for example, in case a pharmaceutical company is applying for basic reimbursement status for a product containing a new active substance or if the reimbursement status of a medicine is extended to a new indication.

When deciding about basic reimbursement status, the Pharmaceuticals Pricing Board assesses the therapeutic value of the product. A medicinal product for the treatment of an illness can only be granted basic reimbursement status to the extent defined in its Summary of Product Characteristics and for indications listed therein. The Summary of Product Characteristics must be approved by the marketing authorisation authorities. A medicinal product is not considered eligible for reimbursement under the Basic Refund Category if, for

example, the therapeutic value of the product is not considered significant or if the product is used for purposes other than the treatment of an illness. The Pharmaceuticals Pricing Board also has the authority to restrict, when necessary, the eligibility for basic reimbursement to clearly defined indications (Medicinal Products Eligible for Restricted Basic Refund).

An over-the-counter product may be granted basic reimbursement status only if the product is considered, on medical grounds, to be an indispensable medicinal product.

When considering the reasonableness of the proposed wholesale price, the Pharmaceuticals Pricing Board takes into account the cost of the drug therapy and the benefits to be gained from its use as regards both the patient and the overall health care and social costs. The Pricing Board will also consider the benefits and costs of treatment alternatives, the prices of comparable medicinal products in Finland, the price of the medicine in question in other EEA countries as well as the funds available for reimbursement payments. It is also possible to consider manufacturing, research and development costs in the decision-making, provided that sufficiently detailed, comparable and reliable product-specific data relating to these costs have been submitted.



The wholesale price confirmed for a first generic alternative can be a maximum of 50 per cent of the confirmed wholesale price of the corresponding product, and for a first biosimilar product, a maximum of 70 per cent of the confirmed wholesale price of the corresponding product. For a generic alternative including a new dose dispensing device, the confirmed wholesale price can be a maximum of 60 per cent of the confirmed wholesale price of the corresponding product.

The use of new medicines is often shadowed by uncertainty about the overall costs, cost effects and therapeutic value. In Finland, a new method to control this uncertainty, the so-called provisional reimbursement status, has been launched. The possibility of being granted provisional reimbursement status primarily concerns new medicinal therapies. In practice, this refers to new active pharmaceutical products already included in the reimbursement system. The Pharmaceuticals Pricing Board will assess the preconditions for initiating negotiations concerning provisional reimbursement status on a case by case basis. While the negotiations are underway, the processing time of the relevant application is suspended. If the negotiations end up with a positive result, the final decision will be accompanied by an agreement between the

Marketing Authorisation Holder and the Pharmaceuticals Pricing Board concerning the terms and conditions for the monitoring and management of the uncertainty linked with the product. If no agreement is reached through negotiations, the processing of the application will continue as a normal application procedure. The regulations concerning the provisional reimbursement status are valid for a fixed period, until the end of 2025.

Special reimbursement status and reasonable wholesale price

Certain medicines that are used to treat serious and chronic illnesses are eligible for reimbursement payments under the Special Refund Categories. Medicinal products granted special reimbursement status attract higher reimbursement payments than those granted basic reimbursement status. The illnesses that make medicinal products used in their treatment eligible for inclusion in the Special Refund Categories are decided by the Finnish Government. The Pharmaceuticals Pricing Board decides which medicinal products are to be granted special reimbursement status; these decisions are product-specific. In order to qualify for special reimbursement status the medicinal product must be used to treat an illness defined by Government decree, and it must be deemed necessary in the treatment of a serious and chronic illness.

The application for special reimbursement status, submitted by the Marketing Authorisation Holder, must demonstrate that the product fulfils the criteria for special reimbursement status. Moreover, the application must include a statement regarding the cost-effectiveness of special reimbursement status and a market forecast which takes into account competing products. The application must also include an evaluation of the envisaged cost effects following the granting of special reimbursement status.

When making decisions on special reimbursement status, the Pharmaceuticals Pricing Board will consider the nature of the illness and the therapeutic value, indispensability, replacement or remedial effects, necessity and cost-effectiveness of the medicine as proven in clinical practice and by research, as well as the funds available for special reimbursement payments. The Board also has the opinions of both the group of experts and Kela at its disposal.

A medicinal product may be granted special reimbursement status if it is already included in the Basic Refund Category, and if sufficient clinical experience and research data are available on the product meeting the criteria for special reimbursement (therapeutic value, usefulness in comparison with treatment alternatives, indispensability,

replacement or remedial effects, necessity and cost-effectiveness). The special reimbursement status of a medicinal product can also be restricted to certain forms or grades of the disease. With an application for special reimbursement status, the reasonableness of the price is always reassessed.

Reference Price System

Under the reference price system, reimbursement for a medicinal product is calculated from a reference price, which is determined separately. If the medicine purchased is more expensive than the reference price, and the patient declines substitution, the cost in excess of the reference price is paid by the patient. Reimbursement under the Health Insurance Scheme can only be paid for the price of a medicine that exceeds the reference price if the prescribing physician forbids substitution on medical or therapeutic grounds.

Under the reference price system, medicines are divided into reference price groups. The reference price groups are based on the list of substitutable medicinal products compiled by the Finnish Medicines Agency Fimea. Medicinal products with a corresponding pharmaceutical form and pack size and which contain equal amounts of the same active substance are grouped together in the same reference price group. Products grouped in the same reference price group are interchangeable with each other.



Reference prices are based on the retail price of the medicinal products (inclusive of VAT), and they are updated every three months on the basis of price notifications submitted to the Pharmaceuticals Pricing Board by Marketing Authorisation Holders. A reference price is calculated from the least expensive product within the group by adding EUR 0.50 to its retail price (inclusive of VAT).

In December 2020, more than a half (65%) of all reimbursable medicinal product packages with marketing authorisation were included in the reference price system.

Reimbursement status and maximum wholesale price in the reference price system

The application process applied under the reference price system entails the Pharmaceuticals Pricing Board confirming the reimbursement status and maximum wholesale price for a new product to be included in the system. The Marketing Authorisation Holder must apply for reimbursement status for a new medicinal product under the reference price system, if the product is eligible for generic substitution and other corresponding products marketed are already included in the reference price system.

The application process in the reference price system places the Marketing Authorisation Holder under an obligation to provide the same documentation, as far as is appropriate, as described above for applications regarding basic and special reimbursement status. The application must also include a proposal for the maximum wholesale price of the product.

The confirmed maximum wholesale price must not exceed the price level of corresponding products. The maximum wholesale price refers to the maximum price at which the product may be sold to pharmacies. When deciding on the reimbursement status of medicinal products to be included in the reference price system the Pharmaceuticals Pricing Board considers corresponding matters as described above for decisions concerning basic and special reimbursement status.

Matters regarding reimbursement status and price processed in 2020

In 2020, the Pharmaceuticals Pricing Board processed 883 applications for reimbursement status and price (Table 5.10.). The majority of these applications, i.e., 93.4%, were approved, 3.4% were rejected and 3.2% were withdrawn. The applications processed by the Board refer to a specific product.

The renewal of reimbursement status and wholesale price approved for a fixed period was the most common type of application. There were 436 renewal applications, and 418 of these applications were approved, 8 were rejected and 10 withdrawn. A total of 33 applications for reimbursement status relating to the reference price system were processed.

There were a total of 56 applications for reimbursement status and price concerning a new active substance or other new pharmaceutical product; 31 of these applications were applications for basic reimbursement status and price, and 25 for special reimbursement status and price. Of the applications for basic reimbursement status and price, 20 were approved, and 23 applications for special reimbursement status and price were approved. During 2020, a total of 16 new active substances were included in the reimbursement system, and 19 new active substances were granted special reimbursement status (Table 5.9.).

Time taken to process an application

The Pharmaceuticals Pricing Board is under an obligation to issue its decisions on applications within a set time period. A decision regarding reimbursement status and wholesale price must be issued to the applicant within 180 days of receipt of the application. Should the information supporting the application be insufficient, the Board may suspend the application process until the applicant has provided the required information. If necessary, the Director may intervene. The final decision must be issued to the applicant within 180 days of the receipt of the requested additional information. Should the decision be made regard only an increase of a previously confirmed wholesale price, and not the reimbursement status of the medicinal product, the decision must be issued to the applicant within 90 days of receipt of the application. When the number of applications for price increases is exceptionally high, the Board may extend the process time by 60 days.

The decision issued by the Pharmaceuticals Pricing Board will enter into force at the beginning of the second calendar month following the issue date, unless otherwise specified in the decision.



The average processing times of applications in 2020 are presented in Table 5.11. The applications are grouped according to the type of application. The median time taken to reach a positive decision ranged from 8 to 143 days, and that of a negative decision from 122 to 167 days depending on the type of application. The median time to reach a positive decision on an application for basic reimbursement status and price concerning a new active substance was 119 days, whereas the median time taken to reach a negative decision was 153 days. The median time to reach a positive decision on an application for special reimbursement status and price concerning a new active substance was 85 days and the median time taken to reach a negative decision was 167 days. Issuing a decision may be preceded by several requests to the applicant for detailed additional information to support the application. Moreover, in order to make an assessment the Board may request the opinion of relevant specialists, and in certain cases also hear evidence from the applicant. It is also possible for the applicant to request the processing of the application to be suspended.

The Pharmaceuticals Pricing Board is able to transfer the decision-making directly to the Director of the Board in cases where the application refers to a new strength of the medicinal product, generic alternatives, biosimilars, parallel imports, a new pack size or a new pharmaceutical form. Decisions regarding products in the reference price system may also be transferred to the Director. The processing times of decisions issued by the Director are usually considerably shorter.

**Table 5.8. Calculation formula for retail prices, without VAT, of medicinal products in 2020****Prescription medicine**

Wholesale price euros	Retail price
- 9.25	1.45 x wholesale price
9.26 - 46.25	1.35 x wholesale price + 0.92 euro
46.26 - 100.91	1.25 x wholesale price + 5.54 euro
100.92 - 420.47	1.15 x wholesale price + 15.63 euro
420.48 -	1.1 x wholesale price + 36.65 euro

Over the counter medicine

Wholesale price euros	Retail price
- 9.25	1.5 x wholesale price + 0.50 euro
9.26 - 46.25	1.4 x wholesale price + 1.43 euro
46.26 - 100.91	1.3 x wholesale price + 6.05 euro
100.92 - 420.47	1.2 x wholesale price + 16.15 euro
420.48 -	1.125 x wholesale price + 47.68 euro

Source: Government Decree on the Price List of Drugs (713/2013).

Table 5.9. New active substances in 2020

Basic reimbursement, approved	Special reimbursement, approved	Basic reimbursement, rejected	Special reimbursement, rejected
Abemaciclib	Abemaciclib	Esketamine	Brigatinib
Apalutamide	Alirocumab	Ivacaftor	
Benralizumab	Binimetinib	Ivacaftor and lumacaftor	
Burosumab	Brexpiprazole	Ivacaftor and tezacaftor	
Dacomitinib	Damoctocog alfa pegol	Opicapone	
Darolutamide	Encorafenib	Siponimod	
Galcanezumab	Ertugliflozin	Talazoparib	
Gilteritinib	Ibrutinib	Trientine	
Larotrectinib	Cariprazine		
Letemovir	Cladribine		
Lorlatinib	Mepolizumab		
Mepolizumab	Niraparib		
Neratinib	Nonacog beta pegol		
Pitolisant	Olaparib		
Upadacitinib	Ribociclib		
Vedolizumab	Sucroferric oxyhydroxide		
	Upadacitinib		
	Venetoclax		
	Vortioxetine		

Source: Pharmaceuticals Pricing Board.

Table 5.10. Number of applications for reasonable wholesale prices and reimbursement status processed by the Pharmaceuticals Pricing Board in 2020¹

Type of application	Approved	Rejected	Withdrawn
Applications for reimbursement status and price	825	30	28
Medicinal products with marketing authorization	718	22	13
New active substance or other new product, basic reimbursement status	20	10	1
New active substance or other new product, special reimbursement status	23	1	1
New combination of active substances	3	–	–
New pharmaceutical form	5	–	–
New strength	21	–	1
New package size/form	51	–	–
Expansion of reimbursement status	31	3	–
Generic product	25	–	–
Parallel import	84	–	–
Biosimilar	3	–	–
Reimbursement status in reference price system	33	–	–
Price increase application	1	–	–
Renewal of a price and reimbursement status approved for a fixed-period	418	8	10
Clinical nutritional preparations²	12	–	–
Basic topical ointments	4	–	1
Non-registered medicinal products	91	8	14

1 Each application includes all reimbursement categories and subsequent strengths, pharmaceutical forms and package sizes.

2 Includes products belonging to refund categories of 40% and 65%.


Source: Pharmaceuticals Pricing Board.

Table 5.11. Median process times of applications (number of days) approved or rejected by the Pharmaceuticals Pricing Board, according to the type of application, in 2020

Type of application	Approved	Rejected
Applications for reimbursement status and price		
Medicinal products with marketing authorization		
New active substance or other new product, basic reimbursement status	119	153
New active substance or other new product, special reimbursement status	85	167
New combination of active substances	121	–
New pharmaceutical form	143	–
New strength	20	–
New package size/form	8	–
Expansion of reimbursement status	128	122
Generic product	33	–
Parallel import	21	–
Biosimilar	29	–
Reimbursement status in reference price system	23	–
Price increase	47	–
Renewal of a price and reimbursement status approved for a fixed-period	129	162

Source: Pharmaceuticals Pricing Board.

6. Tables: Reimbursement of medicine costs





Medicine costs and their reimbursement annually and according to hospital district

Table 6.1. Medicine costs and their reimbursement in 2005–2020

All refunds¹

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	3,261,540	62.1	1,076,908	1,598,998	20,872	28,796
2006	3,584,719	67.9	1,100,344	1,588,395	24,583	32,801
2007	3,674,582	69.3	1,142,074	1,638,996	26,417	35,061
2008	3,723,521	69.9	1,242,879	1,744,381	27,515	36,781
2009	3,756,438	70.2	1,244,758	1,768,848	28,890	39,208
2010	3,801,154	70.7	1,225,445	1,719,013	29,255	39,889
2011	3,855,198	71.4	1,262,066	1,753,506	29,646	40,588
2012	3,866,724	71.2	1,303,129	1,812,241	30,267	41,608
2013	3,829,177	70.2	1,273,049	1,811,263	29,574	40,317
2014	3,843,226	70.2	1,306,453	1,860,024	29,945	40,687
2015	3,811,748	69.4	1,377,934	1,948,772	31,268	43,991
2016	3,136,095	56.9	1,411,990	1,947,443	28,033	40,506
2017	3,036,110	55.0	1,386,661	1,938,802	28,758	41,844
2018	3,034,776	54.9	1,460,140	2,003,219	29,482	43,400
2019	3,042,434	54.9	1,550,985	2,088,902	30,376	45,198
2020	2,953,465	53.3	1,634,903	2,168,295	29,972	46,123

1 Includes reimbursements for dosage service charges and Additional Refunds.

2 The figures do not include purchases that did not clear the initial deductible limit.

Basic Refund Category

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	3,100,214	59.0	369,861	879,037	14,216	19,635
2006	3,465,440	65.7	366,551	870,280	17,591	23,459
2007	3,563,435	67.2	368,732	877,974	19,114	25,422
2008	3,619,457	68.0	395,494	941,888	20,009	26,924
2009	3,659,959	68.4	402,717	963,650	21,121	29,049
2010	3,705,813	68.9	377,545	908,516	21,347	29,568
2011	3,760,290	69.6	357,149	860,191	21,600	30,048
2012	3,771,227	69.5	354,338	852,663	22,041	30,860
2013	3,729,090	68.4	297,673	827,010	21,356	29,678
2014	3,740,015	68.3	298,518	859,694	21,575	29,916
2015	3,709,187	67.6	310,080	891,529	22,302	32,104
2016	3,022,273	54.9	316,104	837,187	19,097	28,467
2017	2,925,270	53.0	318,145	831,281	19,560	29,171
2018	2,925,818	52.9	307,056	802,044	19,787	29,864
2019	2,934,104	53.0	316,354	822,783	20,222	30,870
2020	2,839,771	51.3	308,455	802,273	19,642	31,183

Table continued



Table 6.1. continued

Higher Special Refund Category

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	454,512	8.6	370,102	380,498	2,098	2,738
2006	468,291	8.9	393,324	402,305	2,223	2,820
2007	480,712	9.1	432,580	441,672	2,345	2,950
2008	497,121	9.3	465,619	474,945	2,427	3,029
2009	516,050	9.6	470,530	480,517	2,546	3,160
2010	535,762	10.0	498,984	509,989	2,673	3,313
2011	560,243	10.4	552,042	562,929	2,761	3,415
2012	581,985	10.7	595,277	606,765	2,920	3,602
2013	603,085	11.1	610,419	622,072	3,043	3,747
2014	619,292	11.3	620,592	632,746	3,175	3,896
2015	635,358	11.6	665,822	678,402	3,484	4,361
2016	637,262	11.6	696,153	720,456	3,577	4,547
2017	553,666	10.0	604,660	623,803	2,809	3,560
2018	489,952	8.9	626,444	645,522	2,795	3,548
2019	495,035	8.9	653,167	672,560	2,894	3,680
2020	498,400	9.0	700,049	720,306	2,954	3,792

Lower Special Refund Category

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	828,191	15.8	237,409	339,464	4,558	6,423
2006	833,665	15.8	226,380	315,580	4,769	6,521
2007	835,283	15.8	229,353	318,920	4,958	6,689
2008	842,503	15.8	235,011	326,833	5,080	6,828
2009	850,307	15.9	230,585	323,452	5,223	7,000
2010	851,717	15.8	210,117	298,539	5,235	7,008
2011	853,920	15.8	230,141	327,432	5,285	7,125
2012	851,478	15.7	246,897	348,884	5,306	7,146
2013	849,208	15.6	233,749	357,237	5,174	6,892
2014	844,440	15.4	235,018	365,194	5,195	6,875
2015	840,877	15.3	243,565	377,463	5,482	7,526
2016	831,193	15.1	245,711	388,649	5,359	7,493
2017	941,101	17.0	305,560	482,557	6,389	9,113
2018	962,071	17.4	352,231	554,415	6,900	9,988
2019	975,518	17.6	376,243	592,235	7,260	10,647
2020	988,705	17.8	408,750	644,233	7,376	11,147

1 Includes reimbursements for dosage service charges and Additional Refunds.

2 The figures do not include purchases that did not clear the initial deductible limit.

Source: Register of Statistical Information on National Health Insurance General Benefit Payments.

**Table 6.2. Medicine costs and their reimbursement according to hospital district, in 2020**

Hospital district	Recipients of reimbursement		Reimbursements		Total costs ¹		No. of dispensations ¹	
	Number of recipients	As a proportion of the population, %	EUR 1,000	EUR per recipient	EUR 1,000	EUR per recipient	In thousands	Per recipient
Whole country	2,953,463	53.3	1,634,650	553	2,166,811	734	46,123	16
Helsinki and Uusimaa	825,317	48.5	413,247	501	552,169	669	11,743	14
Southwest Finland	268,599	55.4	152,540	568	202,513	754	3,755	14
Satakunta	125,606	58.3	70,779	564	94,125	749	2,046	16
Kanta-Häme	96,948	56.7	58,500	603	76,573	790	1,583	16
Pirkanmaa	292,564	54.1	165,772	567	218,533	747	4,324	15
Päijät-Häme	116,798	55.7	66,166	567	87,952	753	1,963	17
Kymenlaakso	95,088	58.2	57,147	601	75,902	798	1,838	19
South Karelia	70,158	55.3	39,096	557	51,873	739	1,083	15
South Savo	59,051	60.5	35,319	598	47,169	799	1,000	17
Itä-Savo	24,733	62.0	13,785	557	18,587	752	408	17
North Karelia	95,216	58.2	54,381	571	72,532	762	1,783	19
North Savo	147,143	60.4	81,025	551	109,326	743	2,703	18
Central Finland	136,318	53.9	75,986	557	100,821	740	2,116	16
South Ostrobothnia	106,977	55.6	62,654	586	82,212	769	1,784	17
Vaasa	80,400	47.4	49,132	611	63,073	784	1,148	14
Central Ostrobothnia	41,011	53.1	23,645	577	31,053	757	708	17
North Ostrobothnia	213,523	51.9	124,407	583	162,273	760	3,575	17
Kainuu	42,734	59.6	23,593	552	31,575	739	774	18
Länsi-Pohja	33,106	55.5	18,554	560	24,584	743	544	16
Lapland	65,266	55.7	41,110	630	53,487	820	1,069	16
Åland	13,159	43.7	6,640	505	8,869	674	150	11

¹ The figures do not include purchases that did not clear the initial deductible limit.

Source: Register of Statistical Information on National Health Insurance General Benefit Payments.

Medicine costs and their reimbursement in diseases entitling patients to special refund

Table 6.3. Patients entitled to reimbursement under the Special Refund Categories, and cost of the diseases per recipient in 2020

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Anterior pituitary hypofunction (101)	4,802	3,342	1,460	1,546	1,618	1,386
Diabetes insipidus (102)	1,212	564	648	939	1,082	816
Diabetes, insulin-treated (103)	377,250	206,078	171,172	695	734	642
Thyroid insufficiency (104)	85,745	13,181	72,564	40	45	39
Adrenal cortical hypofunction (105)	1,537	571	966	139	149	133
Hypoparathyroidism (106)	2,232	381	1,851	250	340	230
Pernicious anaemia (107)	14,367	5,517	8,850	32	32	32
Myasthenia gravis (108)	1,645	750	895	428	402	450
Multiple sclerosis (109)	9,392	2,584	6,808	220	274	198
Parkinson's disease and comparable movement disorders (110)	19,765	10,791	8,974	1,409	1,422	1,393
Epilepsy and comparable convulsive disorders (111)	71,609	35,942	35,667	307	324	287
Severe psychotic and other severe mental disorders (112)	98,317	46,433	51,884	856	977	752
Anxiety disorders associated with mental retardation (113)	7,341	4,292	3,049	290	308	256
Glaucoma (114)	100,887	39,121	61,766	262	258	264
Breast cancer (115)	42,288	194	42,094	587	800	586
Prostate cancer (116)	26,967	26,967	0	1,572	1,572	0
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue (117)	23,195	11,837	11,358	1,388	1,434	1,346
Trigeminal neuralgia or glossopharyngeusneuralgia (119)	2,624	721	1,903	116	138	106
Hypogammaglobulinaemia (120)	751	308	443	24,957	25,960	24,215

Table continued



Table 6.3. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Severe hypofunction of sexual glands (121)	8,302	3,531	4,771	310	529	103
Aplastic anaemia (122)	413	223	190	9,192	11,387	6,207
Chronic disorders of vitamin D metabolism (123)	9,149	5,709	3,440	129	126	134
Inborn metabolic disorders (124)	329	170	159	6,735	4,291	9,065
Chronic coagulation defects (126)	1,130	577	553	72,730	102,621	6,371
Transplant complication (127)	6,770	3,941	2,829	3,755	3,888	3,558
Cancers of female genital organs (128)	4,684	0	4,684	2,043	0	2,043
Idiopathic thrombocytopaenia or granulocytopenia (129)	1,079	454	625	11,103	12,938	9,626
Malignant tumour (130)	30,643	17,430	13,213	3,584	3,375	3,839
Sarcoidosis (132)	3,593	1,761	1,832	26	27	26
Severe chronic pancreatic insufficiency (133)	6,273	3,742	2,531	867	876	853
General erythroderma (134)	2,129	1,403	726	294	304	276
Pemphigus (135)	279	102	177	50	52	49
Uraemia requiring dialysis (137)	2,607	1,594	1,013	22,527	23,123	21,643
Severe anaemia associated with chronic renal failure (138)	8,147	4,915	3,232	2,800	2,890	2,679
Dasatinib (150)	176	91	85	21,975	21,553	22,441
Palbociclib (1501)	1,469	11	1,458	23,338	23,906	23,332
Cabozantinib (1502)	443	296	147	44,901	43,926	47,326
Emicizumab (haemophilia A, with inhibitors) (1503)	9	9	0	162,325	162,325	0
Alectinib (1504)	68	17	51	54,564	59,867	52,796
Ixazomib (1505)	171	91	80	46,640	44,202	48,033
The combination of trifluridine and tipiracil (1506)	377	228	149	12,031	14,585	8,201
Pomalidomide (1507)	284	153	131	0	0	0

Table continued



Table 6.3. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Lenvatinib (1508)	92	57	35	0	0	0
Dabrafenib and trametinib (1509)	192	111	81	0	0	0
Eliglustat, imiglucerase and velaglucerase alfa (151)	13	4	9	258,154	218,412	275,817
Niraparib (1510)	41	0	41	0	0	0
Olaparib (1511)	87	0	87	0	0	0
Ibrutinib (1512)	393	263	130	0	0	0
Binimetinib and encorafenib (melanoma) (1513)	71	38	33	0	0	0
Ribociclib (1514)	9	0	9	0	0	0
Abemaciclib (1515)	20	0	20	0	0	0
Romiplostim (1516)	78	42	36	0	0	0
Eltrombopag (1517)	226	130	96	0	0	0
Venetoclax (1518)	102	67	35	0	0	0
Nilotinib (152)	179	83	96	24,339	24,638	24,064
Lenalidomid (153)	1,650	834	816	43,145	44,952	41,550
Afatinib and gefitinib (155)	262	93	169	16,834	15,041	17,642
Lapatinib (156)	83	0	83	18,897	0	18,897
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis) (157)	4,869	1,309	3,560	10,760	10,945	10,688
Everolimus (158)	221	135	86	17,730	19,944	14,726
Pazopanib (159)	358	201	157	24,256	23,341	25,172
Exenatide and liraglutide (160)	16,145	8,564	7,581	0	0	0
Preparation with von Willebrand's factor (161)	4	0	4	116,982	0	116,982
Liraglutide (162)	8,139	4,288	3,851	0	0	0
Abiraterone and enzalutamide (163)	2,649	2,649	0	35,140	35,140	0

Table continued



Table 6.3. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Cladribine and fingolimod (164)	1,232	297	935	20,450	19,907	20,638
Preservative-free combination product containing bimatoprost and timolol (165)	156	36	120	0	0	0
Dalteparin and tinzaparin (treatment for more than 6 months) (166)	1,661	796	865	2,258	2,252	2,265
Vemurafenib (167)	250	151	99	58,419	60,324	56,330
Axitinib (168)	128	86	42	27,142	24,755	30,723
Crizotinib (169)	73	22	51	37,593	38,218	37,175
Bosutinib (170)	43	21	22	26,366	27,171	24,919
Insulin degludec (171)	1,122	374	748	0	0	0
Blood coagulation factor VIII and von Willebrand factor for desensitisation treatment in inhibitor-positive patients with haemophilia A (172)	3	3	0	431,609	431,609	0
Trastuzumab injection (173)	14	0	14	0	0	0
Ruxolitinib (174)	226	113	113	38,412	39,932	36,990
Deferasirox (175)	99	55	44	14,158	16,365	11,951
Regorafenib (176)	303	189	114	12,280	13,835	9,688
Insulin glargine 300 U/ml (177)	16,132	9,218	6,914	0	0	0
Combination product containing tegafur, gimeracil and oteracil (178)	208	131	77	2,193	2,379	1,823
Vismodegib (179)	20	12	8	30,004	35,442	22,753
Interferon alfa (180)	610	331	279	0	0	0
Retigabine and vigabatrin (181)	1,320	637	683	888	881	897
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide (182)	22,156	10,300	11,856	1,360	1,402	1,324
Lamotrigin and topiramate (183)	11,328	4,359	6,969	577	598	564
Paclitaxel (184)	2	0	2	0	0	0
Docetaxel (185)	2	0	2	0	0	0

Table continued



Table 6.3. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Growth retardation associated with renal failure (growth hormone) (186)	1,164	735	429	6,766	6,790	6,690
Treatment-resistant psychosis (188)	7,166	3,497	3,669	0	0	0
Imatinib (189)	810	452	358	9,986	10,336	9,545
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide (190)	1,484	971	513	1,234	1,266	1,175
Erlotinib (191)	170	65	105	12,253	10,588	13,568
Fulvestrant (192)	1,120	5	1,115	6,867	7,280	6,864
Rasagiline (193)	3,297	1,805	1,492	111	112	109
Blood coagulation factor VIII and von Willebrand factor for the treatment of von Willebrand disease (194)	52	26	26	187,633	184,206	189,346
Agalsidase alfa, agalsidase beta and migalastat (195)	45	19	26	215,806	234,938	202,255
Paricalcitol and cinacalcet (196)	1,356	826	530	1,685	1,683	1,688
Sunitinib (197)	632	404	228	21,480	22,561	19,659
Sorafenib (198)	342	262	80	19,561	21,919	15,467
Rufinamide (199)	228	137	91	2,502	2,608	2,345
Chronic cardiac insufficiency (201)	29,540	17,475	12,065	141	135	150
Connective tissue diseases, rheumatoid arthritis and comparable disease (202)	123,173	43,197	79,976	314	330	307
Chronic asthma and similar chronic obstructive pulmonary diseases (203)	285,865	117,094	168,771	377	387	370
Chronic hypertension (205)	402,599	194,834	207,765	139	138	140
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease (206)	183,190	117,452	65,738	131	131	131
Chronic arrhythmias (207)	154,480	77,821	76,659	77	76	78
Ulcerative colitis and Crohn's disease (208)	54,295	28,575	25,720	632	656	605
Severe hereditary disorders of lipid metabolism (familial hypercholesterolaemia and type III dyslipoproteinemia) (211)	4,896	2,273	2,623	101	100	102
Gout (212)	9,720	7,585	2,135	53	53	48
Severe and chronic narcolepsy (214)	467	185	282	947	983	917

Table continued



Table 6.3. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Diabetes, non-insulin-treated (215)	377,258	206,087	171,171	403	424	376
Clopidogrel (280)	126	68	58	0	0	0
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab (281)	16,524	6,688	9,836	9,797	9,925	9,704
Sodium oxybat (282)	413	163	250	4,353	4,737	4,095
Ivabradine (283)	67	48	19	607	533	744
Nintedanib and pirfenidone (284)	782	566	216	24,967	26,064	21,918
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (type 2 diabetes, adults) (285)	37,448	19,907	17,541	1,521	1,517	1,524
Ciclosporin eye drop (286)	216	11	205	861	774	864
Ticagrelor 60 mg (287)	295	233	62	731	736	713
Febuxostat (288)	1,927	1,319	608	210	208	215
Combination product containing sacubitril and valsartan (289)	3,277	2,570	707	2,073	2,049	2,160
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation (290)	159,564	81,199	78,365	968	955	981
Tofacitinib (291)	988	269	719	9,882	10,121	9,797
Alirocumab and evolocumab for the treatment of familial hypercholesterolaemia (292)	280	149	131	6,029	5,936	6,164
Baricitinib (293)	807	163	644	10,810	10,904	10,783
Alirocumab and evolocumab for the treatment of hypercholesterolaemia and dyslipidaemia (294)	468	312	156	5,043	5,077	4,950
Liraglutide (type 2 diabetes, children and adolescents) (295)	3	2	1	0	0	0
Rivaroxaban for the treatment of coronary artery disease (296)	121	85	36	0	0	0

When calculating the average costs, only those persons whose entitlement to special reimbursement for medicines has been in force throughout the year, and who have purchased such medicines, have been included.

Source: Dispensations reimbursable under the National Health Insurance Scheme register (includes purchases falling under the initial deductible) and Special Reimbursement Entitlement Register.

**Table 6.4. Patients receiving reimbursement payments under the Special Refund Categories and total cost and reimbursement payments in the Special Refund Categories in 2020**

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
All diseases under the Special Refund Categories	1,241,618	1,384,681	1,190,140
Anterior pituitary hypofunction (101)	4,031	6,121	5,958
Diabetes insipidus (102)	837	770	743
Diabetes, insulin-treated (103)	125,803	84,633	80,525
Thyroid insufficiency (104)	75,677	3,283	1,331
Adrenal cortical hypofunction (105)	1,335	186	131
Hypoparathyroidism (106)	1,469	361	309
Pernicious anaemia (107)	10,588	374	240
Myasthenia gravis (108)	1,263	528	470
Multiple sclerosis (109)	2,247	510	452
Parkinson's disease and comparable movement disorders (110)	16,773	21,225	20,364
Epilepsy and comparable convulsive disorders (111)	37,827	11,254	9,830
Severe psychotic and other severe mental disorders (112)	76,882	65,647	60,737
Anxiety disorders associated with mental retardation (113)	2,766	792	688
Glaucoma (114)	85,550	21,597	17,962
Breast cancer (115)	26,890	20,374	19,286
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 115)	535	488	478
Prostate cancer (116)	17,335	25,215	24,584
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 116)	202	211	208

1 The figures include purchases falling under the initial deductible.

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue (117)	10,331	14,967	14,595
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 117)	444	344	336
Trigeminal neuralgia or glossofaryngeusneuralgia (119)	716	84	67
Hypogammaglobulinaemia (120)	552	12,948	12,923
Severe hypofunction of sexual glands (121)	5,522	1,707	1,483
Aplastic anaemia (122)	190	2,101	2,092
Chronic disorders of vitamin D metabolism (123)	4,609	549	460
Inborn metabolic disorders (124)	185	1,166	1,161
Chronic coagulation defects (126)	455	36,285	36,268
Transplant complication (127)	5,420	19,983	19,636
Tacrolimus cream (an addendum to the prescription + 127)	27	2	2
Tacrolimus granules (an addendum to the prescription + 127)	22	111	110
Cancers of female genital organs (128)	1,740	3,271	3,205
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 128)	229	234	229
Idiopathic thrombocytopaenia or granulocytopenia (129)	443	4,770	4,754
Malignant tumour (130)	14,332	30,868	30,271
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 130)	1,695	1,734	1,699
Sarcoidosis (132)	741	22	10

Table continued



Table 6.4. continued

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Severe chronic pancreatic insufficiency (133)	4,953	3,945	3,821
General erythroderma (134)	771	235	217
Pemphigus (135)	100	6	4
Uraemia requiring dialysis (137)	483	8,676	8,652
Severe anaemia associated with chronic renal failure (138)	3,956	9,601	9,495
Dasatinib (150)	131	2,516	2,510
Palbociclib (1501)	1,005	17,673	17,651
Cabozantinib (1502)	332	10,283	10,276
Emicizumab (haemophilia A, with inhibitors) (1503)	6	1,635	1,635
Alectinib (1504)	61	2,401	2,400
Ixazomib (1505)	116	3,560	3,558
The combination of trifluridine and tipiracil (1506)	269	2,083	2,080
Pomalidomide (1507)	182	9,151	9,150
Lenvatinib (1508)	66	951	951
Dabrafenib and trametinib (1509)	88	2,276	2,276
Eliglustat, imiglucerase and velaglucerase alfa (151)	13	3,356	3,355
Niraparib (1510)	32	1,314	1,313
Olaparib (1511)	65	2,242	2,242
Ibrutinib (1512)	277	13,241	13,238
Binimetinib and encorafenib (melanoma) (1513)	32	1,050	1,049
Ribociclib (1514)	3	22	22
Abemaciclib (1515)	10	32	32

1 The figures include purchases falling under the initial deductible.

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Romiplostim (1516)	54	230	229
Eltrombopag (1517)	146	478	478
Venetoclax (1518)	66	459	459
Nilotinib (152)	136	3,131	3,124
Lenalidomid (153)	1,046	37,372	37,346
Afatinib and gefitinib (155)	193	2,499	2,493
Lapatinib (156)	42	531	530
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis) (157)	4,056	42,070	41,847
Everolimus (158)	77	940	938
Pazopanib (159)	152	2,444	2,440
Preparation with von Willebrand's factor (161)	1	117	117
Abiraterone and enzalutamide (163)	2,122	57,624	57,564
Cladribine and fingolimod (164)	867	17,707	17,661
Dalteparin and tinzaparin (treatment for more than 6 months) (166)	1,081	1,726	1,700
Vemurafenib (167)	147	6,781	6,777
Axitinib (168)	63	1,121	1,119
Crizotinib (169)	44	1,369	1,367
Bosutinib (170)	22	440	439
Blood coagulation factor VIII and von Willebrand factor for desensitisation treatment in inhibitor-positive patients with haemophilia A (172)	3	1,295	1,295

Table continued



Table 6.4. continued

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Ruxolitinib (174)	177	5,715	5,707
Deferasirox (175)	52	513	511
Regorafenib (176)	140	1,106	1,104
Combination product containing tegafur, gimeracil and oteracil (178)	59	84	83
Vismodegib (179)	16	368	367
Retigabine and vigabatrin (181)	121	98	95
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabalin and zonisamide (182)	17,175	21,337	20,681
Lamotrigin and topiramate (183)	7,072	3,938	3,631
Growth retardation associated with renal failure (growth hormone) (186)	701	1,167	1,164
Imatinib (189)	662	6,075	6,045
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide (190)	982	1,027	1,011
Erlotinib (191)	90	664	661
Fulvestrant (192)	640	3,409	3,378
Rasagiline (193)	1,728	187	148
Blood coagulation factor VIII and von Willebrand factor for the treatment of von Willebrand disease (194)	16	2,816	2,815
Agalsidase alfa, agalsidase beta and migalastat (195)	42	8,903	8,899
Paricalcitol and cinacalcet (196)	678	1,001	983
Sunitinib (197)	284	4,651	4,643

1 The figures include purchases falling under the initial deductible.

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Sorafenib (198)	158	1,947	1,940
Rufinamide (199)	117	279	276
Chronic cardiac insufficiency (201)	26,350	3,556	2,124
Connective tissue diseases, rheumatoid arthritis and comparable disease (202)	75,618	23,695	16,425
Chronic asthma and similar chronic obstructive pulmonary diseases (203)	230,692	86,547	57,292
Chronic hypertension (205)	375,130	52,298	30,263
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease (206)	165,662	22,638	13,296
Ticagrelor 90mg (an addendum to the prescription + 206)	6,917	3,486	2,336
Rivaroxaban in the management of acute coronary syndrome (an addendum to the prescription + 206)	16	4	3
Prasugrel (an addendum to the prescription + 206)	172	69	47
Ezetimibe (an addendum to the prescription + 206)	1	0	0
Chronic arrhythmias (207)	81,888	5,870	3,518
Ulcerative colitis and Crohn's disease (208)	37,101	23,408	15,755
Severe hereditary disorders of lipid metabolism (familial hypercholesterolaemia and type III dyslipoproteinemia) (211)	3,194	349	188
Gout (212)	4,794	248	146
Severe and chronic narcolepsy (214)	226	208	183
Diabetes, non-insulin-treated (215)	288,710	112,457	75,157

Table continued



Table 6.4. continued

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000¹	Reimbursement payments, EUR 1,000
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab (281)	13,180	123,175	116,598
Sodium oxybat (282)	268	1,119	1,017
Ivabradine (283)	47	25	18
Nintedanib and pirfenidone (284)	615	13,008	12,693
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (type 2 diabetes, adults) (285)	28,896	40,265	32,495
Ciclosporin eye drop (286)	140	111	86
Ticagrelor 60 mg (287)	208	144	101
Febuxostat (288)	1,311	252	165
Combination product containing sacubitril and valsartan (289)	2,700	4,732	3,927
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation (290)	145,017	125,576	87,344
Tofacitinib (291)	593	5,428	5,165
Alirocumab and evolocumab for the treatment of familial hypercholesterolaemia (292)	225	1,188	1,095
Baricitinib (293)	559	5,561	5,306
Alirocumab and evolocumab for the treatment of hypercholesterolaemia and dyslipidaemia (294)	325	1,343	1,241
Liraglutide (type 2 diabetes, children and adolescents) (295)	3	3	2
Rivaroxaban for the treatment of coronary artery disease (296)	75	22	18

1 The figures include purchases falling under the initial deductible.

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

**Table 6.5. Drug treatment statistics of the most common diseases entitling the patients to reimbursement under the Special Refund Categories, in 2020**

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1, 2}	Cost per patient, euro	Disease/Medication	ATC code	No. of persons who purchased medicines ^{1, 2}	Cost per patient, euro
Chronic hypertension (205)		383,064	136	Sitagliptin	A10BH01	48,598	459
Bisoprolol	C07AB07	143,107	40	Linagliptin	A10BH05	29,079	451
Amlodipine	C08CA01	120,198	29	Insulin detemir	A10AE05	27,115	520
Furosemide	C03CA01	66,584	42	Metformin and sitagliptin	A10BD07	25,705	463
Losartan	C09CA01	53,405	53	Dapagliflozin	A10BK01	23,236	491
Metoprolol	C07AB02	44,012	66	Insulin degludec	A10AE06	22,941	478
Lercanidipine	C08CA13	42,350	58	Semaglutide	A10BJ06	15,444	1,166
Candesartan	C09CA06	41,914	52	Liraglutide	A10BJ02	10,536	1,379
Ramipril	C09AA05	37,413	28	Insulin lispro	A10AB04	9,083	292
Enalapril	C09AA02	30,295	45	Vildagliptin	A10BH02	6,591	395
Losartan and diuretics	C09DA01	29,455	90	Metformin and empagliflozin	A10BD20	5,916	462
Candesartan and diuretics	C09DA06	21,736	135	Chronic asthma and similar chronic obstructive pulmonary diseases (203)		235,482	368
Felodipine	C08CA02	21,349	107	Salbutamol	R03AC02	121,194	35
Valsartan	C09CA03	21,167	72	Formoterol and budesonide	R03AK07	53,115	300
Spironolactone	C03DA01	20,350	48	Salmeterol and fluticasone	R03AK06	45,609	250
Enalapril and diuretics	C09BA02	19,154	67	Montelukast	R03DC03	44,624	39
Diabetes (103, 171, 177, 215, 285, 295)		345,624	686	Prednisolone	H02AB06	33,350	14
Metformin	A10BA02	218,018	79	Fluticasone	R03BA05	32,985	167
Insulin glargine	A10AE04	71,210	494	Budesonide	R03BA02	28,213	152
Insulin aspart	A10AB05	58,766	322	Tiotropium bromide	R03BB04	25,030	391
Empagliflozin	A10BK03	49,010	496				

Table continued



Table 6.5. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Ciclesonide	R03BA08	22,748	171
Terbutaline	R03AC03	16,799	36
Vilanterol and fluticasone furoate	R03AK10	16,699	414
Beclometasone	R03BA01	16,573	144
Formoterol and beclometasone	R03AK08	14,070	387
Formoterol and fluticasone	R03AK11	7,240	391
Formoterol	R03AC13	4,783	238
Chronic coronary heart disease (206, 294, 296, an addendum to the prescription + 206)		168,614	142
Bisoprolol	C07AB07	70,752	35
Atorvastatin	C10AA05	69,762	48
Rosuvastatin	C10AA07	39,517	56
Isosorbide mononitrate	C01DA14	39,353	72
Isosorbide dinitrate	C01DA08	37,298	26
Simvastatin	C10AA01	35,201	54
Ezetimibe	C10AX09	26,681	49
Glyceryl trinitrate	C01DA02	24,737	24
Amlodipine	C08CA01	21,796	27
Clopidogrel	B01AC04	20,095	33
Metoprolol	C07AB02	18,041	57
Ticagrelor	B01AC24	6,917	505
Pravastatin	C10AA03	3,216	105
Fluvastatin	C10AA04	2,586	86
Propranolol	C07AA05	1,427	25

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Chronic arrhythmias (207, 290)		161,878	812
Apixaban	B01AF02	71,050	842
Bisoprolol	C07AB07	62,039	39
Rivaroxaban	B01AF01	49,438	849
Dabigatran etexilate	B01AE07	18,494	904
Digoxin	C01AA05	14,614	60
Edoxaban	B01AF03	9,047	781
Flecainide	C01BC04	7,847	176
Metoprolol	C07AB02	7,407	58
Amiodarone	C01BD01	2,967	79
Propranolol	C07AA05	1,629	35
Atenolol	C07AB03	1,383	58
Verapamil	C08DA01	1,262	61
Diltiazem	C08DB01	880	121
Sotalol	C07AA07	414	76
Betaxolol	C07AB05	162	46

Table continued



Table 6.5. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Glaucoma (114)		85,995	250
Timolol, combinations	S01ED51	50,097	193
Latanoprost	S01EE01	23,047	125
Brinzolamide	S01EC04	15,315	82
Tafluprost	S01EE05	13,395	232
Bimatoprost	S01EE03	8,398	157
Travoprost	S01EE04	5,674	179
Brinzolamide, combinations	S01EC54	4,468	167
Brimonidine	S01EA05	4,204	99
Timolol	S01ED01	3,767	112
Dorzolamide	S01EC03	1,889	98
Acetazolamide	S01EC01	1,621	211
Betaxolol	S01ED02	1,138	109

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Disseminated connective tissue diseases, rheumatoid arthritis and comparable conditions (202, 281, 284, 286, 291, 293)		82,503	2,072
Methotrexate	L04AX03	39,280	328
Prednisolone	H02AB06	27,671	17
Hydroxychloroquine	P01BA02	25,169	89
Sulfasalazine	A07EC01	21,337	187
Adalimumab	L04AB04	4,620	8,017
Leflunomide	L04AA13	4,383	195
Etanercept	L04AB01	4,033	7,497
Ursodeoxycholic acid	A05AA02	3,378	517
Azathioprine	L04AX01	2,785	111
Prednisone	H02AB07	2,698	22
Golimumab	L04AB06	2,276	10,842
Methylprednisolone	H02AB04	1,534	53
Methotrexate	L01BA01	1,195	166
Certolizumab pegol	L04AB05	859	9,467
Ciclosporin	L04AD01	761	1,103

Table continued



Table 6.5. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Severe psychotic and other severe mental disorders (112)		78,562	830
Quetiapine	N05AH04	25,174	116
Olanzapine	N05AH03	22,293	584
Aripiprazole	N05AX12	12,833	747
Risperidone	N05AX08	11,316	722
Clozapine	N05AH02	11,012	500
Mirtazapine	N06AX11	10,307	81
Valproic acid	N03AG01	9,442	228
Lamotrigine	N03AX09	7,132	305
Venlafaxine	N06AX16	6,483	223
Escitalopram	N06AB10	5,409	35
Citalopram	N06AB04	5,329	58
Lithium	N05AN01	5,203	147
Sertraline	N06AB06	4,995	77
Perphenazine	N05AB03	4,576	154
Levomepromazine	N05AA02	4,086	69

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Cancers (115–117, 128, 130, 150, 152, 153, 155, 156, 158, 159, 163, 166–170, 173, 174, 176, 178–180, 189, 191, 192, 197, 198, 1501, 1502, 1504–1515, 1518, an addendum to the prescription + 115–117, 128 or 130)		73,190	4,153
Letrozole	L02BG04	14,068	204
Oxycodone	N02AA05	12,997	115
Dexamethasone	H02AB02	9,859	102
Prednisolone	H02AB06	9,337	19
Leuprorelin	L02AE02	8,858	1,142
Tamoxifen	L02BA01	6,425	117
Denosumab	M05BX04	6,235	1,664
Bicalutamide	L02BB03	4,231	609
Palonosetron, combinations	A04AA55	4,082	354
Tramadol	N02AX02	4,037	50
Pegfilgrastim	L03AA13	3,858	2,770
Hydroxycarbamide	L01XX05	3,844	193
Capecitabine	L01BC06	3,826	358
Fentanyl	N02AB03	3,069	647
Filgrastim	L03AA02	2,711	860

Table continued



Table 6.5. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Epilepsy and comparable convulsive disorders (111, 181–183, 199)		49,761	739
Valproic acid	N03AG01	15,041	234
Levetiracetam	N03AX14	13,291	779
Oxcarbazepine	N03AF02	12,315	344
Carbamazepine	N03AF01	9,234	146
Lamotrigine	N03AX09	5,795	431
Midazolam	N05CD08	3,804	270
Lacosamide	N03AX18	3,362	1,717
Clobazam	N05BA09	2,645	80
Clonazepam	N03AE01	2,395	59
Topiramate	N03AX11	1,734	828
Pregabalin	N03AX16	1,046	265
Gabapentin	N03AX12	922	284
Brivaracetam	N03AX23	891	1,907
Phenytoin	N03AB02	825	169
Zonisamide	N03AX15	739	1,509

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Ulcerative colitis and Crohn's disease (208)		37,698	621
Mesalazine	A07EC02	28,036	694
Azathioprine	L04AX01	8,393	139
Prednisolone	H02AB06	6,078	19
Budesonide	A07EA06	4,582	292
Mercaptopurine	L01BB02	2,566	123
Sulfasalazine	A07EC01	2,098	200
Metronidazole	P01AB01	1,733	34
Methotrexate	L04AX03	1,319	322
Prednisone	H02AB07	447	18
Methylprednisolone	H02AB04	219	49
Hydrocortisone	H02AB09	159	27
Olsalazine	A07EC03	80	345
Ciclosporin	L04AD01	64	773
Dexamethasone	H02AB02	43	56
Methotrexate	L01BA01	17	130

Table continued



Table 6.5. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Chronic cardiac insufficiency (201, 283, 289)		26,916	309
Bisoprolol	C07AB07	18,348	45
Furosemide	C03CA01	15,022	50
Ramipril	C09AA05	8,334	29
Spironolactone	C03DA01	7,273	43
Digoxin	C01AA05	3,613	61
Losartan	C09CA01	3,345	51
Isosorbide mononitrate	C01DA14	3,210	64
Isosorbide dinitrate	C01DA08	3,012	29
Metoprolol	C07AB02	2,925	63
Valsartan and sacubitril	C09DX04	2,700	1,752
Glyceryl trinitrate	C01DA02	2,215	32
Candesartan	C09CA06	2,142	47
Enalapril	C09AA02	2,131	43
Valsartan	C09CA03	1,164	64
Carvedilol	C07AG02	828	63

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Parkinson's disease and other comparable movement disorders (110, 193)		16,843	1,268
Levodopa and decarboxylase inhibitor	N04BA02	13,680	1,030
Pramipexole	N04BC05	3,976	303
Levodopa, decarboxylase inhibitor and COMT inhibitor	N04BA03	3,450	923
Selegiline	N04BD01	2,468	194
Ropinirole	N04BC04	2,287	296
Rasagiline	N04BD02	1,745	107
Rotigotine	N04BC09	571	1,277
Amantadine	N04BB01	361	146
Orphenadrine (citrate)	M03BC01	343	26
Biperiden	N04AA02	314	61
Entacapone	N04BX02	309	737
Apomorphine	N04BC07	50	10,016
Cabergoline	N04BC06	3	52
Bromocriptine	G02CB01	3	144

1 The data covers all beneficiaries who in 2020 purchased medicines under the Special Refund Categories for any of the listed diseases, including purchases that did not clear the initial deductible limit.

2 One patient may use medicines from several medicine groups.

Source: Dispensations reimbursable under the National Health Insurance Scheme register.



Medicinal products eligible for restricted basic refund

Table 6.6. Medicines eligible for restricted basic refund: Number of purchasers and the cost of reimbursed drugs in 2020

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000	Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Medicinal products eligible for restricted basic refund, total	85,447	1,988	169,838	Brigatinib (3017)	4	21,852	87
Ribociclib (3002)	5	11,505	58	The combination of trifluridine and tipiracil (3018)
Osimertinib (3004)	77	41,283	3,179	Lenvatinib (3019)	24	14,722	353
Tofacitinib (3005)	173	8,875	1,535	Patiromer (3020)	8	2,214	18
Baricitinib (3006)	13	2,956	38	Ketoconazole (3021)
Erenumab, fremanezumab and galcanezumab (3007)	3,683	6,247	23,009	Allergen extract of birch pollen (adults) (3023)	961	811	779
Tolvaptan (3008)	7	18,360	129	Dabrafenib and trametinib (3024)	7	20,176	141
Niraparib (3009)	69	22,897	1,580	Calcium carbonate (3025)	8	20	0
Growth hormone (301)	821	6,012	4,936	Lorlatinib (3026)	7	24,236	170
Midodrine (3010)	53	832	44	Benralizumab (3027)	74	6,675	494
Tafamidis (3011)	4	161,812	647	Mepolizumab (3028)	176	6,061	1,067
Cabozantinib (3012)	Upadacitinib (3029)	66	4,369	288
Rivaroxaban for the treatment of coronary artery disease and peripheral artery disease (3013)	72	385	28	Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis) (303)
Midostaurin (3014)	13	96,401	1,253	Abemaciclib (3030)	5	5,478	27
Alirocumab, evolocumab and inclisiran for the treatment of hypercholesterolaemia and dyslipidaemia (3015)	92	2,397	221	Apalutamide (3031)	12	11,075	133
Binimetinib and encorafenib (melanoma) (3016)	27	31,818	859	Gilteritinib (3033)
				Larotrectinib (3034)

Table continued



Table 6.6. continued

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Pitolisant (3035)	6	1,177	7
Darolutamide (3036)
Romiplostim (3038)
Eltrombopag (3039)	5	4,107	21
Dornase alfa (304)	61	7,018	428
Erythropoietin and darbepoetin (306)	19	7,240	138
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine (308)	2,494	130	325
Nalmefene and naltrexone (309)	317	188	60
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases) (313)	360	8,203	2,953
Topical pimecrolimus and tacrolimus (317)	4,097	129	529
Teriparatide (318)	395	2,526	998
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis) (319)	2,125	12,829	27,261
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide (320)
Paricalcitol and cinacalcet (321)	827	1,685	1,394
Sorafenib (323)
Adalimumab, golimumab, infliximab and ustekinumab (intestinal diseases) (326)	2,238	11,601	25,964

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Lenalidomide (329)
Atomoxetine, dexamphetamine, guanfacine and lisdexamphetamine (331)	8,197	973	7,979
Treprostinil (334)	18	143,194	2,577
C1-esterase inhibitor, conestat alfa, icatibant and lanadelumab (338)	58	115,587	6,704
Product containing buprenorfine and naloxone (339)	357	1,042	372
Everolimus (340)	27	32,147	868
Dronedarone (342)	710	635	451
Omalizumab (344)	291	8,782	2,555
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (type 2 diabetes, adults) (346)	1,931	276	533
Roflumilast (348)	477	542	258
Febuxostat (349)	7	150	1
Capsaicin (350)	24	1,305	31
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation (351)	428	214	92
Abiraterone and enzalutamide (352)
Cladribine and fingolimod (353)	131	35,201	4,611
Dienogest (355)	624	488	304
Nintedanib and pirfenidone (356)	5	7,682	38
Vemurafenib (362)	54	5,317	287

Table continued



Table 6.6. continued

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Allergen extract of birch pollen and allergen extract of grass pollen (364)	7	1,264	9
Combination product containing naproxen and esomeprazole (366)	86	156	13
Combination product containing docusate sodium and sorbitol (368)	151	1,210	183
Regorafenib (369)	4	5,300	21
Idelalisib (372)	44	28,192	1,240
Ponatinib (373)	24	35,286	847
Cyanocobalamin (376)
Apremilast and dimethyl fumarate (psoriasis) (377)	613	7,401	4,537
Apixaban, dabigatran, edoxaban and rivaroxaban for the long-term prevention of recurrent deep vein thrombosis and pulmonary embolism (379)	12,093	832	10,064
Adalimumab (hidradenitis suppurativa) (380)	128	16,967	2,172
Combination product containing sacubitril and valsartan (381)	9	372	3
Selexipag (383)	16	60,376	966
Levofloxacin nebuliser solution (385)
Ticagrelor 60 mg (386)
Asfotase alfa (387)
Alirocumab, evolocumab and inclisiran for the treatment of familial hypercholesterolaemia (388)	31	1,495	46
Olaparib (389)	34	12,635	430

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Ibrutinib (390)	186	12,894	2,398
Obeticholic acid (391)	6	15,788	95
Ferric maltol (392)	10	271	3
Pomalidomide (393)	69	10,375	716
Palbociclib (394)
Dupilumab (395)	244	13,368	3,262
Idebenone (396)	7	43,944	308
Venetoclax (399)	83	37,976	3,152
Apixaban, dabigatran, edoxaban and rivaroxaban (an addendum to the prescription)	18,101	209	3,785
Enoxaparin (an addendum to the prescription)
Fidaxomicin (an addendum to the prescription)	44	2,022	89
Granisetron (an addendum to the prescription)	52	748	39
Letermovir (an addendum to the prescription)	27	20,238	546
Prasugrel (an addendum to the prescription)	102	144	15
Tacrolimus (an addendum to the prescription)
Ticagrelor (an addendum to the prescription)	4,052	227	920
Tinzaparin (an addendum to the prescription)
Zolmitriptan (an addendum to the prescription)	535	376	201
Varenicline (an addendum to the prescription)	18,896	232	4,382

Source: Dispensations reimbursable under the National Health Insurance Scheme register.



Clinical nutritional preparations

Table 6.7. Clinical nutritional preparations reimbursable under the Health Insurance Scheme: Number of purchasers and the cost of reimbursed preparations in 2020

Disease	No. of purchasers	Average cost per patient, euro	Total cost, EUR 1,000
Whole group	5,284	1,773	9,366
Inborn metabolic disorders (503)	227	3,145	714
Conditions requiring daily forced enteral nutrition (504)	2,498	2,478	6,189
Allergy to cow's milk in infants (505)	795	927	737
Allergy to cow's milk and hypersensitivity to conventional formula in infants (506)	193	3,504	676
Severe malabsorption of nutrients, mainly fats (601)	1,051	607	638
Children's severe malnutrition (602)	634	650	412

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

Medicine costs and their reimbursement according to prescriber

Table 6.8. Medicine prescribers, 2015 – 2020

Doctor

Year	Number of prescribers	Dispensations/prescriber	Costs/prescriber, EUR
2015	27,845	1,576	69,937
2016	28,306	1,642	71,685
2017	28,163	1,720	71,091
2018	28,409	1,781	73,630
2019	29,313	1,811	74,858
2020	29,999	1,817	75,644


Dentist

Year	Number of prescribers	Dispensations/prescriber	Costs/prescriber, EUR
2015	5,466	93	958
2016	5,447	91	928
2017	5,132	87	864
2018	5,058	86	840
2019	5,113	87	826
2020	5,038	74	731

Nurse

Year	Number of prescribers	Dispensations/prescriber	Costs/prescriber, EUR
2015	194	51	853
2016	229	53	914
2017	275	54	924
2018	315	49	751
2019	389	41	562
2020	413	33	486

Figure 6.1. Percentages of medicine prescribers, 2020



The figures only include prescriber-specific IDs.
The figures include purchases falling under the initial deductible.

Sources: Dispensations reimbursable under the National Health Insurance Scheme register.

**Table 6.9. Average number and cost (before reimbursement is deducted) of dispensations per doctor, according to speciality, in 2020 (only those dispensations entitled to reimbursement are included)****Doctors**

Medical speciality	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
No speciality	13,598	2,248	67,309
Specialist clinical chemistry	121	550	13,971
Specialist anaesthesiology and intensive care medicin	1,092	168	4,017
Specialist endocrinology	89	2,214	229,934
Specialist phoniatics	30	103	3,016
Specialist physiatrics	239	600	13,379
Specialist gastroenterology	166	1,431	213,093
Specialist surgery: gastroenterology	359	281	9,328
Specialist geriatrics	429	3,922	63,955
Specialist dermatology and allergology	312	1,577	146,586
Specialist infectious diseases	144	472	81,331
Specialist cardiology	355	1,440	79,820
Specialist respiratory medicine and allergology	315	1,448	131,115
Specialist clinical pharmacology	40	463	12,478
Specialist clinical neurophysiology	87	260	11,960
Specialist clinical haematology	114	986	902,483
Specialist emergency medicine	121	309	9,657

Medical speciality	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
Specialist clinical microbiology	86	429	5,732
Specialist clinical physiology	87	71	5,508
Specialist otorhinolaryngology	496	473	10,927
Specialist hand surgery	94	248	3,325
Specialist paediatric surgery	92	197	5,077
Specialist child neurology	139	407	33,024
Specialist child psychiatry	332	315	13,117
Specialist paediatrics	925	554	59,599
Specialist forensic medicine	46	696	17,861
Specialist obstetrics and gynaecology	1,051	714	34,107
Specialist nephrology	119	2,002	247,894
Specialist neurosurgery	111	161	3,569
Specialist neurology	458	1,210	224,878
Specialist adolescent psychiatry	201	540	18,222
Specialist sports medicine	46	370	10,573
Specialist surgery: orthopaedics and traumatology	685	485	8,863
Specialist pathology	198	58	1,702

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

Table continued



Table 6.9. continued

Doctors

Medical speciality	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
Specialist cardiothoracic surgery	44	62	1,419
Specialist plastic surgery	152	158	3,389
Specialist psychiatry	1,278	875	36,283
Specialist forensic psychiatry	75	313	11,901
Specialist diagnostic radiology	740	30	794
Specialist rheumatology	170	2,993	641,216
Specialist ophthalmology	747	854	35,748
Specialist internal medicine	763	1,212	97,486
Specialist oral and maxillofacial surgery	24	258	6,203
Specialist clinical genetics	44	170	6,391
Specialist oncology	272	1,175	423,314
Specialist public health	129	524	15,255
Specialist occupational health	1,251	1,282	32,207
Specialist urology	203	1,131	180,838
Specialist vascular surgery	180	144	3,766
Specialist general surgery	192	495	11,341
Specialist general practice	2,772	3,947	114,737
All	29,999	1,817	75,644

Dentists

Medical speciality	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
No speciality	4,464	69	679
Dental specialist dental diagnostics	7	11	153
Dental specialist orthodontics	73	6	69
Dental specialist clinical dentistry	366	48	612
Dental specialist oral and maxillofacial surgery	129	337	3,230
Dental specialist public health	43	16	162
All	5,038	74	731

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

**Table 6.10. Data relating to purchases of reimbursable medicines eligible for generic substitution and savings generated through substitution, in 2016–2020****All reimbursed medicines**

	Year				
	2016	2017	2018	2019	2020
Dispensations, million	47.0	48.9	51.1	53.5	54.9
Total cost, EUR million	2,034.5	2,006.9	2,096.3	2,198.8	2,273.2
Refunds, EUR million	1,405.3	1,360.0	1,454.7	1,558.5	1,639.0
Customers	3,817,051	3,805,016	3,842,848	3,861,862	3,730,259

Purchases of products eligible for generic substitution

	Year				
	2016	2017	2018	2019	2020
Dispensations, million	30.7	31.6	32.3	33.4	32.9
Cost, EUR million	1,100.0	972.1	963.6	962.5	954.8
Refunds, EUR million	673.6	538.1	544.2	558.5	572.1
Dispensations substituted, %	5.8	6.6	7.4	8.6	9.0
Number of patients who accepted substitution for at least one productn	1,712,795	1,814,073	1,929,821	2,074,350	2,110,178

Table continued



Table continued

Table 6.10. continued

Purchases in reference price system

	Year				
	2016	2017	2018	2019	2020
Dispensations, million	26.8	28.3	29.6	30.0	29.5
Cost, EUR million	628.2	685.7	696.5	647.7	646.8
Refunds, EUR million	290.6	337.1	347.6	322.0	336.4
Dispensations substituted, %	5.6	6.4	7.2	8.4	8.9
Number of patients who accepted substitution for at least one product	1,673,567	1,784,469	1,913,794	2,049,581	2,094,543

Savings generated through generic substitution


	Year				
	2016	2017	2018	2019	2020
Total, EUR million	78.2	70.1	77.8	75.5	75.1
Saving, EUR / each substitution	28.8	23.7	22.9	19.0	18.2

Sources: Dispensations reimbursable under the National Health Insurance Scheme register.
Price and reference price information from the Pharmaceutical Database.

The statistics include additional refunds.

The statistics also cover purchases made prior to reaching the initial deductible.

7. Tables: Sales statistics according to medicine group





A Alimentary tract and metabolism

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A	Alimentary tract and metabolism	294,610	299,707	308,950	320,864	8	7	7	7	302.14	304.84	314.78	326.10	4	4	4	3
A01	Stomatological preparations	2,124	1,906	1,931	2,086	8	7	7	8	12.64	11.00	12.81	14.27	8	6	4	4
A02	Drugs for acid related disorders	37,438	34,813	32,374	30,561	7	4	3	3	68.22	69.19	71.03	72.93	3	3	3	
A03	Drugs for functional gastrointestinal disorders	5,660	5,387	5,734	5,341	47	44	50	45	2.85	2.77	2.78	2.71	9	9	9	9
A04	Antiemetics and anti-nauseants	4,569	4,117	4,185	4,831	53	43	40	48	0.28	0.28	0.29	0.29	46	44	43	41
A05	Bile and liver therapy	2,130	2,067	2,198	1,393	2	1	2	2	0.77	0.82	0.93	0.92	2	1	2	2
A06	Drugs for constipation	25,581	25,560	27,108	29,103	14	13	12	11	46.67	46.81	48.03	51.30	11	10	9	8
A07	Antidiarrheals, intestinal anti-inflammatory/anti-infective agents	28,628	28,856	29,635	28,945	6	5	5	5	13.49	13.42	13.58	13.56	3	2	2	2
A08	Anti-obesity preparations, excl. diet products	351	558	638	602	1	0	0	0	0.10	0.09	0.08	0.07	1	1	0	0
A09	Digestives, incl. enzymes	2,444	2,613	3,219	3,146	4	4	4	3	0.97	1.04	1.28	1.25	4	4	4	4
A10	Drugs used in diabetes	147,956	154,837	161,244	170,838	2	2	2	2	91.70	95.75	99.91	101.74	2	2	2	2
A11	Vitamins	9,715	9,305	9,120	9,352	12	13	13	14	25.36	23.27	23.53	25.42	3	4	3	3
A12	Mineral supplements	15,034	15,792	15,838	16,449	5	5	5	4	39.04	40.36	40.49	41.61	4	4	3	
A14	Anabolic agents for systemic use	20	17	12	12	16	22	17	22	0.03	0.02	0.02	0.02	16	22	17	22
A16	Other alimentary tract and metabolism products	12,960	13,880	15,712	18,204	44	40	34	40	0.02	0.02	0.02	0.03	45	44	39	48

**A01 Stomatological preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A01	Stomatological preparations	2,124	1,906	1,931	2,086	8	7	7	8	12.64	11.00	12.81	14.27	8	6	4	4
A01A	Stomatological preparations	2,124	1,906	1,931	2,086	8	7	7	8	12.64	11.00	12.81	14.27	8	6	4	4
A01AA	Caries prophylactic agents	1,041	619	610	662	11	12	11	7	10.64	8.66	10.48	11.90	8	5	4	3
A01AA01	Sodium fluoride	787	497	557	610	14	15	12	8	10.64	8.66	10.48	11.90	8	5	4	3
A01AA03	Olafur (DDD 1.10 mg)	48	50	54	52	1	1	1	1								
A01AA51	Sodium fluoride, combinations	206	71			1	1										
A01AB	Antiinfectives for local oral treatment	940	1,048	1,096	1,262	5	6	6	10	2.01	2.30	2.30	2.35	6	6	6	8
A01AB03	Chlorhexidine (DDD 30 mg)	702	821	880	927	7	7	7	6	1.77	2.08	2.09	2.02	7	7	7	6
A01AB09	Miconazole (DDD 0.20 g)																
A01AB11	Various	238	227	216	335	0	0	0	21	0.24	0.22	0.21	0.33	0	0	0	21
A01AB22	Doxycycline		0	0			100	100									
A01AC	Corticosteroids for local oral treatment	143	135	153	113	1	1	1	1								
A01AC01	Triamcinolone	143	135	153	113	1	1	1	1								
A01AD	Other agents for local oral treatment		104	72	49		0				0.04	0.03	0.02		0		
A01AD02	Benzydamine (DDD 9 mg)		104	72	49		0				0.04	0.03	0.02		0		



A02 Drugs for acid related disorders

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A02	Drugs for acid related disorders	37,438	34,813	32,374	30,561	7	4	3	3	68.22	69.19	71.03	72.93	3	3	3	3
A02A	Antacids	3,385	3,356	3,565	3,680	1	1	1	1	2.30	2.20	2.22	2.23	1	1	1	1
A02AA	Magnesium compounds	154	171	151	141	19	22	22	22	0.10	0.08	0.07	0.07	19	22	22	22
A02AA04	Magnesium hydroxide (DDD 3 g)	154	171	151	141	19	22	22	22	0.10	0.08	0.07	0.07	19	22	22	22
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds	3,231	3,185	3,414	3,539	0	0	0	0	2.20	2.12	2.15	2.17	0	0	0	0
A02AD01	Ordinary salt combinations (DDD 10 UD)	3,231	3,185	3,414	3,539	0	0	0	0	2.20	2.12	2.15	2.17	0	0	0	0
A02B	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	34,053	31,457	28,809	26,881	7	4	3	4	65.92	66.99	68.81	70.69	3	3	3	3
A02BA	H ₂ -receptor antagonists	988	949	733	504	1	1	1	1	1.08	1.08	0.73	0.16	2	2	2	1
A02BA02	Ranitidine (DDD 0.30 g)	628	616	394	1	2	2	2	1	0.97	0.98	0.62	0.00	2	2	2	1
A02BA03	Famotidine (DDD 40 mg)	360	333	339	503	0	0	1	1	0.11	0.10	0.10	0.15	0	0	1	1
A02BB	Prostaglandins	45	48	41	61	69	64	66	50	0.02	0.02	0.02	0.03	69	64	66	50
A02BB01	Misoprostol (DDD 0.80 mg)	45	48	41	61	69	64	66	50	0.02	0.02	0.02	0.03	69	64	66	50

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A02BC	Proton pump inhibitors	30,701	28,037	25,416	23,391	8	4	4	4	63.64	64.71	66.89	69.23	3	3	3	3
A02BC01	Omeprazole (DDD 20 mg)	3,141	2,677	2,499	2,370	2	2	1	1	9.89	9.27	8.83	8.59	2	2	2	1
A02BC02	Pantoprazole (DDD 40 mg)	13,463	11,336	9,516	8,047	16	8	6	8	32.20	33.31	35.99	37.90	5	5	4	4
A02BC03	Lansoprazole (DDD 30 mg)	3,174	2,655	2,077	1,205	0	0	0	1	6.46	5.82	5.67	5.47	0	0	0	1
A02BC04	Rabeprazole (DDD 20 mg)	687	760	852	922	0	0	0	0	1.27	1.37	1.48	1.59	0	0	0	0
A02BC05	Esomeprazole (DDD 30 mg)	10,237	10,609	10,472	10,848	3	2	2	2	13.81	14.95	14.92	15.67	2	2	2	2
A02BD	Combinations for eradication of helicobacter pylori	322	309	303	218	0	0	0	0	0.03	0.03	0.03	0.02	0	0	0	0
A02BD03	Lansoprazole, metronidazole and amoxicillin (DDD 9 UD)	74	72	74	23	0	0	0	0	0.01	0.01	0.01	0.00	0	0	0	0
A02BD07	Lansoprazole, amoxicillin and clarithromycin (DDD 8 UD)	248	238	229	196	0	0	0	0	0.02	0.02	0.02	0.02	0	0	0	0
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	1,997	2,113	2,317	2,706	3	3	3	3	1.14	1.14	1.15	1.25	3	3	3	3
A02BX02	Sucralfate (DDD 4 g)	316	328	380	455	1	0	0	1	0.20	0.20	0.23	0.28	1	0	0	1
A02BX13	Alginic acid	1,681	1,786	1,937	2,251	4	4	3	3	0.95	0.94	0.91	0.98	4	4	4	3



A03 Drugs for functional gastrointestinal disorders

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A03	Drugs for functional gastrointestinal disorders	5,660	5,387	5,734	5,341	47	44	50	45	2.85	2.77	2.78	2.71	9	9	9	9
A03A	Drugs for functional gastrointestinal disorders	1,805	1,769	1,868	1,889	17	18	20	19	1.23	1.16	1.24	1.17	6	6	7	7
A03AB	Synthetic anticholinergics, quaternary ammonium compounds	300	307	382	370	91	92	88	86	0.04	0.04	0.05	0.05	91	92	88	87
A03AB02	Glycopyrronium bromide	300	307	382	370	91	92	88	86	0.04	0.04	0.05	0.05	91	92	88	87
A03AX	Other drugs for functional gastrointestinal disorders	1,505	1,462	1,486	1,519	2	2	2	2	1.18	1.12	1.18	1.12	3	3	3	3
A03AX13	Silicones (DDD 0.50 g)	1,505	1,462	1,468	1,385	2	2	2	2	1.18	1.12	1.18	1.12	3	3	3	3
A03AX15	Menthae piperitae aetheroleum			18	134			0	0								
A03B	Belladonna and derivatives, plain	546	522	624	329	86	95	95	92	0.07	0.05	0.06	0.04	81	94	95	93
A03BA	Belladonna alkaloids, tertiary amines	411	436	542	272	94	94	94	92	0.06	0.05	0.06	0.04	94	94	94	93
A03BA01	Atropine (DDD 1.50 mg)	411	436	542	272	94	94	94	92	0.06	0.05	0.06	0.04	94	94	94	93
A03BB	Belladonna alkaloids semisynthetic, quaternary ammonium compounds	135	86	82	57	61	99	99	95	0.01	0.00	0.00	0.00	27	99	99	97
A03BB01	Butylscopolamine (DDD 60 mg)	135	86	82	57	61	99	99	95	0.01	0.00	0.00	0.00	27	99	99	97

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A03C	Antispasmodics in combination with psycholeptics	231	194	222	195	1	1	1	1	0.24	0.20	0.21	0.18	1	1	1	1
A03CA	Synthetic anticholinergic agents in combination with psycholeptics	231	194	222	195	1	1	1	1	0.24	0.20	0.21	0.18	1	1	1	1
A03CA02	Clidinium and psycholeptics (DDD 4 UD)	231	194	222	195	1	1	1	1	0.24	0.20	0.21	0.18	1	1	1	1
A03D	Antispasmodics in combination with analgesics	2,633	2,515	2,649	2,526	67	57	68	63	0.32	0.38	0.28	0.31	9	7	9	7
A03DA	Synthetic anticholinergic agents in combination with analgesics	2,633	2,515	2,649	2,526	67	57	68	63	0.32	0.38	0.28	0.31	9	7	9	7
A03DA02	Pitofenone and analgesics	2,633	2,515	2,649	2,526	67	57	68	63	0.32	0.38	0.28	0.31	9	7	9	7
A03F	Propulsives	445	387	370	401	28	31	34	31	1.00	0.98	1.00	1.00	11	10	10	10
A03FA	Propulsives	445	387	370	401	28	31	34	31	1.00	0.98	1.00	1.00	11	10	10	10
A03FA01	Metoclopramide (DDD 30 mg)	445	387	370	401	28	31	34	31	1.00	0.98	1.00	1.00	11	10	10	10



A04 Antiemetics and antinauseants

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A04	Antiemetics and antinauseants	4,569	4,117	4,185	4,831	53	43	40	48	0.28	0.28	0.29	0.29	46	44	43	41
A04A	Antiemetics and antinauseants	4,569	4,117	4,185	4,831	53	43	40	48	0.28	0.28	0.29	0.29	46	44	43	41
A04AA	Serotonin (5HT ₃) antagonists	3,341	3,172	3,337	4,102	58	42	38	48	0.21	0.22	0.23	0.23	51	48	47	44
A04AA01	Ondansetron (DDD 16 mg)	1,160	1,042	996	1,837	51	44	40	65	0.14	0.14	0.15	0.16	52	51	50	45
A04AA02	Granisetron	1,144	886	870	850	52	43	44	41	0.06	0.06	0.06	0.06	43	38	35	38
A04AA05	Palonosetron	532	313	294	257	100	100	99	99	0.01	0.01	0.01	0.01	100	100	100	100
A04AA55	Palonosetron, combinations (DDD 1 UD)	505	930	1,178	1,157	45	20	16	14	0.00	0.01	0.01	0.01	45	20	15	14
A04AD	Other antiemetics	1,228	946	848	729	37	44	49	49	0.07	0.07	0.06	0.06	27	28	29	28
A04AD01	Scopolamine (DDD 1 UD)	278	298	296	371	27	27	26	26	0.05	0.06	0.05	0.06	27	27	26	26
A04AD12	Aprepitant	946	633	528	359	40	52	62	73	0.01	0.01	0.01	0.01	30	41	47	51
A04AD14	Rolapitant (DDD 0.18 g)	4	14	24		92	66	53		0.00	0.00	0.00		92	66	53	

A05 Bile and liver therapy

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A05	Bile and liver therapy	2,130	2,067	2,198	1,393	2	1	2	2	0.77	0.82	0.93	0.92	2	1	2	2
A05A	Bile therapy	2,130	2,067	2,198	1,393	2	1	2	2	0.77	0.82	0.93	0.92	2	1	2	2
A05AA	Bile acids and derivatives	2,130	2,067	2,198	1,393	2	1	2	2	0.77	0.82	0.93	0.92	2	1	2	2
A05AA02	Ursodeoxycholic acid (DDD 0.75 g)	2,130	2,067	2,164	1,321	2	1	2	2	0.77	0.82	0.93	0.92	2	1	2	2
A05AA04	Obeticholic acid (DDD 10 mg)			35	72				4			0.00	0.00				4

**A06 Drugs for constipation**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A06	Drugs for constipation	25,581	25,560	27,108	29,103	14	13	12	11	46.67	46.81	48.03	51.30	11	10	9	8
A06A	Drugs for constipation	25,581	25,560	27,108	29,103	14	13	12	11	46.67	46.81	48.03	51.30	11	10	9	8
A06AB	Contact laxatives	3,917	3,788	3,784	3,739	10	9	9	7	6.62	6.29	6.21	6.31	8	7	6	5
A06AB02	Bisacodyl (DDD 10 mg)	426	385	363	265	7	6	5	2	1.08	0.97	0.91	0.71	6	5	4	2
A06AB06	Senna glycosides	128	119	60	52	1	0	0	0	0.31	0.29	0.15	0.13	1	0	0	0
A06AB08	Sodium picosulfate (DDD 5 mg)	2,736	2,653	2,688	2,819	8	7	6	4	5.22	5.02	5.15	5.48	9	8	7	6
A06AB56	Senna glycosides, combinations	201	183	169	163	0	0	0	0								
A06AB58	Sodium picosulfate, combinations (DDD 33 UD)	427	448	505	441	35	30	31	31	0.00	0.00	0.00	0.00	35	30	31	30
A06AC	Bulk-forming laxatives	4,764	4,878	5,287	5,843	2	2	2	2	9.83	9.95	10.76	11.98	0	0	0	0
A06AC01	Ispaghula (psylla seeds) (DDD 7 g)	4,505	4,635	5,050	5,613	2	2	2	2	9.16	9.33	10.15	11.40	0	0	0	0
A06AC51	Ispaghula, combinations (DDD 15 UD)	260	243	238	230	2	2	1	1	0.66	0.62	0.61	0.59	2	2	1	1
A06AD	Osmotically acting laxatives	13,806	13,664	14,745	16,135	15	15	14	12	28.72	29.04	29.56	31.51	14	13	12	11
A06AD10	Mineral salts in combination (DDD 1 UD)																
A06AD11	Lactulose (DDD 6.70 g)	3,021	2,862	2,711	2,628	12	11	10	9	15.01	14.17	13.46	13.23	12	11	10	9
A06AD15	Macrogol (DDD 10 g)	8,321	8,939	10,211	11,750	16	15	14	12	11.88	13.43	14.86	17.21	18	16	14	13
A06AD17	Sodium phosphate (DDD 50 g)	74	51	55	41	12	17	16	18								
A06AD65	Macrogol, combinations	2,390	1,813	1,768	1,716	17	21	20	21	1.83	1.43	1.24	1.08	2	2	3	3

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A06AG	Enemas	2,692	2,628	2,510	2,411	27	23	21	17	1.44	1.43	1.36	1.30	21	18	16	10
A06AG02	Bisacodyl (DDD 1 UD)	497	463	419	411	46	40	36	31	0.30	0.28	0.25	0.24	46	41	37	32
A06AG10	Docusate sodium, incl. combinations (DDD 1 UD)	656	609	588	551	55	51	48	45	0.07	0.06	0.06	0.05	57	54	51	48
A06AG11	Laurilsulfate, incl. combinations (DDD 1 UD)	1,539	1,556	1,504	1,449	8	7	7	2	1.08	1.09	1.06	1.01	11	10	9	3
A06AH	Peripheral opioid receptor antagonists	250	443	623	756	71	52	44	39	0.02	0.07	0.11	0.13	48	39	33	28
A06AH01	Methylnaltrexone bromide (DDD 6 mg)	145	119	118	133	96	93	95	97	0.00	0.00	0.00	0.00	96	93	95	97
A06AH03	Naloxegol (DDD 25 mg)	105	324	505	624	38	37	32	26	0.02	0.07	0.11	0.13	36	36	31	26
A06AX	Other drugs for constipation	151	158	159	218	5	5	4	5	0.03	0.04	0.04	0.05	5	4	4	4
A06AX04	Linaclotide (DDD 0.29 mg)	83	77	66	111	3	2	2	1	0.02	0.02	0.02	0.03	3	2	2	1
A06AX05	Prucalopride (DDD 2 mg)	68	81	93	107	8	7	6	9	0.01	0.02	0.02	0.02	7	6	5	9

**A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A07	Antidiarrheals, intestinal antiinflammatory/antiinfective agents	28,628	28,856	29,635	28,945	6	5	5	5	13.49	13.42	13.58	13.56	3	2	2	2
A07A	Intestinal antiinfectives	1,423	1,737	2,397	2,666	58	45	40	34	0.04	0.08	0.14	0.17	34	28	25	21
A07AA	Antibiotics	1,423	1,737	2,397	2,666	58	45	40	34	0.04	0.08	0.14	0.17	34	28	25	21
A07AA02	Nystatin (DDD 1.50 MU)	21	292	668	679	60	27	22	18	0.00	0.03	0.07	0.07	60	26	21	18
A07AA09	Vancomycin (DDD 2 g)	671	670	702	687	57	57	59	53	0.01	0.01	0.01	0.01	57	57	59	53
A07AA11	Rifaximin (DDD 0.60 g)	355	545	735	1,026	26	25	24	20	0.03	0.05	0.07	0.09	26	25	24	20
A07AA12	Fidaxomicin (DDD 0.40 g)	376	231	292	274	87	77	78	73	0.00	0.00	0.00	0.00	87	77	78	73
A07B	Intestinal adsorbents	691	645	619	622	43	44	49	51	0.15	0.13	0.12	0.13	45	45	54	52
A07BA	Charcoal preparations	691	645	619	622	43	44	49	51	0.15	0.13	0.12	0.13	45	45	54	52
A07BA01	Medicinal charcoal (DDD 5 g)	691	645	619	622	43	44	49	51	0.15	0.13	0.12	0.13	45	45	54	52
A07C	Electrolytes with carbohydrates	272	269	228	138	5	6	5	5	0.02	0.01	0.01	0.01	5	6	5	5
A07CA	Oral rehydration salt formulations	545	539	456	275	10	11	9	9	0.03	0.03	0.02	0.01	10	11	9	9
A07D	Antipropulsives	4,197	4,290	4,426	3,787	1	1	1	1	1.33	1.31	1.37	1.20	2	2	2	2
A07DA	Antipropulsives	4,197	4,290	4,426	3,787	1	1	1	1	1.33	1.31	1.37	1.20	2	2	2	2
A07DA03	Loperamide (DDD 10 mg)	3,246	3,221	3,407	2,962	1	1	1	1	1.33	1.31	1.37	1.20	2	2	2	2
A07DA06	Eluxadolone (DDD 0.20 g)	13	19	0		2	1			0.00	0.00	0.00		1	1		
A07DA53	Loperamide, combinations	938	1,050	1,019	825												

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A07E	Intestinal antiinflammatory agents	16,586	17,121	17,944	18,961	1	1	1	1	10.18	10.39	10.75	11.23	1	1	1	1
A07EA	Corticosteroids acting locally	1,593	1,667	1,834	1,976	3	3	2	3	0.31	0.30	0.32	0.35	3	3	3	3
A07EA02	Hydrocortisone (DDD 0.10 g)	102	0			3				0.04	0.00			3			
A07EA06	Budesonide	1,491	1,667	1,834	1,976	3	3	2	3	0.27	0.30	0.32	0.35	3	3	3	3
A07EB	Antiallergic agents, excl. corticosteroids	14	-1			1	17			0.00	0.00			1	17		
A07EB01	Cromoglicic acid (DDD 0.80 g)	14	-1			1	17			0.00	0.00			1	17		
A07EC	Aminosalicylic acid and similar agents	14,979	15,455	16,110	16,985	1	1	1	1	9.86	10.10	10.42	10.88	1	1	1	1
A07EC01	Sulfasalazine (DDD 2 g)	2,927	2,900	2,883	2,926	1	1	1	1	3.27	3.23	3.21	3.25	1	1	1	1
A07EC02	Mesalazine (DDD 1.50 g)	12,023	12,534	13,207	14,046	1	1	1	1	6.57	6.85	7.20	7.63	1	1	1	1
A07EC03	Olsalazine (DDD 1 g)	29	21	20	14	1	1	0	0	0.02	0.01	0.01	0.01	1	1	0	0
A07F	Antidiarrheal microorganisms	5,270	4,371	3,568	2,472	9	6	4	4	1.78	1.48	1.19	0.82	9	6	4	4
A07FA	Antidiarrheal microorganisms	5,283	4,371	3,568	2,472	9	6	4	4	1.78	1.48	1.19	0.82	9	6	4	4
A07FA01	Lactic acid producing organisms (DDD 3 UD)	97	71	0		2	1	1,991		0.07	0.05	0.00		2	1	499	
A07FA02	Saccharomyces boulardii (DDD 1 g)	5,160	4,300	3,568	2,472	9	6	4	4	1.72	1.43	1.19	0.82	9	6	4	4
A07X	Other antidiarrheals	188	422	454	299	9	4	5	7								
A07XA	Other antidiarrheals	188	422	454	299	9	4	5	7								
A07XA04	Racecadotril	188	422	454	299	9	4	5	7								

**A08 Antiobesity preparations, excl. diet products**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A08	Antiobesity preparations, excl. diet products	351	558	638	602	1	0	0	0	0.10	0.09	0.08	0.07	1	1	0	0
A08A	Antiobesity preparations, excl. diet products	351	558	638	602	1	0	0	0	0.10	0.09	0.08	0.07	1	1	0	0
A08AA	Centrally acting antiobesity products	7	266	355	334		0	0	0								
A08AA62	Bupropion and naltrexone	7	266	355	334		0	0	0								
A08AB	Peripherally acting antiobesity products	344	292	283	268	1	1	0	0	0.10	0.09	0.08	0.07	1	1	0	0
A08AB01	Orlistat (DDD 0.36 g)	344	292	283	268	1	1	0	0	0.10	0.09	0.08	0.07	1	1	0	0

A09 Digestives, incl. enzymes

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A09	Digestives, incl. enzymes	2,444	2,613	3,219	3,146	4	4	4	3	0.97	1.04	1.28	1.25	4	4	4	4
A09A	Digestives, incl. enzymes	2,444	2,613	3,219	3,146	4	4	4	3	0.97	1.04	1.28	1.25	4	4	4	4
A09AA	Enzyme preparations	2,444	2,613	3,219	3,146	4	4	4	3	0.97	1.04	1.28	1.25	4	4	4	4
A09AA02	Multienzymes (lipase, protease etc.)	2,444	2,613	3,219	3,146	4	4	4	3	0.97	1.04	1.28	1.25	4	4	4	4



A10 Drugs used in diabetes

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A10	Drugs used in diabetes	147,956	154,837	161,244	170,838	2	2	2	2	91.70	95.75	99.91	101.74	2	2	2	2
A10A	Insulins and analogues	63,905	63,779	61,128	58,293	2	3	3	2	31.55	32.14	32.34	31.23	3	3	3	3
A10AB	Insulins and analogues for injection, fast-acting (DDD 40 U)	15,670	16,238	15,441	15,324	3	3	3	3	9.83	10.32	10.70	10.66	3	3	3	3
A10AB01	Insulin (human) (DDD 40 U)	127	107	81	70	34	36	38	40	0.11	0.09	0.07	0.06	34	36	38	40
A10AB04	Insulin lispro (DDD 40 U)	3,683	2,896	2,003	1,774	1	2	2	2	2.30	1.89	1.67	1.56	1	1	1	2
A10AB05	Insulin aspart (DDD 40 U)	10,937	12,413	12,590	12,730	3	3	3	3	6.85	7.82	8.45	8.53	3	3	3	3
A10AB06	Insulin glulisine (DDD 40 U)	923	823	767	750	2	2	2	2	0.57	0.51	0.51	0.49	2	2	2	2
A10AC	Insulins and analogues, intermediate-acting (DDD 40 U)	1,119	1,002	879	720	6	9	10	7	0.80	0.71	0.63	0.51	6	9	10	7
A10AC01	Insulin (human) (DDD 40 U)	1,119	1,002	879	720	6	9	10	7	0.80	0.71	0.63	0.51	6	9	10	7
A10AD	Insulins and analogues, intermediate-acting combined with fast-acting (DDD 40 U)	869	743	593	466	5	5	5	4	0.51	0.43	0.36	0.28	5	5	5	4
A10AD01	Insulin (human) (DDD 40 U)	0								0.00							
A10AD04	Insulin lispro (DDD 40 U)	58	49	34	26	4	4	3	3	0.03	0.03	0.02	0.02	4	4	3	3
A10AD05	Insulin aspart (DDD 40 U)	811	694	560	441	5	5	5	4	0.47	0.41	0.34	0.27	5	5	5	4
A10AE	Insulins and analogues, long-acting	46,246	45,796	44,215	41,782	2	2	2	2	20.41	20.68	20.65	19.78	2	2	2	2
A10AE04	Insulin glargine (DDD 40 U)	29,052	28,672	26,163	24,511	2	2	3	3	13.47	13.68	13.03	12.26	2	2	3	3
A10AE05	Insulin detemir (DDD 40 U)	16,587	15,962	13,167	9,760	2	2	2	2	6.80	6.60	5.59	4.39	2	2	2	2
A10AE06	Insulin degludec (DDD 40 U)	607	1,162	4,884	7,511	2	2	2	1	0.14	0.40	2.03	3.14	2	2	2	1
A10AE54	Insulin glargine and lixisenatide (DDD 40 U)		0	0							0.00	0.00					

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A10B	Blood glucose lowering drugs, excl. insulins	84,052	91,058	100,116	112,544	1	1	1	1	60.15	63.61	67.57	70.51	1	1	1	1
A10BA	Biguanides	10,748	11,327	11,666	11,386	1	1	1	1	30.97	32.43	33.51	33.61	1	1	1	1
A10BA02	Metformin (DDD 2 g)	10,748	11,327	11,666	11,386	1	1	1	1	30.97	32.43	33.51	33.61	1	1	1	1
A10BB	Sulfonylureas	173	138	110	87	2	1	2	2	1.76	1.41	1.12	0.88	1	1	1	1
A10BB07	Glipizide (DDD 10 mg)	2				4				0.01				4			
A10BB12	Glimepiride (DDD 2 mg)	171	138	110	87	2	1	2	2	1.75	1.41	1.12	0.88	1	1	1	1
A10BD	Combinations of oral blood glucose lowering drugs	13,126	13,744	13,556	13,689	0	0	0	1	5.86	6.06	6.22	6.28	0	0	0	1
A10BD05	Metformin and pioglitazone (DDD 2 UD)	285	17	6		0	0	0		0.17	0.01	0.01		0	0	0	
A10BD07	Metformin and sitagliptin (DDD 2 UD)	9,668	9,669	8,930	8,464	1	1	1	1	4.34	4.36	4.25	4.08	0	1	0	1
A10BD08	Metformin and vildagliptin (DDD 2 UD)	1,563	1,477	1,311	1,221	0	0	0	0	0.67	0.63	0.59	0.55	0	0	0	0
A10BD09	Pioglitazone and alogliptin (DDD 1 UD)	22	22	20	18		0	0	0	0.01	0.01	0.01	0.01		0	0	0
A10BD10	Metformin and saxagliptin (DDD 2 UD)	48	45	37	34	0				0.02	0.02	0.02	0.02	0			
A10BD11	Metformin and linagliptin (DDD 2 UD)	433	463	452	471	0	0	0	1	0.19	0.20	0.20	0.21	0	0	0	1
A10BD13	Metformin and alogliptin (DDD 2 UD)	31	31	22	12	0				0.01	0.01	0.01	0.01	0			
A10BD15	Metformin and dapagliflozin (DDD 2 UD)	531	776	983	1,156	0	0	0	0	0.23	0.33	0.43	0.50	0	0	0	0
A10BD19	Linagliptin and empagliflozin (DDD 1 UD)		141	249	292		0	0	0		0.03	0.06	0.07		0	0	0
A10BD20	Metformin and empagliflozin (DDD 2 UD)	544	1,083	1,505	1,976	0	0	0	0	0.22	0.45	0.64	0.84	0	0	0	0
A10BD21	Saxagliptin and dapagliflozin (DDD 1 UD)	1	20	37	38					0.00	0.00	0.01	0.01				
A10BD23	Metformin and ertugliflozin (DDD 2 UD)			1	2							0.00	0.00				
A10BD24	Sitagliptin and ertugliflozin (DDD 1 UD)		0	5	7						0.00	0.00	0.00				
A10BG	Thiazolidinediones	833	810	710	707	1	1	1	1	0.60	0.56	0.53	0.51	1	1	1	1
A10BG03	Pioglitazone (DDD 30 mg)	833	810	710	707	1	1	1	1	0.60	0.56	0.53	0.51	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors	30,575	30,050	28,602	27,074	2	2	2	2	13.54	13.47	13.43	12.70	2	2	2	2
A10BH01	Sitagliptin (DDD 0.10 g)	19,828	18,649	17,083	16,187	2	2	2	2	8.60	8.21	7.86	7.44	2	2	2	2
A10BH02	Vildagliptin (DDD 0.10 g)	2,623	2,317	1,999	1,792	3	2	2	2	1.22	1.08	0.98	0.87	3	2	2	2
A10BH03	Saxagliptin (DDD 5 mg)	167	144	120	108	1	1	2	1	0.07	0.06	0.05	0.05	1	1	1	1
A10BH04	Alogliptin (DDD 25 mg)	94	85	69	61	1	1	1	0	0.04	0.04	0.03	0.03	1	1	1	0
A10BH05	Linagliptin (DDD 5 mg)	7,864	8,855	9,331	8,926	4	4	3	3	3.61	4.08	4.51	4.31	3	3	3	3
A10BJ	Glucagon-like peptide-1 (GLP-1) analogues	16,053	18,060	23,934	32,819	1	1	1	1	2.44	2.83	3.80	5.42	1	1	1	1
A10BJ01	Exenatide	3,494	3,030	2,545	2,073	1	1	1	1	0.62	0.54	0.47	0.38	1	1	1	1
A10BJ02	Liraglutide (DDD 1.50 mg)	11,652	13,128	14,175	12,084	1	1	1	1	1.64	1.92	2.09	1.77	1	1	1	1
A10BJ03	Lixisenatide (DDD 20 mcg)	21	27	30	22	3	1	1	2	0.00	0.00	0.00	0.00	2	1	1	2
A10BJ05	Dulaglutide (DDD 0.16 mg)	886	1,876	3,080	3,761	1	1	1	1	0.17	0.37	0.64	0.79	1	1	1	1
A10BJ06	Semaglutide (DDD 0.11 mg)			4,104	14,879			0	1			0.61	2.49			0	0
A10BK	Sodium-glucose co-transporter 2 (SGLT2) inhibitors	12,450	16,878	21,470	26,698	1	1	1	1	4.81	6.67	8.80	10.97	1	1	1	1
A10BK01	Dapagliflozin (DDD 10 mg)	5,191	6,267	7,142	8,383	1	1	1	1	2.21	2.67	3.07	3.57	1	1	1	1
A10BK02	Canagliflozin (DDD 0.20 g)			46	572			0	0			0.01	0.19			0	0
A10BK03	Empagliflozin (DDD 17.50 mg)	7,259	10,609	14,258	17,711	1	1	1	1	2.60	4.00	5.71	7.19	1	1	1	1
A10BK04	Ertugliflozin (DDD 10 mg)		2	24	32		2	0	0		0.00	0.01	0.01		2	0	0
A10BX	Other blood glucose lowering drugs, excl. insulins	95	50	69	84	3	2	2	1	0.18	0.18	0.15	0.14	1	1	1	1
A10BX01	Guar gum	62	4			0	1										
A10BX02	Repaglinide (DDD 4 mg)	33	46	69	84	7	2	2	1	0.18	0.18	0.15	0.14	1	1	1	1

**A11 Vitamins**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A11	Vitamins	9,715	9,305	9,120	9,352	12	13	13	14	25.36	23.27	23.53	25.42	3	4	3	3
A11C	Vitamin A and D, incl. combinations of the two	875	932	918	1,043	4	4	3	2	2.69	2.77	4.20	6.10	2	2	1	1
A11CC	Vitamin D and analogues	875	932	918	1,043	4	4	3	2	2.69	2.77	4.20	6.10	2	2	1	1
A11CC01	Ergocalciferol (vitamin D ₂)	13	11	4		2	2	1									
A11CC02	Dihydrotachysterol (DDD 1 mg)	70	78	69	19	2	3	2	2	0.05	0.06	0.05	0.01	2	3	2	2
A11CC03	Alfacalcidol (DDD 1 mcg)	371	409	396	433	9	8	5	4	0.39	0.42	0.42	0.46	6	5	5	4
A11CC05	Colecalciferol (vitamin D ₃) (DDD 20 mcg)	421	434	450	591	1	1	1	1	2.25	2.29	3.72	5.63	1	1	1	1
A11D	Vitamin B ₁ , plain and in combination with vitamin B ₆ and B ₁₂	2,331	2,246	2,215	2,246	45	49	50	54	5.71	5.23	5.05	4.64	11	12	12	12
A11DA	Vitamin B ₁ , plain	1,022	1,059	1,072	1,204	99	99	99	99	0.49	0.49	0.48	0.50	99	99	99	99
A11DA01	Thiamine (vitamin B ₁) (DDD 50 mg)	1,022	1,059	1,072	1,204	99	99	99	99	0.49	0.49	0.48	0.50	99	99	99	99
A11DB	Vitamin B ₁ in comb. with vitamin B ₆ and/or vitamin B ₁₂	2,618	2,375	2,287	2,085	7	8	8	5	10.46	9.49	9.13	8.29	6	6	6	4

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A11E	Vitamin B-complex, incl. combinations	6,049	5,744	5,667	5,697	1	1	1	1	13.57	12.81	12.41	12.41	1	1	1	1
A11EA	Vitamin B-complex (DDD 1 UD)	2,093	2,066	2,022	1,990	8	8	8	8	5.56	5.48	5.35	5.25	8	8	8	8
A11EX	Vitamin B-complex, other combinations	10,004	9,423	9,311	9,405	0	0	0	0	21.58	20.14	19.48	19.57	0	0	0	0
A11G	Ascorbic acid (vitamin C), incl. combinations	204	146	108	138	1	1	1	1	3.06	2.19	1.61	2.06	1	1	1	1
A11GA	Ascorbic acid (vitamin C), plain	204	146	108	138	1	1	1	1	3.06	2.19	1.61	2.06	1	1	1	1
A11GA01	Ascorbic acid (vitamin C) (DDD 0.20 g)	204	146	108	138	1	1	1	1	3.06	2.19	1.61	2.06	1	1	1	1
A11H	Other plain vitamin preparations	257	236	212	227	4	4	4	5	0.33	0.27	0.26	0.21	7	7	9	8
A11HA	Other plain vitamin preparations	257	236	212	227	4	4	4	5	0.33	0.27	0.26	0.21	7	7	9	8
A11HA02	Pyridoxine (vitamin B ₆) (DDD 0.16 g)	53	48	49	43	13	13	14	12	0.16	0.15	0.15	0.13	13	13	14	12
A11HA03	Tocopherol (vitamin E) (DDD 0.20 g)	36	27	23	18	1	1	1	2	0.17	0.12	0.11	0.08	1	1	1	2
A11HA08	Tocofersolan (DDD 0.20 g)				3				100				0.00				100
A11HA30	Dexpanthenol	168	161	140	164	2	1	1	1								

**A12 Mineral supplements**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A12	Mineral supplements	15,034	15,792	15,838	16,449	5	5	5	4	39.04	40.36	40.49	41.61	4	4	3	3
A12A	Calcium	10,444	10,806	10,841	11,382	3	3	2	2	33.50	34.55	34.59	35.50	3	3	2	2
A12AA	Calcium	768	815	816	852	3	2	2	1	1.01	1.10	1.09	1.13	2	2	2	1
A12AA02	Calcium glubionate (DDD 2.75 g)	7				98				0.00				98			
A12AA04	Calcium carbonate (DDD 3 g)	740	809	801	846	2	2	2	1	1.00	1.10	1.08	1.13	2	2	2	1
A12AA06	Calcium lactate gluconate (DDD 3 g)	21	6	15	6	9	9	6	6	0.01	0.00	0.01	0.00	9	9	6	6
A12AX	Calcium, combinations with vitamin D and/or other drugs	19,353	19,982	20,050	21,059	5	5	5	4	64.97	66.89	67.00	68.73	6	5	5	4
A12B	Potassium	4,534	4,909	4,906	4,982	10	9	9	9	5.47	5.70	5.78	6.00	8	8	7	7
A12BA	Potassium	4,534	4,909	4,906	4,982	10	9	9	9	5.47	5.70	5.78	6.00	8	8	7	7
A12BA01	Potassium chloride (DDD 3 g)	4,418	4,780	4,801	4,982	10	10	9	9	5.42	5.65	5.74	6.00	8	8	7	7
A12BA51	Potassium chloride, combinations (DDD 6 UD)	116	130	105		3	3	3		0.05	0.05	0.04		3	3	3	
A12C	Other mineral supplements	56	77	92	86	49	47	39	32	0.07	0.10	0.12	0.11	49	47	39	32
A12CA	Sodium	56	77	92	86	49	47	39	32	0.07	0.10	0.12	0.11	49	47	39	32
A12CA01	Sodium chloride (DDD 1 g)	56	77	92	86	49	47	39	32	0.07	0.10	0.12	0.11	49	47	39	32



A14 Anabolic agents for systemic use

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A14	Anabolic agents for systemic use	20	17	12	12	16	22	17	22	0.03	0.02	0.02	0.02	16	22	17	22
A14A	Anabolic steroids	20	17	12	12	16	22	17	22	0.03	0.02	0.02	0.02	16	22	17	22
A14AB	Estren derivatives	20	17	12	12	16	22	17	22	0.03	0.02	0.02	0.02	16	22	17	22
A14AB01	Nandrolone (DDD 2 mg)	20	17	12	12	16	22	17	22	0.03	0.02	0.02	0.02	16	22	17	22

A16 Other alimentary tract and metabolism products

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A16	Other alimentary tract and metabolism products	12,960	13,880	15,712	18,204	44	40	34	40	0.02	0.02	0.02	0.03	45	44	39	48
A16A	Other alimentary tract and metabolism products	12,960	13,880	15,712	18,204	44	40	34	40	0.02	0.02	0.02	0.03	45	44	39	48
A16AA	Amino acids and derivatives			4	162			100	83			0.00	0.00			100	63
A16AA04	Mercaptamine (DDD 2 g)				22								0.00				
A16AA05	Carglumic acid (DDD 0.20 g)			4	135			100	100			0.00	0.00			100	100
A16AA06	Betaine (DDD 6 g)				6								0.00				
A16AB	Enzymes	11,693	12,360	12,383	13,404	48	44	41	44	0.01	0.01	0.01	0.02	59	57	55	61
A16AB02	Imiglucerase (DDD 300 U)	1,327	1,253	904	662	23	17	12	15	0.00	0.00	0.00	0.00	23	17	12	15
A16AB03	Agalsidase alfa (DDD 1 mg)	1,812	1,837	1,847	1,670	57	60	48	47	0.00	0.00	0.00	0.00	57	60	48	47
A16AB04	Agalsidase beta (DDD 5 mg)	7,521	8,008	8,249	9,230	47	42	41	45	0.01	0.01	0.01	0.01	47	43	41	45

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A16AB05	Laronidase (DDD 1 TU)	257	311	259	258	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
A16AB07	Alglucosidase alfa (DDD 0.10 g)	343	356	396	619	100	100	100	100	0.00	0.00	0.00	0.01	100	100	100	100
A16AB09	Idursulfase	67	3			100	100										
A16AB10	Velaglucerase alfa (DDD 300 U)	365	592	728	965		6	5		0.00	0.00	0.00	0.00		6	5	
A16AX	Various alimentary tract and metabolism products	1,267	1,519	3,326	4,638	7	8	8	25	0.01	0.01	0.01	0.01	4	11	11	24
A16AX03	Sodium phenylbutyrate (DDD 20 g)	335	272	223	220	2	4	3	1	0.00	0.00	0.00	0.00	2	4	3	1
A16AX04	Nitisinone (DDD 20 mg)	530	529	462	510	2	0	1	1	0.00	0.00	0.00	0.00	2	0	0	1
A16AX05	Zinc acetate (DDD 0.15 g)				1				67				0.00				67
A16AX06	Miglustat (DDD 0.30 g)	384	304	208	236	13	6			0.00	0.00	0.00	0.00	13	6		
A16AX08	Teduglutide (DDD 5 mg)	19	38	152	616	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
A16AX09	Glycerol phenylbutyrate (DDD 15 g)		28	142	175		26	1	0		0.00	0.00	0.00		26	1	0
A16AX10	Eliglustat (DDD 0.17 g)		208	1,058	1,114						0.00	0.00	0.00				
A16AX12	Trientine (DDD 0.45 g)			15	488			100	100			0.00	0.00			100	100
A16AX14	Migalastat (DDD 61.50 mg)		100	1,002	1,217			1			0.00	0.00	0.00			1	
A16AX15	Telotristat (DDD 0.75 g)		40	64	60		100	98	96		0.00	0.00	0.00		100	98	96



B Blood and blood forming organs

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
B	Blood and blood forming organs	217,194	237,037	267,902	284,227	32	28	28	26	137.61	135.50	136.64	140.69	4	4	4	4
B01	Antithrombotic agents	96,776	116,481	138,469	155,180	20	17	14	12	114.28	115.10	115.39	116.10	4	4	4	4
B02	Antihemorrhagics	59,382	58,372	56,158	55,131	31	28	28	27	0.27	0.30	0.29	0.34	26	24	24	21
B03	Antianemic preparations	24,611	25,806	35,208	35,604	22	26	39	41	23.06	20.11	20.95	24.25	6	6	6	6
B05	Blood substitutes and perfusion solutions	31,950	31,353	30,862	30,245	78	77	79	80								
B06	Other hematological agents	4,475	5,025	7,205	8,067	19	19	20	34	0.00	0.00	0.00	0.00	19	19	21	40

**B01 Antithrombotic agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
B01	Antithrombotic agents	96,776	116,481	138,469	155,180	20	17	14	12	114.28	115.10	115.39	116.10	4	4	4	4
B01A	Antithrombotic agents	96,776	116,481	138,469	155,180	20	17	14	12	114.28	115.10	115.39	116.10	4	4	4	4
B01AA	Vitamin K antagonists	3,391	2,896	2,313	1,877	2	2	1	2	14.80	12.64	10.10	8.18	2	2	1	1
B01AA03	Warfarin (DDD 7.50 mg)	3,391	2,896	2,313	1,877	2	2	1	2	14.80	12.64	10.10	8.18	2	2	1	1
B01AB	Heparin group	25,313	25,138	24,658	22,932	41	41	41	38	7.16	6.86	6.70	6.52	37	36	36	35
B01AB01	Heparin (DDD 10 TU)	879	805	758	815	99	99	99	99	0.08	0.08	0.08	0.08	99	99	99	99
B01AB02	Antithrombin (DDD 2.10 TU)	301	451	399	381	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AB04	Dalteparin (DDD 2.50 TU)	1,920	1,387	1,221	1,272	16	3	5	8	0.75	0.55	0.47	0.48	13	3	5	7
B01AB05	Enoxaparin	17,542	16,307	15,816	14,217	41	42	42	40	5.68	5.29	5.10	4.90	40	40	41	39
B01AB09	Danaparoid (DDD 1.50 TU)	267	200	210	160	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AB10	Tinzaparin (DDD 3.50 TU)	4,403	5,989	6,254	6,086	33	33	30	28	0.65	0.94	1.05	1.06	27	27	23	21
B01AC	Platelet aggregation inhibitors excl. heparin	20,032	20,059	19,744	20,398	6	7	7	5	83.25	81.55	78.86	77.48	2	2	2	2
B01AC04	Clopidogrel (DDD 75 mg)	1,464	1,372	1,395	1,565	16	22	19	21	7.79	8.38	9.49	10.34	4	4	3	3
B01AC06	Acetylsalicylic acid (DDD 1 UD)	7,931	7,731	7,317	7,323	1	1	1	1	69.16	67.14	63.91	62.33	1	1	1	1
B01AC07	Dipyridamole	460	391	320	156	2	2	2	2	0.53	0.45	0.37	0.18	2	2	2	2
B01AC11	Iloprost	357	304	297	256	38	42	42	47	0.00	0.00	0.00	0.00	64	68	68	72
B01AC13	Abciximab (DDD 25 mg)	80	69	90	-13	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AC16	Eptifibatide (DDD 0.20 g)	95	89	109	90	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AC17	Tirofiban (DDD 10 mg)	67	51	34	27	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AC21	Treprostinil (DDD 4.30 mg)	1,661	2,015	2,048	2,158	8	7	10	3	0.00	0.00	0.00	0.00	7	6	8	2
B01AC22	Prasugrel (DDD 10 mg)	78	82	74	119	23	24	19	15	0.02	0.02	0.02	0.03	22	24	18	14

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
B01AC24	Ticagrelor (DDD 0.18 g)	3,086	3,301	3,480	3,538	5	5	5	4	0.75	0.80	0.84	0.85	4	4	4	4
B01AC25	Cangrelor (DDD 50 mg)	116	137	182	147	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AC27	Selexipag (DDD 1.80 mg)	465	543	776	788	8	12	4	0	0.00	0.00	0.00	0.00	3	6	1	0
B01AC30	Combinations (DDD 2 UD)	4,171	3,975	3,623	4,245	2	2	2	2	4.98	4.75	4.23	3.74	2	2	2	2
B01AD	Enzymes	4,835	4,967	4,726	5,035	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AD02	Alteplase (DDD 0.10 g)	3,648	4,046	4,036	4,075	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AD07	Retepase (DDD 20 U)	500	252			100	100			0.00	0.00			100	100		
B01AD11	Tenecteplase (DDD 40 mg)	688	669	690	960	99	99	99	99	0.00	0.00	0.00	0.00	99	99	99	99
B01AE	Direct thrombin inhibitors	10,141	11,283	12,414	12,618	7	5	4	3	2.07	2.46	2.79	2.87	2	2	2	2
B01AE03	Argatroban (DDD 0.20 g)	78	52	54	83	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AE06	Bivalirudin (DDD 0.25 g)	388	211	186	104	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AE07	Dabigatran etexilate (DDD 0.30 g)	9,675	11,020	12,173	12,431	2	2	2	2	2.07	2.46	2.79	2.87	2	2	2	2
B01AF	Direct factor Xa inhibitors	32,131	51,214	73,796	91,106	4	3	3	3	6.97	11.56	16.91	21.02	3	3	3	2
B01AF01	Rivaroxaban (DDD 20 mg)	18,829	25,299	32,952	37,647	3	3	2	2	4.22	5.99	7.95	9.11	2	2	2	2
B01AF02	Apixaban (DDD 10 mg)	12,844	24,362	36,986	47,651	4	4	4	3	2.65	5.25	8.13	10.67	3	3	3	3
B01AF03	Edoxaban (DDD 60 mg)	458	1,554	3,858	5,808	2	3	3	3	0.09	0.33	0.83	1.24	1	2	2	2
B01AX	Other antithrombotic agents	932	923	818	1,214	83	83	78	85	0.02	0.02	0.03	0.03	10	13	10	10
B01AX01	Defibrotide (DDD 1.75 g)	758	750	613	716	100	99	100	100	0.00	0.00	0.00	0.00	100	99	100	100
B01AX05	Fondaparinux (DDD 2.50 mg)	174	174	205	193	10	14	10	9	0.02	0.02	0.03	0.03	10	13	10	9
B01AX07	Caplacizumab (DDD 10 mg)				305				100				0.00				100

**B02 Antihemorrhagics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
B02	Antihemorrhagics	59,382	58,372	56,158	55,131	31	28	28	27	0.27	0.30	0.29	0.34	26	24	24	21
B02A	Antifibrinolytics	1,633	1,787	1,915	2,264	73	73	76	76	0.22	0.25	0.23	0.27	22	20	21	18
B02AA	Amino acids	1,579	1,678	1,744	2,014	72	71	74	72	0.22	0.24	0.23	0.27	22	20	21	17
B02AA02	Tranexamic acid (DDD 2 g)	1,579	1,678	1,744	2,014	72	71	74	72	0.22	0.24	0.23	0.27	22	20	21	17
B02AB	Proteinase inhibitors	55	109	171	250	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02AB01	Aprotinin (DDD 500 TU)	2	40	118	190	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02AB02	Alfa1 antitrypsin (DDD 0.60 g)	53	69	54	61	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02B	Vitamin K and other hemostatics	57,748	56,585	54,243	52,867	29	26	26	25	0.05	0.05	0.06	0.07	50	41	36	32
B02BA	Vitamin K	156	142	135	107	88	88	88	85	0.02	0.02	0.02	0.02	88	88	88	87
B02BA01	Phytomenadione (DDD 20 mg)	156	142	135	107	88	88	88	85	0.02	0.02	0.02	0.02	88	88	88	87
B02BB	Fibrinogen	1,911	1,484	1,869	1,867	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02BB01	Fibrinogen, human (DDD 5 g)	1,911	1,484	1,869	1,867	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02BC	Local hemostatics	3,443	3,390	3,441	3,172	100	100	100	99								
B02BC30	Combinations	3,443	3,390	3,441	3,172	100	100	100	99								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
B02BD	Blood coagulation factors	49,224	47,523	43,110	40,028	23	20	20	19								
B02BD01	Coagulation factor IX, II, VII and X in combination	6,593	5,738	4,627	4,420	100	100	100	99								
B02BD02	Coagulation factor VIII	24,277	25,506	25,579	24,213	5	4	4	5								
B02BD03	Factor VIII inhibitor bypassing activity	2,321	1,307	1,949	831	28	22	48	37								
B02BD04	Coagulation factor IX	7,185	6,533	5,806	5,447	11	6	11	7								
B02BD06	Von Willebrand factor and coagulation factor VIII in combination	6,401	6,467	4,192	3,851	18	18	17	17								
B02BD07	Coagulation factor XIII	727	739	611	730	39	33	40	37								
B02BD08	Coagulation factor VIIa	765	464	347	483	54	84	82	79								
B02BD10	Von Willebrand factor	955	769		52	13	43		67								
B02BX	Other systemic hemostatics	3,014	4,046	5,688	7,694	11	8	8	7	0.02	0.03	0.04	0.05	11	8	9	8
B02BX04	Romiplostim (DDD 30 mcg)	1,036	1,331	1,379	1,805	11	9	9	8	0.01	0.01	0.01	0.01	11	9	9	9
B02BX05	Eltrombopag (DDD 50 mg)	1,978	2,700	3,751	4,518	11	8	9	9	0.01	0.02	0.03	0.03	11	8	9	9
B02BX06	Emicizumab (DDD 15 mg)		16	559	1,371				2		0.00	0.00	0.00				2

**B03 Antianemic preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
B03	Antianemic preparations	24,611	25,806	35,208	35,604	22	26	39	41	23.06	20.11	20.95	24.25	6	6	6	6
B03A	Iron preparations	7,253	8,915	16,696	16,411	49	52	69	77	5.25	5.74	6.07	5.94	6	6	5	5
B03AA	Iron bivalent, oral preparations	2,774	3,045	3,498	2,332	3	3	2	2	4.06	4.20	4.15	4.14	4	3	3	3
B03AA01	Ferrous glycine sulfate (DDD 0.20 g)	2,211	2,446	2,912	1,903	3	3	2	2	3.00	3.07	3.05	3.24	5	4	3	3
B03AA07	Ferrous sulfate (DDD 0.20 g)	563	599	586	428	3	3	3	3	1.06	1.12	1.10	0.90	4	3	3	3
B03AB	Iron trivalent, oral preparations	941	1,142	1,417	1,348	4	3	3	3	1.06	1.39	1.75	1.63	3	2	2	2
B03AB05	Ferric oxide polymaltose complexes (DDD 90 mg)	941	1,140	1,413	1,343	4	3	3	3	1.06	1.39	1.75	1.63	3	2	2	2
B03AB10	Ferric maltol (DDD 60 mg)	0	2	4	6		6			0.00	0.00	0.00	0.00		5		
B03AC	Iron, parenteral preparations (DDD 0.10 g)	6,951	9,330	23,542	25,461	195	193	195	196	0.25	0.29	0.33	0.34	198	197	196	196
B03AD	Iron in combination with folic acid	62	64	10		3	2	2									
B03AD01	Ferrous amino acid complex	62	64	10		3	2	2									
B03B	Vitamin B ₁₂ and folic acid	3,135	1,937	2,009	2,161	4	5	5	5	16.84	13.31	13.71	17.08	5	6	6	5
B03BA	Vitamin B ₁₂ (cyanocobalamin and derivatives)	2,359	1,146	1,144	1,080	3	5	5	4	9.66	6.06	5.97	5.59	4	5	5	4
B03BA01	Cyanocobalamin	1,564	364	385	369	2	5	5	1	4.61	1.09	1.16	1.11	2	5	5	1
B03BA03	Hydroxocobalamin (DDD 20 mcg)	795	782	759	711	6	5	5	5	5.05	4.96	4.81	4.49	6	5	5	5
B03BB	Folic acid, combinations	777	791	865	1,082	6	6	5	6	7.18	7.26	7.74	11.49	6	6	6	6
B03BB01	Folic acid	777	791	865	1,082	6	6	5	6	7.18	7.26	7.74	11.49	6	6	6	6
B03X	Other antianemic preparations	14,224	14,954	16,503	17,032	13	13	12	11	0.97	1.06	1.18	1.23	13	13	12	11
B03XA	Other antianemic preparations	14,224	14,954	16,503	17,032	13	13	12	11	0.97	1.06	1.18	1.23	13	13	12	11
B03XA01	Erythropoietin (DDD 1 TU)	1,961	2,012	2,094	2,439	19	18	15	18	0.16	0.17	0.19	0.21	19	18	14	17
B03XA02	Darbepoetin alfa (DDD 4.50 mcg)	9,707	10,397	11,850	12,361	12	12	11	10	0.65	0.72	0.82	0.85	12	12	11	10
B03XA03	Methoxy polyethylene glycolepoetin beta (DDD 4 mcg)	2,556	2,546	2,559	2,232	11	10	12	9	0.16	0.17	0.18	0.17	11	10	12	9

**B05 Blood substitutes and perfusion solutions**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
B05	Blood substitutes and perfusion solutions	31,950	31,353	30,862	30,245	78	77	79	80								
B05A	Blood and related products	3,370	3,628	5,175	5,763	100	100	100	100								
B05AA	Blood substitutes and plasma protein fractions	3,370	3,628	5,175	5,763	100	100	100	100								
B05AA01	Albumin	3,333	3,605	5,157	5,756	100	100	100	100								
B05AA05	Dextran	5	1			100	100										
B05AA06	Gelatin agents	18	11	13	7	100	97	96	95								
B05AA07	Hydroxyethylstarch	14	11	4		91	95	100									
B05B	I.V. Solutions	19,939	18,828	17,460	16,929	99	99	99	99								
B05BA	Solutions for parenteral nutrition	5,045	5,193	5,103	5,403	100	100	100	100								
B05BA01	Amino acids	124	108	95	76	100	100	100	100								
B05BA02	Fat emulsions	50	47	39	37	97	97	95	95								
B05BA03	Carbohydrates	446	433	417	416	99	99	99	99								
B05BA10	Combinations	4,426	4,606	4,552	4,874	100	100	100	100								
B05BB	Solutions affecting the electrolyte balance	14,867	13,608	12,331	11,496	99	99	99	99								
B05BB01	Electrolytes	13,719	12,527	11,416	10,675	99	99	99	99								
B05BB02	Electrolytes with carbohydrates	1,148	1,081	915	821	100	100	100	100								
B05BC	Solutions producing osmotic diuresis	27	27	27	30	99	99	99	98								
B05BC01	Mannitol	27	27	27	30	99	99	99	98								
B05D	Peritoneal dialytics	7,336	7,458	6,774	6,108	7	7	7	6								
B05DA	Isotonic solutions	5,591	5,704	5,348	4,945	14	11	13	11								
B05DB	Hypertonic solutions	9,080	9,212	8,199	7,270	13	14	15	11								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
B05X	I.V. Solution additives	1,199	1,272	1,252	1,203	98	99	99	99								
B05XA	Electrolyte solutions	783	837	821	779	98	98	98	98								
B05XA01	Potassium chloride	300	290	276	226	100	100	99	99								
B05XA03	Sodium chloride	187	181	176	131	94	94	94	92								
B05XA05	Magnesium sulfate	10	74	81	107	99	100	99	100								
B05XA06	Potassium phosphate, incl. comb. with other potassium salts	38	34	31	33	98	98	98	99								
B05XA07	Calcium chloride				27				100								
B05XA14	Sodium glycerophosphate	59	68	65	58	97	97	94	96								
B05XA31	Electrolytes in combination with other drugs	189	190	191	197	99	100	100	100								
B05XB	Amino acids	41	41	31	27	100	100	100	100								
B05XB02	Alanyl glutamine	41	41	31	27	100	100	100	100								
B05XC	Vitamins	751	789	800	794	198	198	199	199								
B05Z	Hemodialytics and hemofiltrates	106	167	202	242	100	100	100	100								
B05ZB	Hemofiltrates	212	334	403	485	200	200	200	200								

**B06 Other hematological agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
B06	Other hematological agents	4,475	5,025	7,205	8,067	19	19	20	34	0.00	0.00	0.00	0.00	19	19	21	40
B06A	Other hematological agents	4,475	5,025	7,205	8,067	19	19	20	34	0.00	0.00	0.00	0.00	19	19	21	40
B06AB	Heme products				15				100								
B06AB01	Hemin				15				100								
B06AC	Drugs used in hereditary angioedema	4,475	5,025	7,205	8,052	19	19	20	34	0.00	0.00	0.00	0.00	19	19	21	40
B06AC01	C1-inhibitor, plasma derived (DDD 1.40 TU)	2,715	2,745	3,952	4,425	14	17	20	20	0.00	0.00	0.00	0.00	14	17	19	20
B06AC02	Icatibant (DDD 30 mg)	1,516	1,977	2,837	2,025	16	13	12	11	0.00	0.00	0.00	0.00	16	13	12	11
B06AC04	Conestat alfa (DDD 3.50 TU)	244	303	273	96	100	75	69	100	0.00	0.00	0.00	0.00	100	75	69	100
B06AC05	Lanadelumab (DDD 21.40 mg)			143	1,506			100	100			0.00	0.00			100	100



C Cardiovascular system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C	Cardiovascular system	197,611	172,314	150,664	138,177	8	10	12	13	574.78	598.20	626.28	654.96	2	2	2	2
C01	Cardiac therapy	21,252	22,900	22,057	22,398	53	57	57	61	15.22	14.82	13.97	13.45	7	10	8	8
C02	Antihypertensives	6,451	6,978	7,864	9,119	8	8	7	7	2.97	3.00	3.23	3.18	3	3	3	3
C03	Diuretics	7,938	8,213	8,669	9,143	16	18	20	21	51.66	51.43	51.43	50.50	6	6	6	5
C04	Peripheral vasodilators	81	77	76	76	3	3	2	2	0.11	0.11	0.10	0.10	3	3	2	2
C05	Vasoprotectives	4,506	4,580	4,469	4,515	4	4	5	5								
C07	Beta blocking agents	23,541	21,649	20,279	19,267	4	5	4	4	65.22	65.09	64.39	65.66	2	2	2	2
C08	Calcium channel blockers	18,160	16,292	12,799	11,381	4	3	4	4	86.02	90.14	95.54	99.51	1	1	1	1
C09	Agents acting on the renin-angiotensin system	50,596	46,444	43,195	38,543	1	1	1	1	240.90	253.02	264.38	274.83	1	1	1	1
C10	Lipid modifying agents	65,085	45,180	31,255	23,735	2	1	1	1	112.68	120.58	133.24	147.73	1	1	1	1

**C01 Cardiac therapy**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C01	Cardiac therapy	21,252	22,900	22,057	22,398	53	57	57	61	15.22	14.82	13.97	13.45	7	10	8	8
C01A	Cardiac glycosides	1,202	1,127	1,106	1,052	11	12	14	15	2.48	2.26	2.09	1.91	4	4	4	4
C01AA	Digitalis glycosides	1,202	1,127	1,106	1,052	11	12	14	15	2.48	2.26	2.09	1.91	4	4	4	4
C01AA05	Digoxin (DDD 0.25 mg)	1,202	1,127	1,106	1,052	11	12	14	15	2.48	2.26	2.09	1.91	4	4	4	4
C01B	Antiarrhythmics, class I and III	4,167	4,094	3,730	2,862	33	34	37	41	2.05	2.06	2.01	1.97	3	4	3	4
C01BB	Antiarrhythmics, class IB	311	181	360	283	96	97	97	97	0.00	0.00	0.00	0.00	96	97	97	97
C01BB01	Lidocaine (DDD 3 g)	311	181	360	283	96	97	97	97	0.00	0.00	0.00	0.00	96	97	97	97
C01BC	Antiarrhythmics, class IC	1,969	1,942	1,644	1,177	1	1	1	2	1.44	1.43	1.42	1.40	1	1	1	1
C01BC04	Flecainide (DDD 0.20 g)	1,969	1,942	1,644	1,177	1	1	1	2	1.44	1.43	1.42	1.40	1	1	1	1
C01BD	Antiarrhythmics, class III	1,142	1,209	948	668	28	34	24	23	0.61	0.63	0.58	0.57	8	12	9	10
C01BD01	Amiodarone (DDD 0.20 g)	401	516	307	260	51	61	37	28	0.46	0.49	0.46	0.46	10	15	11	12
C01BD05	Ibutilide (DDD 1 mg)	107	87	109	77	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01BD07	Dronedarone (DDD 0.80 g)	634	607	532	331	1	1	1	1	0.14	0.14	0.12	0.11	1	1	1	1
C01BG	Other antiarrhythmics, class I and III	746	762	778	733	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01BG11	Vernakalant (DDD 0.20 g)	746	762	778	733	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01C	Cardiac stimulants excl. cardiac glycosides	10,101	12,103	11,744	13,210	83	84	84	85	0.57	0.91	0.62	0.69	83	87	83	83
C01CA	Adrenergic and dopaminergic agents	5,773	7,305	6,569	8,064	71	73	70	75	0.57	0.90	0.61	0.68	83	87	83	83
C01CA01	Etilefrine (DDD 50 mg)	346	392	417	259	75	76	77	61	0.06	0.06	0.06	0.06	26	26	23	22
C01CA02	Isoprenaline (DDD 90 mg)				138				100				0.00				100
C01CA03	Norepinephrine (DDD 6 mg)	1,184	1,503	1,359	2,294	99	99	99	100	0.06	0.06	0.06	0.08	99	99	99	99
C01CA04	Dopamine (DDD 0.50 g)	35	33	70	120	81	84	89	91	0.00	0.00	0.00	0.00	81	83	89	91

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C01CA06	Phenylephrine (DDD 4 mg)	443	504	595	675	100	100	99	99	0.00	0.01	0.02	0.02	99	99	100	99
C01CA07	Dobutamine (DDD 0.50 g)	72	79	51	84	100	99	99	100	0.00	0.00	0.00	0.00	100	99	99	100
C01CA17	Midodrine (DDD 30 mg)			41	65			14	17			0.00	0.01			11	15
C01CA24	Epinephrine (DDD 0.50 mg)	3,378	4,496	3,731	4,141	53	59	52	56	0.45	0.77	0.47	0.52	88	91	88	88
C01CA26	Ephedrine	316	298	304	288	99	99	99	98								
C01CE	Phosphodiesterase inhibitors		338	738	819		100	100	100		0.00	0.00	0.00		100	100	100
C01CE02	Milrinone (DDD 50 mg)		338	738	819		100	100	100		0.00	0.00	0.00		100	100	100
C01CX	Other cardiac stimulants	4,328	4,461	4,438	4,328	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01CX08	Levosimendan (DDD 11 mg)	4,328	4,461	4,438	4,328	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01D	Vasodilators used in cardiac diseases	5,019	4,764	4,599	4,561	11	12	10	12	10.08	9.56	9.23	8.85	4	4	4	4
C01DA	Organic nitrates	5,019	4,764	4,599	4,561	11	12	10	12	10.08	9.56	9.23	8.85	4	4	4	4
C01DA02	Glyceryl trinitrate	1,110	1,031	989	1,018	29	32	30	40	0.78	0.70	0.69	0.65	15	17	16	22
C01DA08	Isosorbide dinitrate	1,126	1,082	1,043	991	11	13	10	8	1.74	1.63	1.57	1.50	5	6	6	5
C01DA14	Isosorbide mononitrate (DDD 40 mg)	2,784	2,652	2,566	2,553	3	3	3	3	7.56	7.23	6.97	6.71	3	3	3	3
C01E	Other cardiac preparations	763	812	879	714	95	94	95	95	0.03	0.03	0.03	0.03	64	61	60	49
C01EA	Prostaglandins	271	276	329	287	100	98	100	100	0.00	0.00	0.00	0.00	100	98	100	100
C01EA01	Alprostadil (DDD 0.50 mg)	271	276	329	287	100	98	100	100	0.00	0.00	0.00	0.00	100	98	100	100
C01EB	Other cardiac preparations	493	536	550	427	92	92	91	92	0.03	0.03	0.03	0.03	63	60	60	49
C01EB10	Adenosine (DDD 15 mg)	331	363	363	222	98	98	96	98	0.02	0.02	0.02	0.01	99	100	96	99
C01EB16	Ibuprofen (DDD 30 mg)				9				100				0.00				100
C01EB17	Ivabradine (DDD 10 mg)	34	38	36	33	4	4	3	6	0.01	0.01	0.01	0.02	3	4	2	4
C01EB21	Regadenoson (DDD 0.40 mg)	127	134	151	162	100	100	100	99	0.00	0.00	0.00	0.00	100	100	100	99

**C02 Antihypertensives**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C02	Antihypertensives	6,451	6,978	7,864	9,119	8	8	7	7	2.97	3.00	3.23	3.18	3	3	3	3
C02A	Antiadrenergic agents, centrally acting	1,108	1,246	1,419	1,523	27	30	26	31	2.54	2.52	2.70	2.61	2	3	3	3
C02AC	Imidazoline receptor agonists	1,108	1,246	1,419	1,523	27	30	26	31	2.54	2.52	2.70	2.61	2	3	3	3
C02AC01	Clonidine (DDD 0.45 mg)	316	373	363	460	85	87	86	89	0.06	0.06	0.07	0.06	33	36	36	35
C02AC02	Guanfacine (DDD 3 mg)	133	235	310	439	18	18	14	13	0.02	0.03	0.04	0.07	17	17	15	14
C02AC05	Moxonidine (DDD 0.30 mg)	659	638	745	624	2	2	2	2	2.46	2.43	2.59	2.48	2	2	2	2
C02C	Antiadrenergic agents, peripherally acting	312	341	379	403	4	4	4	4	0.39	0.43	0.48	0.51	4	4	4	4
C02CA	Alpha-adrenoceptor blocking agents	312	341	379	403	4	4	4	4	0.39	0.43	0.48	0.51	4	4	4	4
C02CA01	Prazosin (DDD 5 mg)	312	341	379	403	4	4	4	4	0.39	0.43	0.48	0.51	4	4	4	4
C02K	Other antihypertensives	5,031	5,391	6,066	7,193	4	3	3	2	0.04	0.05	0.05	0.06	3	2	2	2
C02KX	Antihypertensives for pulmonary arterial hypertension	5,031	5,391	6,066	7,193	4	3	3	2	0.04	0.05	0.05	0.06	3	2	2	2
C02KX01	Bosentan (DDD 0.25 g)	1,546	1,010	810	1,317	4	3	4	3	0.02	0.02	0.01	0.01	2	2	4	3
C02KX02	Ambrisentan (DDD 7.50 mg)	785	816	783	797	4	3	2	1	0.01	0.01	0.01	0.01	3	2	1	1
C02KX04	Macitentan (DDD 10 mg)	1,885	2,450	3,094	3,416	5	3	3	2	0.01	0.02	0.02	0.02	5	3	3	2
C02KX05	Riociguat (DDD 4.50 mg)	815	1,115	1,378	1,664	2	1	1	2	0.01	0.01	0.01	0.02	1	1	1	1

**C03 Diuretics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C03	Diuretics	7,938	8,213	8,669	9,143	16	18	20	21	51.66	51.43	51.43	50.50	6	6	6	5
C03A	Low-ceiling diuretics, thiazides	1,172	1,223	1,301	1,429	2	2	2	2	6.53	6.67	6.69	7.11	2	2	2	2
C03AA	Thiazides, plain	1,172	1,223	1,301	1,429	2	2	2	2	6.53	6.67	6.69	7.11	2	2	2	2
C03AA03	Hydrochlorothiazide (DDD 25 mg)	1,172	1,223	1,301	1,429	2	2	2	2	6.53	6.67	6.69	7.11	2	2	2	2
C03B	Low-ceiling diuretics, excl. thiazides	194	183	185	235	1	1	1	15	0.50	0.48	0.48	0.49	1	1	1	3
C03BA	Sulfonamides, plain	194	183	185	235	1	1	1	15	0.50	0.48	0.48	0.49	1	1	1	3
C03BA08	Metolazone (DDD 5 mg)				52				61				0.01				61
C03BA11	Indapamide (DDD 2.50 mg)	194	183	185	183	1	1	1	1	0.50	0.48	0.48	0.48	1	1	1	2
C03C	High-ceiling diuretics	4,420	4,692	5,056	5,239	25	29	33	35	34.92	34.98	35.25	34.94	8	8	8	7
C03CA	Sulfonamides, plain	4,420	4,692	5,056	5,239	25	29	33	35	34.92	34.98	35.25	34.94	8	8	8	7
C03CA01	Furosemide (DDD 40 mg)	4,420	4,692	5,056	5,239	25	29	33	35	34.92	34.98	35.25	34.94	8	8	8	7
C03D	Potassium-sparing agents	1,223	1,303	1,374	1,496	3	3	3	3	2.41	2.56	2.70	2.92	3	3	3	3
C03DA	Aldosterone antagonists	1,223	1,303	1,374	1,496	3	3	3	3	2.41	2.56	2.70	2.92	3	3	3	3
C03DA01	Spironolactone (DDD 75 mg)	1,154	1,231	1,300	1,412	3	3	3	3	2.40	2.55	2.69	2.91	3	3	3	3
C03DA04	Eplerenone (DDD 50 mg)	69	71	74	84	3	3	3	3	0.01	0.01	0.01	0.01	3	3	3	3

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C03E	Diuretics and potassium-sparing agents in combination	837	770	722	609	1	2	2	1	7.30	6.75	6.32	5.04	1	1	2	1
C03EA	Low-ceiling diuretics and potassium-sparing agents	662	615	585	487	1	1	1	1	6.34	5.89	5.57	4.37	1	1	1	1
C03EA01	Hydrochlorothiazide and potassium-sparing agents (DDD 1 UD)	662	615	585	487	1	1	1	1	6.34	5.89	5.57	4.37	1	1	1	1
C03EA02	Trichlormethiazide and potassium-sparing agents (DDD 2 UD)																
C03EB	High-ceiling diuretics and potassium-sparing agents	176	155	137	122	4	5	5	4	0.97	0.85	0.75	0.67	4	5	5	4
C03EB01	Furosemide and potassium-sparing agents (DDD 1 UD)	176	155	137	122	4	5	5	4	0.97	0.85	0.75	0.67	4	5	5	4
C03X	Other diuretics	93	42	31	135	92	93	68	20	0.00	0.00	0.00	0.00	92	93	32	1
C03XA	Vasopressin antagonists	93	42	31	135	92	93	68	20	0.00	0.00	0.00	0.00	92	93	32	1
C03XA01	Tolvaptan (DDD 30 mg)	93	42	31	135	92	93	68	20	0.00	0.00	0.00	0.00	92	93	32	1

C04 Peripheral vasodilators

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C04	Peripheral vasodilators	81	77	76	76	3	3	2	2	0.11	0.11	0.10	0.10	3	3	2	2
C04A	Peripheral vasodilators	81	77	76	76	3	3	2	2	0.11	0.11	0.10	0.10	3	3	2	2
C04AD	Purine derivatives	81	77	76	76	3	3	2	2	0.11	0.11	0.10	0.10	3	3	2	2
C04AD03	Pentoxifylline	81	77	76	76	3	3	2	2	0.11	0.11	0.10	0.10	3	3	2	2

**C05 Vasoprotectives**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C05	Vasoprotectives	4,506	4,580	4,469	4,515	4	4	5	5								
C05A	Agents for treatment of hemorrhoids and anal fissures for topical use	2,821	2,895	2,785	2,786	2	2	2	2								
C05AA	Corticosteroids	2,578	2,646	2,559	2,648	2	2	2	2								
C05AA01	Hydrocortisone	64	57	59	79	32	28	27	29								
C05AA04	Prednisolone	2,180	2,188	2,049	2,131	1	1	1	1								
C05AA08	Fluocortolone	334	400	451	437	2	2	2	1								
C05AE	Muscle relaxants	121	125	134	139	2	4	1	2								
C05AE01	Glyceryl trinitrate	121	125	134	139	2	4	1	2								
C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use	122	124	92		0	0										
C05AX03	Other preparations, combinations	122	124	92		0	0										
C05B	Antivaricose therapy	1,684	1,685	1,684	1,729	7	8	11	11								
C05BA	Heparins or heparinoids for topical use	1,586	1,570	1,515	1,537	2	2	2	2								
C05BA01	Organo-heparinoid	1,586	1,570	1,515	1,537	2	2	2	2								
C05BB	Sclerosing agents for local injection	99	115	169	192	88	89	90	87								
C05BB02	Polidocanol	99	115	169	192	88	89	90	87								

**C07 Beta blocking agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C07	Beta blocking agents	23,541	21,649	20,279	19,267	4	5	4	4	65.22	65.09	64.39	65.66	2	2	2	2
C07A	Beta blocking agents	20,601	18,883	17,820	17,206	5	5	5	5	59.67	59.87	59.57	61.28	2	2	2	2
C07AA	Beta blocking agents, non-selective	1,160	1,083	1,387	1,443	2	2	2	2	2.56	2.44	2.73	2.68	2	2	2	2
C07AA03	Pindolol (DDD 15 mg)																
C07AA05	Propranolol (DDD 0.16 g)	1,028	995	1,240	1,307	2	2	2	2	2.11	2.14	2.23	2.22	2	2	2	2
C07AA07	Sotalol (DDD 0.16 g)	132	88	147	136	2	2	1	1	0.45	0.30	0.50	0.46	2	2	1	1
C07AB	Beta blocking agents, selective	18,000	16,510	15,260	14,716	3	3	3	3	54.79	55.16	54.71	56.58	2	2	2	2
C07AB02	Metoprolol (DDD 0.15 g)	6,163	5,374	4,663	3,881	5	5	5	5	11.01	10.30	10.03	9.71	2	2	2	2
C07AB03	Atenolol (DDD 75 mg)	419	408	365	383	2	2	2	2	2.10	2.05	1.83	1.91	2	2	2	2
C07AB04	Acebutolol (DDD 0.40 g)	84	80	73	59	2	3	3	2	0.16	0.15	0.14	0.11	2	3	3	2
C07AB05	Betaxolol (DDD 20 mg)	270	247	227	90	1	1	1	1	0.75	0.68	0.63	0.25	1	1	1	1
C07AB07	Bisoprolol (DDD 10 mg)	10,360	9,697	9,244	9,665	2	2	2	2	38.22	39.44	39.57	42.16	2	2	2	2
C07AB08	Celiprolol (DDD 0.20 g)	212	193	175	148	1	2	2	1	0.93	0.85	0.77	0.65	1	2	2	1
C07AB09	Esmolol (DDD 2.50 g)	27	25	27	26	99	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C07AB12	Nebivolol (DDD 5 mg)	465	488	484	463	1	1	1	1	1.61	1.69	1.74	1.79	1	1	1	1
C07AB14	Landiolol			2	1			100	100								
C07AG	Alpha and beta blocking agents	1,441	1,290	1,174	1,047	30	35	37	40	2.33	2.27	2.14	2.03	2	2	2	2
C07AG01	Labetalol (DDD 0.60 g)	576	592	593	503	73	74	73	81	0.09	0.09	0.09	0.05	7	8	7	13
C07AG02	Carvedilol (DDD 37.50 mg)	865	698	581	543	2	2	1	2	2.24	2.18	2.05	1.98	2	2	1	2

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C07B	Beta blocking agents and thiazides	1,397	1,320	1,194	1,048	0	0	0	0	3.94	3.72	3.40	3.06	0	0	0	0
C07BB	Beta blocking agents, selective, and thiazides	1,397	1,320	1,194	1,048	0	0	0	0	3.94	3.72	3.40	3.06	0	0	0	0
C07BB02	Metoprolol and thiazides (DDD 1 UD)	315	290	227	142	0	0	0	0	0.68	0.62	0.49	0.32	0	0	0	0
C07BB07	Bisoprolol and thiazides (DDD 1 UD)	1,037	982	923	867	0	0	0	0	3.26	3.09	2.91	2.74	0	0	0	0
C07BB12	Nebivolol and thiazides	45	48	44	38	0	0	0	0								
C07F	Beta blocking agents, other combinations	1,543	1,446	1,264	1,014	0	0	0	1	1.60	1.50	1.41	1.32	0	0	0	1
C07FB	Beta blocking agent and calcium channel blockers	1,543	1,446	1,264	1,014	0	0	0	1	1.60	1.50	1.41	1.32	0	0	0	1
C07FB02	Metoprolol and felodipine (DDD 1 UD)	1,543	1,446	1,264	1,014	0	0	0	1	1.60	1.50	1.41	1.32	0	0	0	1

**C08 Calcium channel blockers**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C08	Calcium channel blockers	18,160	16,292	12,799	11,381	4	3	4	4	86.02	90.14	95.54	99.51	1	1	1	1
C08C	Selective calcium channel blockers with mainly vascular effects	17,087	15,288	11,820	10,496	3	3	4	4	84.41	88.60	94.08	98.05	1	1	1	1
C08CA	Dihydropyridine derivatives	17,087	15,288	11,820	10,496	3	3	4	4	84.41	88.60	94.08	98.05	1	1	1	1
C08CA01	Amlodipine (DDD 5 mg)	6,112	4,786	4,208	4,357	2	1	1	1	58.29	61.62	66.51	69.37	1	1	1	1
C08CA02	Felodipine (DDD 5 mg)	3,450	3,345	2,712	2,250	1	1	1	1	7.22	7.46	7.58	7.56	1	1	1	1
C08CA03	Isradipine (DDD 5 mg)	189	139	13		1	1	1		0.26	0.22	0.02		1	1	1	
C08CA05	Nifedipine (DDD 30 mg)	1,131	911	735	506	2	3	2	2	2.33	1.69	1.02	0.68	1	2	2	2
C08CA06	Nimodipine	368	274	286	305	96	95	95	95	0.01	0.01	0.01	0.00	83	84	84	81
C08CA07	Nisoldipine (DDD 20 mg)	117	38	3		2	3	6		0.08	0.03	0.00		2	3	6	
C08CA10	Nilvadipine (DDD 8 mg)	468	463	434	427	2	1	1	2	0.77	0.77	0.72	0.71	1	1	1	2
C08CA13	Lercanidipine (DDD 10 mg)	5,251	5,332	3,430	2,652	1	1	1	1	15.45	16.81	18.22	19.73	1	1	1	1
C08D	Selective calcium channel blockers with direct cardiac effects	1,073	1,004	979	885	7	6	10	2	1.61	1.54	1.46	1.46	2	2	2	3
C08DA	Phenylalkylamine derivatives	297	285	309	243	19	16	25	1	0.73	0.73	0.72	0.75	2	2	3	3
C08DA01	Verapamil (DDD 0.24 g)	297	285	309	243	19	16	25	1	0.73	0.73	0.72	0.75	2	2	3	3
C08DB	Benzothiazepine derivatives	777	720	670	641	2	2	2	3	0.88	0.81	0.75	0.71	2	2	2	3
C08DB01	Diltiazem (DDD 0.24 g)	777	720	670	641	2	2	2	3	0.88	0.81	0.75	0.71	2	2	2	3

**C09 Agents acting on the renin-angiotensin system**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C09	Agents acting on the renin-angiotensin system	50,596	46,444	43,195	38,543	1	1	1	1	240.90	253.02	264.38	274.83	1	1	1	1
C09A	Ace inhibitors, plain	9,360	9,221	8,175	6,223	2	2	1	1	103.25	104.81	103.86	103.86	2	2	1	1
C09AA	Ace inhibitors, plain	9,360	9,221	8,175	6,223	2	2	1	1	103.25	104.81	103.86	103.86	2	2	1	1
C09AA02	Enalapril (DDD 10 mg)	2,222	2,156	2,049	2,003	1	2	1	1	22.76	22.90	22.03	21.94	1	1	1	1
C09AA03	Lisinopril (DDD 10 mg)	859	731	680	557	1	2	2	1	3.78	3.69	3.64	3.48	1	1	1	1
C09AA04	Perindopril (DDD 4 mg)	1,766	1,734	1,711	1,575	1	1	1	1	4.50	4.60	4.69	4.59	1	1	1	1
C09AA05	Ramipril (DDD 2.50 mg)	4,478	4,570	3,736	2,079	2	2	2	1	72.09	73.52	73.51	73.83	2	2	1	1
C09AA06	Quinapril (DDD 15 mg)	35	30		8	1	1		2	0.11	0.10		0.03	1	1		2
C09AA15	Zofenopril (DDD 30 mg)			0								0.00					
C09B	Ace inhibitors, combinations	5,315	4,786	4,028	3,519	0	0	0	0	12.20	11.92	11.55	11.24	0	0	0	0
C09BA	Ace inhibitors and diuretics	3,823	3,503	2,990	2,433	0	0	0	0	10.44	10.10	9.53	9.09	0	0	0	0
C09BA02	Enalapril and diuretics (DDD 1 UD)	2,384	2,085	1,664	1,223	0	0	0	0	6.97	6.71	6.34	6.02	0	0	0	0
C09BA03	Lisinopril and diuretics (DDD 1 UD)	670	676	634	529	0	0	0	0	1.31	1.32	1.24	1.13	0	0	0	0
C09BA04	Perindopril and diuretics (DDD 1 UD)	550	537	523	505	1	0	0	0	1.04	1.01	1.00	0.97	1	1	0	0
C09BA05	Ramipril and diuretics (DDD 1 UD)	179	172	168	165	0	0	0	0	1.03	0.98	0.96	0.94	0	0	0	0
C09BA06	Quinapril and diuretics (DDD 1 UD)	40	33		11	1	0		1	0.09	0.08		0.03	1	0		1
C09BA15	Zofenopril and diuretics		0														
C09BB	Ace inhibitors and calcium channel blockers	1,191	935	747	777	0	0	0	0	1.46	1.47	1.60	1.67	0	0	0	0
C09BB02	Enalapril and lercanidipine (DDD 1 UD)	123	124	126	123	0	0	0	0	0.35	0.35	0.36	0.36		0	0	0
C09BB04	Perindopril and amlodipine (DDD 1 UD)	990	811	621	654	0	0	0	0	1.01	1.12	1.24	1.32	0	0	0	0
C09BB05	Ramipril and felodipine (DDD 1 UD)	77				0				0.10				0			

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C09BX	Ace inhibitors, other combinations	302	348	291	309	0	0	0	0	0.30	0.35	0.41	0.47	0	0	0	0
C09BX01	Perindopril, amlodipine and indapamide (DDD 1 UD)	299	334	275	293	0	0	0	0	0.29	0.33	0.38	0.43	0	0	0	0
C09BX02	Perindopril and bisoprolol (DDD 1 UD)	3	14	16	17					0.00	0.02	0.04	0.04				
C09C	Angiotensin ii receptor blockers (arbs), plain	18,802	15,483	14,030	13,100	1	1	1	1	93.88	103.89	115.69	125.69	1	1	1	1
C09CA	Angiotensin ii receptor blockers (arbs), plain	18,802	15,483	14,030	13,100	1	1	1	1	93.88	103.89	115.69	125.69	1	1	1	1
C09CA01	Losartan (DDD 50 mg)	9,313	7,571	6,533	5,458	1	1	1	1	38.67	42.27	47.22	49.45	1	1	1	1
C09CA02	Eprosartan (DDD 0.60 g)	369	321	288	202	2	2	1	2	0.40	0.37	0.35	0.27	2	2	1	2
C09CA03	Valsartan (DDD 80 mg)	2,726	2,249	1,940	2,146	1	2	1	1	13.17	15.12	14.79	16.00	1	1	1	1
C09CA06	Candesartan (DDD 8 mg)	4,603	4,083	4,199	3,927	1	1	1	1	32.71	36.71	43.17	49.04	1	1	1	1
C09CA07	Telmisartan (DDD 40 mg)	1,329	1,047	886	986	2	2	2	1	7.93	8.36	9.07	9.81	1	1	1	1
C09CA08	Olmесartan medoxomil (DDD 20 mg)	462	210	185	381	1	1	1	1	1.01	1.07	1.09	1.12	0	0	1	1
C09D	Angiotensin ii receptor blockers (arbs), combinations	17,118	16,954	16,962	15,700	0	1	1	1	31.57	32.40	33.27	34.04	0	0	0	0
C09DA	Angiotensin ii receptor blockers (arbs) and diuretics	10,724	9,744	9,564	9,391	0	0	0	0	27.36	28.12	28.71	29.12	0	0	0	0
C09DA01	Losartan and diuretics (DDD 1 UD)	3,823	3,536	3,837	3,748	0	0	0	0	11.72	12.08	12.77	12.51	0	0	0	0
C09DA02	Eprosartan and diuretics (DDD 1 UD)	375	347	291	240	0	0	0	0	0.40	0.38	0.35	0.32	0	0	0	0
C09DA03	Valsartan and diuretics (DDD 1 UD)	1,490	1,256	1,137	1,103	0	0	0	0	4.47	4.76	4.42	4.53	0	0	0	0
C09DA06	Candesartan and diuretics (DDD 1 UD)	3,482	3,432	3,380	3,352	0	0	0	0	6.68	6.96	7.22	7.52	0	0	0	0
C09DA07	Telmisartan and diuretics (DDD 1 UD)	1,346	1,013	775	785	0	0	0	0	3.73	3.59	3.60	3.89	0	0	0	0
C09DA08	Olmесartan medoxomil and diuretics (DDD 1 UD)	209	159	145	164	0	0	0	0	0.36	0.35	0.35	0.35	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C09DB	Angiotensin II receptor blockers (arbs) and calcium channel blockers	3,409	3,295	2,452	1,369	0	0	0	0	2.67	2.59	2.67	2.81	0	0	0	0
C09DB01	Valsartan and amlodipine (DDD 1 UD)	3,201	3,173	2,384	1,284	0	0	0	0	2.49	2.47	2.56	2.68	0	0	0	0
C09DB02	Olmesartan medoxomil and amlodipine (DDD 1 UD)	208	122	68	85	0	0	0	1	0.18	0.12	0.11	0.14	0	0	0	1
C09DX	Angiotensin ii receptor blockers (arbs), other combinations	2,985	3,915	4,946	4,941	1	2	2	2	1.54	1.69	1.89	2.11	0	1	1	1
C09DX01	Valsartan, amlodipine and hydrochlorothiazide (DDD 1 UD)	2,092	2,181	2,193	1,183	0	0	0	0	1.43	1.49	1.58	1.68	0	0	0	0
C09DX04	Valsartan and sacubitril (DDD 2 UD)	893	1,735	2,753	3,758	4	4	3	3	0.10	0.20	0.31	0.42	4	4	3	3
C09X	Other agents acting on the renin-angiotensin system	1								0.00							
C09XA	Renin-inhibitors	1								0.00							
C09XA02	Aliskiren (DDD 0.15 g)	1								0.00							

**C10 Lipid modifying agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C10	Lipid modifying agents	65,085	45,180	31,255	23,735	2	1	1	1	112.68	120.58	133.24	147.73	1	1	1	1
C10A	Lipid modifying agents, plain	64,691	44,808	31,136	23,544	2	2	2	1	112.52	120.43	133.14	147.61	1	1	1	1
C10AA	HMG CoA reductase inhibitors	54,547	38,828	27,758	19,190	1	1	1	1	107.66	114.76	125.99	138.45	1	1	1	1
C10AA01	Simvastatin (DDD 30 mg)	21,250	17,003	11,269	6,678	1	1	1	1	38.42	36.94	35.63	33.40	1	1	1	1
C10AA02	Lovastatin (DDD 45 mg)	237	240	211	229	1	1	1	1	0.32	0.31	0.30	0.31	1	1	1	1
C10AA03	Pravastatin (DDD 30 mg)	1,303	1,295	1,205	1,029	2	2	2	2	2.26	2.24	2.17	1.83	2	2	2	2
C10AA04	Fluvastatin (DDD 60 mg)	1,081	837	737	600	2	1	2	2	2.20	1.90	1.85	1.76	1	1	1	1
C10AA05	Atorvastatin (DDD 20 mg)	19,424	11,291	8,406	6,166	2	2	2	1	44.34	49.21	56.16	63.10	1	2	1	2
C10AA07	Rosuvastatin (DDD 10 mg)	11,252	8,162	5,929	4,488	1	1	1	1	20.12	24.17	29.87	38.07	1	1	1	1
C10AB	Fibrates	483	447	398	417	2	2	2	1	0.54	0.53	0.49	0.52	2	2	2	1
C10AB02	Bezafibrate (DDD 0.60 g)	79	77	86	88	1	1	1	1	0.06	0.06	0.07	0.07	1	1	1	1
C10AB04	Gemfibrozil (DDD 1.20 g)	23	20	22	17	1	1	2	3	0.03	0.02	0.03	0.02	1	1	2	3
C10AB05	Fenofibrate (DDD 0.20 g)	381	350	290	311	2	2	2	1	0.44	0.44	0.39	0.42	2	2	2	1
C10AC	Bile acid sequestrants	290	173	244	15	3	2	3		0.11	0.06	0.09	0.00	3	2	3	
C10AC01	Colestyramine (DDD 14 g)	287	159	232		3	2	3		0.11	0.06	0.09		3	2	3	
C10AC04	Colesevelam (DDD 3.75 g)	3	14	12	15					0.00	0.00	0.00	0.00				
C10AX	Other lipid modifying agents	9,370	5,360	2,736	3,922	3	2	3	1	4.22	5.08	6.57	8.64	1	1	1	1
C10AX09	Ezetimibe (DDD 10 mg)	9,107	4,874	1,831	1,561	1	2	3	2	4.21	5.06	6.53	8.54	1	1	1	1
C10AX13	Evolocumab (DDD 10 mg)	257	432	687	1,790	82	5	3	1	0.01	0.02	0.03	0.07	80	5	3	1
C10AX14	Alirocumab (DDD 5.40 mg)	7	54	218	571	22			1	0.00	0.00	0.01	0.03	29			1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C10B	Lipid modifying agents, combinations	394	372	120	191	1	0	0	0	0.16	0.16	0.10	0.13	0	0	0	0
C10BA	Combinations of various lipid modifying agents	318	253	12	58	1	1	1		0.12	0.10	0.00		0	0	1	
C10BA02	Simvastatin and ezetimibe (DDD 1 UD)	318	253	12		1	1	1		0.12	0.10	0.00		0	0	1	
C10BA06	Rosuvastatin and ezetimibe				58												
C10BX	Lipid modifying agents in combination with other drugs	76	119	108	134				0	0.04	0.06	0.09	0.13				0
C10BX11	Atorvastatin, amlodipine and perindopril (DDD 1 UD)	76	119	105	117				0	0.04	0.06	0.09	0.13				0
C10BX15	Atorvastatin and perindopril			2	17												



D Dermatologicals

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D	Dermatologicals	40,051	41,751	43,205	43,110	4	4	4	4	2.72	2.85	2.97	2.89	1	1	1	1
D01	Antifungals for dermatological use	5,600	5,815	5,919	5,939	3	3	3	3	1.45	1.55	1.58	1.43	1	1	1	1
D02	Emollients and protectives	2,042	2,232	2,376	49	1	1	1	0								
D03	Preparations for treatment of wounds and ulcers	6,226	6,547	6,688	6,809	4	3	3	2								
D04	Antipruritics, incl. antihistamines, anesthetics, etc.	189	330	425	379												
D05	Antipsoriatics	2,247	2,172	2,151	2,215	3	3	2	2	0.14	0.15	0.15	0.17	2	2	2	2
D06	Antibiotics and chemotherapeutics for dermatological use	4,789	5,072	4,980	4,719	4	4	3	3								
D07	Corticosteroids, dermatological preparations	11,050	11,526	11,804	12,266	3	3	3	3								
D08	Antiseptics and disinfectants	888	920	981	967	54	58	66	67								
D09	Medicated dressings	173	139	141	132	26	24	22	19								
D10	Anti-acne preparations	3,480	3,562	3,531	3,672	1	1	1	1	1.05	1.07	1.15	1.19	1	1	1	1
D11	Other dermatological preparations	3,369	3,436	4,210	5,964	2	4	1	5	0.08	0.08	0.09	0.11	0	1	0	4

**D01 Antifungals for dermatological use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D01	Antifungals for dermatological use	5,600	5,815	5,919	5,939	3	3	3	3	1.45	1.55	1.58	1.43	1	1	1	1
D01A	Antifungals for topical use	4,548	4,667	4,752	4,885	4	4	4	3								
D01AA	Antibiotics	41	44	44	47	4	4	2	2								
D01AA02	Natamycin	41	44	44	47	4	4	2	2								
D01AC	Imidazole and triazole derivatives	2,852	3,022	3,139	3,292	5	5	5	4								
D01AC01	Clotrimazole	235	256	250	224	1	1	1	1								
D01AC02	Miconazole	861	977	982	993	8	8	8	7								
D01AC07	Tioconazole	68	29	20	43	1	2	1	0								
D01AC08	Ketoconazole	933	960	1,062	1,159	2	2	2	1								
D01AC10	Bifonazole				39												
D01AC20	Imidazoles/triazoles in combination with corticosteroids	755	800	825	834	7	7	7	7								
D01AE	Other antifungals for topical use	1,655	1,601	1,568	1,546	1	1	1	1								
D01AE14	Ciclopirox	73	70	61	47	0											
D01AE15	Terbinafine	1,391	1,335	1,303	1,311	1	2	1	1								
D01AE16	Amorolfine	191	196	204	188	1	0	0	1								
D01B	Antifungals for systemic use	1,052	1,148	1,168	1,054	1	1	1	1	1.45	1.55	1.58	1.43	1	1	1	1
D01BA	Antifungals for systemic use	1,052	1,148	1,168	1,054	1	1	1	1	1.45	1.55	1.58	1.43	1	1	1	1
D01BA02	Terbinafine (DDD 0.25 g)	1,052	1,148	1,168	1,054	1	1	1	1	1.45	1.55	1.58	1.43	1	1	1	1



D02 Emollients and protectives

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D02	Emollients and protectives	2,042	2,232	2,376	49	1	1	1	0								
D02A	Emollients and protectives	2,042	2,232	2,376	49	1	1	1	0								
D02AE	Carbamide products	1,069	1,198	1,287	29	1	1	1	0								
D02AE01	Carbamide	1,069	1,198	1,287	29	1	1	1	0								
D02AE51	Carbamide, combinations																
D02AX	Other emollients and protectives	1,947	2,068	2,178	40	1	1	1	0								

D03 Preparations for treatment of wounds and ulcers

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D03	Preparations for treatment of wounds and ulcers	6,226	6,547	6,688	6,809	4	3	3	2								
D03A	Cicatrizants	6,161	6,492	6,688	6,809	3	3	3	2								
D03AX	Other cicatrizants	6,161	6,492	6,688	6,809	3	3	3	2								
D03AX03	Dexpanthenol	6,161	6,492	6,688	6,809	3	3	3	2								
D03B	Enzymes	65	55			68	68										
D03BA	Proteolytic enzymes	65	55			68	68										
D03BA02	Collagenase	65	55			68	68										

**D04 Antipruritics, incl. antihistamines, anesthetics, etc.**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D04	Antipruritics, incl. antihistamines, anesthetics, etc.	189	330	425	379												
D04A	Antipruritics, incl. antihistamines, anesthetics, etc.	189	330	425	379												
D04AA	Antihistamines for topical use	189	330	425	379												
D04AA04	Tripelennamine	189	330	425	379												

D05 Antipsoriatics

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D05	Antipsoriatics	2,247	2,172	2,151	2,215	3	3	2	2	0.14	0.15	0.15	0.17	2	2	2	2
D05A	Antipsoriatics for topical use	1,730	1,777	1,860	1,908	3	3	3	3								
D05AX	Other antipsoriatics for topical use	1,730	1,777	1,860	1,908	3	3	3	3								
D05AX02	Calcipotriol	33	38	42	44	4	3	3	2								
D05AX03	Calcitriol	55	42	38	29	3	3	3	2								
D05AX52	Calcipotriol, combinations	1,642	1,696	1,779	1,836	3	3	3	3								
D05B	Antipsoriatics for systemic use	517	395	291	306	2	2	2	2	0.14	0.15	0.15	0.17	2	2	2	2
D05BB	Retinoids for treatment of psoriasis	517	395	291	306	2	2	2	2	0.14	0.15	0.15	0.17	2	2	2	2
D05BB02	Acitretin (DDD 35 mg)	517	395	291	306	2	2	2	2	0.14	0.15	0.15	0.17	2	2	2	2

**D06 Antibiotics and chemotherapeutics for dermatological use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D06	Antibiotics and chemotherapeutics for dermatological use	4,789	5,072	4,980	4,719	4	4	3	3								
D06A	Antibiotics for topical use	1,870	2,250	2,289	2,221	6	6	5	5								
D06AX	Other antibiotics for topical use	1,870	2,250	2,289	2,221	6	6	5	5								
D06AX01	Fusidic acid	832	968	1,046	1,016	11	11	9	9								
D06AX04	Neomycin	1,017	1,258	1,216	1,180	1	1	1	1								
D06AX09	Mupirocin	21	24	26	26	17	15	16	16								
D06B	Chemotherapeutics for topical use	2,919	2,822	2,691	2,498	2	2	1	1								
D06BA	Sulfonamides	88	74			54	56										
D06BA01	Silver sulfadiazine	88	74			54	56										
D06BB	Antivirals	2,319	2,246	2,182	2,151	1	1	1	1								
D06BB03	Aciclovir	1,184	1,173	1,158	1,129	1	1	1	1								
D06BB04	Podophyllotoxin	130	66			2	3										
D06BB06	Penciclovir	213	202	245	195		0	0									
D06BB10	Imiquimod	427	495	516	631	1	1	1	1								
D06BB12	Sinecatechins																
D06BB53	Aciclovir, combinations	361	310	262	196												
D06BX	Other chemotherapeutics	514	502	509	347	0	0	0	1								
D06BX01	Metronidazole	343	349	353	342	0	0	0	1								
D06BX02	Ingenol mebutate	170	153	156	5	0	1	0									

**D07 Corticosteroids, dermatological preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D07	Corticosteroids, dermatological preparations	11,050	11,526	11,804	12,266	3	3	3	3								
D07A	Corticosteroids, plain	7,517	7,894	8,137	8,632	3	3	3	3								
D07AA	Corticosteroids, weak (group I)	3,231	3,527	3,589	3,724	2	2	2	1								
D07AA02	Hydrocortisone	3,231	3,527	3,589	3,724	2	2	2	1								
D07AB	Corticosteroids, moderately potent (group II)	1,295	1,359	1,305	1,508	4	4	3	3								
D07AB01	Clobetasone	8	8	9	9	1	1	0	0								
D07AB02	Hydrocortisone butyrate	715	714	861	929	3	3	2	2								
D07AB08	Desonide	572	637	435	570	4	5	5	4								
D07AC	Corticosteroids, potent (group III)	2,391	2,377	2,626	2,624	5	5	5	4								
D07AC01	Betamethasone	1,375	1,431	1,622	1,666	7	6	6	5								
D07AC03	Desoximetasone	55	70	81	32	7	11	6	10								
D07AC13	Mometasone	918	839	884	890	3	2	2	2								
D07AC14	Methylprednisolone aceponate	43	38	40	36	0	0	0	1								
D07AD	Corticosteroids, very potent (group IV)	600	630	617	776	4	4	4	4								
D07AD01	Clobetasol	600	630	617	776	4	4	4	4								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D07B	Corticosteroids, combinations with antiseptics	1,200	1,262	1,232	1,247	4	3	3	3								
D07BA	Corticosteroids, weak, combinations with antiseptics	715	765	748	727	3	3	2	2								
D07BA04	Hydrocortisone and antiseptics	715	765	748	727	3	3	2	2								
D07BB	Corticosteroids, moderately potent, combinations with antiseptics	290	307	349	349	4	3	3	3								
D07BB04	Hydrocortisone butyrate and antiseptics	290	307	349	349	4	3	3	3								
D07BC	Corticosteroids, potent, combinations with antiseptics	195	190	135	171	6	5	6	5								
D07BC01	Betamethasone and antiseptics	195	190	135	171	6	5	6	5								
D07C	Corticosteroids, combinations with antibiotics	1,539	1,569	1,625	1,591	5	4	4	4								
D07CA	Corticosteroids, weak, combinations with antibiotics	894	921	949	925	4	4	4	4								
D07CA01	Hydrocortisone and antibiotics	894	921	949	925	4	4	4	4								
D07CC	Corticosteroids, potent, combinations with antibiotics	646	648	676	666	5	4	4	4								
D07CC01	Betamethasone and antibiotics	646	648	676	666	5	4	4	4								
D07X	Corticosteroids, other combinations	793	802	809	796	2	2	2	2								
D07XA	Corticosteroids, weak, other combinations	270	294	300	272				0								
D07XA01	Hydrocortisone	270	294	300	272				0								
D07XC	Corticosteroids, potent, other combinations	523	508	509	524	3	3	3	3								
D07XC01	Betamethasone, combinations	523	508	509	524	3	3	3	3								



D08 Antiseptics and disinfectants

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D08	Antiseptics and disinfectants	888	920	981	967	54	58	66	67								
D08A	Antiseptics and disinfectants	888	920	981	967	54	58	66	67								
D08AC	Biguanides and amidines	511	549	655	635	89	92	96	99								
D08AC02	Chlorhexidine	189	167	64	41	71	72	55	90								
D08AC52	Chlorhexidine, combinations	322	382	591	593	100	100	100	100								
D08AE	Phenol and derivatives																
D08AE04	Triclosan																
D08AG	Iodine products	377	371	326	332	6	7	7	6								
D08AG02	Povidone-iodine	377	371	326	332	6	7	7	6								

D09 Medicated dressings

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D09	Medicated dressings	173	139	141	132	26	24	22	19								
D09A	Medicated dressings	173	139	141	132	26	24	22	19								
D09AA	Ointment dressings with antiinfectives	14	13			36	36										
D09AA02	Fusidic acid	14	13			36	36										
D09AB	Zinc bandages	158	126	141	132	25	22	22	19								
D09AB01	Zinc bandage without supplements	158	126	141	132	25	22	22	19								

**D10 Anti-acne preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D10	Anti-acne preparations	3,480	3,562	3,531	3,672	1	1	1	1	1.05	1.07	1.15	1.19	1	1	1	1
D10A	Anti-acne preparations for topical use	2,127	2,162	2,144	2,317	1	1	1	1								
D10AD	Retinoids for topical use in acne	790	840	908	882	2	2	2	2								
D10AD01	Tretinoin	131	174	206	235	0	0	0	1								
D10AD03	Adapalene	192	179	190	167	1	1	1	1								
D10AD53	Adapalene, combinations	467	487	512	480	2	3	3	3								
D10AE	Peroxides	525	474	452	461	0	1	0	0								
D10AE01	Benzoyl peroxide	525	474	452	461	0	1	0	0								
D10AF	Antiinfectives for treatment of acne	637	669	606	790	1	1	1	1								
D10AF01	Clindamycin	202	138	219	221	2	2	2	2								
D10AF51	Clindamycin, combinations	435	532	387	570	1	1	1	1								
D10AX	Other anti-acne preparations for topical use	175	179	177	183	0	0	0	1								
D10AX03	Azelaic acid	175	179	177	183	0	0	0	1								
D10B	Anti-acne preparations for systemic use	1,353	1,400	1,387	1,356	1	1	1	1	1.05	1.07	1.15	1.19	1	1	1	1
D10BA	Retinoids for treatment of acne	1,353	1,400	1,387	1,356	1	1	1	1	1.05	1.07	1.15	1.19	1	1	1	1
D10BA01	Isotretinoin (DDD 30 mg)	1,353	1,400	1,387	1,356	1	1	1	1	1.05	1.07	1.15	1.19	1	1	1	1

**D11 Other dermatological preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D11	Other dermatological preparations	3,369	3,436	4,210	5,964	2	4	1	5	0.08	0.08	0.09	0.11	0	1	0	4
D11A	Other dermatological preparations	3,369	3,436	4,210	5,964	2	4	1	5	0.08	0.08	0.09	0.11	0	1	0	4
D11AC	Medicated shampoos	94	96	107	113	0	0	0	0								
D11AC03	Selenium compounds	94	96	107	113	0	0	0	0								
D11AF	Wart and anti-corn preparations	46															
D11AH	Agents for dermatitis, excluding corticosteroids	1,993	2,033	2,679	4,318	3	6	2	7	0.01	0.02	0.03	0.05	1	6	1	7
D11AH01	Tacrolimus	1,348	1,234	884	993	3	3	2	2								
D11AH02	Pimecrolimus	367	365	579	438	1	2	1	1								
D11AH04	Alitretinoin (DDD 20 mg)	278	321	316	340	1	1	0	1	0.01	0.02	0.02	0.02	1	1	0	1
D11AH05	Dupilumab (DDD 21.40 mg)		112	899	2,548		71	2	11		0.00	0.01	0.03		70	2	11
D11AX	Other dermatologicals	1,258	1,308	1,424	1,532	0	0	0	0	0.06	0.07	0.06	0.06	0	0	0	1
D11AX01	Minoxidil	673	725	780	887	0		0	0								
D11AX10	Finasteride (DDD 1 mg)	220	223	212	205	0	0	0	1	0.06	0.07	0.06	0.06	0	0	0	1
D11AX16	Eflornithine	41	33	56	44	0	0		0								
D11AX18	Diclofenac	5	5	5	5	2	5	3									
D11AX21	Brimonidine	119	106	112	95	0	0	0	1								
D11AX22	Ivermectin	187	208	251	295	0	0	0	1								
D11AX24	Deoxycholic acid	13	8	8	2	20	20	33									



G Genito urinary system and sex hormones

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
G	Genito urinary system and sex hormones	112,607	110,634	112,664	104,274	5	6	6	6	132.43	134.39	138.46	138.10	4	6	8	8
G01	Gynecological antiinfectives and antiseptics	3,060	3,266	3,425	3,223	1	1	1	1	0.79	0.80	0.81	0.75	1	1	1	1
G02	Other gynecologicals	8,018	7,882	8,154	7,702	32	34	37	39	3.06	2.90	2.77	2.38	4	9	12	12
G03	Sex hormones and modulators of the genital system	57,726	57,759	59,593	56,738	4	5	6	5	80.07	80.43	83.18	81.50	6	9	12	12
G04	Urologicals	43,803	41,727	41,493	36,611	2	2	2	2	48.51	50.27	51.70	53.47	2	2	2	2

**G01 Gynecological antiinfectives and antiseptics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
G01	Gynecological antiinfectives and antiseptics	3,060	3,266	3,425	3,223	1	1	1	1	0.79	0.80	0.81	0.75	1	1	1	1
G01A	Antiinfectives and antiseptics, excl. combinations with corticosteroids	3,060	3,266	3,425	3,223	1	1	1	1	0.79	0.80	0.81	0.75	1	1	1	1
G01AA	Antibiotics	339	395	408	426	0	1	0	1	0.07	0.06	0.06	0.07	1	1	0	1
G01AA10	Clindamycin (DDD 0.10 g)	339	395	408	426	0	1	0	1	0.07	0.06	0.06	0.07	1	1	0	1
G01AC	Quinoline derivatives	61	153	216	229	0	0	0	1	0.00	0.01	0.01	0.02	0	0	0	1
G01AC05	Dequalinium (DDD 20 mg)	61	153	216	229	0	0	0	1	0.00	0.01	0.01	0.02	0	0	0	1
G01AF	Imidazole derivatives	2,660	2,718	2,801	2,567	1	1	1	1	0.71	0.72	0.73	0.67	1	1	1	1
G01AF01	Metronidazole	972	855	831	769	1	1	1	2	0.19	0.17	0.17	0.16	1	1	1	2
G01AF02	Clotrimazole (DDD 0.10 g)	1,521	1,670	1,790	1,674	0	1	0	1	0.40	0.41	0.42	0.42	1	1	0	1
G01AF04	Miconazole (DDD 0.10 g)	167	193	180	124	2	2	2	2	0.13	0.15	0.14	0.10	2	2	2	2



G02 Other gynecologicals

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
G02	Other gynecologicals	8,018	7,882	8,154	7,702	32	34	37	39	3.06	2.90	2.77	2.38	4	9	12	12
G02A	Uterotonics	38	87	75	72	92	99	100	100	0.01	0.00	0.00	0.00	24	43	100	100
G02AB	Ergot alkaloids	4	1			23	31			0.01	0.00			23	31		
G02AB01	Methylergometrine (DDD 0.20 mg)	4	1			23	31			0.01	0.00			23	31		
G02AD	Prostaglandins	34	86	75	72	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
G02AD02	Dinoprostone (DDD 0.50 mg)			7	12			100	100			0.00	0.00			100	100
G02AD06	Misoprostol (DDD 0.20 mg)	34	86	69	60	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
G02B	Contraceptives for topical use	7,368	7,370	7,702	7,195	27	31	34	35	3.02	2.86	2.74	2.35	4	9	12	12
G02BA	Intrauterine contraceptives	5,270	5,540	6,074	5,914	36	39	41	42								
G02BA03	Plastic iud with progestogens	5,270	5,540	6,074	5,914	36	39	41	42								
G02BB	Intravaginal contraceptives	2,098	1,830	1,627	1,280	4	4	7	5	3.02	2.86	2.74	2.35	4	9	12	12
G02BB01	Vaginal ring with progestogen and estrogen (DDD 0.04 UD)	2,098	1,830	1,627	1,280	4	4	7	5	3.02	2.86	2.74	2.35	4	9	12	12
G02C	Other gynecologicals	612	425	377	435	89	84	87	87	0.03	0.03	0.03	0.03	12	10	10	10
G02CB	Prolactin inhibitors	72	75	54	60	10	11	10	9	0.03	0.03	0.03	0.03	9	9	8	9
G02CB01	Bromocriptine (DDD 5 mg)	24	24	18	20	10	9	7	9	0.02	0.03	0.02	0.02	10	9	7	9
G02CB03	Cabergoline (DDD 0.50 mg)	44	45	35	40	12	13	11	9	0.01	0.01	0.01	0.01	12	13	11	9
G02CB04	Quinagolide (DDD 75 mcg)	5	6			1	0			0.00	0.00			1	0		
G02CX	Other gynecologicals	539	350	323	376	100	100	100	99	0.00	0.00	0.00	0.00	100	100	100	99
G02CX01	Atosiban (DDD 165 mg)	539	350	323	376	100	100	100	99	0.00	0.00	0.00	0.00	100	100	100	99

**G03 Sex hormones and modulators of the genital system**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
G03	Sex hormones and modulators of the genital system	57,726	57,759	59,593	56,738	4	5	6	5	80.07	80.43	83.18	81.50	6	9	12	12
G03A	Hormonal contraceptives for systemic use	18,680	18,883	18,635	17,760	9	14	16	15	42.22	43.77	45.39	43.67	11	16	21	21
G03AA	Progestogens and estrogens, fixed combinations	11,322	11,321	10,467	9,633	7	12	15	13	25.82	26.00	25.62	24.52	8	14	19	19
G03AA07	Levonorgestrel and ethinylestradiol	149	160	170	227	0	3	4	12	0.57	0.59	0.60	0.81	0	5	5	21
G03AA09	Desogestrel and ethinylestradiol	1,043	984	886	779	4	8	7	4	3.54	3.43	3.08	2.90	4	9	10	15
G03AA10	Gestodene and ethinylestradiol	1,578	1,370	1,327	1,173	1	3	5	5	5.59	5.08	5.25	4.62	5	9	15	15
G03AA11	Norgestimate and ethinylestradiol	13	13	7	0	0	1	1		0.03	0.03	0.02	0.00	0	1	1	
G03AA12	Drospirenone and ethinylestradiol	6,428	6,534	6,506	5,762	9	15	18	15	12.48	12.78	13.14	12.11	10	17	21	20
G03AA13	Norelgestromin and ethinylestradiol (DDD 0.11 UD)	295	289	265	253	1	5	8	10	0.50	0.48	0.44	0.42	1	5	8	10
G03AA14	Nomegestrol and estradiol (DDD 1 UD)	1,813	1,847	860	770	10	12	20	14	3.11	3.13	1.51	1.30	10	12	23	14
G03AA16	Dienogest and ethinylestradiol	4	125	446	669	2	24	20	15	0.01	0.47	1.58	2.37	4	45	37	31
G03AB	Progestogens and estrogens, sequential preparations	975	918	1,097	996	5	6	8	9	1.61	1.50	1.75	1.58	4	6	8	9
G03AB03	Levonorgestrel and ethinylestradiol (DDD 0.75 UD)	49	40	0		0	0			0.11	0.09	0.00		0	0		
G03AB05	Desogestrel and ethinylestradiol	11	6	2						0.02	0.01	0.00					
G03AB06	Gestodene and ethinylestradiol (DDD 0.75 UD)	26	20	2		0				0.05	0.04	0.00		0			
G03AB08	Dienogest and estradiol (DDD 1 UD)	890	851	1,092	996	5	6	8	9	1.42	1.36	1.74	1.58	5	6	8	9
G03AC	Progestogens	5,360	5,547	5,995	6,173	15	20	22	21	14.74	16.22	17.97	17.53	17	21	25	26
G03AC01	Norethisterone	228	240	228	165	1	2	2	3	0.79	0.85	0.89	0.71	1	2	2	3
G03AC03	Levonorgestrel (DDD 1 UD)	257	272	274	267	14	23	18	23	0.41	0.45	0.46	0.41	4	11	8	8

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
G03AC08 Etonogestrel (DDD 67 mcg)	792	925	1,031	985	40	49	56	59	3.30	3.99	4.69	4.50	40	48	55	59
G03AC09 Desogestrel (DDD 1 UD)	4,083	4,111	4,462	4,100	11	14	16	12	10.24	10.93	11.92	11.91	11	13	16	15
G03AC10 Drospirenone				656				22								
G03AD Emergency contraceptives	1,023	1,098	1,077	958	2	2	2	2	0.05	0.05	0.05	0.04	2	2	2	2
G03AD01 Levonorgestrel	562	554	521	464	3	2	3	2	0.03	0.03	0.03	0.02	2	2	3	2
G03AD02 Ulipristal (DDD 30 mg)	461	544	556	494	1	1	1	2	0.02	0.02	0.02	0.02	1	1	1	1
G03B Androgens	4,587	4,943	5,809	5,915	0	0	0	0	1.85	1.99	2.31	2.43	0	0	0	0
G03BA 3-oxoandrostens (4) derivatives	4,587	4,943	5,809	5,915	0	0	0	0	1.85	1.99	2.31	2.43	0	0	0	0
G03BA03 Testosterone	4,587	4,943	5,809	5,915	0	0	0	0	1.85	1.99	2.31	2.43	0	0	0	0
G03C Estrogens	22,510	22,319	23,582	22,134	1	1	1	1	19.96	18.99	20.09	20.85	1	1	1	1
G03CA Natural and semisynthetic estrogens, plain	22,100	21,997	23,348	21,922	1	1	1	1	19.21	18.28	19.44	20.23	1	1	1	1
G03CA03 Estradiol	20,382	20,136	20,944	18,980	1	1	1	1	13.38	12.77	13.63	14.61	0	0	0	1
G03CA04 Estriol	1,718	1,861	2,404	2,942	1	1	1	1	5.83	5.52	5.81	5.62	2	1	1	2
G03CC Estrogens, combinations with other drugs			15	7												
G03CC07 Conjugated estrogens and bazedoxifene			15	7												
G03CX Other estrogens	411	322	219	205	0	0	0	0	0.75	0.70	0.65	0.62	0	0	0	0
G03CX01 Tibolone (DDD 2.50 mg)	411	322	219	205	0	0	0	0	0.75	0.70	0.65	0.62	0	0	0	0
G03D Progestogens	1,354	1,473	1,462	1,490	0	0	0	1	2.15	2.32	2.30	2.23	1	1	0	1
G03DA Pregnen (4) derivatives	524	533	449	427	0	0	0	2	0.40	0.43	0.46	0.54	0	1	1	1
G03DA02 Medroxyprogesterone	35	40	55	69	1	1	1	1	0.18	0.21	0.29	0.37	1	1	1	1
G03DA04 Progesterone	489	493	393	357	0	0	0	2	0.22	0.22	0.17	0.17	0	0	0	2

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
G03DB	Pregnadien derivatives	371	428	490	619	0	0	0	1	0.41	0.47	0.54	0.71	0	0	0	1
G03DB01	Dydrogesterone (DDD 10 mg)	179	206	240	317	0	0	0	1	0.33	0.38	0.44	0.58	0	0	0	1
G03DB08	Dienogest (DDD 2 mg)	192	222	250	302	0	0	0	1	0.08	0.09	0.10	0.13	0	0	0	1
G03DC	Estren derivatives	459	512	524	445	1	1	0	1	1.35	1.42	1.31	0.98	1	1	0	1
G03DC02	Norethisterone (DDD 5 mg)	407	456	478	445	0	0	0	1	1.12	1.18	1.11	0.98	0	0	0	1
G03DC03	Lynestrenol (DDD 5 mg)	52	57	47		4	2	1		0.23	0.24	0.20		4	2	1	
G03F	Progestogens and estrogens in combination	4,151	4,154	4,236	3,935	0	0	0	0	9.81	9.72	9.79	9.46	0	0	0	0
G03FA	Progestogens and estrogens, combinations	3,352	3,351	3,458	3,249	0	0	0	0	7.63	7.60	7.79	7.59	0	0	0	0
G03FA01	Norethisterone and estrogen	1,230	1,268	1,366	1,085	0	0	0	0	2.91	2.94	3.07	2.63	0	0	0	0
G03FA12	Medroxyprogesterone and estrogen (DDD 1 UD)	673	548	527	515	0	0	0	0	1.51	1.23	1.18	1.15	0	0	0	0
G03FA14	Dydrogesterone and estrogen (DDD 1 UD)	1,092	1,188	1,250	1,403	0	0	0	0	2.73	2.96	3.11	3.48	0	0	0	0
G03FA17	Drospirenone and estrogen (DDD 1 UD)	357	347	315	246	0	0	0	0	0.48	0.47	0.42	0.33	0	0	0	0
G03FB	Progestogens and estrogens, sequential preparations	798	803	778	686	0	0	0	0	2.17	2.12	2.01	1.86	0	0	0	0
G03FB05	Norethisterone and estrogen	279	291	287	185	0	0	0	0	0.72	0.70	0.66	0.51	0	0	0	0
G03FB06	Medroxyprogesterone and estrogen	38	33	28	21	0	0	0	0	0.17	0.15	0.13	0.09	0	0	0	0
G03FB08	Dydrogesterone and estrogen (DDD 1 UD)	481	478	464	479	0	0	0	0	1.28	1.27	1.23	1.26	0	0	0	0
G03FB09	Levonorgestrel and estrogen	0								0.00							
G03G	Gonadotrophins and other ovulation stimulants	4,401	4,401	4,392	4,302	0	0	0	1	0.32	0.22	0.17	0.24	0	0	0	0
G03GA	Gonadotrophins	4,345	4,401	4,392	4,302	0	0	0	1	0.25	0.22	0.17	0.24	0	0	0	0
G03GA01	Chorionic gonadotrophin (DDD 250 U)	159	143	59	109	0	0	0	0	0.16	0.13	0.08	0.16	0	0	0	0
G03GA02	Human menopausal gonadotrophin (DDD 75 U)	1,337	1,138	1,214	1,327	0		0	0	0.03	0.03	0.03	0.03	0		0	0
G03GA04	Urofollitropin (DDD 75 U)	8	56	26	38					0.00	0.00	0.00	0.00				

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
G03GA05 Follitropin alfa (DDD 75 U)	1,767	1,769	1,860	1,783			0	2	0.04	0.05	0.05	0.05			0	2
G03GA06 Follitropin beta (DDD 75 U)	456	216	43	13			0	1	0.01	0.01	0.00	0.00			0	1
G03GA07 Lutropin alfa (DDD 75 U)	2	1	1	1			8		0.00	0.00	0.00	0.00			8	
G03GA08 Choriogonadotropin alfa (DDD 0.25 mg)	137	178	235	191			0	0	0.00	0.00	0.00	0.00			0	0
G03GA09 Corifollitropin alfa (DDD 0.15 mg)	292	290	249	177			0		0.00	0.00	0.00	0.00			0	
G03GA30 Combinations	188	610	706	662												
G03GB Ovulation stimulants, synthetic	56								0.07							
G03GB02 Clomifene (DDD 9 mg)	56								0.07							
G03H Antiandrogens	1,390	1,261	1,152	938	1	1	1	1	3.71	3.39	3.10	2.56	2	3	3	4
G03HA Antiandrogens, plain preparations	142	135	121	103	7	7	5	6	0.05	0.05	0.05	0.04	7	6	5	6
G03HA01 Cyproterone (DDD 0.10 g)	142	135	121	103	7	7	5	6	0.05	0.05	0.05	0.04	7	6	5	6
G03HB Antiandrogens and estrogens	1,248	1,126	1,031	835	1	1	1	1	3.66	3.34	3.05	2.52	2	3	3	4
G03HB01 Cyproterone and estrogen (DDD 0.75 UD)	1,248	1,126	1,031	835	1	1	1	1	3.66	3.34	3.05	2.52	2	3	3	4
G03X Other sex hormones and modulators of the genital system	652	325	323	264	26	47	48	73	0.06	0.03	0.03	0.06	10	23	19	10
G03XB Progesterone receptor modulators	652	325	311	203	26	47	50	95	0.06	0.03	0.02	0.01	10	23	25	84
G03XB01 Mifepristone (DDD 0.20 g)	172	152	155	194	100	100	99	99	0.01	0.01	0.01	0.01	100	100	99	99
G03XB02 Ulipristal (DDD 5 mg)	480	172	156	9	0	0	0	-3	0.05	0.02	0.02	0.00	0	0	0	-3
G03XX Other sex hormones and modulators of the genital system			12	61				1			0.01	0.05				1
G03XX01 Prasterone (DDD 6.50 mg)			12	61				1			0.01	0.05				1

**G04 Urologicals**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
G04	Urologicals	43,803	41,727	41,493	36,611	2	2	2	2	48.51	50.27	51.70	53.47	2	2	2	2
G04B	Urologicals	23,403	20,940	20,964	19,732	2	2	2	2	17.67	18.22	18.68	19.26	1	1	1	2
G04BD	Drugs for urinary frequency and incontinence	11,706	12,375	12,301	11,975	3	2	2	3	6.52	6.80	7.15	7.31	2	2	2	2
G04BD04	Oxybutynin	223	217	211	202	3	2	2	2	0.13	0.14	0.13	0.13	3	2	2	2
G04BD07	Tolterodine (DDD 4 mg)	475	405	310	289	4	4	3	3	0.35	0.31	0.25	0.24	3	3	3	2
G04BD08	Solifenacin (DDD 5 mg)	2,627	2,340	1,463	670	2	2	3	3	1.69	1.51	1.49	1.35	2	2	1	2
G04BD09	Tropium (DDD 40 mg)	256	229	205	194	1	1	1	1	0.23	0.21	0.19	0.18	1	2	1	1
G04BD10	Darifenacin (DDD 7.50 mg)	95	84	51	38	4	4	3	2	0.06	0.06	0.04	0.03	3	3	2	2
G04BD11	Fesoterodine (DDD 4 mg)	951	841	718	611	2	2	2	2	0.62	0.55	0.49	0.44	2	2	2	1
G04BD12	Mirabegron (DDD 50 mg)	7,080	8,259	9,343	9,971	3	2	2	3	3.44	4.02	4.56	4.94	2	2	2	2
G04BE	Drugs used in erectile dysfunction	10,524	7,449	7,613	6,668	1	1	1	1	7.67	8.11	8.40	8.68	0	0	0	0
G04BE01	Alprostadil	847	825	666	419	1	1	0	0	0.06	0.06	0.04	0.04	0	0	0	0
G04BE03	Sildenafil (DDD 50 mg)	2,734	1,744	2,161	2,285	4	3	2	2	6.97	7.38	7.56	7.63	0	0	0	0
G04BE08	Tadalafil (DDD 10 mg)	6,635	4,620	4,516	3,678	0	0	0	0	0.61	0.65	0.77	0.99	0	0	0	0
G04BE09	Vardenafil (DDD 10 mg)	186	128	105	76	0			0	0.02	0.01	0.02	0.01	0			1
G04BE10	Avanafil (DDD 0.10 g)	100	69	60	56	0			0	0.01	0.01	0.01	0.01	0			0
G04BE30	Combinations (DDD 1 UD)	23	62	105	155	4	2	2	1	0.00	0.00	0.00	0.00	4	2	2	1
G04BX	Other urologicals	1,173	1,115	1,051	1,089	3	2	2	4	3.49	3.32	3.13	3.28	3	3	2	4
G04BX01	Magnesium hydroxide (DDD 0.50 g)	1,127	1,071	1,007	1,042	3	3	2	4	3.48	3.31	3.12	3.27	3	3	2	4
G04BX14	Dapoxetine (DDD 30 mg)	45	45	44	47					0.01	0.01	0.01	0.01				

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
G04C	Drugs used in benign prostatic hypertrophy	20,399	20,787	20,528	16,880	2	2	2	2	30.84	32.05	33.02	34.20	2	2	2	2
G04CA	Alpha-adrenoreceptor antagonists	13,819	14,689	14,681	11,227	2	2	1	1	21.70	22.80	23.74	24.79	2	2	2	2
G04CA01	Alfuzosin (DDD 7.50 mg)	2,375	2,527	1,981	1,901	1	1	1	1	5.37	5.60	5.79	6.08	1	1	1	1
G04CA02	Tamsulosin (DDD 0.40 mg)	3,424	3,449	3,494	3,489	2	2	2	2	10.93	11.27	11.69	12.07	3	2	2	2
G04CA52	Tamsulosin and dutasteride (DDD 1 UD)	7,934	8,631	9,126	5,773	1	1	1	1	5.36	5.89	6.22	6.62	1	1	1	1
G04CA53	Tamsulosin and solifenacin (DDD 1 UD)	86	82	81	64	0	1	0	0	0.04	0.03	0.03	0.03	0	1	0	0
G04CB	Testosterone-5-alpha reductase inhibitors	6,033	5,480	5,353	5,231	2	2	2	2	8.40	8.40	8.64	8.85	2	2	2	2
G04CB01	Finasteride (DDD 5 mg)	4,722	4,778	4,865	4,787	2	2	2	2	6.50	6.35	6.18	6.05	2	2	2	2
G04CB02	Dutasteride (DDD 0.50 mg)	1,312	702	487	444	3	3	2	2	1.90	2.05	2.46	2.79	3	3	2	2
G04CX	Other drugs used in benign prostatic hypertrophy	547	618	495	421					0.74	0.85	0.64	0.56				
G04CX02	Sabalís serrulatae fructus (DDD 0.32 g)	547	618	495	421					0.74	0.85	0.64	0.56				



H Systemic hormonal preparations, excl. sex hormones and insulins

ATC classification	Wholesale price (VAT excluded), thousand euros	Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a pro- portion (%) of consumption, DDD/1,000 inhabitants/day							
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020				
H	Systemic hormonal preparations, excl. sex hormones and insulins	43,940	46,821	48,210	49,489	21	19	18	18	53.42	55.81	55.97	55.49	6	6	6	6
H01	Pituitary, hypothalamic hormones and analogues	24,221	26,788	28,230	29,255	11	10	9	9	0.93	1.16	1.30	1.40	6	4	3	3
H02	Corticosteroids for systemic use	10,359	10,355	10,084	10,252	59	57	56	54	18.26	18.81	18.70	17.61	15	15	14	15
H03	Thyroid therapy	6,542	6,848	6,888	6,959	1	1	1	2	34.00	35.59	35.72	36.23	1	1	1	1
H04	Pancreatic hormones	237	251	264	225	58	65	61	60	0.01	0.01	0.01	0.01	62	69	64	65
H05	Calcium homeostasis	2,580	2,580	2,745	2,797	14	13	12	11	0.22	0.23	0.24	0.25	14	11	10	9

**H01 Pituitary, hypothalamic hormones and analogues**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
H01	Pituitary, hypothalamic hormones and analogues	24,221	26,788	28,230	29,255	11	10	9	9	0.93	1.16	1.30	1.40	6	4	3	3
H01A	Anterior pituitary lobe hormones and analogues	7,906	8,914	9,637	9,957	15	14	13	11	0.23	0.27	0.29	0.32	1	1	1	0
H01AB	Thyrotrophin	1,177	1,238	1,220	1,103	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
H01AB01	Thyrotrophin alfa (DDD 0.90 mg)	1,177	1,238	1,220	1,103	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
H01AC	Somatropin and somatropin agonists	6,243	7,235	7,936	8,324	1	0	0	0	0.23	0.26	0.29	0.31	1	0	0	0
H01AC01	Somatropin (DDD 2 U)	6,243	7,235	7,936	8,324	1	0	0	0	0.23	0.26	0.29	0.31	1	0	0	0
H01AX	Other anterior pituitary hormones and analogues	486	441	480	530		1	0		0.00	0.00	0.00	0.00		1	0	
H01AX01	Pegvisomant (DDD 10 mg)	486	441	480	530		1	0		0.00	0.00	0.00	0.00		1	0	
H01B	Posterior pituitary lobe hormones	2,451	2,440	2,667	2,608	26	25	28	33	0.45	0.62	0.72	0.77	9	6	5	5
H01BA	Vasopressin and analogues	2,181	2,250	2,491	2,399	17	19	23	27	0.42	0.60	0.70	0.75	3	2	2	2
H01BA01	Vasopressin (argipressin) (DDD 40 U)			85	137			100	100			0.00	0.00			100	100
H01BA02	Desmopressin	1,900	1,932	2,036	1,872	5	5	6	6	0.42	0.60	0.70	0.75	3	2	2	2
H01BA04	Terlipressin (DDD 12 mg)	281	318	370	391	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
H01BB	Oxytocin and analogues	270	190	176	209	100	100	100	99	0.03	0.02	0.02	0.02	100	100	100	99
H01BB02	Oxytocin	265	177	125	99	100	100	100	99	0.03	0.02	0.02	0.02	100	100	100	99
H01BB03	Carbetocin (DDD 0.10 mg)	4	13	51	110	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
H01C	Hypothalamic hormones	13,864	15,434	15,926	16,689	5	4	4	4	0.24	0.27	0.29	0.31	3	3	2	3
H01CA	Gonadotrophin-releasing hormones	192	232	215	245	0		0	0	0.03	0.04	0.04	0.04	0		0	0
H01CA02	Nafarelin (DDD 0.40 mg)	192	232	215	245	0		0	0	0.03	0.04	0.04	0.04	0		0	0
H01CB	Somatostatin and analogues	13,102	14,763	15,404	16,152	5	5	4	5	0.20	0.22	0.24	0.25	4	3	3	3
H01CB02	Octreotide (DDD 0.70 mg)	7,296	7,797	7,507	7,430	9	8	8	9	0.11	0.12	0.12	0.12	6	6	5	6
H01CB03	Lanreotide (DDD 3 mg)	5,778	6,921	7,853	8,697	1	1	1	1	0.09	0.10	0.12	0.13	1	1	1	1
H01CB05	Pasireotide (DDD 1.20 mg)	28	45	45	25				40	0.00	0.00	0.00	0.00				40
H01CC	Anti gonadotropin releasing hormones	570	439	306	292		0	0	4	0.01	0.01	0.01	0.01	0	0	0	4
H01CC01	Ganirelix (DDD 0.25 mg)	461	376	287	278		0	0	4	0.01	0.01	0.01	0.01		0	0	4
H01CC02	Cetrorelix (DDD 0.25 mg)	109	62	19	13	0				0.00	0.00	0.00	0.00	0			

**H02 Corticosteroids for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
H02	Corticosteroids for systemic use	10,359	10,355	10,084	10,252	59	57	56	54	18.26	18.81	18.70	17.61	15	15	14	15
H02A	Corticosteroids for systemic use, plain	7,813	8,120	7,723	8,182	56	54	53	51	18.15	18.72	18.60	17.52	15	15	14	15
H02AA	Mineralocorticoids	147	153	151	147	6	6	6	6	0.66	0.68	0.67	0.65	6	6	6	6
H02AA02	Fludrocortisone (DDD 0.10 mg)	147	153	151	147	6	6	6	6	0.66	0.68	0.67	0.65	6	6	6	6
H02AB	Glucocorticoids	7,666	7,968	7,571	8,035	57	55	54	52	17.50	18.04	17.92	16.87	15	15	14	15
H02AB01	Betamethasone	149	152	171	170	81	81	82	83	0.27	0.29	0.28	0.27	73	73	71	72
H02AB02	Dexamethasone (DDD 1.50 mg)	1,508	1,535	1,514	2,429	77	78	77	58	2.13	2.15	2.18	2.32	39	39	37	39
H02AB04	Methylprednisolone	2,053	1,929	1,752	1,720	77	75	72	74	1.12	1.14	1.09	1.08	39	39	36	39
H02AB06	Prednisolone (DDD 10 mg)	1,377	1,511	1,571	1,314	15	19	19	12	11.77	12.15	12.42	11.39	8	8	7	6
H02AB07	Prednisone (DDD 10 mg)	140	126	88	82	3	3	2	2	0.91	0.82	0.57	0.54	3	3	2	2
H02AB08	Triamcinolone (DDD 7.50 mg)	891	859	833	874	80	76	76	71	0.09	0.09	0.09	0.09	80	76	76	71
H02AB09	Hydrocortisone (DDD 30 mg)	1,547	1,855	1,641	1,446	38	34	37	39	1.21	1.40	1.29	1.17	16	15	15	16
H02B	Corticosteroids for systemic use, combinations	2,546	2,235	2,361	2,070	68	70	65	64	0.11	0.09	0.10	0.09	68	70	65	64
H02BX	Corticosteroids for systemic use, combinations	2,546	2,235	2,361	2,070	68	70	65	64	0.11	0.09	0.10	0.09	68	70	65	64
H02BX01	Methylprednisolone, combinations (DDD 0.50 UD)	2,546	2,235	2,361	2,070	68	70	65	64	0.11	0.09	0.10	0.09	68	70	65	64



H03 Thyroid therapy

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
H03	Thyroid therapy	6,542	6,848	6,888	6,959	1	1	1	2	34.00	35.59	35.72	36.23	1	1	1	1
H03A	Thyroid preparations	5,855	6,157	6,229	6,317	1	1	1	1	33.43	35.02	35.18	35.70	1	1	1	1
H03AA	Thyroid hormones	5,855	6,157	6,229	6,317	1	1	1	1	33.43	35.02	35.18	35.70	1	1	1	1
H03AA01	Levothyroxine sodium (DDD 0.15 mg)	5,855	6,157	6,229	6,317	1	1	1	1	33.43	35.02	35.18	35.70	1	1	1	1
H03B	Antithyroid preparations	687	690	658	642	2	3	3	3	0.57	0.57	0.54	0.53	2	3	3	3
H03BB	Sulphur-containing imidazole derivatives	687	690	658	642	2	3	3	3	0.57	0.57	0.54	0.53	2	3	3	3
H03BB01	Carbimazole (DDD 15 mg)	687	690	658	642	2	3	3	3	0.57	0.57	0.54	0.53	2	3	3	3

H04 Pancreatic hormones

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
H04	Pancreatic hormones	237	251	264	225	58	65	61	60	0.01	0.01	0.01	0.01	62	69	64	65
H04A	Glycogenolytic hormones	237	251	264	225	58	65	61	60	0.01	0.01	0.01	0.01	62	69	64	65
H04AA	Glycogenolytic hormones	237	251	264	225	58	65	61	60	0.01	0.01	0.01	0.01	62	69	64	65
H04AA01	Glucagon	237	251	264	225	58	65	61	60	0.01	0.01	0.01	0.01	62	69	64	65

Table continued

**H05 Calcium homeostasis**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
H05	Calcium homeostasis	2,580	2,580	2,745	2,797	14	13	12	11	0.22	0.23	0.24	0.25	14	11	10	9
H05A	Parathyroid hormones and analogues	1,326	1,343	1,225	817	7	5	7	7	0.06	0.06	0.06	0.05	7	5	7	7
H05AA	Parathyroid hormones and analogues	1,326	1,343	1,225	817	7	5	7	7	0.06	0.06	0.06	0.05	7	5	7	7
H05AA02	Teriparatide (DDD 20 mcg)	1,326	1,343	1,225	817	7	5	7	7	0.06	0.06	0.06	0.05	7	5	7	7
H05B	Anti-parathyroid agents	1,255	1,236	1,519	1,981	21	22	16	13	0.16	0.17	0.19	0.19	16	13	11	10
H05BA	Calcitonin preparations	13	99	55	28	93	98	97	98	0.00	0.00	0.00	0.00	86	98	97	98
H05BA01	Calcitonin (salmon synthetic)	13	99	55	28	93	98	97	98	0.00	0.00	0.00	0.00	86	98	97	98
H05BX	Other anti-parathyroid agents	1,242	1,137	1,464	1,953	20	16	13	11	0.16	0.17	0.19	0.19	16	12	11	10
H05BX01	Cinacalcet (DDD 60 mg)	1,058	983	1,310	1,779	15	10	9	6	0.13	0.15	0.16	0.17	10	8	7	6
H05BX02	Paricalcitol (DDD 2 mcg)	178	144	136	155	47	49	50	59	0.03	0.02	0.02	0.02	47	45	46	46
H05BX04	Etelcalcetide (DDD 2.10 mg)	6	10	18	18	100	100	98	100	0.00	0.00	0.00	0.00	100	100	98	100



J Antiinfectives for systemic use

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J	Antiinfectives for systemic use	196,723	246,307	267,764	256,591	67	74	77	77	17.77	17.61	16.80	13.92	18	19	19	21
J01	Antibacterials for systemic use	52,363	49,440	44,520	41,360	51	50	49	57	15.73	15.39	14.64	11.86	13	14	14	16
J02	Antimycotics for systemic use	15,913	16,788	17,942	13,200	74	76	81	76	0.41	0.40	0.38	0.35	16	16	16	15
J04	Antimycobacterials	880	1,063	977	759	88	90	85	87	0.19	0.18	0.16	0.16	86	86	85	86
J05	Antivirals for systemic use	59,188	113,135	140,120	127,743	89	93	94	94	1.44	1.65	1.62	1.55	60	59	56	54
J06	Immune sera and immunoglobulins	42,405	40,633	43,065	51,951	84	81	80	80								

**J01 Antibacterials for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J01	Antibacterials for systemic use	52,363	49,440	44,520	41,360	51	50	49	57	15.73	15.39	14.64	11.86	13	14	14	16
J01A	Tetracyclines	2,335	2,390	2,276	1,724	25	32	30	25	3.41	3.17	3.11	2.48	4	4	5	5
J01AA	Tetracyclines	2,335	2,390	2,276	1,724	25	32	30	25	3.41	3.17	3.11	2.48	4	4	5	5
J01AA02	Doxycycline (DDD 0.10 g)	1,224	1,189	1,124	709	14	17	16	8	2.13	2.00	1.93	1.30	5	6	6	8
J01AA04	Lymecycline (DDD 0.60 g)	486	463	453	469	1	1	1	1	0.81	0.77	0.79	0.82	1	1	1	1
J01AA07	Tetracycline (DDD 1 g)	214	189	189	185	2	2	2	2	0.46	0.40	0.39	0.36	3	2	2	2
J01AA12	Tigecycline (DDD 0.10 g)	411	550	510	362	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01C	Beta-lactam antibacterials, penicillins	18,516	16,881	16,832	16,560	48	44	47	63	4.98	4.97	4.95	3.64	11	11	12	15
J01CA	Penicillins with extended spectrum	6,874	7,068	6,691	4,774	14	17	15	22	2.69	2.67	2.64	1.82	8	8	8	10
J01CA01	Ampicillin	552	812	612	712	99	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J01CA04	Amoxicillin	4,719	4,689	4,437	2,612	6	6	7	10	2.01	2.01	1.95	1.20	7	7	8	11
J01CA08	Pivmecillinam (DDD 0.60 g)	1,603	1,567	1,642	1,450	7	7	6	6	0.67	0.66	0.68	0.61	9	9	7	7
J01CE	Beta-lactamase sensitive penicillins	1,618	2,121	2,038	1,562	45	55	53	46	1.25	1.29	1.25	1.01	7	8	9	10
J01CE01	Benzympenicillin (DDD 3.60 g)	708	1,141	1,055	722	99	100	100	93	0.04	0.06	0.06	0.05	99	99	99	92
J01CE02	Phenoxymethylpenicillin (DDD 2 g)	910	981	983	840	3	3	3	5	1.21	1.23	1.19	0.96	3	4	4	6
J01CF	Beta-lactamase resistant penicillins	747	826	1,028	993	69	62	61	58	0.15	0.16	0.20	0.19	64	56	54	51
J01CF02	Cloxacillin (DDD 2 g)	479	479	574	534	100	100	100	98	0.09	0.08	0.10	0.08	100	100	100	98
J01CF05	Flucloxacillin (DDD 2 g)	268	347	454	459	12	10	11	12	0.06	0.08	0.10	0.10	12	10	11	12
J01CR	Combinations of penicillins, incl. beta-lactamase inhibitors	9,277	6,866	7,074	9,230	73	66	74	88	0.89	0.85	0.87	0.62	18	15	20	27
J01CR02	Amoxicillin and beta-lactamase inhibitor	2,699	2,483	2,004	1,288	8	7	9	14	0.80	0.78	0.78	0.53	9	8	11	15
J01CR05	Piperacillin and beta-lactamase inhibitor (DDD 14 g)	6,578	4,382	5,071	7,942	100	100	100	100	0.09	0.07	0.09	0.09	100	100	100	99

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J01D	Other beta-lactam antibacterials	15,313	14,665	12,633	11,170	63	62	60	62	2.77	2.85	2.63	2.27	30	33	33	34
J01DB	First-generation cephalosporins	5,780	5,773	5,190	4,369	6	5	6	6	2.03	2.00	1.86	1.56	6	6	6	7
J01DB01	Cefalexin (DDD 2 g)	5,780	5,770	5,188	4,364	6	5	6	6	2.03	2.00	1.86	1.56	6	6	6	7
J01DB04	Cefazolin (DDD 3 g)	0	3	2	5	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DC	Second-generation cephalosporins	4,757	4,470	3,880	3,155	98	98	98	96	0.60	0.72	0.65	0.57	94	96	96	94
J01DC02	Cefuroxime	4,744	4,468	3,880	3,155	98	98	98	96	0.59	0.72	0.65	0.57	95	96	96	94
J01DC04	Cefaclor (DDD 1 g)	13	2			1				0.00	0.00			1			
J01DD	Third-generation cephalosporins	1,433	1,319	1,246	1,391	95	95	95	95	0.10	0.07	0.08	0.09	98	97	98	98
J01DD01	Cefotaxime (DDD 4 g)	7	3	2	2	100	92	100	100	0.00	0.00	0.00	0.00	100	99	100	100
J01DD02	Ceftazidime (DDD 4 g)	286	186	108	68	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J01DD04	Ceftriaxone (DDD 2 g)	1,112	1,009	958	1,121	94	93	94	94	0.09	0.07	0.07	0.08	98	97	97	98
J01DD52	Ceftazidime and beta-lactamase inhibitor (DDD 6 g)	29	121	178	200	96	100	100	99	0.00	0.00	0.00	0.00	96	100	100	99
J01DE	Fourth-generation cephalosporins	2	4	4	6	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DE01	Cefepime (DDD 4 g)	2	4	4	6	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DF	Monobactams	46	43	41	32	100	100	100	95	0.00	0.00	0.00	0.00	100	100	100	95
J01DF01	Aztreonam	46	43	41	32	100	100	100	95	0.00	0.00	0.00	0.00	100	100	100	95
J01DH	Carbapenems	3,042	2,750	2,059	1,921	100	100	100	100	0.06	0.05	0.04	0.04	100	100	100	100
J01DH02	Meropenem (DDD 3 g)	1,975	1,640	1,049	910	100	100	100	100	0.04	0.04	0.03	0.03	100	100	100	100
J01DH03	Ertapenem (DDD 1 g)	1,066	1,111	1,010	1,011	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J01DH51	Imipenem and cilastatin (DDD 4 UD)																
J01DI	Other cephalosporins and penems	253	306	214	297	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DI02	Ceftaroline fosamil (DDD 1.20 g)	38	77	83	127	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DI54	Ceftolozane and beta-lactamase inhibitor (DDD 3 UD)	215	229	131	170	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J01E	Sulfonamides and trimethoprim	1,490	1,466	1,525	1,352	8	9	6	7	1.12	1.08	1.14	1.02	7	7	7	8
J01EA	Trimethoprim and derivatives	830	817	879	817	5	6	6	6	0.77	0.74	0.77	0.70	5	6	6	7
J01EA01	Trimethoprim (DDD 0.40 g)	830	817	879	817	5	6	6	6	0.77	0.74	0.77	0.70	5	6	6	7
J01EE	Combinations of sulfonamides and trimethoprim, incl. derivatives	660	649	646	535	11	13	7	8	0.35	0.34	0.36	0.33	9	10	9	10
J01EE01	Sulfamethoxazole and trimethoprim	140	159	175	203	36	39	14	11	0.12	0.13	0.15	0.16	14	14	12	11
J01EE02	Sulfadiazine and trimethoprim	520	490	471	332	4	5	5	7	0.22	0.21	0.21	0.17	6	7	8	8
J01F	Macrolides, lincosamides and streptogramins	4,035	3,745	3,060	2,488	29	35	35	47	0.87	0.83	0.75	0.55	14	16	17	21
J01FA	Macrolides	2,001	1,654	1,502	1,095	18	23	29	44	0.60	0.55	0.49	0.31	11	12	14	21
J01FA01	Erythromycin	64	79	77	93	100	99	100	100	0.00	0.00	0.00	0.00	100	99	100	100
J01FA06	Roxithromycin (DDD 0.30 g)	183	153	165	100	9	8	12	11	0.10	0.10	0.07	0.04	9	9	10	11
J01FA09	Clarithromycin	530	444	365	209	15	18	18	28	0.14	0.11	0.10	0.06	12	14	16	22
J01FA10	Azithromycin	1,179	978	895	693	16	21	30	46	0.35	0.33	0.31	0.21	11	11	13	22
J01FA15	Telithromycin (DDD 0.80 g)	45				1				0.01				1			
J01FF	Lincosamides	2,034	2,091	1,558	1,393	40	45	42	49	0.27	0.28	0.26	0.24	21	23	22	22
J01FF01	Clindamycin	2,034	2,091	1,558	1,393	40	45	42	49	0.27	0.28	0.26	0.24	21	23	22	22
J01G	Aminoglycoside antibacterials	994	1,192	1,193	1,074	54	51	49	49	0.01	0.02	0.02	0.02	55	50	49	48
J01GB	Other aminoglycosides	994	1,192	1,193	1,074	54	51	49	49	0.01	0.02	0.02	0.02	55	50	49	48
J01GB01	Tobramycin	663	794	848	725	32	27	28	25	0.01	0.01	0.01	0.01	46	40	41	37
J01GB03	Gentamicin (DDD 0.24 g)	171	210	155	118	99	99	98	97	0.00	0.00	0.00	0.00	97	97	97	95
J01GB06	Amikacin (DDD 1 g)	160	188	190	230	98	100	100	100	0.00	0.00	0.00	0.00	98	100	100	100
J01M	Quinolone antibacterials	3,978	3,461	2,581	2,441	45	43	45	52	0.88	0.82	0.63	0.55	25	25	25	29
J01MA	Fluoroquinolones	3,978	3,461	2,581	2,441	45	43	45	52	0.88	0.82	0.63	0.55	25	25	25	29

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J01MA01	Ofloxacin (DDD 0.40 g)	2								0.00							
J01MA02	Ciprofloxacin	1,998	1,749	1,418	1,235	32	28	34	37	0.51	0.48	0.38	0.32	17	17	17	18
J01MA12	Levofloxacin	1,294	1,175	778	808	52	52	52	59	0.27	0.25	0.18	0.18	36	36	35	44
J01MA14	Moxifloxacin (DDD 0.40 g)	684	538	385	398	69	70	70	86	0.10	0.09	0.07	0.05	37	37	35	47
J01X	Other antibacterials	5,701	5,638	4,421	4,552	65	66	63	64	1.69	1.65	1.42	1.35	10	10	9	10
J01XA	Glycopeptide antibacterials	1,192	1,497	1,083	1,051	100	100	100	98	0.03	0.03	0.02	0.03	100	100	99	98
J01XA01	Vancomycin (DDD 2 g)	965	1,175	799	749	100	100	100	97	0.03	0.03	0.02	0.03	100	100	99	98
J01XA02	Teicoplanin (DDD 0.40 g)	227	279	193	188	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01XA04	Dalbavancin (DDD 1.50 g)		43	90	115		100	100	100		0.00	0.00	0.00		100	100	100
J01XB	Polymyxins	49	119	160	177	8		22	8	0.00	0.00	0.00	0.00	8		22	8
J01XB01	Colistin	49	119	160	177	8		22	8	0.00	0.00	0.00	0.00	8		22	8
J01XC	Steroid antibacterials	15	12	12	1	13	13	13	10	0.00	0.00	0.00	0.00	14	13	13	10
J01XC01	Fusidic acid (DDD 1.50 g)	15	12	12	1	13	13	13	10	0.00	0.00	0.00	0.00	14	13	13	10
J01XD	Imidazole derivatives	1,298	979	689	1,031	100	100	100	100	0.05	0.06	0.04	0.05	100	100	100	100
J01XD01	Metronidazole (DDD 1.50 g)	1,298	979	689	1,031	100	100	100	100	0.05	0.06	0.04	0.05	100	100	100	100
J01XE	Nitrofurantoin derivatives	714	605	471	558	3	3	4	3	0.46	0.35	0.27	0.31	5	4	6	5
J01XE01	Nitrofurantoin (DDD 0.20 g)	714	605	471	558	3	3	4	3	0.46	0.35	0.27	0.31	5	4	6	5
J01XX	Other antibacterials	2,432	2,426	2,006	1,734	50	51	47	47	1.15	1.21	1.08	0.96	6	5	4	4
J01XX01	Fosfomicin		10	11	9		100	100	100		0.00	0.00	0.00		100	100	100
J01XX05	Methenamine	988	1,030	931	840	6	5	4	3	1.14	1.19	1.07	0.94	6	4	4	3
J01XX08	Linezolid (DDD 1.20 g)	988	816	552	434	72	74	70	74	0.01	0.01	0.01	0.01	63	68	61	57
J01XX09	Daptomycin (DDD 0.28 g)	456	568	511	450	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01XX11	Tedizolid (DDD 0.20 g)		2								0.00						

**J02 Antimycotics for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J02	Antimycotics for systemic use	15,913	16,788	17,942	13,200	74	76	81	76	0.41	0.40	0.38	0.35	16	16	16	15
J02A	Antimycotics for systemic use	15,913	16,788	17,942	13,200	74	76	81	76	0.41	0.40	0.38	0.35	16	16	16	15
J02AA	Antibiotics	2,042	2,358	2,691	1,778	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J02AA01	Amphotericin (DDD 35 mg)	2,042	2,358	2,691	1,778	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J02AB	Imidazole derivatives	2	1	1	9	33	100	100		0.00	0.00	0.00	0.00	33	100	100	
J02AB02	Ketoconazole (DDD 0.20 g)	2	1	1	9	33	100	100		0.00	0.00	0.00	0.00	33	100	100	
J02AC	Triazole derivatives	5,427	5,224	4,694	4,095	22	24	29	24	0.39	0.38	0.36	0.34	12	12	11	11
J02AC01	Fluconazole (DDD 0.20 g)	3,270	2,837	2,506	2,080	11	12	12	14	0.28	0.27	0.26	0.23	15	14	14	14
J02AC02	Itraconazole (DDD 0.20 g)	399	385	373	378	1	1	1	1	0.09	0.09	0.09	0.08	1	1	1	1
J02AC03	Voriconazole (DDD 0.40 g)	850	788	661	235	45	51	71	54	0.01	0.01	0.01	0.01	28	26	25	22
J02AC04	Posaconazole (DDD 0.30 g)	810	873	688	718	52	48	47	45	0.00	0.00	0.00	0.01	51	48	48	39
J02AC05	Isavuconazole (DDD 0.20 g)	99	341	466	684	64	27	51	38	0.00	0.00	0.00	0.00	59	19	36	25
J02AX	Other antimycotics for systemic use	8,441	9,205	10,555	7,318	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J02AX04	Caspofungin (DDD 50 mg)	3,730	3,458	4,377	1,848	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J02AX05	Micafungin (DDD 0.10 g)	2,961	3,934	4,388	2,587	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J02AX06	Anidulafungin (DDD 0.10 g)	1,750	1,814	1,790	2,883	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

**J04 Antimycobacterials**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J04	Antimycobacterials	880	1,063	977	759	88	90	85	87	0.19	0.18	0.16	0.16	86	86	85	86
J04A	Drugs for treatment of tuberculosis	880	1,063	977	759	88	90	85	87	0.19	0.18	0.16	0.16	86	86	85	86
J04AA	Aminosalicylic acid and derivatives	21	22	-3	2	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J04AA01	Aminosalicylic acid (DDD 12 g)	21	22	-3	2	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J04AB	Antibiotics	377	439	387	362	73	77	75	74	0.08	0.09	0.08	0.07	69	74	71	71
J04AB02	Rifampicin (DDD 0.60 g)	304	371	294	298	66	73	68	70	0.07	0.09	0.07	0.07	66	73	68	70
J04AB04	Rifabutin (DDD 0.15 g)	73	68	93	64	98	97	96	94	0.01	0.01	0.01	0.01	98	97	96	94
J04AC	Hydrazides	114	84	98	109	97	98	98	98	0.06	0.04	0.05	0.05	97	98	98	98
J04AC01	Isoniazid	114	84	98	109	97	98	98	98	0.06	0.04	0.05	0.05	97	98	98	98
J04AK	Other drugs for treatment of tuberculosis	368	518	496	285	99	100	90	100	0.05	0.04	0.04	0.04	99	100	98	99
J04AK01	Pyrazinamide (DDD 1.50 g)	80	72	61	85	99	100	98	100	0.02	0.02	0.01	0.01	99	100	98	100
J04AK02	Ethambutol (DDD 1.20 g)	218	191	179	154	99	100	99	99	0.03	0.03	0.03	0.02	99	100	99	99
J04AK05	BEDaquiline (DDD 86 mg)	70	255	255	46	100	100	82	100	0.00	0.00	0.00	0.00	100	100	82	100

Table continued

**J05 Antivirals for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J05	Antivirals for systemic use	59,188	113,135	140,120	127,743	89	93	94	94	1.44	1.65	1.62	1.55	60	59	56	54
J05A	Direct acting antivirals	59,188	113,135	140,120	127,743	89	93	94	94	1.44	1.65	1.62	1.55	60	59	56	54
J05AB	Nucleosides and nucleotides excl. Reverse transcriptase inhibitors	10,002	10,637	11,151	10,486	37	38	35	37	0.58	0.63	0.70	0.72	7	8	7	8
J05AB01	Aciclovir (DDD 4 g)	2,882	2,703	2,729	2,873	24	24	20	28	0.26	0.27	0.31	0.32	4	4	3	4
J05AB06	Ganciclovir	284	168	251	174	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AB09	Famciclovir (DDD 0.75 g)	102	131	131	126	0	0	1	2	0.01	0.01	0.01	0.01	0	0	1	2
J05AB11	Valaciclovir (DDD 3 g)	4,146	4,542	5,059	4,511	3	3	3	3	0.29	0.32	0.35	0.36	3	3	3	3
J05AB14	Valganciclovir (DDD 0.90 g)	2,588	3,094	2,980	2,802	99	100	99	100	0.02	0.03	0.03	0.03	99	100	99	100
J05AE	Protease inhibitors	3,546	2,652	1,878	496	100	100	100	100	0.08	0.06	0.05	0.03	100	100	100	100
J05AE01	Saquinavir (DDD 1.80 g)	24	12	8		100	100	100		0.00	0.00	0.00		100	100	100	
J05AE03	Ritonavir (DDD 1.20 g)	277	198	141	104	100	100	100	99	0.01	0.01	0.00	0.00	100	100	100	99
J05AE07	Fosamprenavir (DDD 1.40 g)	21	6			100	100			0.00	0.00			100	100		
J05AE08	Atazanavir (DDD 0.30 g)	1,019	669	451	142	100	100	100	100	0.03	0.02	0.02	0.01	100	100	100	100
J05AE10	Darunavir (DDD 1.20 g)	2,205	1,767	1,277	250	100	100	100	100	0.04	0.03	0.03	0.02	100	100	100	100
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors	1,581	1,181	1,277	1,142	100	99	100	100	0.07	0.07	0.07	0.07	100	99	100	100
J05AF01	Zidovudine (DDD 0.60 g)	14	14	4		100	100	100		0.00	0.00	0.00		100	100	100	
J05AF02	Didanosine (DDD 0.40 g)																

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J05AF05	Lamivudine (DDD 0.30 g)	91	77	65	50	99	98	97	100	0.01	0.01	0.01	0.00	99	98	97	100
J05AF06	Abacavir (DDD 0.60 g)	117	81	69	45	100	100	100	100	0.01	0.00	0.00	0.00	100	100	100	100
J05AF07	Tenofovir disoproxil (DDD 0.25 g)	1,094	639	695	655	100	100	100	100	0.04	0.04	0.05	0.05	100	100	100	100
J05AF08	Adefovir dipivoxil (DDD 10 mg)	33	32	38	31	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AF09	Emtricitabine (DDD 0.20 g)	11	9	11	8	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AF10	Entecavir (DDD 0.50 Mg)	110	118	167	117	100	96	100	99	0.00	0.00	0.01	0.01	99	95	100	99
J05AF13	Tenofovir alafenamide (DDD 25 mg)	112	211	229	235	100	100	100	100	0.00	0.01	0.01	0.01	100	100	100	100
J05AG	Non-nucleoside reverse transcriptase inhibitors	1,047	963	885	761	100	100	100	100	0.05	0.05	0.04	0.04	100	100	100	100
J05AG01	Nevirapine (DDD 0.40 g)	541	496	475	207	100	100	100	100	0.02	0.02	0.02	0.02	100	100	100	100
J05AG03	Efavirenz (DDD 0.60 g)	135	115	81	115	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J05AG04	Etravirine (DDD 0.40 g)	253	202	160	83	100	100	100	100	0.01	0.01	0.01	0.00	100	100	100	100
J05AG05	Rilpivirine (DDD 25 mg)	118	151	117	133	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J05AG06	Doravirine (DDD 0.10 g)			52	223			100	100			0.00	0.01			100	100
J05AH	Neuraminidase inhibitors	647	1,409	783	358	50	33	37	14	0.06	0.14	0.08	0.04	50	33	37	15
J05AH01	Zanamivir (DDD 20 mg)	0				17				0.00				17			
J05AH02	Oseltamivir (DDD 0.15 g)	647	1,409	783	358	50	33	37	14	0.06	0.14	0.08	0.04	50	33	37	15
J05AJ	Integrase inhibitors	5,701	7,207	7,179	7,045	100	100	100	100	0.14	0.18	0.19	0.19	100	100	100	100
J05AJ01	Raltegravir (DDD 0.80 g)	1,987	2,195	2,232	2,179	100	100	100	100	0.05	0.07	0.07	0.07	100	100	100	100
J05AJ03	Dolutegravir (DDD 50 mg)	3,714	5,012	4,946	4,866	100	100	100	100	0.09	0.12	0.12	0.12	100	100	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J05AP	Antivirals for treatment of HCV infections	11,936	64,610	90,287	84,527	100	100	100	100	0.03	0.07	0.08	0.08	100	100	100	100
J05AP01	Ribavirin	832	545	281	42	100	100	100	99	0.02	0.01	0.01	0.00	100	100	100	99
J05AP05	Simeprevir (DDD 0.15 g)	29				100				0.00				100			
J05AP07	Daclatasvir (DDD 60 mg)																
J05AP08	Sofosbuvir (DDD 0.40 g)	826	42	42	126	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AP09	Dasabuvir (DDD 0.50 g)	55	1			100	100			0.00	0.00			100	100		
J05AP51	Sofosbuvir and IEDipasvir (DDD 1 UD)	754	312	49	361	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AP53	Ombitasvir, paritaprevir and ritonavir (DDD 2 UD)	636	14			100	100			0.00	0.00			100	100		
J05AP54	Elbasvir and grazoprevir (DDD 1 UD)	4,058	22,937	17,130	4,388	100	100	100	100	0.00	0.02	0.02	0.01	100	100	100	100
J05AP55	Sofosbuvir and velpatasvir (DDD 1 UD)	3,903	40,246	63,353	58,351	100	100	100	100	0.00	0.03	0.05	0.05	100	100	100	100
J05AP56	Sofosbuvir, velpatasvir and voxilaprevir (DDD 1 UD)		108	216	1,205		100	100	100		0.00	0.00	0.00		100	100	100
J05AP57	Glecaprevir and pibrentasvir (DDD 3 UD)	842	406	9,215	20,054	100	100	100	100	0.00	0.00	0.01	0.02	100	100	100	100
J05AR	Antivirals for treatment of hiv infections, combinations	24,636	24,398	26,192	21,672	100	100	100	100	0.44	0.45	0.41	0.37	100	100	98	94
J05AR01	Zidovudine and lamivudine (DDD 2 UD)	56	23	30	12	99	97	100	100	0.00	0.00	0.00	0.00	99	96	100	100
J05AR02	Lamivudine and abacavir (DDD 1 UD)	1,231	792	401	155	100	100	99	99	0.04	0.04	0.03	0.03	100	100	99	99
J05AR03	Tenofovir disoproxil and emtricitabine (DDD 1 UD)	1,502	2,757	2,281	1,215	100	100	99	94	0.04	0.06	0.09	0.13	100	100	92	83
J05AR04	Zidovudine, lamivudine and abacavir (DDD 2 UD)	13	11	4		100	100	100		0.00	0.00	0.00		100	100	100	
J05AR06	Emtricitabine, tenofovir disoproxil and efavirenz (DDD 1 UD)	2,503	1,249	736	194	100	100	100	97	0.04	0.02	0.01	0.01	100	100	100	96
J05AR08	Emtricitabine, tenofovir disoproxil and rilpivirine (DDD 1 UD)	374	203	198	137	95	97	98	100	0.01	0.00	0.00	0.00	95	97	98	100
J05AR09	Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat (DDD 1 UD)	341	205	156	96	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J05AR10	Lopinavir and ritonavir (DDD 0.80 g)	352	138	79	27	100	100	100	98	0.01	0.00	0.00	0.00	100	100	100	98
J05AR13	Lamivudine, abacavir and dolutegravir (DDD 1 UD)	6,920	6,992	7,385	6,124	100	100	100	100	0.09	0.09	0.10	0.08	100	100	100	100
J05AR14	Darunavir and cobicistat (DDD 1 UD)	120	177	218	242	100	100	100	100	0.00	0.00	0.01	0.01	100	100	100	100
J05AR17	Emtricitabine and tenofovir alafenamide (DDD 1 UD)	5,671	5,171	3,810	2,651	100	100	100	100	0.14	0.13	0.10	0.07	100	100	100	100
J05AR18	Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat (DDD 1 UD)	3,711	3,136	1,416	1,092	100	100	100	100	0.05	0.04	0.02	0.01	100	100	100	100
J05AR19	Emtricitabine, tenofovir alafenamide and rilpivirine (DDD 1 UD)	1,820	2,050	1,896	1,420	100	100	100	100	0.03	0.03	0.03	0.02	100	100	100	100
J05AR20	Emtricitabine, tenofovir alafenamide and bictegravir		942	5,411	4,632		100	100	100								
J05AR21	Dolutegravir and rilpivirine		59	182	215		100	100	100								
J05AR22	Emtricitabine, tenofovir alafenamide, darunavir and cobicistat (DDD 1 UD)	21	495	1,458	1,010	100	100	100	100	0.00	0.01	0.02	0.02	100	100	100	100
J05AR24	Lamivudine, tenofovir disoproxil and doravirine			456	1,901			100	100								
J05AR25	Lamivudine and dolutegravir			74	549			100	100								
J05AX	Other antivirals	92	77	488	1,256	100	100	100	65	0.00	0.00	0.00	0.00	100	100	100	74
J05AX07	Enfuvirtide (DDD 0.18 g)	24	2			100	100			0.00	0.00			100	100		
J05AX09	Maraviroc (DDD 0.60 g)	69	75	83	82	100	100	100	97	0.00	0.00	0.00	0.00	100	100	100	98
J05AX18	Letermovir (DDD 0.48 g)			405	1,173			100	62			0.00	0.00			100	61

**J06 Immune sera and immunoglobulins**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a pro- portion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
J06	Immune sera and immunoglobulins	42,405	40,633	43,065	51,951	84	81	80	80								
J06B	Immunoglobulins	42,405	40,633	43,065	51,951	84	81	80	80								
J06BA	Immunoglobulins, normal human	40,631	39,068	41,450	50,569	83	80	79	80								
J06BA01	Immunoglobulins, normal human, for extravascular adm.	7,047	7,852	8,816	10,595	3	3	3	3								
J06BA02	Immunoglobulins, normal human, for intravascular adm.	33,585	31,217	32,634	39,974	100	100	100	100								
J06BB	Specific immunoglobulins	1,774	1,565	1,615	1,381	100	100	100	100								
J06BB01	Anti-d (rh) immunoglobulin	682	618	617	645	100	100	100	100								
J06BB16	Palivizumab	885	793	794	550	100	100	100	100								
J06BB21	Bezlotoxumab	207	153	204	186	100	100	100	100								



J07 Vaccines

ATC classification		Doses per year			
		2017	2018	2019	2020
J07	Vaccines	4 060 700	4 241 400	4 054 300	6 015 500
J07A	Bacterial vaccines	812,600	682,800	585,800	626,200
J07AE	Cholera vaccines	6,700	7,000	5,700	2,200
J07AG	Haemophilus influenzae B vaccines	100	200	900	900
J07AH	Meningococcal vaccines	74,200	46,600	56,100	55,000
J07AJ	Pertussis vaccines	114,800	148,400	118,500	108,800
J07AL	Pneumococcal vaccines	228,500	226,700	196,200	275,600
J07AM	Tetanus vaccines	322,700	196,200	162,000	153,200
J07AN	Tuberculosis vaccines	34,100	35,700	25,400	24,800
J07AP	Typhoid vaccines	31,200	22,200	20,900	5,700
J07B	Viral vaccines	3,028,800	3,199,900	3,088,000	5,060,600
J07BA	Encephalitis vaccines	311,100	268,700	241,100	232,300
J07BB	Influenza vaccines	1,872,700	2,024,300	2,082,100	4,050,800
J07BC	Hepatitis vaccines	314,200	319,500	264,400	138,000
J07BD	Measles vaccines	163,400	186,200	190,700	153,400
J07BF	Poliomyelitis vaccines	20,900	19,400	13,400	11,700
J07BH	Rota virus diarrhea vaccines	138,800	153,300	132,800	135,300
J07BK	Varicella zoster vaccines	150,000	154,300	77,000	75,000
J07BL	Yellow fever vaccines	10,700	10,300	8,800	3,100
J07BM	Papillomavirus vaccines	46,800	63,700	77,700	215,000
J07BX	Other viral vaccines				45,800
J07BX03	COVID-19 vaccines				45,800
J07C	Bacterial and viral vaccines, combined	219,400	358,800	380,500	328,700
J07CA	Bacterial and viral vaccines, combined	219,400	358,800	380,500	328,700



L Antineoplastic and immunomodulating agents

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L	Antineoplastic and immunomodulating agents	569,574	690,176	782,969	813,258	44	44	44	42	20.56	22.22	23.45	24.18	10	11	11	12
L01	Antineoplastic agents	224,763	259,554	308,366	328,299	77	75	70	68								
L02	Endocrine therapy	40,120	55,958	65,173	70,383	3	3	3	2	7.37	7.60	7.87	7.75	3	3	3	3
L03	Immunostimulants	39,533	37,862	31,836	31,137	14	14	13	16	0.84	0.77	0.70	0.68	6	5	5	7
L04	Immunosuppressants	265,158	336,801	377,594	383,439	27	31	32	30	12.35	13.85	14.88	15.76	14	15	16	17

**L01 Antineoplastic agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L01	Antineoplastic agents	224,763	259,554	308,366	328,299	77	75	70	68								
L01A	Alkylating agents	5,559	4,912	6,109	6,214	68	65	69	73								
L01AA	Nitrogen mustard analogues	3,274	2,536	2,665	2,803	95	94	94	95								
L01AA01	Cyclophosphamide	899	816	753	710	96	96	96	96								
L01AA02	Chlorambucil	79	113	112	96	16	15	14	14								
L01AA03	Melphalan	72	63	65	457	24	38	40	93								
L01AA05	Chlormethine				10				100								
L01AA06	Ifosfamide	400	407	501	451	100	100	100	100								
L01AA09	Bendamustine	1,823	1,138	1,235	1,080	100	100	100	100								
L01AB	Alkyl sulphonates	133	119	224	646	100	100	100	100								
L01AB01	Busulfan	133	119	108	120	100	100	100	100								
L01AB02	Treosulfan			116	525			100	100								
L01AC	Ethylene imines	311	407	537	460	100	100	100	100								
L01AC01	Thiotepa	311	407	537	460	100	100	100	100								
L01AD	Nitrosoureas	26	38	784	633	98	99	100	99								
L01AD01	Carmustine		13	716	547		100	100	100								
L01AD02	Lomustine	26	26	18	28	98	99	93	84								
L01AD04	Streptozocin			51	57			100	100								
L01AX	Other alkylating agents	1,815	1,812	1,899	1,672	12	13	10	8								
L01AX03	Temozolomide	1,657	1,693	1,802	1,603	4	7	5	4								
L01AX04	Dacarbazine	159	118	97	69	100	100	100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L01B	Antimetabolites	15,874	16,623	17,659	17,391	88	87	84	82								
L01BA	Folic acid analogues	6,942	6,942	6,420	6,349	97	98	98	98								
L01BA01	Methotrexate	855	636	475	421	77	73	69	70								
L01BA04	Pemetrexed	6,087	6,306	5,944	5,928	100	100	100	100								
L01BB	Purine analogues	517	475	646	537	75	69	47	39								
L01BB02	Mercaptopurine	55	90	250	299	25	18	5	6								
L01BB04	Cladribine	123	101	62	94	100	98	90	100								
L01BB05	Fludarabine	187	176	179	103	53	60	44	57								
L01BB06	Clofarabine	114	107	119	38	100	100	100	100								
L01BB07	Nelarabine	37		35	4	100		100	100								
L01BC	Pyrimidine analogues	8,415	9,205	10,594	10,505	81	80	78	74								
L01BC01	Cytarabine	223	212	98	156	100	100	100	100								
L01BC02	Fluorouracil	127	374	359	403	100	100	100	100								
L01BC05	Gemcitabine	502	1,147	997	531	100	100	100	100								
L01BC06	Capecitabine	1,273	1,221	1,145	955	2	2	2	2								
L01BC07	Azacitidine	5,892	5,330	6,353	6,417	100	100	100	100								
L01BC08	Decitabine	23	231	386	216	100	100	100	100								
L01BC52	Fluorouracil, combinations	1	1	2	6												
L01BC53	Tegafur, combinations	349	144	127	100	1	6	8	9								
L01BC59	Trifluridine, combinations	26	545	1,126	1,720	12	1	0	1								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L01C	Plant alkaloids and other natural products	11,853	13,672	14,740	13,968	89	90	90	94								
L01CA	Vinca alkaloids and analogues	1,801	1,822	1,844	1,183	39	37	36	52								
L01CA01	Vinblastine	23	27	26	35	94	100	100	95								
L01CA02	Vincristine	173	138	103	174	100	100	99	99								
L01CA03	Vindesine	5	5			100	100										
L01CA04	Vinorelbine	1,389	1,520	1,570	810	21	25	25	31								
L01CA05	Vinflunine	212	132	145	165	100	100	100	100								
L01CB	Podophyllotoxin derivatives	267	336	350	452	70	72	72	76								
L01CB01	Etoposide	267	336	350	452	70	72	72	76								
L01CD	Taxanes	7,800	10,062	11,010	11,102	100	100	100	100								
L01CD01	Paclitaxel	3,563	5,789	5,410	6,198	100	100	100	100								
L01CD02	Docetaxel	818	890	922	739	100	100	100	100								
L01CD04	Cabazitaxel	3,419	3,383	4,679	4,165	100	100	100	100								
L01CE	Topoisomerase 1 (top1) inhibitors	1,300	809	951	700	94	88	84	85								
L01CE01	Topotecan	176	156	238	185	57	37	35	45								
L01CE02	Irinotecan	1,124	653	713	515	100	100	100	100								
L01CX	Other plant alkaloids and other natural products	685	644	585	530	100	100	100	100								
L01CX01	Trabectedin	685	644	585	530	100	100	100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L01D	Cytotoxic antibiotics and related substances	4,913	4,302	3,244	2,561	100	99	99	99								
L01DB	Anthracyclines and related substances	4,366	3,843	2,680	2,173	100	100	100	100								
L01DB01	Doxorubicin	2,006	1,932	1,769	1,487	100	100	100	100								
L01DB03	Epirubicin	1,814	1,342	490	274	100	100	100	100								
L01DB06	Idarubicin	420	329	257	268	100	100	100	100								
L01DB07	Mitoxantrone	121	158	97	111	99	100	100	100								
L01DB11	Pixantrone	6	82	67	32	100	100	100	100								
L01DC	Other cytotoxic antibiotics	547	459	564	389	98	96	97	97								
L01DC01	Bleomycin	67	72	81	101	100	100	100	100								
L01DC03	Mitomycin	480	387	482	287	98	95	96	96								
L01E	Protein kinase inhibitors	47,243	60,088	82,710	91,282	5	5	4	4								
L01EA	BCR-ABL tyrosine kinase inhibitors	12,419	12,257	11,942	10,865	3	3	2	3								
L01EA01	Imatinib	6,960	5,977	5,501	4,913	1	1	1	0								
L01EA02	Dasatinib	2,544	2,621	2,752	2,174	10	5	3	6								
L01EA03	Nilotinib	2,369	2,505	2,548	2,576	1	1	0	1								
L01EA04	Bosutinib	250	436	293	342	5	2										
L01EA05	Ponatinib	295	718	849	860	10	18	8	20								
L01EB	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	3,967	3,927	4,873	5,257	6	9	1	1								
L01EB01	Gefitinib	830	904	618	232	5	4	2	1								
L01EB02	Erlotinib	2,080	1,521	992	553	1	3	1	3								
L01EB03	Afatinib	836	1,106	1,729	1,806	3	2	1	1								
L01EB04	Osimertinib	220	396	1,533	2,666	76	62	2	1								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L01EC	B-Raf serine-threonine kinase (BRAF) inhibitors	5,085	5,778	6,324	5,820	3	1	2	1								
L01EC01	Vemurafenib	931	631	400	225	4	2	1	1								
L01EC02	Dabrafenib	4,154	5,147	5,675	4,694	3	1	2	1								
L01EC03	Encorafenib			249	900			8	0								
L01ED	Anaplastic lymphoma kinase (ALK) inhibitors	1,090	1,581	2,690	3,592	7	5	3	7								
L01ED01	Crizotinib	1,032	1,540	1,468	1,169	7	5	2	4								
L01ED02	Ceritinib	58				10											
L01ED03	Alectinib		41	1,174	2,061		28	2	2								
L01ED04	Brigatinib			48	223			56	68								
L01ED05	Lorlatinib				139												
L01EE	Mitogen-activated protein kinase (MEK) inhibitors		1,976	3,168	3,695		2	3	1								
L01EE01	Trametinib		1,976	2,939	2,892		2	2	1								
L01EE03	Binimetinib			229	803			9	1								
L01EF	Cyclin-dependent kinase (CDK) inhibitors	69	1,141	11,040	14,586	17	1	0	0								
L01EF01	Palbociclib	69	1,141	11,002	14,439	17	1	0	0								
L01EF02	Ribociclib			38	76												
L01EF03	Abemaciclib				72				3								
L01EG	Mammalian target of rapamycin (mTOR) kinase inhibitors	1,853	2,010	1,613	1,609	8	8	9	8								
L01EG01	Temsirolimus	67	34	59	61	100	100	100	100								
L01EG02	Everolimus	1,786	1,976	1,554	1,548	4	6	5	5								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L01EH	Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors	608	618	541	436	1	1	0	3								
L01EH01	Lapatinib	608	618	541	436	1	1	0	3								
L01EJ	Janus-associated kinase (JAK) inhibitors	2,958	3,818	4,720	5,631	18	12	17	17								
L01EJ01	Ruxolitinib	2,958	3,818	4,720	5,631	18	12	17	17								
L01EK	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors	2,127	1,661	1,102	911	1	0		0								
L01EK01	Axitinib	2,127	1,661	1,102	911	1	0		0								
L01EL	Bruton's tyrosine kinase (BTK) inhibitors		4,413	10,349	12,908		5	1	1								
L01EL01	Ibrutinib		4,413	10,349	12,908		5	1	1								
L01EM	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	2,477	2,351	1,490	1,024	4	4	2	1								
L01EM01	Idelalisib	2,477	2,351	1,490	1,024	4	4	2	1								
L01EX	Other protein kinase inhibitors	14,591	18,556	22,859	24,947	4	6	7	6								
L01EX01	Sunitinib	5,269	5,886	5,547	3,792	2	2	1	1								
L01EX02	Sorafenib	2,820	2,217	1,882	1,880	6	13	15	14								
L01EX03	Pazopanib	2,928	2,889	2,411	2,045	1	1	2	2								
L01EX04	Vandetanib	123	145	108	30	100	100	100	100								
L01EX05	Regorafenib	1,244	1,369	1,145	926	2		1	0								
L01EX07	Cabozantinib	40	1,827	6,350	8,588	86	1	4	2								
L01EX08	Lenvatinib	84	375	543	1,106	36		3	4								
L01EX09	Nintedanib	2,084	3,238	3,841	4,562	1	1	1	1								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L01EX10	Midostaurin		610	1,031	1,813		100	77	44								
L01EX12	Larotrectinib				86				85								
L01EX13	Gilteritinib				119				14								
L01X	Other antineoplastic agents	139,320	159,958	183,903	196,884	98	98	96	94								
L01XA	Platinum compounds	630	1,221	1,086	1,317	100	100	100	100								
L01XA01	Cisplatin	65	234	249	273	100	100	100	100								
L01XA02	Carboplatin	314	325	334	467	100	99	100	100								
L01XA03	Oxaliplatin	251	662	503	577	100	100	100	100								
L01XC	Monoclonal antibodies	115,409	131,780	153,457	162,695	100	100	100	100								
L01XC02	Rituximab	35,080	35,153	35,693	28,912	100	100	100	100								
L01XC03	Trastuzumab	24,813	26,036	27,840	30,979	100	100	100	100								
L01XC05	Gemtuzumab ozogamicin		14	101	137		100	100	100								
L01XC06	Cetuximab	2,128	2,580	3,053	2,104	100	100	100	100								
L01XC07	Bevacizumab	22,264	24,275	25,352	25,984	100	100	100	100								
L01XC08	Panitumumab	4,138	4,403	4,613	4,775	100	100	100	100								
L01XC10	Ofatumumab	124	222	13		100	100	100									
L01XC11	Ipilimumab	52	170	840	1,240	100	100	100	100								
L01XC12	Brentuximab vedotin	1,350	921	1,063	1,160	100	100	100	100								
L01XC13	Pertuzumab	7,922	9,767	10,894	12,253	100	100	100	100								
L01XC14	Trastuzumab emtansine	3,991	3,734	4,787	5,676	100	100	100	100								
L01XC15	Obinutuzumab	1,061	1,349	1,705	1,461	100	100	100	100								
L01XC17	Nivolumab	5,633	8,200	10,989	12,347	100	100	100	100								

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L01XC18 Pembrolizumab	3,678	6,365	14,753	22,396	100	100	100	100								
L01XC19 Blinatumomab	883	363	2,050	1,156	100	100	100	100								
L01XC21 Ramucirumab	149	317	411	551	97	100	100	100								
L01XC22 Necitumumab	6	6			100	100										
L01XC23 Elotuzumab		63	199	42		100	100	100								
L01XC24 Daratumumab	1,839	5,383	5,670	6,187	100	100	100	100								
L01XC26 Inotuzumab ozogamicin	120	339	309	399	100	100	100	100								
L01XC27 Olaratumab	148	1,308	99		100	100	100									
L01XC28 Durvalumab			346	863			100	100								
L01XC31 Avelumab			63	2			100									
L01XC32 Atezolizumab	31	813	2,591	3,894	100	100	100	100								
L01XC33 Cemiplimab			23	109			100	100								
L01XC37 Polatuzumab vedotin				66				100								
L01XD Sensitizers used in photodynamic/radiation therapy	910	935	1,005	1,051	99	100	99	99								
L01XD03 Methyl aminolevulinate	668	698	751	820	99	100	99	99								
L01XD04 Aminolevulinic acid	242	237	254	231	100	100	100	100								
L01XF Retinoids for cancer treatment	465	411	385	391	100	100	100	100								
L01XF01 Tretinoin	51	49	31	32	99	99	100	99								
L01XF03 Bexarotene	415	362	354	359	100	100	100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L01XG	Proteasome inhibitors	16,992	20,535	19,761	17,723	100	99	90	88								
L01XG01	Bortezomib	10,924	11,412	10,295	8,001	100	100	100	100								
L01XG02	Carfilzomib	5,884	8,673	7,348	7,531	100	100	100	100								
L01XG03	Ixazomib	183	450	2,119	2,190	100	71	5	3								
L01XJ	Hedgehog pathway inhibitors	342	258	293	319	8	5	10	4								
L01XJ01	Vismodegib	342	258	293	319	8	5	10	4								
L01XK	Poly (ADP-ribose) polymerase (PARP) inhibitors	20	713	1,813	4,683		1		0								
L01XK01	Olaparib	20	713	1,513	2,249		1		1								
L01XK02	Niraparib			300	2,433												
L01XX	Other antineoplastic agents	4,552	4,106	5,890	8,339	58	64	52	52								
L01XX05	Hydroxycarbamide	468	468	493	533	2	2	2	2								
L01XX11	Estramustine	19	6	3	1	5	2	8	19								
L01XX23	Mitotane	200	256	178	197	1	4	5	4								
L01XX24	Pegaspargase	559	630	486	622	100	100	96	100								
L01XX27	Arsenic trioxide	155	172	341	298	100	100	100	100								
L01XX35	Anagrelide	1,237	677	395	351	1	1	1	1								
L01XX41	Eribulin	1,142	1,182	1,078	1,358	100	100	99	100								
L01XX44	Aflibercept	694	509	380	295	100	100	100	100								
L01XX51	Talimogene laherparepvec	79		55	347	100		100	100								
L01XX52	Venetoclax		207	2,482	4,338		49	28	32								
L01XY	Combinations of antineoplastic agents			213	366			100	100								
L01XY01	Cytarabine and daunorubicin			213	366			100	100								



L02 Endocrine therapy

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L02	Endocrine therapy	40,120	55,958	65,173	70,383	3	3	3	2	7.37	7.60	7.87	7.75	3	3	3	3
L02A	Hormones and related agents	11,382	11,781	12,182	12,168	5	5	5	5	1.63	1.72	1.81	1.85	5	5	5	5
L02AB	Progestogens	95	101	94	89	9	7	6	8	0.01	0.01	0.01	0.01	9	7	6	8
L02AB02	Medroxyprogesterone (DDD 1 g)	95	101	94	89	9	7	6	8	0.01	0.01	0.01	0.01	9	7	6	8
L02AE	Gonadotrophin releasing hormone analogues	11,287	11,680	12,089	12,079	5	5	5	5	1.62	1.70	1.80	1.84	4	4	5	5
L02AE01	Buserelin	33	28	16						0.00	0.00	0.00					
L02AE02	Leuprorelin	9,160	9,074	8,835	8,531	5	5	5	6	1.32	1.33	1.32	1.31	5	5	5	5
L02AE03	Goserelin (DDD 0.13 mg)	1,484	1,409	1,342	1,213	5	5	6	4	0.21	0.20	0.19	0.18	5	5	6	4
L02AE04	Triptorelin	610	1,170	1,896	2,335	2	3	2	2	0.09	0.17	0.28	0.35	2	3	2	2
L02B	Hormone antagonists and related agents	28,738	44,178	52,991	58,215	2	2	2	2	5.74	5.89	6.06	5.90	3	3	3	3
L02BA	Anti-estrogens	2,825	2,946	3,543	3,661	3	5	6	7	1.19	1.20	1.23	1.20	1	2	2	2
L02BA01	Tamoxifen (DDD 20 mg)	547	551	549	515	1	1	1	1	1.06	1.07	1.06	1.02	1	1	1	1
L02BA02	Toremifene (DDD 60 mg)	12	11	11	7	0				0.01	0.01	0.01	0.00	0			
L02BA03	Fulvestrant (DDD 8.30 mg)	2,267	2,384	2,983	3,138	4	6	7	8	0.12	0.13	0.17	0.17	4	6	6	7
L02BB	Anti-androgens	14,060	27,317	32,374	34,846	1	1	1	1	1.71	1.73	1.68	1.56	2	2	2	2
L02BB01	Flutamide (DDD 0.75 g)	56	36	27	16	6	5	5	4	0.01	0.01	0.00	0.00	6	5	5	4
L02BB03	Bicalutamide (DDD 50 mg)	1,471	1,373	1,308	1,949	3	2	2	3	1.64	1.59	1.53	1.39	2	2	2	3
L02BB04	Enzalutamide (DDD 0.16 g)	12,533	25,909	31,039	32,729	1	1	1	1	0.06	0.13	0.15	0.16	1	1	1	1
L02BB05	Apalutamid (DDD 0.24 g)				114				2				0.00				2
L02BB06	Darolutamide				38												

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L02BG	Aromatase inhibitors	1,021	1,166	2,758	2,882	2	2	2	2	2.54	2.65	2.83	2.78	2	2	2	2
L02BG03	Anastrozole (DDD 1 mg)	177	173	330	278	1	2	3	3	0.36	0.27	0.29	0.24	2	2	3	2
L02BG04	Letrozole (DDD 2.50 mg)	700	828	1,983	2,031	1	1	1	1	1.99	2.15	2.28	2.26	2	2	1	1
L02BG06	Exemestane (DDD 25 mg)	144	165	445	573	5	3	3	3	0.20	0.24	0.26	0.28	4	3	2	2
L02BX	Other hormone antagonists and related agents	10,831	12,748	14,316	16,825	4	4	4	3	0.30	0.31	0.32	0.36	18	19	21	21
L02BX02	Degarelix (DDD 2.70 mg)	2,003	1,969	1,938	2,138	16	17	19	19	0.26	0.26	0.26	0.29	21	23	25	26
L02BX03	Abiraterone (DDD 1 g)	8,829	10,779	12,378	14,688	1	1	1	1	0.04	0.05	0.06	0.07	1	1	1	1

**L03 Immunostimulants**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L03	Immunostimulants	39,533	37,862	31,836	31,137	14	14	13	16	0.84	0.77	0.70	0.68	6	5	5	7
L03A	Immunostimulants	39,533	37,862	31,836	31,137	14	14	13	16	0.84	0.77	0.70	0.68	6	5	5	7
L03AA	Colony stimulating factors	18,645	19,383	15,703	16,115	15	16	16	15	0.22	0.23	0.24	0.29	14	15	15	13
L03AA02	Filgrastim (DDD 0.35 mg)	3,688	3,247	2,606	2,704	35	39	37	33	0.04	0.03	0.04	0.04	33	34	31	25
L03AA10	Lenograstim (DDD 0.35 mg)	29	28	18	29	43	34	49	23	0.00	0.00	0.00	0.00	43	34	49	23
L03AA13	Pegfilgrastim (DDD 0.30 mg)	8,354	9,330	9,299	9,916	9	15	17	15	0.10	0.11	0.15	0.18	9	15	16	15
L03AA14	Lipegfilgrastim (DDD 0.30 mg)	6,574	6,777	3,780	3,467	13	7	1	1	0.09	0.09	0.06	0.07	13	7	1	1
L03AB	Interferons	12,725	10,496	8,998	7,863	9	2	2	8	0.51	0.43	0.36	0.29	4	1	1	3
L03AB04	Interferon alfa-2a (DDD 2 MU)	215	204	669		1	1	1		0.01	0.01	0.03		1	1	1	
L03AB05	Interferon alfa-2b (DDD 2 MU)	846	778	57		1	1	1		0.04	0.03	0.00		0	1	1	
L03AB07	Interferon beta-1a (DDD 4.30 mcg)	8,132	6,762	5,684	4,793	0	0	0	0	0.38	0.32	0.27	0.22	0	0	0	0
L03AB08	Interferon beta-1b (DDD 4 MU)	1,387	1,050	790	713	0			0	0.04	0.03	0.02	0.02	0			0
L03AB10	Peginterferon alfa-2b (DDD 7.50 mcg)	216	21			100	100			0.01	0.00			100	100		
L03AB11	Peginterferon alfa-2a (DDD 26 mcg)	872	140	145	607	100	100	97	99	0.01	0.00	0.00	0.01	100	100	97	99
L03AB13	Peginterferon beta-1a (DDD 8.90 mcg)	1,058	1,540	1,653	1,712	0	0		0	0.02	0.03	0.03	0.04	0	0		0
L03AB15	Ropeginterferon alfa-2b				37				100								
L03AX	Other immunostimulants	8,163	7,983	7,135	7,159	18	24	20	27	0.12	0.11	0.10	0.10	0	0	0	0
L03AX03	Bcg vaccine (DDD 1.80 mg)	688	714	627	918	99	99	100	99								
L03AX13	Glatiramer acetate (DDD 20 mg)	6,732	6,105	5,684	5,213	0	0	0	0	0.12	0.11	0.10	0.10	0	0	0	0
L03AX16	Plerixafor (DDD 16.80 mg)	743	1,165	824	1,028	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

**L04 Immunosuppressants**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L04	Immunosuppressants	265,158	336,801	377,594	383,439	27	31	32	30	12.35	13.85	14.88	15.76	14	15	16	17
L04A	Immunosuppressants	265,158	336,801	377,594	383,439	27	31	32	30	12.35	13.85	14.88	15.76	14	15	16	17
L04AA	Selective immunosuppressants	51,195	65,739	82,246	89,486	42	42	44	44	1.45	1.60	1.88	2.03	15	17	18	19
L04AA04	Antithymocyte immunoglobulin (DDD 0.10 g)	245	249	166	104	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
L04AA06	Mycophenolic acid (DDD 2 g)	4,419	4,577	4,743	4,839	5	5	5	4	0.43	0.44	0.47	0.49	3	3	3	3
L04AA10	Sirolimus (DDD 3 mg)	149	159	191	193	16	18	16	16	0.01	0.01	0.01	0.01	16	18	16	16
L04AA13	Leflunomide (DDD 20 mg)	463	379	416	611	1	2	2	1	0.53	0.49	0.54	0.56	1	2	2	1
L04AA18	Everolimus (DDD 1.50 mg)	79	89	157	172	100	98	97	97	0.00	0.00	0.00	0.00	100	98	97	97
L04AA23	Natalizumab (DDD 10 mg)	6,817	7,168	7,444	7,027	100	100	100	100	0.05	0.05	0.05	0.05	100	100	100	100
L04AA24	Abatacept (DDD 27 mg)	7,340	7,914	7,430	7,512	37	36	37	34	0.08	0.08	0.08	0.09	42	42	41	36
L04AA26	Belimumab (DDD 25 mg)	415	379	412	478	100	100	100	100	0.01	0.00	0.01	0.01	100	100	100	100
L04AA27	Fingolimod (DDD 0.50 mg)	12,707	14,370	13,974	12,807	0	0	0	0	0.12	0.14	0.13	0.12	0	0	0	0
L04AA28	Belatacept (DDD 12.50 mg)				5				100				0.00				100
L04AA29	Tofacitinib (DDD 10 mg)	239	2,357	5,226	5,574	71	3	4	1	0.00	0.04	0.09	0.10	71	3	4	1
L04AA31	Teriflunomide (DDD 14 mg)	5,974	6,544	7,417	7,721	0	0	0	0	0.10	0.12	0.13	0.15	0	0	0	0
L04AA32	Apremilast (DDD 60 mg)	1,532	2,061	2,847	3,601		0	0	1	0.03	0.04	0.06	0.07		0	0	1
L04AA33	Vedolizumab (DDD 5.40 mg)	9,181	13,688	19,173	20,271	100	100	100	100	0.09	0.13	0.18	0.21	100	100	100	100
L04AA34	Alemtuzumab (DDD 0.13 mg)	1,530	985	427	83	100	97	100	100	0.01	0.01	0.00	0.00	100	97	100	100
L04AA36	Ocrelizumab (DDD 3.29 mg)		1,700	5,118	8,537		100	100	100		0.01	0.04	0.06		100	100	100
L04AA37	Baricitinib (DDD 4 mg)	105	2,208	4,049	4,477	7	2	1	1	0.00	0.03	0.07	0.07	7	2	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L04AA40	Cladribine (DDD 0.34 mg)		913	3,057	5,240		5			0.01	0.02	0.04		4			
L04AA44	Upadacitinib				235												
L04AB	Tumor necrosis factor alpha (TNF- α) inhibitors	132,627	172,902	177,797	163,610	30	39	43	39	2.77	3.41	3.85	4.21	47	46	45	47
L04AB01	Etanercept (DDD 7 mg)	27,502	26,327	23,508	24,182	0	0	0	0	0.43	0.56	0.53	0.55	0	0	0	0
L04AB02	Infliximab (DDD 3.75 mg)	38,327	66,381	75,481	63,663	100	100	100	100	1.27	1.53	1.70	1.94	100	100	100	100
L04AB04	Adalimumab (DDD 2.90 mg)	43,959	51,988	50,241	47,071	2	2	1	1	0.65	0.77	1.00	1.07	2	2	1	1
L04AB05	Certolizumab pegol (DDD 14 mg)	5,297	6,206	6,895	6,606	3	2	1	0	0.09	0.10	0.13	0.12	3	2	1	0
L04AB06	Golimumab (DDD 1.66 mg)	17,543	22,001	21,672	22,088	1	1	1	1	0.34	0.45	0.50	0.53	2	1	1	1
L04AC	Interleukin inhibitors	25,971	34,078	40,641	48,846	24	21	19	18	0.48	0.65	0.82	1.04	24	23	20	22
L04AC01	Daclizumab (DDD 5 mg)	53	14			24				0.00	0.00			19			
L04AC02	Basiliximab (DDD 40 mg)	213	256	349	386	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
L04AC03	Anakinra (DDD 0.10 g)	453	466	465	539	6	11	9	9	0.01	0.01	0.01	0.01	6	11	9	9
L04AC05	Ustekinumab (DDD 0.54 mg)	8,998	12,005	13,522	17,729	17	17	18	25	0.22	0.33	0.40	0.56	23	24	24	31
L04AC07	Tocilizumab (DDD 20 mg)	8,040	9,001	9,065	7,892	55	54	54	47	0.12	0.14	0.15	0.14	51	49	47	38
L04AC08	Canakinumab (DDD 2.70 mg)				156				100				0.00				100
L04AC10	Secukinumab (DDD 10 mg)	7,432	9,818	9,863	9,749	0	0	0	0	0.11	0.14	0.15	0.15	0	0	0	0
L04AC11	Siltuximab (DDD 37 mg)			3				100				0.00				100	
L04AC12	Brodalumab (DDD 15 mg)		14	134	205						0.00	0.00	0.00				
L04AC13	Ixekizumab (DDD 2.90 mg)	782	1,923	3,785	4,870				0	1	0.01	0.03	0.06	0.08		0	1
L04AC14	Sarilumab (DDD 14.30 mg)		197	731	1,081						0.00	0.01	0.02				
L04AC16	Guselkumab (DDD 1.79 mg)		382	2,715	4,655				1		0.01	0.04	0.07				1
L04AC18	Risankizumab (DDD 1.67 mg)			8	1,584				0			0.00	0.03				0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
L04AD	Calcineurin inhibitors	11,694	11,653	12,122	11,798	5	5	5	5	0.69	0.74	0.78	0.79	4	5	5	4
L04AD01	Ciclosporin (DDD 0.25 g)	6,055	4,932	4,744	4,418	4	4	4	4	0.40	0.40	0.39	0.36	4	4	4	4
L04AD02	Tacrolimus (DDD 5 mg)	5,639	6,721	7,378	7,380	6	6	6	5	0.29	0.34	0.39	0.42	5	5	6	5
L04AX	Other immunosuppressants	43,671	52,429	64,788	69,698	5	4	2	2	6.96	7.45	7.56	7.69	1	1	1	1
L04AX01	Azathioprine (DDD 0.15 g)	997	1,078	861	919	1	1	1	1	1.39	1.48	1.17	1.22	1	1	1	1
L04AX02	Thalidomide (DDD 0.10 g)	130	94	78	72	17	23	39	25	0.00	0.00	0.00	0.00	17	23	39	25
L04AX03	Methotrexate (DDD 2.50 mg)	6,446	7,411	8,337	9,582	1	0	0	0	5.32	5.67	6.04	6.10	1	1	1	1
L04AX04	Lenalidomide (DDD 10 mg)	21,553	24,332	30,185	31,671	8	6	4	3	0.07	0.08	0.10	0.10	7	6	3	3
L04AX05	Pirfenidone (DDD 2.40 g)	3,397	4,277	5,643	6,083	1	2	1	1	0.02	0.03	0.04	0.04	1	2	1	1
L04AX06	Pomalidomide (DDD 3 mg)	427	1,623	6,451	8,259	100	22	4	1	0.00	0.00	0.01	0.01	100	23	3	1
L04AX07	Dimethyl fumarate (DDD 0.48 g)	10,721	13,614	13,233	13,112	0	0	0	0	0.15	0.19	0.20	0.22	0	0	0	0



M Musculo-skeletal system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
M	Musculo-skeletal system	96,062	101,897	102,349	97,706	14	23	22	20	98.63	99.35	101.83	98.59	2	2	2	2
M01	Antiinflammatory and antirheumatic products	49,262	45,537	46,056	42,895	2	2	2	2	78.83	79.56	80.91	77.44	1	1	1	1
M02	Topical products for joint and muscular pain	13,721	12,941	12,952	14,131	1	1	1	1								
M03	Muscle relaxants	13,267	14,322	15,236	14,648	62	63	64	62	5.20	4.67	5.26	5.15	2	3	3	2
M04	Antigout preparations	1,782	1,935	1,940	1,791	3	3	2	2	3.71	3.99	4.20	4.46	2	2	2	2
M05	Drugs for treatment of bone diseases	15,572	16,113	16,516	16,915	15	14	12	15	10.82	11.05	11.42	11.52	5	5	5	5
M09	Other drugs for disorders of the musculo-skeletal system	2,458	11,048	9,650	7,325	91	98	98	98	0.07	0.07	0.05	0.02	75	77	72	42

**M01 Antiinflammatory and antirheumatic products**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
M01	Antiinflammatory and antirheumatic products	49,262	45,537	46,056	42,895	2	2	2	2	78.83	79.56	80.91	77.44	1	1	1	1
M01A	Antiinflammatory and antirheumatic products, non-steroids	49,178	45,459	45,917	42,686	2	2	2	2	78.70	79.44	80.86	77.44	1	1	1	1
M01AB	Acetic acid derivatives and related substances	2,471	2,293	2,246	2,120	7	6	6	6	4.35	4.04	3.93	3.75	2	2	2	2
M01AB01	Indometacin (DDD 0.10 g)	141	136	128	138	1	1	1	1	0.21	0.19	0.17	0.18	1	1	1	1
M01AB05	Diclofenac (DDD 0.10 g)	2,158	2,004	1,982	1,862	5	5	5	4	4.04	3.77	3.68	3.51	2	2	2	2
M01AB08	Etodolac (DDD 0.40 g)																
M01AB15	Ketorolac (DDD 30 mg)	67	61	53	49	81	81	82	83	0.02	0.02	0.02	0.02	81	81	82	84
M01AB51	Indometacin, combinations (DDD 3 UD)																
M01AB55	Diclofenac, combinations (DDD 2 UD)	106	92	83	71	1	1	1	0	0.08	0.07	0.06	0.05	1	1	1	0
M01AC	Oxicams	485	413	363	336	1	1	1	1	1.46	1.25	1.11	1.02	1	1	1	1
M01AC06	Meloxicam (DDD 15 mg)	485	413	363	336	1	1	1	1	1.46	1.25	1.11	1.02	1	1	1	1
M01AE	Propionic acid derivatives	34,198	33,737	34,732	32,547	1	1	1	2	59.63	60.10	61.54	58.19	1	1	1	2
M01AE01	Ibuprofen (DDD 1.20 g)	29,676	29,508	30,661	28,990	1	1	1	1	50.64	51.50	52.79	49.98	1	1	1	1
M01AE02	Naproxen (DDD 0.50 g)	2,093	1,882	1,649	1,405	2	2	2	2	6.04	5.81	5.95	5.59	2	2	2	2
M01AE03	Ketoprofen (DDD 0.15 g)	534	494	462	421	1	1	1	1	0.81	0.74	0.67	0.60	2	1	1	1
M01AE17	Dexketoprofen (DDD 75 mg)	166	192	201	162	83	83	84	82	0.03	0.04	0.05	0.05	88	88	76	63
M01AE51	Ibuprofen, combinations (DDD 3 UD)	817	776	867	691				0	0.55	0.51	0.56	0.46				0
M01AE52	Naproxen and esomeprazole (DDD 0.50 g)	912	884	892	878	0	0	0	1	1.56	1.51	1.52	1.49	0	0	0	1
M01AG	Fenamates	97	90	90	81	0	0	0	0	0.23	0.21	0.21	0.19	0	0	0	0
M01AG01	Mefenamic acid (DDD 1 g)	18	15	15	13	1	0	1	1	0.04	0.04	0.03	0.03	1	0	1	1
M01AG02	Tolfenamic acid (DDD 0.30 g)	79	75	75	68	0	0	0	0	0.19	0.18	0.18	0.16	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
M01AH	Coxibs	6,859	4,012	3,743	3,238	3	3	3	3	8.20	9.55	10.72	11.43	2	1	1	1
M01AH01	Celecoxib (DDD 0.20 g)	318	240	214	178	4	2	2	2	0.73	0.67	0.65	0.61	2	2	3	3
M01AH04	Parecoxib (DDD 40 mg)	46	50	50	51	97	99	98	99	0.00	0.00	0.00	0.00	97	99	98	99
M01AH05	Etoricoxib (DDD 60 mg)	6,495	3,722	3,480	3,008	2	2	2	1	7.47	8.88	10.07	10.82	1	1	1	1
M01AX	Other antiinflammatory and antirheumatic agents, non-steroids	5,068	4,915	4,743	4,364	1	1	1	0	4.83	4.28	3.34	2.86	1	1	1	1
M01AX01	Nabumetone (DDD 1 g)	20	18	14	8	1	1	1	1	0.04	0.04	0.03	0.02	1	1	1	1
M01AX05	Glucosamine (DDD 1.50 g)	2,720	2,452	2,048	1,788	1	1	1	1	4.79	4.25	3.31	2.85	1	1	1	1
M01AX25	Chondroitin sulfate	2,327	2,445	2,681	2,568	0	0	0	0								
M01C	Specific antirheumatic agents	84	78	139	209	1	1	0	0	0.13	0.12	0.05		1	1	1	
M01CB	Gold preparations	84	78	33		1	1	1		0.13	0.12	0.05		1	1	1	
M01CB01	Sodium aurothiomalate (DDD 2.40 mg)	84	78	33		1	1	1		0.13	0.12	0.05		1	1	1	
M01CX	Other specific antirheumatic agents			210	418			1	0								

**M02 Topical products for joint and muscular pain**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
M02	Topical products for joint and muscular pain	13,721	12,941	12,952	14,131	1	1	1	1								
M02A	Topical products for joint and muscular pain	13,721	12,941	12,952	14,131	1	1	1	1								
M02AA	Antiinflammatory preparations, non-steroids for topical use	12,623	11,955	12,045	13,258	1	1	1	1								
M02AA07	Piroxicam	966	897	864	880	4	3	3	2								
M02AA10	Ketoprofen	118	94	98	96	16	26	25	23								
M02AA13	Ibuprofen		616	1,116	760			0	0								
M02AA15	Diclofenac	11,538	10,348	9,968	11,522	0	0	0	0								
M02AC	Preparations with salicylic acid derivatives	2,196	1,973	1,813	1,747	11	11	11	9								

**M03 Muscle relaxants**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
M03	Muscle relaxants	13,267	14,322	15,236	14,648	62	63	64	62	5.20	4.67	5.26	5.15	2	3	3	2
M03A	Muscle relaxants, peripherally acting agents	9,254	10,226	10,167	9,751	82	81	79	76								
M03AB	Choline derivatives	495	637	500	639	99	99	99	99								
M03AB01	Suxamethonium	495	637	500	639	99	99	99	99								
M03AC	Other quaternary ammonium compounds	1,758	1,910	1,860	1,083	98	99	99	98								
M03AC09	Rocuronium bromide	1,637	1,798	1,759	914	98	99	99	98								
M03AC10	Mivacurium chloride	26	22	22	14	92	93	89	87								
M03AC11	Cisatracurium	95	89	80	154	100	100	100	100								
M03AX	Other muscle relaxants, peripherally acting agents	7,001	7,679	7,807	8,029	76	75	73	72								
M03AX01	Botulinum toxin	7,001	7,679	7,807	8,029	76	75	73	72								
M03B	Muscle relaxants, centrally acting agents	4,013	4,097	5,068	4,897	15	20	33	32	5.20	4.67	5.26	5.15	2	3	3	2
M03BC	Ethers, chemically close to antihistamines	1,241	1,076	1,244	1,143	42	43	39	37	2.77	2.25	2.82	2.76	2	2	1	1
M03BC01	Orphenadrine (citrate) (DDD 0.12 g)	1,116	951	1,097	1,025	47	49	44	42	2.52	1.99	2.52	2.52	2	2	2	1
M03BC51	Orphenadrine, combinations (DDD 4 UD)	125	125	147	117	1	1	0	0	0.26	0.26	0.31	0.24	1	1	0	0
M03BX	Other centrally acting agents	2,772	3,020	3,825	3,755	3	12	31	31	2.43	2.42	2.43	2.39	3	3	4	3
M03BX01	Baclofen	498	818	1,652	1,617	7	38	68	69	0.46	0.51	0.54	0.53	7	8	11	9
M03BX02	Tizanidine (DDD 12 mg)	2,274	2,202	2,172	2,137	2	2	2	2	1.97	1.91	1.89	1.86	2	2	2	2



M04 Antigout preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
M04	Antigout preparations	1,782	1,935	1,940	1,791	3	3	2	2	3.71	3.99	4.20	4.46	2	2	2	2
M04A	Antigout preparations	1,782	1,935	1,940	1,791	3	3	2	2	3.71	3.99	4.20	4.46	2	2	2	2
M04AA	Preparations inhibiting uric acid production	1,756	1,898	1,897	1,739	3	3	2	2	3.70	3.97	4.18	4.44	2	2	2	2
M04AA01	Allopurinol (DDD 0.40 g)	1,399	1,501	1,567	1,493	2	2	2	2	3.50	3.75	3.92	4.15	2	2	2	2
M04AA03	Febuxostat (DDD 80 mg)	357	397	330	246	5	4	3	3	0.19	0.22	0.26	0.29	4	4	3	3
M04AC	Preparations with no effect on uric acid metabolism	26	37	43	52	11	16	17	11	0.01	0.02	0.02	0.02	11	16	17	11
M04AC01	Colchicine (DDD 1 mg)	26	37	43	52	11	16	17	11	0.01	0.02	0.02	0.02	11	16	17	11

**M05 Drugs for treatment of bone diseases**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
M05	Drugs for treatment of bone diseases	15,572	16,113	16,516	16,915	15	14	12	15	10.82	11.05	11.42	11.52	5	5	5	5
M05B	Drugs affecting bone structure and mineralization	15,572	16,113	16,516	16,915	15	14	12	15	10.82	11.05	11.42	11.52	5	5	5	5
M05BA	Bisphosphonates	3,360	3,082	2,709	3,199	45	44	41	54	3.79	3.58	3.41	3.26	3	3	2	2
M05BA02	Clodronic acid	248	167	126	86	2	1	2	2	0.02	0.02	0.01	0.01	2	1	2	1
M05BA03	Pamidronic acid (DDD 60 mg)	93	91	51	43	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	97
M05BA04	Alendronic acid (DDD 10 mg)	930	946	953	895	3	2	2	2	2.39	2.31	2.31	2.27	3	2	2	2
M05BA06	Ibandronic acid	302	261	204	168	3	9	6	3	0.66	0.59	0.48	0.43	2	2	2	2
M05BA07	Risedronic acid (DDD 5 mg)	403	389	355	335	2	4	3	3	0.72	0.66	0.59	0.54	2	3	3	3
M05BA08	Zoledronic acid (DDD 4 mg)	1,383	1,229	1,020	1,672	99	99	99	99	0.01	0.01	0.00	0.00	99	99	99	100
M05BB	Bisphosphonates, combinations	369	264	139	121	1	1	1	2	0.30	0.26	0.23	0.20	1	1	1	2
M05BB03	Alendronic acid and colecalciferol (DDD 10 mg)	369	264	139	121	1	1	1	2	0.30	0.26	0.23	0.20	1	1	1	2
M05BC	Bone morphogenetic proteins	31	40	55	46	100	100	100	100								
M05BC01	Dibotermin alfa	31	40	55	46	100	100	100	100								
M05BX	Other drugs affecting mineralization	11,812	12,727	13,613	13,550	7	6	6	6	6.72	7.21	7.78	8.06	7	7	6	6
M05BX03	Strontium ranelate (DDD 2 g)	61	0			3	100			0.03	0.00			3	100		
M05BX04	Denosumab (DDD 0.33 mg)	11,752	12,727	13,613	13,550	7	6	6	6	6.69	7.21	7.78	8.06	7	7	6	6

**M09 Other drugs for disorders of the musculo-skeletal system**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
M09	Other drugs for disorders of the musculo-skeletal system	2,458	11,048	9,650	7,325	91	98	98	98	0.07	0.07	0.05	0.02	75	77	72	42
M09A	Other drugs for disorders of the musculo-skeletal system	2,458	11,048	9,650	7,325	91	98	98	98	0.07	0.07	0.05	0.02	75	77	72	42
M09AB	Enzymes	983	1,021	1,230	9	97	97	96	100	0.00	0.00	0.00	0.00	97	97	96	100
M09AB02	Collagenase clostridium histolyticum (DDD 0.90 mg)	983	1,021	1,230	9	97	97	96	100	0.00	0.00	0.00	0.00	97	97	96	100
M09AX	Other drugs for disorders of the musculo-skeletal system	1,475	10,026	8,420	7,316	87	98	98	98	0.07	0.07	0.05	0.02	74	77	71	42
M09AX01	Hyaluronic acid (DDD 3.60 mg)	725	610	420	150	74	74	68	24	0.07	0.07	0.05	0.02	74	74	68	24
M09AX07	Nusinersen (DDD 0.10 mg)	750	9,416	7,999	7,166	100	100	100	100	0.00	0.01	0.01	0.01	100	100	100	100



N Nervous system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N	Nervous system	296,698	293,614	305,890	319,715	16	16	16	16	260.85	270.51	278.93	288.22	5	5	4	4
N01	Anesthetics	18,905	19,352	18,679	16,832	88	89	88	87								
N02	Analgesics	66,543	63,895	74,421	82,065	16	16	13	11	55.11	55.05	56.72	59.05	7	6	6	5
N03	Antiepileptics	54,786	54,697	52,622	47,894	10	9	9	8	21.45	22.25	23.27	24.26	5	4	4	4
N04	Anti-parkinson drugs	19,468	18,743	17,289	16,860	5	4	4	4	5.22	5.21	5.27	5.06	4	4	4	4
N05	Psycholeptics	70,930	69,864	70,388	72,917	14	14	14	14	80.61	83.89	85.01	86.25	5	5	5	5
N06	Psychoanaleptics	49,203	49,986	53,905	58,436	4	3	3	3	91.49	96.89	101.18	105.64	3	2	2	2
N07	Other nervous system drugs	16,863	17,078	18,586	24,710	19	19	24	40	6.97	7.22	7.48	7.95	11	14	17	19

**N01 Anesthetics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N01	Anesthetics	18,905	19,352	18,679	16,832	88	89	88	87								
N01A	Anesthetics, general	9,532	10,239	9,472	8,021	96	96	97	96								
N01AB	Halogenated hydrocarbons	2,915	3,016	2,622	2,314	97	98	97	98								
N01AB06	Isoflurane	9	10	11	12	91	100	100	100								
N01AB07	Desflurane	633	698	588	390	99	100	100	100								
N01AB08	Sevoflurane	2,273	2,308	2,023	1,912	97	97	97	97								
N01AF	Barbiturates, plain	89	107	27	50	99	99	99	99								
N01AF03	Thiopental	89	107	27	50	99	99	99	99								
N01AH	Opioid anesthetics	1,555	1,702	1,558	1,698	93	95	95	94								
N01AH01	Fentanyl	223	216	228	225	97	98	98	99								
N01AH02	Alfentanil	175	167	165	138	93	93	92	87								
N01AH03	Sufentanil	44	37	36	30	100	100	100	100								
N01AH06	Remifentanil	1,112	1,282	1,128	1,304	92	94	95	94								
N01AX	Other general anesthetics	4,973	5,414	5,266	3,959	96	96	96	96								
N01AX03	Ketamine	31	52	53	26	92	88	91	89								
N01AX10	Propofol	3,860	4,115	3,799	2,844	95	96	96	95								
N01AX14	Esketamine	1,082	1,247	1,413	1,089	97	97	98	98								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N01B	Anesthetics, local	9,373	9,113	9,206	8,811	80	80	80	79								
N01BB	Amides	8,946	8,694	8,730	8,352	80	80	79	79								
N01BB01	Bupivacaine	967	846	747	565	89	89	87	96								
N01BB02	Lidocaine	1,956	1,688	1,698	1,639	83	79	78	75								
N01BB03	Mepivacaine	6	5	5	5	8	13	10	10								
N01BB04	Prilocaine				1				82								
N01BB09	Ropivacaine	1,318	1,449	1,541	1,550	96	96	97	96								
N01BB10	Levobupivacaine	965	983	1,010	975	99	99	99	98								
N01BB20	Combinations	1,087	1,098	1,097	1,034	50	51	48	45								
N01BB51	Bupivacaine, combinations	46	39	44	24	93	89	80	92								
N01BB52	Lidocaine, combinations	1,062	1,077	1,117	1,214	80	82	81	81								
N01BB54	Prilocaine, combinations	156	145	118	149	59	61	62	62								
N01BB58	Articaine, combinations	1,382	1,364	1,355	1,196	65	67	68	66								
N01BX	Other local anesthetics	427	419	476	459	90	90	88	83								
N01BX04	Capsaicin	427	419	476	459	90	90	88	83								



N02 Analgesics

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N02	Analgesics	66,543	63,895	74,421	82,065	16	16	13	11	55.11	55.05	56.72	59.05	7	6	6	5
N02A	Opioids	31,058	27,596	25,790	24,779	24	24	25	24	14.73	14.02	13.75	13.31	9	9	9	9
N02AA	Natural opium alkaloids	10,515	10,423	10,189	10,338	52	50	50	49	2.28	2.33	2.37	2.36	37	34	35	35
N02AA01	Morphine	1,523	1,641	1,397	1,642	88	86	87	87	0.31	0.28	0.29	0.31	83	84	90	91
N02AA03	Hydromorphone	473	511	618	544	66	63	71	70	0.08	0.09	0.11	0.09	58	55	63	63
N02AA05	Oxycodone	5,074	4,922	5,089	4,955	51	48	48	45	1.63	1.68	1.68	1.68	27	25	25	24
N02AA55	Oxycodone and naloxone (DDD 75 mg)	3,444	3,349	3,083	3,196	37	34	32	30	0.27	0.28	0.29	0.28	37	35	33	32
N02AB	Phenylpiperidine derivatives	4,274	3,826	3,209	3,061	21	20	21	17	0.89	0.82	0.75	0.67	21	19	17	14
N02AB03	Fentanyl	4,274	3,826	3,209	3,061	21	20	21	17	0.89	0.82	0.75	0.67	21	19	17	14
N02AE	Oripavine derivatives	7,646	5,482	5,124	5,084	9	8	7	7	1.39	1.45	1.48	1.49	8	7	6	5
N02AE01	Buprenorphine (DDD 1.20 mg)	7,646	5,482	5,124	5,084	9	8	7	7	1.39	1.45	1.48	1.49	8	7	6	5
N02AJ	Opioids in combination with non-opioid analgesics	4,405	3,904	3,663	3,230	1	1	1	1	7.36	6.75	6.51	6.26	2	1	1	1
N02AJ06	Codeine and paracetamol	3,984	3,307	3,073	2,749	1	1	1	1	7.11	6.32	5.97	5.69	2	2	2	1
N02AJ08	Codeine and ibuprofen (DDD 4 UD)	279	341	294	265	0	0	0	0	0.10	0.14	0.11	0.11	0	0	0	0
N02AJ13	Tramadol and paracetamol (DDD 3 UD)	142	251	289	208	1	1	1	1	0.15	0.29	0.43	0.46	1	1	1	1
N02AJ14	Taramadol and dexketoprofen	1	4	8	9				0								
N02AX	Other opioids	4,217	3,961	3,605	3,066	4	4	4	4	2.80	2.67	2.64	2.54	2	2	2	2
N02AX02	Tramadol (DDD 0.30 g)	4,217	3,961	3,605	3,066	4	4	4	4	2.80	2.67	2.64	2.54	2	2	2	2

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N02B	Other analgesics and antipyretics	30,079	29,788	28,299	31,386	10	10	10	9	38.28	38.72	40.15	42.60	6	5	5	4
N02BA	Salicylic acid and derivatives	4,957	4,569	1,506	3,388	4	0	1	0	1.87	1.68	1.02	1.33	1	0	1	1
N02BA01	Acetylsalicylic acid	1,461	1,142	997	1,033	12	1	1	1	0.95	0.83	0.77	0.73	2	1	1	1
N02BA51	Acetylsalicylic acid, combinations excl. psycholeptics	3,496	3,427	509	2,355	0	0	0	0	0.93	0.85	0.25	0.59	0	0	0	0
N02BE	Anilides	25,027	25,095	26,613	27,809	12	12	11	10	36.41	37.04	39.12	41.27	7	6	5	5
N02BE01	Paracetamol (DDD 3 g)	24,560	24,615	25,749	27,209	12	12	11	10	36.23	36.87	38.84	41.07	7	6	5	5
N02BE51	Paracetamol, combinations excl. psycholeptics (DDD 6 UD)	466	480	864	600				0	0.18	0.17	0.28	0.20				0
N02BG	Other analgesics and antipyretics	96	123	181	189	19	17	47	52	0.00	0.00	0.00	0.00	19	16	10	17
N02BG09	Methoxyflurane		2	75	88		100	99	94								
N02BG10	Cannabinoids (DDD 8 UD)	96	121	105	101	19	16	10	17	0.00	0.00	0.00	0.00	19	16	10	17
N02C	Antimigraine preparations	5,406	6,511	20,332	25,900	1	7	2	0	2.10	2.31	2.82	3.14	1	1	1	1
N02CC	Selective 5HT1-receptor agonists	5,406	6,004	8,056	7,876	1	1	1	1	2.10	2.29	2.41	2.34	1	1	1	1
N02CC01	Sumatriptan	2,313	2,793	4,820	4,717	3	2	2	2	1.36	1.49	1.55	1.46	1	1	1	1
N02CC02	Naratriptan (DDD 2.50 mg)	163	152	94	79	0	0	0	0	0.03	0.02	0.03	0.03	0	0	0	0
N02CC03	Zolmitriptan (DDD 2.50 mg)	762	817	909	865	1	1	1	1	0.18	0.19	0.19	0.19	1	1	1	1
N02CC04	Rizatriptan (DDD 10 mg)	605	645	669	700	0	0	0	0	0.12	0.13	0.14	0.14	0	0	0	0
N02CC05	Almotriptan (DDD 12.50 mg)	417	437	448	440	0	0	0	0	0.09	0.10	0.11	0.11	0	0	0	0
N02CC06	Eletriptan (DDD 40 mg)	592	592	543	479	0	0	0	0	0.18	0.20	0.23	0.24	0	0	0	0
N02CC07	Frovatriptan (DDD 2.50 mg)	554	567	574	595	0	0	0	0	0.14	0.15	0.16	0.17	0	0	0	0
N02CD	Calcitonin gene-related peptide (CGRP) antagonists		507	12,276	18,024		79	3	0		0.02	0.41	0.80		79	3	0
N02CD01	Erenumab (DDD 2.50 mg)		507	12,247	13,284		79	3	0		0.02	0.41	0.63		79	3	0
N02CD02	Galcanezumab (DDD 4 mg)				288								0.01				
N02CD03	Fremanezumab (DDD 7.50 mg)			29	4,452				0			0.00	0.16				0

**N03 Antiepileptics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N03	Antiepileptics	54,786	54,697	52,622	47,894	10	9	9	8	21.45	22.25	23.27	24.26	5	4	4	4
N03A	Antiepileptics	54,786	54,697	52,622	47,894	10	9	9	8	21.45	22.25	23.27	24.26	5	4	4	4
N03AB	Hydantoin derivatives	1,229	907	1,046	723	89	86	89	86	0.21	0.19	0.17	0.15	12	10	12	8
N03AB02	Phenytoin (DDD 0.30 g)	149	138	127	107	7	7	8	5	0.20	0.18	0.17	0.14	7	7	8	5
N03AB05	Fosphenytoin (DDD 0.45 g)	1,080	769	919	616	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
N03AE	Benzodiazepine derivatives	558	533	501	471	3	3	3	2	0.79	0.74	0.69	0.64	3	2	2	2
N03AE01	Clonazepam (DDD 8 mg)	558	533	501	471	3	3	3	2	0.79	0.74	0.69	0.64	3	2	2	2
N03AF	Carboxamide derivatives	4,695	4,912	4,942	4,993	4	4	4	3	3.64	3.66	3.62	3.58	3	3	2	2
N03AF01	Carbamazepine (DDD 1 g)	1,235	1,246	1,159	1,097	5	9	7	6	1.44	1.40	1.32	1.26	3	3	3	2
N03AF02	Oxcarbazepine (DDD 1 g)	3,000	3,073	3,117	3,180	3	3	3	2	2.15	2.20	2.22	2.25	3	3	2	2
N03AF03	Rufinamide (DDD 1.40 g)	183	204	220	235	7	6	6	5	0.01	0.01	0.02	0.02	7	5	6	5
N03AF04	Eslicarbazepine (DDD 0.80 g)	276	389	447	481	2	3	2	2	0.04	0.05	0.06	0.06	2	3	2	2
N03AG	Fatty acid derivatives	4,805	4,795	4,717	4,700	11	11	10	9	3.64	3.62	3.60	3.57	7	6	6	6
N03AG01	Valproic acid (DDD 1.50 g)	4,713	4,707	4,634	4,617	11	11	10	9	3.62	3.60	3.58	3.55	7	6	6	6
N03AG04	Vigabatrin (DDD 2 g)	91	89	83	83	10	10	9	9	0.02	0.02	0.02	0.02	10	10	9	9

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N03AX	Other antiepileptics	43,499	43,549	41,417	37,008	8	7	8	8	13.18	14.05	15.19	16.32	4	4	4	4
N03AX09	Lamotrigine (DDD 0.30 g)	4,899	4,830	4,749	4,559	3	3	3	3	2.05	2.12	2.23	2.32	3	3	3	2
N03AX11	Topiramate (DDD 0.30 g)	1,654	1,635	1,567	1,504	5	5	4	4	0.37	0.37	0.36	0.36	6	5	5	5
N03AX12	Gabapentin (DDD 1.80 g)	5,435	5,964	6,107	6,487	4	4	4	4	2.66	3.09	3.54	4.20	4	4	4	4
N03AX14	Levetiracetam (DDD 1.50 g)	8,267	8,220	8,623	8,689	17	12	10	8	2.41	2.53	2.70	2.77	7	7	6	5
N03AX15	Zonisamide (DDD 0.20 g)	971	920	857	833	3	3	3	2	0.19	0.20	0.19	0.19	2	2	3	2
N03AX16	Pregabalin (DDD 0.30 g)	17,900	16,541	12,512	6,563	4	4	4	3	5.07	5.19	5.43	5.57	4	3	3	3
N03AX17	Stiripentol (DDD 1 g)	283	293	319	341	7	3	1	3	0.01	0.01	0.01	0.01	7	3	1	3
N03AX18	Lacosamide (DDD 0.30 g)	3,458	4,183	4,839	5,561	24	23	22	21	0.36	0.45	0.52	0.61	8	8	7	7
N03AX21	Retigabine (DDD 0.90 g)	1				35				0.00				35			
N03AX22	Perampanel (DDD 8 mg)	503	737	884	958	7	7	7	6	0.04	0.06	0.08	0.09	5	5	5	5
N03AX23	Brivaracetam (DDD 0.10 g)	129	226	960	1,513	49	29	16	14	0.01	0.03	0.11	0.20	12	9	6	5

**N04 Anti-parkinson drugs**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N04	Anti-parkinson drugs	19,468	18,743	17,289	16,860	5	4	4	4	5.22	5.21	5.27	5.06	4	4	4	4
N04A	Anticholinergic agents	109	102	94	91	5	5	4	5	0.20	0.18	0.17	0.16	5	5	4	5
N04AA	Tertiary amines	109	102	94	91	5	5	4	5	0.20	0.18	0.17	0.16	5	5	4	5
N04AA02	Biperiden (DDD 10 mg)	109	102	94	91	5	5	4	5	0.20	0.18	0.17	0.16	5	5	4	5
N04B	Dopaminergic agents	19,359	18,641	17,195	16,770	5	4	4	4	5.03	5.02	5.10	4.90	4	4	4	4
N04BA	Dopa and dopa derivatives	13,473	13,417	13,120	13,127	5	5	5	4	2.37	2.39	2.47	2.31	6	6	6	5
N04BA02	Levodopa and decarboxylase inhibitor (DDD 0.60 g)	11,217	11,295	11,210	10,853	5	5	5	4	1.64	1.65	1.75	1.60	6	6	6	5
N04BA03	Levodopa, decarboxylase inhibitor and COMT inhibitor (DDD 0.45 g)	2,256	2,122	1,910	2,274	6	6	5	6	0.73	0.74	0.72	0.71	6	6	6	5
N04BC	Dopamine agonists	4,761	4,428	3,362	2,974	2	3	3	3	1.43	1.48	1.45	1.46	2	2	2	2
N04BC01	Bromocriptine (DDD 40 mg)	8	8	6	6	13	19	12	18	0.00	0.00	0.00	0.00	13	19	12	18
N04BC04	Ropinirole (DDD 6 mg)	1,003	821	589	464	2	2	2	2	0.68	0.69	0.70	0.68	2	2	2	2
N04BC05	Pramipexole (DDD 2.50 mg)	2,871	2,694	1,802	1,514	2	2	2	3	0.64	0.67	0.64	0.67	2	2	2	3
N04BC06	Cabergoline (DDD 3 mg)	70	68	71	74	6	5	4	7	0.01	0.01	0.01	0.01	6	5	4	7
N04BC07	Apomorphine (DDD 20 mg)	204	229	329	348	4	3	3	2	0.01	0.01	0.01	0.01	5	3	3	2
N04BC09	Rotigotine (DDD 6 mg)	605	609	566	568	3	4	4	3	0.09	0.09	0.08	0.09	3	4	3	3
N04BD	Monoamine oxidase type B inhibitors	904	614	557	499	4	4	3	3	1.19	1.13	1.16	1.10	2	3	2	4
N04BD01	Selegiline (DDD 5 mg)	384	355	367	341	2	2	2	2	0.81	0.75	0.78	0.73	2	2	2	2
N04BD02	Rasagiline (DDD 1 mg)	518	257	190	158	6	5	5	6	0.38	0.38	0.37	0.37	3	3	3	7
N04BD03	Safinamide (DDD 75 mg)	2	2	0	1		8		20	0.00	0.00	0.00	0.00		6		19
N04BX	Other dopaminergic agents	221	182	155	169	9	7	9	6	0.04	0.03	0.02	0.03	9	7	9	6
N04BX01	Tolcapone (DDD 0.45 g)	0								0.00							
N04BX02	Entacapone (DDD 1 g)	221	182	155	169	9	7	9	6	0.04	0.03	0.02	0.03	9	7	9	6

**N05 Psycholeptics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N05	Psycholeptics	70,930	69,864	70,388	72,917	14	14	14	14	80.61	83.89	85.01	86.25	5	5	5	5
N05A	Antipsychotics	51,615	49,941	50,472	51,762	12	11	11	11	21.33	21.85	22.16	22.95	8	7	7	7
N05AA	Phenothiazines with aliphatic side chain	387	361	362	347	8	7	6	6	0.37	0.34	0.33	0.31	9	7	6	6
N05AA02	Levomepromazine	387	361	362	347	8	7	6	6	0.37	0.34	0.33	0.31	9	7	6	6
N05AB	Phenothiazines with piperazine structure	596	573	571	568	6	5	5	5	0.48	0.45	0.45	0.44	5	5	5	5
N05AB02	Fluphenazine	2				2				0.01				2			
N05AB03	Perphenazine	569	550	551	549	6	6	5	6	0.45	0.44	0.43	0.43	5	5	5	5
N05AB04	Prochlorperazine	25	22	21	19	2	2	2	2	0.02	0.01	0.01	0.01	2	2	2	2
N05AC	Phenothiazines with piperidine structure	27	8			6	5			0.03	0.01			6	4		
N05AC01	Periciazine	27	8			6	5			0.03	0.01			6	4		
N05AD	Butyrophenone derivatives	541	523	502	499	47	47	49	50	0.46	0.44	0.41	0.42	22	23	23	27
N05AD01	Haloperidol	384	371	346	360	26	27	26	32	0.44	0.42	0.39	0.40	19	20	20	24
N05AD08	Droperidol (DDD 2.50 mg)	157	152	157	139	97	98	98	96	0.02	0.02	0.02	0.02	97	98	98	96
N05AE	Indole derivatives	1,235	1,304	1,480	1,551	7	8	7	7	0.28	0.29	0.32	0.33	6	7	6	6
N05AE03	Sertindole (DDD 16 mg)	464	431	412	387	7	6	6	4	0.08	0.07	0.07	0.06	6	6	5	4
N05AE04	Ziprasidone	665	611	603	592	5	5	4	4	0.19	0.17	0.17	0.16	4	4	3	4
N05AE05	Lurasidone (DDD 60 mg)	107	262	465	572	23	17	13	12	0.02	0.05	0.08	0.10	28	18	12	11
N05AF	Thioxanthene derivatives	637	621	594	579	12	12	12	13	0.76	0.70	0.67	0.65	9	8	8	9
N05AF01	Flupentixol	66	71	70	69	4	4	3	3	0.06	0.06	0.06	0.05	5	5	4	3
N05AF03	Chlorprothixene	280	267	262	247	4	3	4	3	0.29	0.26	0.26	0.24	4	3	4	3
N05AF05	Zuclopenthixol	292	283	263	263	21	23	22	24	0.41	0.38	0.36	0.35	13	12	12	14

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N05AH	Diazepines, oxazepines, thiazepines and oxepines	22,787	20,745	19,820	20,079	14	12	12	12	13.50	13.82	13.93	14.52	7	7	7	7
N05AH01	Loxapine	22	5			100	100			0.00	0.00			100	100		
N05AH02	Clozapine (DDD 0.30 g)	5,229	4,953	3,874	3,884	9	9	9	9	2.32	2.30	2.25	2.36	9	9	9	9
N05AH03	Olanzapine (DDD 10 mg)	11,412	11,605	11,991	12,282	20	16	16	16	5.89	6.22	6.30	6.66	9	9	9	9
N05AH04	Quetiapine (DDD 0.40 g)	5,979	4,058	3,833	3,798	6	4	3	3	5.27	5.28	5.36	5.48	5	4	4	4
N05AH05	Asenapine (DDD 20 mg)	145	125	122	114	13	15	16	15	0.02	0.02	0.02	0.02	13	13	13	12
N05AL	Benzamides	116	109	100	102	9	9	7	8	0.05	0.05	0.04	0.04	10	9	7	9
N05AL01	Sulpiride (DDD 0.80 g)	116	109	100	102	9	9	7	8	0.05	0.05	0.04	0.04	10	9	7	9
N05AN	Lithium	590	607	615	621	6	6	6	6	0.94	0.97	0.98	0.99	6	6	6	6
N05AN01	Lithium (DDD 168 mg)	590	607	615	621	6	6	6	6	0.94	0.97	0.98	0.99	6	6	6	6
N05AX	Other antipsychotics	24,698	25,094	26,426	27,415	11	10	10	10	4.46	4.79	5.04	5.25	8	7	7	7
N05AX08	Risperidone	10,802	10,159	9,332	8,669	6	6	5	5	1.87	1.91	1.83	1.84	7	7	6	6
N05AX12	Aripiprazole	6,712	6,946	7,587	8,269	17	13	11	10	2.17	2.39	2.62	2.75	7	7	6	6
N05AX13	Paliperidone	7,185	7,987	9,436	10,257	13	12	13	12	0.42	0.48	0.58	0.64	14	13	13	12
N05AX15	Cariprazine (DDD 3 mg)		1	61	143		50	56	56		0.00	0.01	0.03		64	54	53
N05AX16	Brexpiprazole (DDD 3 mg)			10	77			23	23			0.00	0.01			23	24
N05B	Anxiolytics	6,577	6,329	5,989	6,916	11	11	11	25	18.65	17.43	16.22	15.48	6	6	6	6
N05BA	Benzodiazepine derivatives	5,239	5,014	4,676	5,588	12	12	13	30	17.12	15.95	14.76	14.04	6	6	6	6
N05BA01	Diazepam (DDD 10 mg)	1,653	1,599	1,411	1,295	32	32	28	27	5.09	4.70	4.30	3.98	9	9	9	9
N05BA02	Chlordiazepoxide	131	54			14	13			0.53	0.19			15	14		
N05BA04	Oxazepam (DDD 50 mg)	1,807	1,767	1,753	1,698	3	3	4	4	5.08	4.92	4.85	4.70	4	4	4	4

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N05BA06	Lorazepam (DDD 2.50 mg)	402	401	446	1,578	8	8	25	78	1.95	1.90	1.81	1.79	10	10	10	13
N05BA09	Clobazam (DDD 20 mg)	114	121	113	129	5	4	4	4	0.34	0.36	0.33	0.38	5	4	4	4
N05BA12	Alprazolam (DDD 1 mg)	1,131	1,071	953	887	1	1	1	1	4.13	3.88	3.47	3.19	1	1	1	1
N05BB	Diphenylmethane derivatives	823	751	727	725	6	5	5	4	1.32	1.25	1.22	1.19	7	6	5	5
N05BB01	Hydroxyzine (DDD 75 mg)	823	751	727	725	6	5	5	4	1.32	1.25	1.22	1.19	7	6	5	5
N05BE	Azaspirodecanedione derivatives	516	565	586	604	7	9	11	12	0.21	0.23	0.24	0.25	7	9	11	12
N05BE01	Buspirone (DDD 30 mg)	516	565	586	604	7	9	11	12	0.21	0.23	0.24	0.25	7	9	11	12
N05C	Hypnotics and sedatives	12,738	13,593	13,927	14,239	22	26	25	21	40.62	44.61	46.63	47.83	4	4	4	4
N05CD	Benzodiazepine derivatives	3,248	3,321	3,330	3,472	10	12	13	15	7.38	6.77	5.85	5.29	5	5	5	6
N05CD02	Nitrazepam (DDD 5 mg)	117	106	112	102	3	2	3	2	0.41	0.33	0.31	0.26	3	3	3	2
N05CD05	Triazolam	51	38	40	33	0	1	0	0	0.04	0.03	0.03	0.03	0	1	0	0
N05CD07	Temazepam (DDD 20 mg)	1,903	1,863	1,798	1,800	3	3	3	3	6.71	6.20	5.30	4.78	4	4	4	4
N05CD08	Midazolam	1,176	1,315	1,380	1,536	24	25	27	30	0.22	0.21	0.20	0.22	36	40	45	55
N05CF	Benzodiazepine related drugs	2,937	2,674	2,510	2,505	2	2	2	2	19.25	17.83	16.74	16.02	2	2	2	2
N05CF01	Zopiclone (DDD 7.50 mg)	2,216	2,017	1,912	1,886	2	2	2	2	14.17	12.97	12.13	11.43	3	3	3	3
N05CF02	Zolpidem (DDD 10 mg)	721	657	598	619	1	1	1	1	5.08	4.86	4.60	4.59	1	1	1	1
N05CH	Melatonin receptor agonists	3,955	4,467	5,131	5,662	6	6	5	4	13.71	19.79	23.94	26.29	5	5	5	4
N05CH01	Melatonin (DDD 2 mg)	3,955	4,467	5,131	5,662	6	6	5	4	13.71	19.79	23.94	26.29	5	5	5	4
N05CM	Other hypnotics and sedatives	2,598	3,131	2,956	2,600	84	90	95	83	0.28	0.23	0.11	0.22	4	6	12	6
N05CM09	Valerianae radix	415	309	147	451				0	0.27	0.21	0.09	0.21				0
N05CM18	Dexmedetomidine (DDD 1 mg)	2,183	2,822	2,809	2,149	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100

**N06 Psychoanaleptics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N06	Psychoanaleptics	49,203	49,986	53,905	58,436	4	3	3	3	91.49	96.89	101.18	105.64	3	2	2	2
N06A	Antidepressants	30,297	31,382	33,491	36,009	3	2	2	2	70.47	74.87	78.31	81.52	2	2	2	2
N06AA	Non-selective monoamine reuptake inhibitors	3,159	3,308	3,300	3,419	2	2	2	2	4.29	4.35	4.12	3.92	2	2	2	2
N06AA04	Clomipramine (DDD 0.10 g)	148	147	148	161	3	3	3	4	0.20	0.20	0.20	0.22	3	3	3	4
N06AA06	Trimipramine (DDD 0.15 g)	71	73	61	65	4	4	3	2	0.10	0.10	0.09	0.09	4	4	3	2
N06AA09	Amitriptyline (DDD 75 mg)	2,294	2,364	2,492	2,758	2	2	2	2	2.96	3.01	2.89	3.01	2	2	2	2
N06AA10	Nortriptyline	322	392	422	436	2	2	2	2	0.53	0.55	0.58	0.60	3	3	2	2
N06AA12	Doxepin (DDD 0.10 g)	325	332	176		3	3	2		0.49	0.48	0.36		3	3	2	
N06AB	Selective serotonin reuptake inhibitors	8,041	6,655	6,618	6,819	3	2	2	2	39.88	41.39	43.41	44.58	2	2	1	2
N06AB03	Fluoxetine (DDD 20 mg)	958	989	1,035	1,089	2	2	2	2	4.11	4.27	4.41	4.50	2	2	2	2
N06AB04	Citalopram (DDD 20 mg)	1,969	1,580	1,463	1,343	2	2	2	2	10.09	9.60	9.11	8.50	2	2	1	1
N06AB05	Paroxetine (DDD 20 mg)	723	716	701	652	1	1	1	1	2.33	2.32	2.32	2.33	1	1	1	1
N06AB06	Sertraline (DDD 50 mg)	2,487	1,573	1,413	1,610	2	2	2	2	7.88	8.58	9.70	10.88	2	2	2	2
N06AB08	Fluvoxamine (DDD 0.10 g)	88	83	78	76	1	1	1	1	0.16	0.15	0.14	0.14	1	1	1	1
N06AB10	Escitalopram (DDD 10 mg)	1,816	1,714	1,929	2,048	5	3	2	2	15.31	16.47	17.73	18.24	2	2	1	1
N06AG	Monoamine oxidase type A inhibitors	269	271	267	268	2	1	1	1	0.35	0.35	0.34	0.34	1	1	1	1
N06AG02	Moclobemide (DDD 0.30 g)	269	271	267	268	2	1	1	1	0.35	0.35	0.34	0.34	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N06AX	Other antidepressants	18,828	21,148	23,306	25,502	3	3	2	3	25.96	28.79	30.44	32.69	3	3	2	2
N06AX03	Mianserin (DDD 60 mg)	254	273	241	190	2	2	2	2	0.28	0.30	0.26	0.20	2	2	2	2
N06AX05	Trazodone (DDD 0.30 g)	138	139	169	179	3	3	3	3	0.16	0.16	0.19	0.20	3	3	3	3
N06AX11	Mirtazapine (DDD 30 mg)	4,070	4,230	4,612	5,077	5	5	4	4	7.96	8.07	8.25	8.47	4	4	4	3
N06AX12	Bupropion (DDD 0.30 g)	3,276	3,670	4,088	4,057	1	1	1	1	1.84	2.08	2.32	2.53	1	1	1	1
N06AX16	Venlafaxine (DDD 0.10 g)	5,663	6,299	6,478	6,982	2	2	2	2	10.07	11.19	11.04	11.67	2	2	2	2
N06AX17	Milnacipran (DDD 0.10 g)	67	68	51	23	2	2	2	1	0.05	0.05	0.04	0.02	2	2	2	1
N06AX18	Reboxetin (DDD 8 mg)	34	33	34	30	2	1	2	2	0.03	0.03	0.03	0.03	2	1	2	2
N06AX21	Duloxetine (DDD 60 mg)	1,403	1,147	1,228	1,308	3	3	2	4	3.19	3.61	3.93	4.14	2	2	2	2
N06AX22	Agomelatine (DDD 25 mg)	1,142	1,240	860	778	3	3	3	2	0.70	0.77	0.91	1.04	3	3	2	2
N06AX25	Hyperici herba	56															
N06AX26	Vortioxetine (DDD 10 mg)	2,725	4,049	5,547	6,834	3	3	3	2	1.68	2.53	3.47	4.39	3	3	2	2
N06AX27	Esketamine				45				73								
N06B	Psychostimulants, agents used for adhd and nootropics	9,428	11,432	13,732	16,115	4	4	3	3	3.79	4.60	5.56	6.70	1	1	1	1
N06BA	Centrally acting sympathomimetics	9,077	11,106	13,332	15,562	1	1	1	1	3.74	4.55	5.51	6.66	1	1	1	1
N06BA02	Dexamfetamine (DDD 15 mg)	441	540	646	739	0	0	0	0	0.08	0.11	0.13	0.15	0	0	0	0
N06BA04	Methylphenidate (DDD 30 mg)	5,279	6,086	7,201	8,107	1	1	1	1	3.13	3.69	4.28	4.95	1	1	1	1
N06BA07	Modafinil (DDD 0.30 g)	619	712	773	765	0	1	0	1	0.07	0.08	0.08	0.08	0	0	0	1
N06BA09	Atomoxetine (DDD 80 mg)	1,378	1,588	1,280	876	5	5	4	5	0.13	0.16	0.17	0.20	5	5	4	4
N06BA12	Lisdexamfetamine (DDD 30 mg)	1,361	2,179	3,432	5,075	2	1	1	1	0.33	0.52	0.84	1.27	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N06BC	Xanthine derivatives	298	275	274	253	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
N06BC01	Caffeine (DDD 0.40 g)	298	275	274	253	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
N06BX	Other psychostimulants and nootropics	53	52	126	300	6	4	5	1	0.05	0.05	0.05	0.05	6	4	3	3
N06BX03	Piracetam	53	52	54	52	6	4	3	3	0.05	0.05	0.05	0.05	6	4	3	3
N06BX13	Idebenone (DDD 0.90 g)			73	248			6				0.00	0.00			6	
N06C	Psycholeptics and psychoanaleptics in combination	486	468	457	439	1	1	1	1	0.81	0.78	0.75	0.71	1	1	1	1
N06CA	Antidepressants in combination with psycholeptics	486	468	457	439	1	1	1	1	0.81	0.78	0.75	0.71	1	1	1	1
N06CA01	Amitriptyline and psycholeptics	486	468	457	439	1	1	1	1	0.81	0.78	0.75	0.71	1	1	1	1
N06D	Anti-dementia drugs	8,992	6,703	6,225	5,874	7	6	5	5	16.42	16.65	16.57	16.70	5	5	4	4
N06DA	Anticholinesterases	7,379	5,156	4,362	4,451	7	6	5	5	10.03	10.06	9.84	9.83	5	4	4	4
N06DA02	Donepezil (DDD 7.50 mg)	520	411	467	649	4	3	4	3	6.26	6.27	6.02	5.94	4	4	3	3
N06DA03	Rivastigmine	5,347	3,490	2,643	2,470	8	7	7	6	2.27	2.23	2.23	2.23	6	5	5	5
N06DA04	Galantamine (DDD 16 mg)	1,512	1,255	1,252	1,332	4	4	3	4	1.50	1.56	1.59	1.66	4	4	3	4
N06DX	Other anti-dementia drugs	1,613	1,547	1,863	1,423	7	6	5	6	6.39	6.59	6.73	6.88	7	6	5	5
N06DX01	Memantine (DDD 20 mg)	1,613	1,547	1,863	1,423	7	6	5	6	6.39	6.59	6.73	6.88	7	6	5	5



N07 Other nervous system drugs

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N07	Other nervous system drugs	16,863	17,078	18,586	24,710	19	19	24	40	6.97	7.22	7.48	7.95	11	14	17	19
N07A	Parasympathomimetics	486	471	460	489	47	44	38	43	0.24	0.25	0.27	0.27	7	6	5	5
N07AA	Anticholinesterases	469	459	445	477	49	45	39	44	0.24	0.25	0.27	0.27	7	6	5	5
N07AA02	Pyridostigmine	241	255	277	271	3	3	3	2	0.23	0.24	0.26	0.26	3	3	3	2
N07AA51	Neostigmine, combinations (DDD 1 UD)	228	204	168	206	97	98	98	98	0.01	0.01	0.01	0.01	97	98	98	98
N07AX	Other parasympathomimetics	17	13	15	12	3	4	1	1	0.00	0.00	0.00	0.00	3	4	1	1
N07AX01	Pilocarpine	17	13	15	12	3	4	1	1	0.00	0.00	0.00	0.00	3	4	1	1
N07B	Drugs used in addictive disorders	14,183	14,307	15,374	21,262	20	21	28	44	3.98	4.20	4.39	4.82	18	22	27	31
N07BA	Drugs used in nicotine dependence	10,294	10,360	10,366	11,083	4	4	4	4	2.57	2.56	2.47	2.67	5	5	6	6
N07BA01	Nicotine ¹	7,327	7,373	7,014	7,666	5	5	6	6	2.00	1.99	1.83	2.02	7	7	7	7
N07BA03	Varenicline (DDD 2 mg)	2,967	2,987	3,352	3,418	0	0	1	1	0.57	0.57	0.64	0.65	0	0	1	1
N07BB	Drugs used in alcohol dependence	678	658	642	604	5	5	6	6	0.67	0.66	0.65	0.63	6	6	6	7
N07BB01	Disulfiram (DDD 0.20 g)	427	417	410	396	6	6	7	7	0.57	0.56	0.55	0.53	6	6	7	7
N07BB04	Naltrexone (DDD 50 mg)	150	150	157	156	6	5	5	5	0.09	0.09	0.09	0.09	6	5	5	5
N07BB05	Nalmefene (DDD 18 mg)	100	91	75	52	1	3	1	2	0.01	0.01	0.01	0.01	1	3	1	2
N07BC	Drugs used in opioid dependence	3,211	3,289	4,366	9,575	77	80	86	93	0.74	0.98	1.27	1.52	76	77	81	86
N07BC01	Buprenorphine	24	17	1,739	7,415	92	95	98	97	0.00	0.00	0.12	0.53	92	95	98	97
N07BC02	Methadone (DDD 25 mg)	962	1,427	1,610	1,586	84	91	90	90	0.39	0.56	0.62	0.61	77	86	86	86
N07BC05	Levomethadone (DDD 15 mg)				74				73				0.02				73
N07BC51	Buprenorphine, combinations	2,225	1,846	1,017	500	73	71	61	52	0.35	0.42	0.52	0.36	74	67	71	71

¹ Includes nicotine replacement products sold to pharmacies and institutional customers. See also Nicotine replacement therapy page 238.

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N07C	Antivertigo preparations	754	699	701	706	1	1	1	1	2.70	2.71	2.76	2.80	1	1	1	1
N07CA	Antivertigo preparations	754	699	701	706	1	1	1	1	2.70	2.71	2.76	2.80	1	1	1	1
N07CA01	Betahistine (DDD 24 mg)	753	699	700	705	1	1	1	1	2.70	2.71	2.76	2.80	1	1	1	1
N07CA52	Cinnarizine, combinations (DDD 90 mg)	1	0	1	1			6		0.00	0.00	0.00	0.00			6	
N07X	Other nervous system drugs	1,439	1,601	2,051	2,253	2	2	6	8	0.05	0.05	0.05	0.06	5	4	4	4
N07XX	Other nervous system drugs	1,439	1,601	2,051	2,253	2	2	6	8	0.05	0.05	0.05	0.06	5	4	4	4
N07XX02	Riluzole (DDD 0.10 g)	187	208	179	210	6	6	8	8	0.02	0.02	0.02	0.02	6	6	8	8
N07XX04	Sodium oxybate (DDD 7.50 g)	1,073	1,231	1,367	1,100	0	1	0	1	0.02	0.02	0.03	0.03	0	1	0	1
N07XX06	Tetrabenazine (DDD 0.10 g)	69	83	80	63	17	10	8	11	0.01	0.01	0.01	0.00	17	10	8	11
N07XX07	Fampridine (DDD 20 mg)	110	79	74	106	6	8	10	7	0.00	0.00	0.00	0.01	5	5	6	5
N07XX08	Tafamidis (DDD 20 mg)			285	654			31	22			0.00	0.00			31	22
N07XX11	Pitolisant (DDD 18 mg)			68	120			1				0.00	0.00			0	



P Antiparasitic products, insecticides and repellents

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
P	Antiparasitic products, insecticides and repellents	6,220	6,205	6,296	5,749	4	3	3	3	2.30	2.34	2.42	2.51	2	2	2	2
P01	Antiprotozoals	3,313	3,296	3,064	2,668	4	4	3	5	2.06	2.10	2.12	2.24	2	2	2	3
P02	Anthelmintics	1,414	1,428	1,679	1,515	0	0	0	0	0.24	0.25	0.29	0.27	0	0	0	0
P03	Ectoparasiticides, incl. scabicides, insecticides and repellents	1,493	1,481	1,553	1,566	6	4	4	4								

**P01 Antiprotozoals**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
P01	Antiprotozoals	3,313	3,296	3,064	2,668	4	4	3	5	2.06	2.10	2.12	2.24	2	2	2	3
P01A	Agents against amoebiasis and other protozoal diseases	852	810	743	659	6	7	7	7	0.32	0.31	0.30	0.26	8	10	9	9
P01AB	Nitroimidazole derivatives	852	810	743	659	6	7	7	7	0.32	0.31	0.30	0.26	8	10	9	9
P01AB01	Metronidazole (DDD 2 g)	852	810	743	659	6	7	7	7	0.32	0.31	0.30	0.26	8	10	9	9
P01B	Antimalarials	2,461	2,487	2,320	2,009	3	3	2	4	1.74	1.79	1.83	1.98	1	1	1	2
P01BA	Aminoquinolines	1,507	1,555	1,594	1,754	1	1	1	2	1.70	1.75	1.79	1.97	1	1	1	2
P01BA02	Hydroxychloroquine (DDD 0.52 g)	1,507	1,555	1,594	1,754	1	1	1	2	1.70	1.75	1.79	1.97	1	1	1	2
P01BB	Biguanides	814	798	623	217	7	7	5	20	0.03	0.03	0.03	0.01	7	6	4	20
P01BB51	Proguanil, combinations (DDD 4 UD)	814	798	623	217	7	7	5	20	0.03	0.03	0.03	0.01	7	6	4	20
P01BC	Quinine alkaloids	140	134	104	37	0	0	0	6	0.01	0.01	0.00	0.00	0	0	0	6
P01BC02	Mefloquine (DDD 1 g)	140	134	104	37	0	0	0	6	0.01	0.01	0.00	0.00	0	0	0	6



P02 Anthelmintics

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
P02	Anthelmintics	1,414	1,428	1,679	1,515	0	0	0	0	0.24	0.25	0.29	0.27	0	0	0	0
P02C	Antinematodal agents	1,414	1,428	1,679	1,515	0	0	0	0	0.24	0.25	0.29	0.27	0	0	0	0
P02CX	Other antinematodals	1,414	1,428	1,679	1,515	0	0	0	0	0.24	0.25	0.29	0.27	0	0	0	0
P02CX01	Pyrvinium (DDD 0.35 g)	1,414	1,428	1,679	1,515	0	0	0	0	0.24	0.25	0.29	0.27	0	0	0	0

P03 Ectoparasiticides, incl. scabicides, insecticides and repellents

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
P03	Ectoparasiticides, incl. scabicides, insecticides and repellents	1,493	1,481	1,553	1,566	6	4	4	4								
P03A	Ectoparasiticides, incl. scabicides	1,493	1,481	1,553	1,566	6	4	4	4								
P03AC	Pyrethrines, incl. synthetic compounds	1,485	1,481	1,553	1,566	7	4	4	4								
P03AC04	Permethrin	1,485	1,481	1,553	1,566	7	4	4	4								
P03AX	Other ectoparasiticides, incl. scabicides	8				2											
P03AX03	Malathion	8				2											



R Respiratory system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R	Respiratory system	150,033	154,205	152,760	148,602	5	6	6	6	175.35	182.99	189.26	194.04	2	2	2	2
R01	Nasal preparations	22,979	24,823	26,971	23,802	1	1	1	1	34.07	35.48	37.04	33.25	1	1	1	1
R02	Throat preparations	7,156	7,938	7,555	5,708	0	0	0	0	3.49	3.68	3.28	2.51	0	0	0	0
R03	Drugs for obstructive airway diseases	92,433	93,537	91,012	93,802	7	8	9	8	76.09	78.39	79.93	83.83	3	3	3	3
R05	Cough and cold preparations	11,750	12,032	10,667	7,100	2	2	2	2	5.47	5.38	4.73	3.13	2	2	2	2
R06	Antihistamines for systemic use	14,838	14,992	15,862	17,165	1	1	0	1	56.24	60.06	64.28	71.32	1	1	1	1
R07	Other respiratory system products	877	884	693	1,027	100	100	100	83	0.00	0.00	0.00	0.00	100	100	100	87

**R01 Nasal preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R01	Nasal preparations	22,979	24,823	26,971	23,802	1	1	1	1	34.07	35.48	37.04	33.25	1	1	1	1
R01A	Decongestants and other nasal preparations for topical use	17,634	19,047	20,916	19,755	1	1	1	1	32.06	33.52	35.13	31.97	1	1	1	1
R01AA	Sympathomimetics, plain	4,584	4,874	5,853	5,294	1	1	1	1	10.24	10.74	11.11	9.17	1	1	1	1
R01AA05	Oxymetazoline (DDD 0.40 mg)	261	267	284	260	0	0	0	0	0.75	0.78	0.82	0.75	0	0	0	0
R01AA07	Xylometazoline (DDD 0.80 mg)	4,323	4,607	5,569	5,034	1	1	1	1	9.49	9.96	10.30	8.42	1	1	1	1
R01AB	Sympathomimetics, combinations excl. corticosteroids	539	540	612	492		0	0		0.82	0.80	0.83	0.64		0	0	0
R01AB06	Xylometazoline (DDD 0.80 ml)	539	540	612	492		0	0		0.82	0.80	0.83	0.64		0	0	0
R01AC	Antiallergic agents, excl. corticosteroids	237	314	303	246	1	0	1	0	0.26	0.35	0.33	0.22	1	1	1	0
R01AC01	Cromoglicic acid (DDD 40 mg)	123	144	133	21	1	1	1	0	0.16	0.20	0.19	0.03	1	1	1	0
R01AC02	Levocabastine (DDD 0.60 mg)	66	104	98	137	0	0		0	0.04	0.07	0.07	0.09	0	0		0
R01AC03	Azelastine (DDD 0.56 mg)	49	67	71	87					0.05	0.07	0.08	0.09				
R01AD	Corticosteroids	11,633	12,887	13,708	13,275	1	1	1	1	19.73	21.26	22.50	21.63	1	1	1	1
R01AD01	Beclometasone (DDD 0.40 mg)	533	549	506	535	0	0	0	0	1.12	1.13	1.07	1.04	0	0	0	0
R01AD05	Budesonide (DDD 0.20 mg)	264	225	186	92	0	0	0	0	0.57	0.52	0.47	0.23	0	0	0	0
R01AD08	Fluticasone (DDD 0.20 mg)	2,161	2,223	2,368	2,361	2	2	2	1	4.03	4.18	4.48	4.43	2	2	2	1
R01AD09	Mometasone (DDD 0.20 mg)	2,375	2,531	2,290	1,866	0	1	1	1	6.08	6.35	6.35	5.86	0	1	1	1
R01AD11	Triamcinolone (DDD 0.22 mg)	363	479	506	537	0	0	0	0	0.48	0.60	0.63	0.67	0	0	0	0
R01AD12	Fluticasone furoate (DDD 0.11 mg)	2,662	2,841	3,016	2,836	0	0	0	1	4.38	4.67	4.95	4.65	0	0	0	1
R01AD58	Fluticasone, combinations (DDD 4 UD)	3,274	4,039	4,837	5,048	0	1	1	1	3.07	3.81	4.56	4.75	0	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R01AX	Other nasal preparations	640	432	440	449	9	8	10	16	1.00	0.38	0.35	0.31	6	4	4	4
R01AX02	Retinol (DDD 800 U)	185				7				0.61				7			
R01AX03	Ipratropium bromide (DDD 0.24 mg)	158	159	164	186	6	7	8	7	0.11	0.11	0.12	0.13	6	7	7	7
R01AX06	Mupirocin	144	130	149	163	23	16	20	35								
R01AX10	Various (DDD 2 ml)	153	143	127	100	2	2	2	3	0.28	0.26	0.23	0.18	2	2	2	3
R01B	Nasal decongestants for systemic use	5,345	5,775	6,054	4,047	1	1	1	1	2.01	1.97	1.91	1.28	2	1	1	1
R01BA	Sympathomimetics	5,345	5,775	6,054	4,047	1	1	1	1	2.01	1.97	1.91	1.28	2	1	1	1
R01BA01	Phenylpropanolamine (DDD 0.10 g)	53	52	52	48	1	1	1	1	0.13	0.13	0.13	0.12	1	1	1	1
R01BA51	Phenylpropanolamine, combinations																
R01BA52	Pseudoephedrine, combinations	5,292	5,724	6,003	3,999	1	1	1	1	1.87	1.83	1.78	1.15	2	1	1	1



R02 Throat preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R02	Throat preparations	7,156	7,938	7,555	5,708	0	0	0	0	3.49	3.68	3.28	2.51	0	0	0	0
R02A	Throat preparations	7,156	7,938	7,555	5,708	0	0	0	0	3.49	3.68	3.28	2.51	0	0	0	0
R02AA	Antiseptics	3,915	4,241	4,259	2,976	0	0	0	0	1.63	1.61	1.52	1.06	0	0	0	0
R02AA03	Dichlorobenzyl alcohol (DDD 6 UD)	3,409	3,567	3,636	2,626	0	0	0	0	1.58	1.57	1.51	1.05	0	0	0	0
R02AA05	Chlorhexidine	70	47	28	12	3	3	9	5	0.05	0.03	0.02	0.01	3	3	9	5
R02AA20	Various	436	626	594	338	0	0	1	2								
R02AB	Antibiotics	2,189	2,456	2,232	2,065	1	1	1	1	1.23	1.38	1.18	1.06	1	1	1	1
R02AB30	Gramicidin (DDD 6 UD)	2,189	2,456	2,232	2,065	1	1	1	1	1.23	1.38	1.18	1.06	1	1	1	1
R02AX	Other throat preparations	1,052	1,242	1,065	667			0	0	0.63	0.70	0.58	0.38				0
R02AX01	Flurbiprofen (DDD 44 mg)	169	285	275	169		0	0	0	0.04	0.06	0.06	0.04		0	0	0
R02AX03	Benzydamine (DDD 9 mg)	883	956	790	498					0.59	0.64	0.52	0.35				

**R03 Drugs for obstructive airway diseases**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R03	Drugs for obstructive airway diseases	92,433	93,537	91,012	93,802	7	8	9	8	76.09	78.39	79.93	83.83	3	3	3	3
R03A	Adrenergics, inhalants	55,362	56,600	53,769	55,920	3	3	3	3	41.47	43.72	45.46	48.11	3	3	3	3
R03AC	Selective beta-2-adrenoceptor agonists	8,080	8,071	7,754	7,567	2	2	2	3	14.33	14.77	14.94	14.87	3	3	3	4
R03AC02	Salbutamol	5,463	5,634	5,515	5,334	3	3	3	3	11.73	12.28	12.61	12.54	4	4	3	5
R03AC03	Terbutaline	540	555	507	519	1	1	1	1	1.17	1.20	1.14	1.16	1	1	1	1
R03AC12	Salmeterol (DDD 0.10 mg)	563	520	482	481	1	1	1	1	0.39	0.36	0.34	0.34	1	1	1	1
R03AC13	Formoterol (DDD 24 mcg)	1,068	1,001	945	966	1	1	1	1	0.73	0.68	0.65	0.66	1	1	1	1
R03AC18	Indacaterol (DDD 0.15 mg)	284	229	183	160	2	3	2	3	0.21	0.17	0.14	0.12	2	2	2	3
R03AC19	Olodaterol (DDD 5 mcg)	163	132	122	107	4	3	3	3	0.10	0.08	0.07	0.07	4	3	3	3
R03AK	Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics	43,598	42,950	37,912	38,253	3	3	2	2	25.46	26.71	27.68	29.87	2	2	2	2
R03AK06	Salmeterol and fluticasone	20,139	17,977	12,393	9,864	4	4	4	4	7.90	7.50	7.11	7.21	4	4	4	3
R03AK07	Formoterol and budesonide (DDD 2 UD)	15,786	14,932	14,420	15,132	1	1	1	1	13.27	13.53	13.71	14.41	1	1	1	1
R03AK08	Formoterol and beclometasone (DDD 2 UD)	2,287	3,164	3,688	4,497	1	2	2	2	1.82	2.46	3.08	3.81	1	2	2	2
R03AK10	Vilanterol and fluticasone furoate (DDD 1 UD)	3,498	4,710	5,262	6,389	1	1	1	1	1.36	1.91	2.37	2.90	1	1	1	1
R03AK11	Formoterol and fluticasone	1,889	2,168	2,148	2,369	2	2	2	2	1.11	1.30	1.41	1.54	2	2	2	2
R03AK14	Indacaterol and mometasone				1												

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R03AL	Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids	3,684	5,578	8,102	10,101	13	10	7	6	1.68	2.24	2.83	3.37	12	11	9	10
R03AL01	Fenoterol and ipratropium bromide	302	294	277	306	16	18	14	27	0.50	0.48	0.46	0.56	6	6	5	24
R03AL02	Salbutamol and ipratropium bromide (DDD 3 UD)	693	627	411	281	50	51	51	41	0.31	0.31	0.30	0.24	50	50	50	41
R03AL03	Vilanterol and umeclidinium bromide (DDD 1 UD)	757	1,049	1,120	1,170	2	3	2	2	0.25	0.35	0.37	0.40	2	3	2	2
R03AL04	Indacaterol and glycopyrronium bromide (DDD 1 UD)	687	523	448	369	3	3	3	3	0.21	0.18	0.15	0.13	3	3	3	3
R03AL05	Formoterol and aclidinium bromide (DDD 2 UD)	281	205	169	142	2	2	2	2	0.09	0.07	0.06	0.05	2	2	2	2
R03AL06	Olodaterol and tiotropium bromide (DDD 2 UD)	964	1,759	2,165	2,342	4	5	5	5	0.33	0.60	0.74	0.82	4	5	5	5
R03AL07	Formoterol and glycopyrronium bromide (DDD 4 UD)			7	21			2	3			0.00	0.01			2	3
R03AL08	Vilanterol, umeclidinium bromide and fluticasone furoate (DDD 1 UD)		507	1,688	2,585		3	2	3		0.13	0.44	0.67		3	2	3
R03AL09	Formoterol, glycopyrronium bromide and beclometasone (DDD 4 UD)	1	615	1,818	2,884		4	6	7	0.00	0.11	0.31	0.51		6	9	10
R03AL12	Indacaterol, glycopyrronium bromide and mometasone (DDD 1 UD)				1								0.00				
R03B	Other drugs for obstructive airway diseases, inhalants	30,865	29,646	28,302	28,235	4	4	4	3	26.18	26.03	25.66	26.56	4	4	4	3
R03BA	Glucocorticoids	18,163	18,004	16,936	17,154	3	3	3	3	19.03	19.26	19.17	20.14	2	2	2	2
R03BA01	Beclometasone	2,589	2,487	2,370	2,426	2	2	2	2	2.63	2.54	2.49	2.53	2	2	2	2
R03BA02	Budesonide	4,817	4,684	4,567	4,728	6	6	6	5	4.78	4.67	4.43	4.55	3	3	3	3
R03BA05	Fluticasone	7,626	7,435	6,512	6,200	3	3	3	2	5.60	5.52	5.39	5.59	3	3	3	3
R03BA07	Mometasone (DDD 0.40 mg)	207	190	160	150	1	1	1	1	0.21	0.20	0.17	0.16	1	1	1	1
R03BA08	Ciclesonide (DDD 0.16 mg)	2,924	3,208	3,328	3,650	1	1	1	1	5.80	6.34	6.68	7.31	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R03BB	Anticholinergics	12,599	11,642	11,366	11,081	4	5	4	5	7.07	6.77	6.50	6.43	7	8	7	7
R03BB01	Ipratropium bromide	262	276	263	281	41	41	40	45	0.59	0.62	0.59	0.54	49	48	47	47
R03BB04	Tiotropium bromide	11,553	10,503	10,326	10,072	4	4	4	4	6.12	5.75	5.55	5.53	4	4	3	4
R03BB05	Acclidinium bromide (DDD 0.64 mg)	117	98	85	74	3	2	2	2	0.05	0.05	0.04	0.04	3	2	2	2
R03BB06	Glycopyrronium bromide (DDD 44 mcg)	278	232	186	154	2	3	2	1	0.13	0.11	0.09	0.08	2	3	2	1
R03BB07	Umeclidinium bromide (DDD 55 mcg)	389	532	505	501	1	2	2	2	0.18	0.25	0.24	0.24	1	2	2	2
R03BC	Antiallergic agents, excl. corticosteroids	103				0				0.08				0			
R03BC01	Cromoglicic acid	3				1				0.00				1			
R03BC03	Nedocromil (DDD 8 mg)	99				0				0.07				0			
R03C	Adrenergics for systemic use	139	98	104	74	3	2	2	3	0.06	0.04	0.03	0.03	4	3	3	3
R03CC	Selective beta-2-adrenoceptor agonists	139	98	104	74	3	2	2	3	0.06	0.04	0.03	0.03	4	3	3	3
R03CC02	Salbutamol (DDD 12 mg)	139	98	104	74	3	2	2	3	0.06	0.04	0.03	0.03	4	3	3	3
R03D	Other systemic drugs for obstructive airway diseases	6,067	7,193	8,837	9,572	59	68	67	48	8.37	8.60	8.78	9.13	2	2	2	2
R03DA	Xanthines	317	288	260	195	4	3	3	3	0.85	0.76	0.70	0.64	4	3	3	3
R03DA04	Theophylline (DDD 0.40 g)	238	211	194	192	4	3	3	3	0.82	0.73	0.68	0.64	4	3	3	3
R03DA05	Aminophylline (DDD 0.60 g)	4	3	3	1	4	4	2	4	0.01	0.01	0.01	0.00	4	4	2	4
R03DA54	Theophylline, combinations excl. psycholeptics (DDD 12 UD)	75	74	63	2	1	1	1	4	0.02	0.02	0.02	0.00	1	1	1	4

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R03DC	Leukotriene receptor antagonists	1,635	1,383	1,327	1,301	2	1	1	1	7.37	7.67	7.90	8.29	2	1	1	1
R03DC01	Zafirlukast (DDD 40 mg)	102	30	1		2	2	5		0.08	0.02	0.00		2	2	5	
R03DC03	Montelukast (DDD 10 mg)	1,532	1,352	1,326	1,301	2	1	1	1	7.29	7.65	7.89	8.29	2	1	1	1
R03DX	Other systemic drugs for obstructive airway diseases	4,116	5,523	7,251	8,077	86	88	81	56	0.15	0.16	0.18	0.19	35	42	43	32
R03DX05	Omalizumab (DDD 16 mg)	2,420	2,875	3,304	3,347	86	85	65	40	0.03	0.04	0.05	0.05	86	85	65	40
R03DX07	Roflumilast (DDD 0.50 mg)	248	236	221	217	7	7	5	5	0.10	0.09	0.09	0.09	6	7	5	4
R03DX08	Reslizumab (DDD 7.10 mg)	191	424	363	179	100	100	100	100	0.00	0.01	0.00	0.00	100	100	100	100
R03DX09	Mepolizumab (DDD 3.60 mg)	1,257	1,881	2,593	2,756	99	100	100	68	0.01	0.02	0.03	0.03	99	100	100	63
R03DX10	Benralizumab (DDD 0.54 mg)		106	771	1,577		100	100	74		0.00	0.01	0.02		100	100	71



R05 Cough and cold preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R05	Cough and cold preparations	11,750	12,032	10,667	7,100	2	2	2	2	5.47	5.38	4.73	3.13	2	2	2	2
R05C	Expectorants, excl. combinations with cough suppressants	4,637	4,460	4,251	3,077	5	4	4	5	2.90	2.79	2.64	1.89	4	3	3	3
R05CA	Expectorants	314	248	157	112	0	0	0	0	0.24	0.17	0.09	0.06	0	0	0	0
R05CA03	Guaifenesin (DDD 0.90 g)	88	81	14						0.07	0.06	0.01					
R05CA10	Combinations	225	167	144	112	0	0	0	0	0.17	0.11	0.08	0.06	0	0	0	0
R05CB	Mucolytics	4,323	4,211	4,093	2,965	5	4	4	5	2.66	2.62	2.54	1.83	4	3	3	3
R05CB01	Acetylcysteine	768	763	774	562	5	4	4	3	0.68	0.67	0.68	0.50	5	3	2	1
R05CB02	Bromhexine (DDD 24 mg)	1,563	1,513	1,357	968	0	0	0	0	1.18	1.14	1.02	0.72	0	0	0	0
R05CB03	Carbocisteine (DDD 1.50 g)	119	108	95	58	0	0	0	1	0.07	0.06	0.06	0.03	0	0	0	1
R05CB06	Ambroxol (DDD 0.12 g)	690	607	676	429	3	3	3	4	0.25	0.24	0.28	0.18	3	3	3	4
R05CB13	Dornase alfa (desoxyribonuclease) (DDD 2.50 mg)	305	305	360	388	15	7	10	11	0.01	0.01	0.01	0.01	15	7	10	11
R05CB15	Erdosteine (DDD 0.60 g)	878	914	830	561	11	10	10	11	0.46	0.50	0.50	0.37	12	11	10	11

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R05D	Cough suppressants, excl. combinations with expectorants	2,278	2,322	2,329	1,561	1	1	0	1	1.18	1.15	1.08	0.69	1	1	1	1
R05DA	Opium alkaloids and derivatives	1,726	1,742	1,839	1,202	1	1	1	1	1.00	0.96	0.91	0.57	1	1	1	1
R05DA01	Ethylmorphine (DDD 50 mg)	594	655	867	579	0	1	0	1	0.23	0.23	0.27	0.16	0	1	0	1
R05DA09	Dextromethorphan (DDD 90 mg)	1,132	1,087	972	622	1	1	1	1	0.77	0.73	0.65	0.42	1	1	1	1
R05DB	Other cough suppressants	552	580	490	359	0	0	0	0	0.18	0.19	0.16	0.12	0	0	0	0
R05DB05	Pentoxyverine (DDD 0.10 g)	552	580	490	359	0	0	0	0	0.18	0.19	0.16	0.12	0	0	0	0
R05F	Cough suppressants and expectorants, combinations	4,196	4,541	3,484	1,968	1	1	1	0	1.39	1.44	1.02	0.55	1	1	1	0
R05FA	Opium derivatives and expectorants	2,610	2,565	1,715	589	1	1	1	0	0.93	0.88	0.58	0.22	1	1	1	0
R05FA02	Opium derivatives and expectorants	2,610	2,565	1,715	589	1	1	1	0	0.93	0.88	0.58	0.22	1	1	1	0
R05FB	Other cough suppressants and expectorants	1,586	1,976	1,769	1,380	1	0	0	0	0.47	0.56	0.43	0.33	1	0	0	0
R05FB02	Cough suppressants and expectorants	1,586	1,976	1,769	1,380	1	0	0	0	0.47	0.56	0.43	0.33	1	0	0	0
R05X	Other cold preparations	1,276	1,419	1,206	988	0	0	0	0								

**R06 Antihistamines for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R06	Antihistamines for systemic use	14,838	14,992	15,862	17,165	1	1	0	1	56.24	60.06	64.28	71.32	1	1	1	1
R06A	Antihistamines for systemic use	14,838	14,992	15,862	17,165	1	1	0	1	56.24	60.06	64.28	71.32	1	1	1	1
R06AA	Aminoalkyl ethers	55	81	108	137	2	2	1	1	0.04	0.06	0.08	0.10	2	1	1	1
R06AA09	Doxylamine (DDD 25 mg)	55	81	108	137	2	2	1	1	0.04	0.06	0.08	0.10	2	1	1	1
R06AE	Piperazine derivatives	8,208	8,064	8,494	9,335	1	1	1	1	32.15	33.05	35.08	37.92	1	1	1	1
R06AE03	Cyclizine	140	94		14	0	0		0	0.07	0.05		0.00	0	0		0
R06AE05	Meclozine (DDD 50 mg)	334	320	439	234	0	0	0	0	0.14	0.14	0.19	0.09	0	0	0	0
R06AE07	Cetirizine (DDD 10 mg)	6,277	6,183	6,591	7,583	1	1	1	1	27.41	28.13	30.17	32.82	2	2	1	1
R06AE09	Levocetirizine (DDD 5 mg)	1,457	1,468	1,464	1,505	0	0	0	0	4.53	4.74	4.73	5.01	0	0	0	0
R06AX	Other antihistamines for systemic use	6,575	6,846	7,259	7,693	0	0	0	0	24.06	26.95	29.12	33.30	0	0	0	0
R06AX13	Loratadine (DDD 10 mg)	664	687	635	751	1	1	1	1	3.12	3.26	3.07	3.53	1	1	1	0
R06AX18	Acrivastine (DDD 24 mg)	169	157	144	144	0	0	0	0	0.14	0.13	0.08	0.08	0	0	0	0
R06AX22	Ebastine (DDD 10 mg)	2,105	2,272	2,335	2,541	0	0	0	0	6.79	7.48	7.66	9.16	0	0	0	0
R06AX26	Fexofenadine (DDD 0.12 g)	1,294	1,431	1,664	1,733	0	0	0	0	2.79	3.10	3.87	4.20	0	0	0	0
R06AX27	Desloratadine (DDD 5 mg)	2,193	2,143	2,307	2,337	1	1	1	1	10.88	12.63	14.06	15.91	0	0	0	1
R06AX28	Rupatadine (DDD 10 mg)	1	0							0.00	0.00						
R06AX29	Bilastine (DDD 20 mg)	149	155	174	187	0	0	0	0	0.34	0.35	0.39	0.41	0	0	0	0

**R07 Other respiratory system products**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R07	Other respiratory system products	877	884	693	1,027	100	100	100	83	0.00	0.00	0.00	0.00	100	100	100	87
R07A	Other respiratory system products	877	884	693	1,027	100	100	100	83	0.00	0.00	0.00	0.00	100	100	100	87
R07AA	Lung surfactants	877	884	693	857	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
R07AA02	Natural phospholipids (DDD 0.16 g)	877	884	693	857	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
R07AX	Other respiratory system products				170												0.00
R07AX02	Ivacaftor (DDD 0.30 g)				85												0.00
R07AX31	Ivacaftor and tezacaftor				85												



S Sensory organs

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
S	Sensory organs	57,111	63,148	67,365	67,883	36	40	41	44	26.76	28.34	30.04	31.29	2	2	2	2
S01	Ophthalmologicals	55,222	61,131	65,280	65,919	37	41	43	46	26.76	28.34	30.04	31.29	2	2	2	2
S02	Otologicals	1,652	1,774	1,887	1,784	2	2	2	3								
S03	Ophthalmological and otological preparations	237	243	197	180	9	10	8	11								

**S01 Ophthalmologicals**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
S01	Ophthalmologicals	55,222	61,131	65,280	65,919	37	41	43	46	26.76	28.34	30.04	31.29	2	2	2	2
S01A	Antiinfectives	4,080	4,286	4,435	3,503	9	9	9	11								
S01AA	Antibiotics	3,424	3,623	3,775	2,842	9	9	9	11								
S01AA01	Chloramphenicol	2,876	3,038	3,196	2,427	8	8	7	9								
S01AA12	Tobramycin	13	8	13	12	8	14	7	8								
S01AA13	Fusidic acid	424	453	415	270	4	4	4	6								
S01AA26	Azithromycin	56	58	60	30	1	0	0	1								
S01AA27	Cefuroxime	54	66	90	103	89	91	92	87								
S01AD	Antivirals	39	35	4	34	7	8	11	12								
S01AD03	Aciclovir	39	35	4	34	7	8	11	12								
S01AE	Fluoroquinolones	616	628	656	627	8	8	8	9								
S01AE01	Ofloxacin	104	105	94	54	2	2	3	4								
S01AE05	Levofloxacin	500	510	549	563	9	10	9	9								
S01AE07	Moxifloxacin	13	13	12	11	13	12	20	21								
S01B	Antiinflammatory agents	3,164	3,409	3,622	3,789	42	42	37	38								
S01BA	Corticosteroids, plain	2,567	2,783	2,864	2,993	51	50	46	48								
S01BA01	Dexamethasone	1,407	1,416	1,475	1,558	72	78	74	73								
S01BA02	Hydrocortisone	3	57	91	113		0	0	1								
S01BA04	Prednisolone	705	800	856	839	2	2	2	2								
S01BA05	Triamcinolone	264	278	225	283	100	100	100	100								
S01BA07	Fluorometholone	189	232	217	201	2	1	1	1								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
S01BC	Antiinflammatory agents, non-steroids	597	626	758	796	4	4	1	2								
S01BC03	Diclofenac	76	87	82	87	16	24	5	6								
S01BC05	Ketorolac	6	6			12	14										
S01BC10	Nepafenac	489	497	621	645	2	1	1	1								
S01BC11	Bromfenac	26	37	55	64	0	0	0	1								
S01C	Antiinflammatory agents and antiinfectives in combination	953	958	1,022	978	9	10	9	10								
S01CA	Corticosteroids and antiinfectives in combination	953	958	1,022	978	9	10	9	10								
S01CA01	Dexamethasone and antiinfectives	693	701	743	708	10	11	10	10								
S01CA03	Hydrocortisone and antiinfectives	260	257	279	270	7	7	7	8								
S01E	Antiglaucoma preparations and miotics	14,373	14,553	14,565	14,581	3	3	3	3	26.76	28.34	30.04	31.29	2	2	2	2
S01EA	Sympathomimetics in glaucoma therapy	469	449	452	422	24	26	30	30	0.71	0.67	0.63	0.58	8	8	9	9
S01EA03	Apraclonidine (DDD 0.30 ml)	129	133	155	148	75	78	79	77	0.04	0.04	0.04	0.04	62	64	64	61
S01EA05	Brimonidine (DDD 0.20 ml)	340	315	297	274	4	5	5	4	0.67	0.62	0.59	0.54	4	5	5	5
S01EB	Parasympathomimetics	45	45	37	41	54	56	49	57	0.12	0.11	0.11	0.10	13	12	13	12
S01EB01	Pilocarpine	21	19	18	16	13	12	13	12	0.12	0.11	0.11	0.10	13	12	13	12
S01EB09	Acetylcholine	25	26	19	25	88	87	83	86								
S01EC	Carbonic anhydrase inhibitors	1,181	1,262	1,353	1,386	2	3	2	3	2.49	2.62	2.81	2.88	3	3	2	3
S01EC03	Dorzolamide (DDD 0.30 ml)	134	133	126	121	4	4	3	3	0.19	0.19	0.18	0.18	4	4	3	3
S01EC04	Brinzolamide (DDD 0.20 ml)	656	680	734	759	3	3	2	3	1.84	1.90	2.05	2.12	3	3	2	3
S01EC54	Brinzolamide, combinations (DDD 0.20 ml)	390	450	492	506	1	2	2	2	0.45	0.52	0.57	0.59	1	2	2	2

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
S01ED	Beta blocking agents	7,091	7,159	7,130	6,928	2	2	2	2	12.93	13.96	15.13	15.95	2	2	1	1
S01ED01	Timolol (DDD 0.20 ml)	287	282	281	286	3	3	2	3	0.66	0.64	0.58	0.51	4	3	3	3
S01ED02	Betaxolol (DDD 0.20 ml)	81	79	80	78	3	3	3	3	0.31	0.30	0.30	0.30	3	3	3	3
S01ED51	Timolol, combinations	6,722	6,798	6,769	6,565	2	2	2	2	11.96	13.02	14.25	15.15	2	1	1	1
S01EE	Prostaglandin analogues	5,587	5,638	5,593	5,804	2	2	2	2	10.50	10.98	11.37	11.78	2	2	2	2
S01EE01	Latanoprost (DDD 0.10 ml)	1,883	1,801	1,817	1,984	2	2	2	2	4.69	4.83	5.00	5.10	3	2	2	2
S01EE03	Bimatoprost (DDD 0.10 ml)	943	1,023	915	907	2	2	2	2	3.10	3.38	3.55	3.86	1	1	1	1
S01EE04	Travoprost (DDD 0.10 ml)	959	912	789	686	2	2	2	2	1.00	0.95	0.88	0.79	3	3	3	3
S01EE05	Tafluprost (DDD 0.30 ml)	1,801	1,902	2,072	2,227	1	1	1	1	1.71	1.82	1.93	2.03	1	1	1	1
S01F	Mydriatics and cycloplegics	551	616	610	635	61	64	61	58								
S01FA	Anticholinergics	476	545	533	553	59	63	60	56								
S01FA01	Atropine	15	18	20	29	18	19	18	15								
S01FA02	Scopolamine	55	59	39		13	16	17									
S01FA04	Cyclopentolate	97	97	98	113	57	60	50	41								
S01FA06	Tropicamide	201	215	241	272	54	56	54	51								
S01FA56	Tropicamide, combinations	108	157	134	139	98	97	96	87								
S01FB	Sympathomimetics excl. antiglaucoma preparations	75	70	76	82	72	73	72	71								
S01FB01	Phenylephrine	75	70	76	82	72	73	72	71								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
S01G	Decongestants and antiallergics	3,147	3,733	3,810	3,310	1	1	1	1								
S01GA	Sympathomimetics used as decongestants	258	247	252	201	0	0	0	0								
S01GA02	Tetryzoline	258	247	252	201	0	0	0	0								
S01GX	Other antiallergics	2,889	3,486	3,559	3,109	1	1	1	1								
S01GX01	Cromoglicic acid	2,118	2,527	2,618	2,304	1	1	1	1								
S01GX02	Levocabastine	160	206	122	176	0	0	0	0								
S01GX05	Lodoxamide	30	36	56	35		0										
S01GX06	Emedastine	22	30	34	27	0	0	0	1								
S01GX07	Azelastine	7	24	26		1	0	0									
S01GX08	Ketotifen	505	611	640	516	0	0	0	1								
S01GX09	Olopatadine	47	52	63	52	0	0	0	0								
S01H	Local anesthetics	198	195	221	228	78	81	80	78								
S01HA	Local anesthetics	198	195	221	228	78	81	80	78								
S01HA02	Oxybuprocaine	198	195	221	228	78	81	80	78								
S01J	Diagnostic agents	187	190	187	200	58	58	56	58								
S01JA	Colouring agents	187	190	187	200	58	58	56	58								
S01JA01	Fluorescein	25	19	14	17	99	99	98	97								
S01JA51	Fluorescein, combinations	162	171	173	183	51	54	53	54								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
S01L	Ocular vascular disorder agents	17,626	21,798	24,651	26,776	100	100	100	100								
S01LA	Antineovascularisation agents	17,626	21,798	24,651	26,776	100	100	100	100								
S01LA01	Verteporfin	277	203	167	161	100	100	100	100								
S01LA04	Ranibizumab	269	319	327	299	100	100	100	100								
S01LA05	Aflibercept	17,080	21,277	24,157	26,263	100	100	100	100								
S01LA06	Brolucizumab				54				100								
S01X	Other ophthalmologicals	10,943	11,394	12,157	11,919	3	3	3	2								
S01XA	Other ophthalmologicals	10,943	11,394	12,157	11,919	3	3	3	2								
S01XA02	Retinol	375	407	519	526	3	3	3	3								
S01XA18	Ciclosporin	325	442	600	660	1	1	0	1								
S01XA20	Artificial tears and other indifferent preparations	10,243	10,540	11,037	10,682	3	3	3	2								
S01XA21	Mercaptamine				51												
S01XA22	Ocriplasmin		3				100										



S02 Otologicals

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
S02	Otologicals	1,652	1,774	1,887	1,784	2	2	2	3								
S02A	Antiinfectives	617	691	715	735	2	2	2	2								
S02AA	Antiinfectives	617	691	715	735	2	2	2	2								
S02AA03	Boric acid	594	661	691	718	2	2	2	2								
S02AA15	Ciprofloxacin	23	30	24	17	1	2	2	2								
S02B	Corticosteroids			10	16			0	0								
S02BA	Corticosteroids			10	16			0	0								
S02BA08	Fluocinolone acetonide			10	16			0	0								
S02C	Corticosteroids and antiinfectives in combination	800	861	958	919	3	3	3	3								
S02CA	Corticosteroids and antiinfectives in combination	800	861	958	919	3	3	3	3								
S02CA02	Flumetasone and antiinfectives	74	1	180	224	2	8	3	3								
S02CA03	Hydrocortisone and antiinfectives	528	624	486	378	4	4	4	5								
S02CA05	Fluocinolone acetonide and antiinfectives	198	236	292	317	3	2	2	2								
S02D	Other otologicals	235	222	204	114	0	1	0	1								
S02DA	Analgesics and anesthetics	235	222	204	114	0	1	0	1								
S02DA04	Cinchocaine	235	222	204	114	0	1	0	1								



S03 Ophthalmological and otological preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
S03	Ophthalmological and otological preparations	237	243	197	180	9	10	8	11								
S03C	Corticosteroids and antiinfectives in combination	237	243	197	180	9	10	8	11								
S03CA	Corticosteroids and antiinfectives in combination	237	243	197	180	9	10	8	11								
S03CA04	Hydrocortisone and antiinfectives	237	243	197	180	9	10	8	11								



V Various

ATC classification

Wholesale price (VAT excluded), thousand euros

Sales to hospitals and other health care units as a proportion (%) of wholesale value

Consumption, DDD/1,000 inhabitants/day

Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day

		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
V	Various	32,692	35,580	38,871	39,677	90	90	89	86	0.15	0.19	0.19	0.19	40	39	41	42
V01	Allergens	2,131	2,369	3,248	4,979	54	56	59	46								
V03	All other therapeutic products	7,616	8,749	9,762	9,317	77	76	77	75	0.15	0.19	0.19	0.19	40	39	41	42
V04	Diagnostic agents	893	991	963	897	84	87	87	89								
V06	General nutrients	4	0			4	29										
V07	All other non-therapeutic products	2,986	3,223	3,234	3,046	95	95	95	94								
V08	Contrast media	18,835	20,124	21,481	21,387	99	99	99	99								

**V01 Allergens**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
V01	Allergens	2,131	2,369	3,248	4,979	54	56	59	46								
V01A	Allergens	2,131	2,369	3,248	4,979	54	56	59	46								
V01AA	Allergen extracts	2,131	2,369	3,248	4,979	54	56	59	46								
V01AA02	Grass pollen	699	704	704	846	1	0	0	1								
V01AA03	House dust mites	16	27	43	50	49	21	24	22								
V01AA05	Tree pollen	1,251	1,443	2,205	3,736	80	79	74	53								
V01AA07	Insects	100	126	194	215	98	98	99	99								
V01AA11	Animals	64	69	101	131	72	77	78	78								
V01AA20	Various	1	1	1	1	81	57	92	84								

**V03 All other therapeutic products**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
V03	All other therapeutic products	7,616	8,749	9,762	9,317	77	76	77	75	0.15	0.19	0.19	0.19	40	39	41	42
V03A	All other therapeutic products	7,616	8,749	9,762	9,317	77	76	77	75	0.15	0.19	0.19	0.19	40	39	41	42
V03AB	Antidotes	4,243	4,703	5,355	5,439	94	97	96	94								
V03AB14	Protamine	301	305	311	251	100	100	100	100								
V03AB15	Naloxone	170	82	177	252	89	90	89	92								
V03AB17	Methylthioninium chloride	99	94	133	108	100	100	99	98								
V03AB21	Potassium iodide	242	177	257	455	17	45	41	44								
V03AB25	Flumazenil	82	86	67	77	97	98	99	99								
V03AB33	Hydroxocobalamin	196	149	152	159	98	98	95	97								
V03AB34	Fomepizole	128	122	140	85	100	100	100	100								
V03AB35	Sugammadex	2,754	3,382	3,379	3,431	100	99	99	99								
V03AB37	Idarucizumab	273	308	278	198	100	100	100	100								
V03AB38	Andexanet alfa			461	422			100	100								
V03AC	Iron chelating agents	747	906	1,038	1,011	5	4	6	6								
V03AC01	Deferoxamine	9	10	20	19	65	87	88	85								
V03AC02	Deferiprone	7	8	6		18	20	4									
V03AC03	Deferasirox	731	888	1,013	992	4	3	4	5								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia	896	1,227	1,208	1,231	18	18	18	17	0.11	0.14	0.13	0.13	19	19	19	18
V03AE01	Polystyrene sulphonate (DDD 45 g)	115	119	114	105	23	25	22	23	0.03	0.03	0.03	0.03	23	25	22	23
V03AE02	Sevelamer (DDD 6.40 g)	365	390	381	401	19	17	17	16	0.04	0.04	0.04	0.04	19	17	17	16
V03AE03	Lanthanum carbonate (DDD 2.25 g)	417	717	704	684	16	17	17	15	0.04	0.06	0.06	0.06	15	16	16	15
V03AE04	Calcium acetate and magnesium carbonate																
V03AE05	Sucroferric oxyhydroxide (DDD 1.50 g)		0	5	14		100	90	12		0.00	0.00	0.00		100	90	12
V03AE09	Patiromer calcium (DDD 8.40 g)			4	26			100	45			0.00	0.00			100	45
V03AF	Detoxifying agents for cytostatic treatment	1,729	1,913	2,160	1,636	94	95	96	94	0.04	0.05	0.06	0.06	93	95	95	95
V03AF01	Mesna	393	487	534	448	100	100	100	100								
V03AF02	Dexrazoxane (DDD 1.50 g)	149	307	365	133	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
V03AF03	Calcium folinate (DDD 60 mg)	734	745	781	625	87	88	89	84	0.04	0.05	0.05	0.06	93	95	95	95
V03AF04	Calcium levofolinate (DDD 30 mg)																
V03AF07	Rasburicase (DDD 14 mg)	365	318	426	413	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
V03AF08	Palifermin (DDD 4.20 mg)	30	25	15		100	100	100		0.00	0.00	0.00		100	100	100	
V03AF10	Sodium levofolinate (DDD 30 mg)	59	31	39	18	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
V03AX	Other therapeutic products			0				100				0.00				100	
V03AX03	Cobicistat (DDD 0.15 g)			0				100				0.00				100	

**V04 Diagnostic agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
V04	Diagnostic agents	893	991	963	897	84	87	87	89								
V04C	Other diagnostic agents	893	991	963	897	84	87	87	89								
V04CD	Tests for pituitary function	81	102	108	108	38	38	25	29								
V04CD01	Metyrapone	81	102	108	108	38	38	25	29								
V04CF	Tuberculosis diagnostics	3	2	6	6	84	70	80	80								
V04CF01	Tuberculin	3	2	6	6	84	70	80	80								
V04CL	Tests for allergic diseases	451	399	296	180	153	151	158	163								
V04CX	Other diagnostic agents	584	688	701	694	93	97	98	100								
V04CX05	13C-urea	61	24	18	2	45	36	13	2								
V04CX06	Hexaminolevulinate	522	664	683	692	99	100	100	100								

**V06 General nutrients**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
V06	General nutrients	4	0			4	29										
V06D	Other nutrients	4	0			4	29										
V06DD	Amino acids, incl. combinations with polypeptides	8	1			9	57										

V07 All other non-therapeutic products

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
V07	All other non-therapeutic products	2,986	3,223	3,234	3,046	95	95	95	94								
V07A	All other non-therapeutic products	2,986	3,223	3,234	3,046	95	95	95	94								
V07AB	Solvents and diluting agents, incl. irrigating solutions	5,971	6,447	6,467	6,092	190	190	190	188								

**V08 Contrast media**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
V08	Contrast media	18,835	20,124	21,481	21,387	99	99	99	99								
V08A	X-ray contrast media, iodinated	14,149	15,085	16,343	17,036	100	100	100	99								
V08AA	Watersoluble, nephrotropic, high osmolar X-ray contrast media	122	95	101	116	100	99	100	100								
V08AA01	Diatrizoic acid	122	95	101	116	100	99	100	100								
V08AB	Watersoluble, nephrotropic, low osmolar X-ray contrast media	14,027	14,990	16,242	16,920	100	100	100	99								
V08AB02	Iohexol	10,792	12,091	12,974	13,413	100	100	100	100								
V08AB03	Ioxaglic acid	403	94			100	100										
V08AB07	Ioversol	391	102	11	2	100	100	100	100								
V08AB09	Iodixanol	1,071	1,190	1,193	1,060	96	98	98	98								
V08AB10	Iomeprol	1,370	1,514	2,064	2,445	100	99	100	100								
V08B	X-ray contrast media, non-iodinated	36	22	0		100	100	100									
V08BA	Barium sulfate containing X-ray contrast media	36	22	0		100	100	100									
V08BA01	Barium sulfate with suspending agents	36	22	0		100	100	100									

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
V08C	Magnetic resonance imaging contrast media	4,537	4,919	5,050	4,281	96	97	96	98								
V08CA	Paramagnetic contrast media	4,537	4,919	5,050	4,281	96	97	96	98								
V08CA02	Gadoteric acid	4,210	4,595	4,812	4,045	96	97	96	97								
V08CA04	Gadoteridol	94	128	48	13	91	99	95	78								
V08CA08	Gadobenic acid	50	3	0	0	100	100	100	100								
V08CA09	Gadobutrol	38	26	20	16	100	100	100	100								
V08CA10	Gadoxetic acid	145	167	170	207	100	99	100	100								
V08D	Ultrasound contrast media	113	98	88	70	94	100	100	100								
V08DA	Ultrasound contrast media	113	98	88	70	94	100	100	100								
V08DA01	Microspheres of human albumin	1	2	2	2	100	100	100	100								
V08DA05	Sulphur hexafluoride	112	96	87	68	94	100	100	100								



Nicotine replacement therapy

Total

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2017	2018	2019	2020	2017	2018	2019	2020
Nicotine	54,532	57,716	61,368	71,691	12.45	13.80	14.78	17.86

Pharmacies

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2017	2018	2019	2020	2017	2018	2019	2020
Nicotine	6,941	6,986	6,609	7,228	1.85	1.83	1.65	1.88
Medicated chewing gums (DDD 30 mg)	2,658	2,375	2,044	1,919	0.83	0.77	0.64	0.60
Losenzes and sublingual tablets (DDD 30 mg)	949	876	791	727	0.17	0.16	0.15	0.13
Transdermal patches (DDD 14 mg)	1,104	1,086	1,092	1,146	0.39	0.38	0.39	0.40
Other formulations	2,230	2,649	2,681	3,436	0.46	0.52	0.48	0.74

Table continued



Other

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2017	2018	2019	2020	2017	2018	2019	2020
Nicotine	47,206	50,344	54,354	64,025	10.84	11.83	13.00	15.84
Medicated chewing gums (DDD 30 mg)	31,590	32,040	32,020	34,644	7.98	8.14	8.22	9.01
Losenzes and sublingual tablets (DDD 30 mg)	10,665	11,022	11,996	13,307	1.71	1.77	1.95	2.17
Transdermal patches (DDD 14 mg)	113	127	221	282	0.04	0.05	0.08	0.10
Other formulations	4,837	7,154	10,117	11,229	1.11	1.87	2.74	4.55

Hospital

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2017	2018	2019	2020	2017	2018	2019	2020
Nicotine	386	387	406	438	0.13	0.13	0.13	0.14



OTC medicines in outpatient care

ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A	Alimentary tract and metabolism	93.44	88.09	86.97	89.53	59,932	59,326	60,805	61,418	101,859	100,887	103,447	104,044
A01	Stomatological preparations	6.03	2.79	2.33	2.37	1,607	1,340	1,258	1,299	2,821	2,390	2,241	2,288
A01A	Stomatological preparations	6.03	2.79	2.33	2.37	1,607	1,340	1,258	1,299	2,821	2,390	2,241	2,288
A01AA	Caries prophylactic agents	4.02	0.45			574	112			990	194		
A01AA01	Sodium fluoride	4.02	0.45			369	41			633	70		
A01AA51	Sodium fluoride, combinations					205	71			357	124		
A01AB	Antiinfectives for local oral treatment	2.01	2.30	2.30	2.35	891	991	1,034	1,138	1,586	1,766	1,853	2,011
A01AB03	Chlorhexidine	1.77	2.08	2.09	2.02	653	765	819	872	1,172	1,372	1,477	1,547
A01AB11	Various	0.24	0.22	0.21	0.33	238	226	215	266	414	394	376	463
A01AC	Corticosteroids for local oral treatment					142	133	152	112	245	231	261	193
A01AC01	Triamcinolone					142	133	152	112	245	231	261	193
A01AD	Other agents for local oral treatment		0.04	0.03	0.02		104	72	49		198	127	84
A01AD02	Benzydamine		0.04	0.03	0.02		104	72	49		198	127	84
A02	Drugs for acid related disorders	7.05	7.16	7.15	7.04	10,432	10,469	11,007	11,403	18,366	18,448	19,390	20,005
A02A	Antacids	2.30	2.20	2.22	2.23	3,354	3,318	3,530	3,648	6,021	5,955	6,330	6,522
A02AA	Magnesium compounds	0.10	0.08	0.07	0.07	125	135	118	110	217	235	206	193
A02AA04	Magnesium hydroxide	0.10	0.08	0.07	0.07	125	135	118	110	217	235	206	193
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds	2.20	2.12	2.15	2.17	3,229	3,183	3,412	3,537	5,804	5,720	6,124	6,330
A02AD01	Ordinary salt combinations	2.20	2.12	2.15	2.17	3,229	3,183	3,412	3,537	5,804	5,720	6,124	6,330

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A02B	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	4.75	4.96	4.94	4.80	7,078	7,151	7,477	7,756	12,345	12,493	13,060	13,483
A02BA	H ₂ -receptor antagonists	0.38	0.36	0.27	0.15	652	603	514	497	1,150	1,063	906	862
A02BA02	Ranitidine	0.27	0.26	0.17		292	270	177		525	485	318	
A02BA03	Famotidine	0.11	0.10	0.10	0.15	360	333	338	497	625	578	588	862
A02BC	Proton pump inhibitors	3.22	3.45	3.52	3.39	4,491	4,501	4,712	4,626	7,850	7,904	8,282	8,101
A02BC01	Omeprazole	1.45	1.20	1.08	0.99	1,460	1,220	1,137	1,044	2,540	2,123	1,979	1,812
A02BC02	Pantoprazole	0.99	0.97	1.02	0.99	2,247	2,216	2,260	2,230	3,895	3,831	3,924	3,851
A02BC03	Lansoprazole	0.16	0.13	0.14	0.13	312	227	227	213	551	407	406	389
A02BC04	Rabeprazole		0.03	0.05	0.05		37	77	79		65	137	139
A02BC05	Esomeprazole	0.62	1.13	1.23	1.24	472	801	1,011	1,060	863	1,478	1,836	1,911
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	1.14	1.14	1.15	1.25	1,935	2,047	2,251	2,632	3,346	3,526	3,872	4,521
A02BX02	Sucalfate	0.20	0.20	0.23	0.28	314	326	378	452	539	560	648	773
A02BX13	Alginic acid	0.95	0.94	0.91	0.98	1,621	1,721	1,873	2,180	2,806	2,966	3,224	3,747
A03	Drugs for functional gastrointestinal disorders	1.18	1.12	1.18	1.12	1,470	1,427	1,452	1,487	2,507	2,432	2,480	2,528
A03A	Drugs for functional gastrointestinal disorders	1.18	1.12	1.18	1.12	1,470	1,427	1,452	1,487	2,507	2,432	2,480	2,528
A03AX	Other drugs for functional gastrointestinal disorders	1.18	1.12	1.18	1.12	1,470	1,427	1,452	1,487	2,507	2,432	2,480	2,528
A03AX13	Silicones	1.18	1.12	1.18	1.12	1,470	1,427	1,434	1,353	2,507	2,432	2,449	2,305
A03AX15	Menthae piperitae aetheroleum							18	134			31	224

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A06	Drugs for constipation	40.86	40.51	40.93	43.28	19,814	19,669	20,852	22,570	33,258	33,109	35,099	37,872
A06A	Drugs for constipation	40.86	40.51	40.93	43.28	19,814	19,669	20,852	22,570	33,258	33,109	35,099	37,872
A06AB	Contact laxatives	6.62	6.28	6.20	6.23	3,512	3,441	3,446	3,466	6,009	5,906	5,899	5,923
A06AB02	Bisacodyl	1.08	0.97	0.91	0.71	394	361	344	259	689	631	601	453
A06AB06	Senna glycosides	0.31	0.29	0.15	0.13	127	118	60	52	222	207	104	91
A06AB08	Sodium picosulfate	5.22	5.02	5.14	5.39	2,513	2,464	2,523	2,687	4,311	4,250	4,342	4,609
A06AB56	Senna glycosides, combinations					200	182	168	162	334	304	280	270
A06AB58	Sodium picosulfate, combinations	0.00	0.00	0.00	0.00	278	315	351	306	453	513	572	499
A06AC	Bulk-forming laxatives	4.08	3.76	3.82	4.24	2,626	2,575	2,716	2,982	4,401	4,308	4,542	4,983
A06AC01	Ispaghula (psylla seeds)	3.42	3.14	3.22	3.66	2,372	2,336	2,481	2,754	3,968	3,901	4,143	4,597
A06AC51	Ispaghula, combinations	0.66	0.62	0.61	0.59	254	239	235	228	433	406	399	386
A06AD	Osmotically acting laxatives	28.71	29.03	29.55	31.51	11,701	11,631	12,719	14,119	19,524	19,490	21,343	23,602
A06AD10	Mineral salts in combination												
A06AD11	Lactulose	15.01	14.17	13.46	13.23	2,651	2,546	2,439	2,395	4,573	4,392	4,192	4,118
A06AD15	Macrogol	11.88	13.43	14.85	17.20	6,998	7,602	8,820	10,340	11,548	12,614	14,705	17,169
A06AD17	Sodium phosphate					65	42	46	34	107	69	76	55
A06AD65	Macrogol, combinations	1.83	1.43	1.24	1.08	1,988	1,441	1,414	1,350	3,296	2,416	2,371	2,261
A06AG	Enemas	1.44	1.43	1.36	1.30	1,975	2,023	1,971	2,002	3,325	3,405	3,315	3,364
A06AG02	Bisacodyl	0.30	0.28	0.25	0.24	270	278	266	281	444	455	435	461
A06AG10	Docusate sodium, incl. combinations	0.07	0.06	0.06	0.05	293	300	307	303	459	474	485	480
A06AG11	Laurilsulfate, incl. combinations	1.08	1.09	1.06	1.01	1,411	1,444	1,399	1,418	2,422	2,477	2,395	2,423

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A07	Antidiarrheals, intestinal antiinflammatory/antiinfective agents	2.89	2.53	2.26	1.72	9,242	8,910	8,307	6,327	15,982	15,453	14,471	11,002
A07B	Intestinal adsorbents	0.15	0.13	0.12	0.13	395	360	318	305	670	610	540	515
A07BA	Charcoal preparations	0.15	0.13	0.12	0.13	395	360	318	305	670	610	540	515
A07BA01	Medicinal charcoal	0.15	0.13	0.12	0.13	395	360	318	305	670	610	540	515
A07C	Electrolytes with carbohydrates	0.02	0.01	0.01	0.01	258	254	218	131	446	434	372	224
A07CA	Oral rehydration salt formulations	0.03	0.03	0.02	0.01	517	508	435	263	891	868	744	449
A07D	Antipropulsives	0.94	0.91	0.94	0.77	3,745	3,806	3,922	3,254	6,725	6,834	7,047	5,820
A07DA	Antipropulsives	0.94	0.91	0.94	0.77	3,745	3,806	3,922	3,254	6,725	6,834	7,047	5,820
A07DA03	Loperamide	0.94	0.91	0.94	0.77	2,807	2,756	2,903	2,429	5,043	4,956	5,225	4,354
A07DA53	Loperamide, combinations					938	1,050	1,019	825	1,682	1,878	1,823	1,466
A07F	Antidiarrheal microorganisms	1.78	1.48	1.19	0.82	4,787	4,129	3,430	2,370	8,043	6,943	5,781	3,976
A07FA	Antidiarrheal microorganisms	1.78	1.48	1.19	0.82	4,787	4,129	3,430	2,370	8,043	6,943	5,781	3,976
A07FA01	Lactic acid producing organisms	0.07	0.05	0.00		96	71	0		163	120	0	
A07FA02	Saccharomyces boulardii	1.72	1.43	1.19	0.82	4,691	4,058	3,430	2,370	7,880	6,822	5,781	3,976
A07X	Other antidiarrheals					56	361	418	267	99	632	731	467
A07XA	Other antidiarrheals					56	361	418	267	99	632	731	467
A07XA04	Racecadotril					56	361	418	267	99	632	731	467
A08	Antiobesity preparations, excl. diet products	0.07	0.06	0.04	0.04	235	209	192	182	372	333	303	288
A08A	Antiobesity preparations, excl. diet products	0.07	0.06	0.04	0.04	235	209	192	182	372	333	303	288
A08AB	Peripherally acting antiobesity products	0.07	0.06	0.04	0.04	235	209	192	182	372	333	303	288
A08AB01	Orlistat	0.07	0.06	0.04	0.04	235	209	192	182	372	333	303	288

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A09	Digestives, incl. enzymes	0.97	1.04	1.28	1.25	2,344	2,501	3,090	3,036	3,737	3,984	4,923	4,846
A09A	Digestives, incl. enzymes	0.97	1.04	1.28	1.25	2,344	2,501	3,090	3,036	3,737	3,984	4,923	4,846
A09AA	Enzyme preparations	0.97	1.04	1.28	1.25	2,344	2,501	3,090	3,036	3,737	3,984	4,923	4,846
A09AA02	Multienzymes (lipase, protease etc.)	0.97	1.04	1.28	1.25	2,344	2,501	3,090	3,036	3,737	3,984	4,923	4,846
A10	Drugs used in diabetes					61	4			103	6		
A10B	Blood glucose lowering drugs, excl. insulins					61	4			103	6		
A10BX	Other blood glucose lowering drugs, excl. insulins					61	4			103	6		
A10BX01	Guar gum					61	4			103	6		
A11	Vitamins	20.32	18.22	17.20	17.25	6,800	6,315	6,159	6,173	11,586	10,723	10,458	10,451
A11C	Vitamin A and D, incl. combinations of the two	1.10	1.08	1.14	1.13	131	128	127	122	238	232	231	222
A11CC	Vitamin D and analogues	1.10	1.08	1.14	1.13	131	128	127	122	238	232	231	222
A11CC01	Ergocalciferol (vitamin D ₂)					13	10	4		23	19	8	
A11CC05	Colecalciferol (vitamin D ₃)	1.10	1.08	1.14	1.13	118	117	123	122	215	213	223	222
A11D	Vitamin B ₁ , plain and in combination with vitamin B ₆ and B ₁₂	5.21	4.73	4.55	4.14	1,259	1,135	1,094	1,015	2,137	1,913	1,842	1,708
A11DB	Vitamin B ₁ in comb. with vitamin B ₆ and/or vitamin B ₁₂	10.42	9.46	9.11	8.28	2,518	2,271	2,189	2,031	4,274	3,826	3,683	3,416
A11E	Vitamin B-complex, incl. combinations	10.79	10.07	9.74	9.79	4,996	4,706	4,652	4,699	8,479	7,967	7,881	7,927
A11EX	Vitamin B-complex, other combinations	21.58	20.14	19.48	19.57	9,992	9,411	9,303	9,398	16,958	15,934	15,762	15,855
A11G	Ascorbic acid (vitamin C), incl. combinations	3.06	2.19	1.61	2.06	203	145	106	137	361	258	189	245
A11GA	Ascorbic acid (vitamin C), plain	3.06	2.19	1.61	2.06	203	145	106	137	361	258	189	245
A11GA01	Ascorbic acid (vitamin C)	3.06	2.19	1.61	2.06	203	145	106	137	361	258	189	245

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
A11H	Other plain vitamin preparations	0.16	0.15	0.15	0.13	211	201	180	200	371	353	316	349
A11HA	Other plain vitamin preparations	0.16	0.15	0.15	0.13	211	201	180	200	371	353	316	349
A11HA02	Pyridoxine (vitamin B ₆)	0.16	0.15	0.15	0.13	46	42	42	38	78	71	72	64
A11HA30	Dexpanthenol					165	159	138	162	293	282	244	285
A12	Mineral supplements	14.08	14.67	14.58	15.46	7,927	8,482	8,488	8,941	13,126	14,009	14,081	14,764
A12A	Calcium	8.62	8.97	8.80	9.46	3,833	4,033	4,020	4,391	6,502	6,821	6,860	7,415
A12AA	Calcium	1.01	1.10	1.09	1.13	742	798	802	843	1,284	1,378	1,388	1,456
A12AA04	Calcium carbonate	1.00	1.10	1.08	1.13	723	793	788	837	1,249	1,368	1,362	1,445
A12AA06	Calcium lactate gluconate	0.01	0.00	0.01	0.00	19	5	14	6	35	9	26	10
A12AX	Calcium, combinations with vitamin D and/or other drugs	15.21	15.73	15.43	16.66	6,182	6,471	6,436	7,096	10,437	10,887	10,944	11,918
A12B	Potassium	5.47	5.70	5.78	6.00	4,094	4,449	4,468	4,550	6,624	7,188	7,221	7,349
A12BA	Potassium	5.47	5.70	5.78	6.00	4,094	4,449	4,468	4,550	6,624	7,188	7,221	7,349
A12BA01	Potassium chloride	5.42	5.65	5.74	6.00	3,982	4,324	4,366	4,550	6,441	6,985	7,057	7,349
A12BA51	Potassium chloride, combinations	0.05	0.05	0.04		112	125	102		183	203	164	



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
B	Blood and blood forming organs	78.88	73.43	69.80	68.08	13,013	11,983	12,084	10,876	22,318	20,611	20,797	18,673
B01	Antithrombotic agents	69.15	67.13	63.90	62.32	7,825	7,625	7,221	7,231	13,632	13,312	12,595	12,608
B01A	Antithrombotic agents	69.15	67.13	63.90	62.32	7,825	7,625	7,221	7,231	13,632	13,312	12,595	12,608
B01AC	Platelet aggregation inhibitors excl. heparin	69.15	67.13	63.90	62.32	7,825	7,625	7,221	7,231	13,632	13,312	12,595	12,608
B01AC06	Acetylsalicylic acid	69.15	67.13	63.90	62.32	7,825	7,625	7,221	7,231	13,632	13,312	12,595	12,608
B03	Antianemic preparations	9.73	6.30	5.90	5.76	5,121	4,297	4,796	3,579	8,583	7,198	8,093	5,956
B03A	Iron preparations	5.12	5.59	5.90	5.76	3,585	4,069	4,796	3,579	6,060	6,867	8,093	5,956
B03AA	Iron bivalent, oral preparations	4.06	4.20	4.15	4.14	2,682	2,964	3,421	2,275	4,576	5,048	5,829	3,809
B03AA01	Ferrous glycine sulfate	3.00	3.07	3.05	3.24	2,138	2,383	2,851	1,857	3,651	4,058	4,859	3,100
B03AA07	Ferrous sulfate	1.06	1.12	1.10	0.90	544	582	570	417	925	990	970	709
B03AB	Iron trivalent, oral preparations	1.06	1.39	1.75	1.63	904	1,105	1,375	1,304	1,484	1,819	2,264	2,146
B03AB05	Ferric oxide polymaltose complexes	1.06	1.39	1.75	1.63	904	1,105	1,375	1,304	1,484	1,819	2,264	2,146
B03B	Vitamin B ₁₂ and folic acid	4.60	0.71			1,536	228			2,523	332		
B03BA	Vitamin B ₁₂ (cyanocobalamin and derivatives)	4.60	0.71			1,536	228			2,523	332		
B03BA01	Cyanocobalamin	4.60	0.71			1,536	228			2,523	332		
B05	Blood substitutes and perfusion solutions					67	62	67	67	103	101	109	110
B05B	I.V. Solutions					67	62	67	67	103	101	109	110
B05BB	Solutions affecting the electrolyte balance					67	62	67	67	103	101	109	110
B05BB01	Electrolytes					67	62	67	67	103	101	109	110



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
C	Cardiovascular system	0.11	0.11	0.10	0.10	3,908	3,896	3,678	3,691	6,660	6,635	6,244	6,257
C04	Peripheral vasodilators	0.11	0.11	0.10	0.10	79	75	74	75	130	124	123	123
C04A	Peripheral vasodilators	0.11	0.11	0.10	0.10	79	75	74	75	130	124	123	123
C04AD	Purine derivatives	0.11	0.11	0.10	0.10	79	75	74	75	130	124	123	123
C04AD03	Pentoxifylline	0.11	0.11	0.10	0.10	79	75	74	75	130	124	123	123
C05	Vasoprotectives					3,830	3,821	3,604	3,616	6,530	6,511	6,122	6,134
C05A	Agents for treatment of hemorrhoids and anal fissures for topical use					2,276	2,282	2,116	2,109	3,918	3,928	3,625	3,605
C05AA	Corticosteroids					2,154	2,157	2,024	2,109	3,702	3,707	3,462	3,605
C05AA04	Prednisolone					2,154	2,157	2,024	2,109	3,702	3,707	3,462	3,605
C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use					122	124	92		217	220	163	
C05AX03	Other preparations, combinations					122	124	92		217	220	163	
C05B	Antivaricose therapy					1,554	1,540	1,488	1,507	2,612	2,584	2,497	2,529
C05BA	Heparins or heparinoids for topical use					1,554	1,540	1,488	1,507	2,612	2,584	2,497	2,529
C05BA01	Organo-heparinoid					1,554	1,540	1,488	1,507	2,612	2,584	2,497	2,529



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D	Dermatologicals					21,544	22,838	23,360	21,333	37,374	39,600	40,414	36,953
D01	Antifungals for dermatological use					3,866	3,958	4,038	4,208	6,680	6,823	6,931	7,214
D01A	Antifungals for topical use					3,866	3,958	4,038	4,208	6,680	6,823	6,931	7,214
D01AA	Antibiotics					39	42	43	46	69	74	76	81
D01AA02	Natamycin					39	42	43	46	69	74	76	81
D01AC	Imidazole and triazole derivatives					2,473	2,623	2,732	2,889	4,274	4,502	4,687	4,947
D01AC01	Clotrimazole					232	253	247	223	411	448	436	392
D01AC02	Miconazole					792	898	909	921	1,381	1,555	1,571	1,592
D01AC07	Tioconazole					51	13	4	29	89	23	6	50
D01AC08	Ketoconazole					912	942	1,045	1,143	1,556	1,590	1,768	1,927
D01AC10	Bifonazole								39				69
D01AC20	Imidazoles/triazoles in combination with corticosteroids					486	517	528	535	838	886	905	917
D01AE	Other antifungals for topical use					1,354	1,292	1,262	1,272	2,337	2,247	2,168	2,185
D01AE15	Terbinafine					1,354	1,292	1,262	1,272	2,337	2,247	2,168	2,185
D02	Emollients and protectives					2,024	2,214	2,357	49	3,372	3,711	3,945	86
D02A	Emollients and protectives					2,024	2,214	2,357	49	3,372	3,711	3,945	86
D02AE	Carbamide products					1,055	1,183	1,271	29	1,755	1,981	2,124	52
D02AE01	Carbamide					1,055	1,183	1,271	29	1,755	1,981	2,124	52
D02AE51	Carbamide, combinations												
D02AX	Other emollients and protectives					1,937	2,060	2,172	40	3,233	3,460	3,640	67
D03	Preparations for treatment of wounds and ulcers					5,960	6,316	6,508	6,674	10,500	11,095	11,400	11,645
D03A	Cicatrizants					5,960	6,316	6,508	6,674	10,500	11,095	11,400	11,645
D03AX	Other cicatrizants					5,960	6,316	6,508	6,674	10,500	11,095	11,400	11,645
D03AX03	Dexpanthenol					5,960	6,316	6,508	6,674	10,500	11,095	11,400	11,645

Table continued



ATC classification	Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D04	Antipruritics, incl. antihistamines, anesthetics, etc.				189	330	425	379	355	587	776	696
D04A	Antipruritics, incl. antihistamines, anesthetics, etc.				189	330	425	379	355	587	776	696
D04AA	Antihistamines for topical use				189	330	425	379	355	587	776	696
D04AA04	Tripelennamine				189	330	425	379	355	587	776	696
D06	Antibiotics and chemotherapeutics for dermatological use				2,911	3,087	3,028	2,837	5,050	5,370	5,257	4,921
D06A	Antibiotics for topical use				1,005	1,243	1,202	1,165	1,770	2,185	2,114	2,048
D06AX	Other antibiotics for topical use				1,005	1,243	1,202	1,165	1,770	2,185	2,114	2,048
D06AX04	Neomycin				1,005	1,243	1,202	1,165	1,770	2,185	2,114	2,048
D06B	Chemotherapeutics for topical use				1,907	1,844	1,826	1,672	3,280	3,186	3,143	2,873
D06BB	Antivirals				1,705	1,637	1,621	1,480	2,941	2,837	2,799	2,550
D06BB03	Aciclovir				1,127	1,125	1,114	1,089	1,951	1,956	1,925	1,882
D06BB06	Penciclovir				213	202	245	195	366	352	427	334
D06BB53	Aciclovir, combinations				361	310	262	196	617	528	448	334
D06BX	Other chemotherapeutics				204	207	205	192	342	348	344	322
D06BX01	Metronidazole				204	207	205	192	342	348	344	322
D07	Corticosteroids, dermatological preparations				4,753	5,153	5,225	5,304	8,357	9,068	9,179	9,307
D07A	Corticosteroids, plain				3,178	3,472	3,535	3,671	5,622	6,149	6,246	6,478
D07AA	Corticosteroids, weak (group I)				3,178	3,472	3,535	3,671	5,622	6,149	6,246	6,478
D07AA02	Hydrocortisone				3,178	3,472	3,535	3,671	5,622	6,149	6,246	6,478
D07B	Corticosteroids, combinations with antiseptics				694	744	731	709	1,216	1,303	1,280	1,240
D07BA	Corticosteroids, weak, combinations with antiseptics				694	744	731	709	1,216	1,303	1,280	1,240
D07BA04	Hydrocortisone and antiseptics				694	744	731	709	1,216	1,303	1,280	1,240

Table continued



ATC classification	Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
	2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
	D07C	Corticosteroids, combinations with antibiotics				611	643	659	653	1,038	1,090	1,115
D07CA	Corticosteroids, weak, combinations with antibiotics				611	643	659	653	1,038	1,090	1,115	1,106
D07CA01	Hydrocortisone and antibiotics				611	643	659	653	1,038	1,090	1,115	1,106
D07X	Corticosteroids, other combinations				270	294	300	271	482	526	538	483
D07XA	Corticosteroids, weak, other combinations				270	294	300	271	482	526	538	483
D07XA01	Hydrocortisone				270	294	300	271	482	526	538	483
D08	Antiseptics and disinfectants				409	390	331	315	720	684	578	555
D08A	Antiseptics and disinfectants				409	390	331	315	720	684	578	555
D08AC	Biguanides and amidines				55	46	29	4	92	77	46	7
D08AC02	Chlorhexidine				55	46	29	4	91	77	45	7
D08AC52	Chlorhexidine, combinations				1	0	0	0	1	0	0	0
D08AE	Phenol and derivatives											
D08AE04	Triclosan											
D08AG	Iodine products				353	344	302	311	628	607	532	548
D08AG02	Povidone-iodine				353	344	302	311	628	607	532	548
D09	Medicated dressings				119	98	110	107	192	157	176	172
D09A	Medicated dressings				119	98	110	107	192	157	176	172
D09AB	Zinc bandages				119	98	110	107	192	157	176	172
D09AB01	Zinc bandage without supplements				119	98	110	107	192	157	176	172

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
D10	Anti-acne preparations					523	472	450	460	885	799	762	777
D10A	Anti-acne preparations for topical use					523	472	450	460	885	799	762	777
D10AE	Peroxides					523	472	450	460	885	799	762	777
D10AE01	Benzoyl peroxide					523	472	450	460	885	799	762	777
D11	Other dermatological preparations					790	821	887	1,000	1,262	1,306	1,410	1,580
D11A	Other dermatological preparations					790	821	887	1,000	1,262	1,306	1,410	1,580
D11AC	Medicated shampoos					94	96	107	113	166	170	187	198
D11AC03	Selenium compounds					94	96	107	113	166	170	187	198
D11AF	Wart and anti-corn preparations					46				84			
D11AX	Other dermatologicals					673	725	780	886	1,054	1,136	1,222	1,382
D11AX01	Minoxidil					673	725	780	886	1,054	1,136	1,222	1,382



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
G	Genito urinary system and sex hormones	11.54	11.24	11.19	11.02	11,145	12,101	12,756	12,696	18,537	20,012	21,052	20,928
G01	Gynecological antiinfectives and antiseptics	0.53	0.55	0.56	0.51	1,677	1,849	1,959	1,785	2,864	3,154	3,330	3,037
G01A	Antiinfectives and antiseptics, excl. combinations with corticosteroids	0.53	0.55	0.56	0.51	1,677	1,849	1,959	1,785	2,864	3,154	3,330	3,037
G01AF	Imidazole derivatives	0.53	0.55	0.56	0.51	1,677	1,849	1,959	1,785	2,864	3,154	3,330	3,037
G01AF02	Clotrimazole	0.40	0.41	0.42	0.42	1,514	1,659	1,783	1,664	2,580	2,826	3,025	2,828
G01AF04	Miconazole	0.13	0.15	0.14	0.10	163	190	176	121	284	328	305	208
G03	Sex hormones and modulators of the genital system	6.80	6.53	6.87	6.67	7,823	8,591	9,316	9,491	12,949	14,110	15,273	15,528
G03A	Hormonal contraceptives for systemic use	0.05	0.05	0.05	0.04	1,003	1,077	1,055	942	1,679	1,804	1,751	1,591
G03AD	Emergency contraceptives	0.05	0.05	0.05	0.04	1,003	1,077	1,055	942	1,679	1,804	1,751	1,591
G03AD01	Levonorgestrel	0.03	0.03	0.03	0.02	545	541	506	456	927	923	863	779
G03AD02	Ulipristal	0.02	0.02	0.02	0.02	457	536	549	486	752	881	888	812
G03C	Estrogens	6.75	6.48	6.83	6.63	6,821	7,514	8,261	8,549	11,270	12,305	13,522	13,937
G03CA	Natural and semisynthetic estrogens, plain	6.75	6.48	6.83	6.63	6,821	7,514	8,261	8,549	11,270	12,305	13,522	13,937
G03CA03	Estradiol	0.99	1.03	1.08	1.07	5,153	5,700	5,979	5,891	8,432	9,234	9,686	9,547
G03CA04	Estriol	5.76	5.45	5.75	5.56	1,668	1,814	2,282	2,658	2,837	3,071	3,836	4,390
G04	Urologicals	4.22	4.16	3.76	3.83	1,645	1,661	1,481	1,420	2,724	2,749	2,449	2,364
G04B	Urologicals	3.48	3.31	3.12	3.27	1,098	1,044	986	999	1,837	1,745	1,648	1,683
G04BX	Other urologicals	3.48	3.31	3.12	3.27	1,098	1,044	986	999	1,837	1,745	1,648	1,683
G04BX01	Magnesium hydroxide	3.48	3.31	3.12	3.27	1,098	1,044	986	999	1,837	1,745	1,648	1,683
G04C	Drugs used in benign prostatic hypertrophy	0.74	0.85	0.64	0.56	547	618	495	421	887	1,004	801	681
G04CX	Other drugs used in benign prostatic hypertrophy	0.74	0.85	0.64	0.56	547	618	495	421	887	1,004	801	681
G04CX02	Sabalıs serrulatae fructus	0.74	0.85	0.64	0.56	547	618	495	421	887	1,004	801	681



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
H	Systemic hormonal preparations, excl. sex hormones and insulins	0.54	0.69	0.58	0.46	776	1,029	837	677	1,398	1,922	1,606	1,226
H02	Corticosteroids for systemic use	0.54	0.69	0.58	0.46	776	1,029	837	677	1,398	1,922	1,606	1,226
H02A	Corticosteroids for systemic use, plain	0.54	0.69	0.58	0.46	776	1,029	837	677	1,398	1,922	1,606	1,226
H02AB	Glucocorticoids	0.54	0.69	0.58	0.46	776	1,029	837	677	1,398	1,922	1,606	1,226
H02AB09	Hydrocortisone	0.54	0.69	0.58	0.46	776	1,029	837	677	1,398	1,922	1,606	1,226
J	Antiinfectives for systemic use	0.17	0.18	0.19	0.18	2,782	2,497	2,371	1,985	4,819	4,420	4,183	3,550
J02	Antimycotics for systemic use	0.09	0.09	0.09	0.09	1,580	1,296	1,123	909	2,745	2,344	2,016	1,661
J02A	Antimycotics for systemic use	0.09	0.09	0.09	0.09	1,580	1,296	1,123	909	2,745	2,344	2,016	1,661
J02AC	Triazole derivatives	0.09	0.09	0.09	0.09	1,580	1,296	1,123	909	2,745	2,344	2,016	1,661
J02AC01	Fluconazole	0.09	0.09	0.09	0.09	1,580	1,296	1,123	909	2,745	2,344	2,016	1,661
J05	Antivirals for systemic use	0.08	0.09	0.10	0.10	1,202	1,201	1,248	1,077	2,073	2,076	2,167	1,889
J05A	Direct acting antivirals	0.08	0.09	0.10	0.10	1,202	1,201	1,248	1,077	2,073	2,076	2,167	1,889
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors	0.08	0.09	0.10	0.10	1,202	1,201	1,248	1,077	2,073	2,076	2,167	1,889
J05AB01	Aciclovir	0.03	0.03	0.04	0.04	343	312	323	286	597	550	579	514
J05AB11	Valaciclovir	0.05	0.06	0.06	0.06	859	889	925	791	1,476	1,525	1,588	1,374



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
M	Musculo-skeletal system	23.85	24.28	24.71	23.08	33,415	33,060	33,850	33,171	58,897	58,541	59,755	58,078
M01	Antiinflammatory and antirheumatic products	23.85	24.28	24.71	23.08	21,889	22,285	23,058	21,267	39,614	40,362	41,679	38,299
M01A	Antiinflammatory and antirheumatic products, non-steroids	23.85	24.28	24.71	23.08	21,889	22,285	23,058	21,267	39,614	40,362	41,679	38,299
M01AE	Propionic acid derivatives	23.85	24.28	24.71	23.08	21,889	22,285	23,058	21,267	39,614	40,362	41,679	38,299
M01AE01	Ibuprofen	23.08	23.56	23.95	22.44	20,649	21,114	21,820	20,250	37,386	38,256	39,454	36,474
M01AE02	Naproxen	0.04	0.04	0.03	0.02	90	83	73	55	157	145	127	97
M01AE03	Ketoprofen	0.19	0.18	0.17	0.15	333	312	298	271	634	594	567	516
M01AE51	Ibuprofen, combinations	0.55	0.51	0.56	0.46	817	776	867	691	1,437	1,367	1,531	1,213
M02	Topical products for joint and muscular pain					11,526	10,775	10,792	11,903	19,283	18,179	18,076	19,779
M02A	Topical products for joint and muscular pain					11,526	10,775	10,792	11,903	19,283	18,179	18,076	19,779
M02AA	Antiinflammatory preparations, non-steroids for topical use					10,489	9,844	9,937	11,071	17,523	16,600	16,625	18,366
M02AA07	Piroxicam					486	471	437	447	839	815	754	771
M02AA13	Ibuprofen						616	1,116	759		1,182	1,915	1,302
M02AA15	Diclofenac					10,003	8,757	8,384	9,864	16,684	14,604	13,956	16,293
M02AC	Preparations with salicylic acid derivatives					2,073	1,861	1,711	1,665	3,519	3,158	2,902	2,826



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
N	Nervous system	10.95	11.54	11.14	13.33	25,663	25,984	23,851	27,488	33,697	34,122	31,073	36,228
N01	Anesthetics					267	268	287	295	460	462	495	507
N01B	Anesthetics, local					267	268	287	295	460	462	495	507
N01BB	Amides					267	268	287	295	460	462	495	507
N01BB20	Combinations					267	268	287	295	460	462	495	507
N02	Analgesics	8.23	8.22	7.79	8.73	17,895	18,194	16,465	18,977	32,251	32,671	29,656	33,943
N02B	Other analgesics and antipyretics	8.23	8.22	7.79	8.73	17,883	18,170	16,446	18,965	32,230	32,629	29,622	33,922
N02BA	Salicylic acid and derivatives	1.87	1.68	1.02	1.33	4,783	4,559	1,496	3,376	8,413	8,020	2,666	5,915
N02BA01	Acetylsalicylic acid	0.95	0.83	0.77	0.73	1,288	1,132	988	1,022	2,313	2,034	1,774	1,830
N02BA51	Acetylsalicylic acid, combinations excl. psycholeptics	0.93	0.85	0.25	0.59	3,496	3,427	508	2,354	6,100	5,986	891	4,085
N02BE	Anilides	6.36	6.54	6.77	7.40	13,100	13,611	14,950	15,589	23,818	24,609	26,957	28,006
N02BE01	Paracetamol	6.18	6.37	6.49	7.20	12,634	13,131	14,089	14,995	22,987	23,760	25,433	26,965
N02BE51	Paracetamol, combinations excl. psycholeptics	0.18	0.17	0.28	0.20	466	480	861	593	831	849	1,524	1,041
N02C	Antimigraine preparations	0.00	0.00	0.00	0.00	12	24	19	12	21	42	34	21
N02CC	Selective 5HT1-receptor agonists	0.00	0.00	0.00	0.00	12	24	19	12	21	42	34	21
N02CC01	Sumatriptan	0.00	0.00	0.00	0.00	12	24	19	12	21	42	34	21
N05	Psycholeptics	0.72	1.33	1.52	2.58	504	536	490	988	893	989	922	1,777
N05C	Hypnotics and sedatives	0.72	1.33	1.52	2.58	504	536	490	988	893	989	922	1,777
N05CH	Melatonin receptor agonists	0.44	1.12	1.42	2.37	89	227	343	538	180	458	669	1,018
N05CH01	Melatonin	0.44	1.12	1.42	2.37	89	227	343	538	180	458	669	1,018
N05CM	Other hypnotics and sedatives	0.27	0.21	0.09	0.21	415	309	147	450	713	531	254	760
N05CM09	Valerianae radix	0.27	0.21	0.09	0.21	415	309	147	450	713	531	254	760



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
P	Antiparasitic products, insecticides and repellents	0.24	0.25	0.29	0.27	2,810	2,843	3,170	3,024	4,552	4,601	5,118	4,883
P02	Anthelmintics	0.24	0.25	0.29	0.27	1,414	1,427	1,678	1,513	2,298	2,318	2,722	2,451
P02C	Antinematodal agents	0.24	0.25	0.29	0.27	1,414	1,427	1,678	1,513	2,298	2,318	2,722	2,451
P02CX	Other antinematodals	0.24	0.25	0.29	0.27	1,414	1,427	1,678	1,513	2,298	2,318	2,722	2,451
P02CX01	Pyvvinium	0.24	0.25	0.29	0.27	1,414	1,427	1,678	1,513	2,298	2,318	2,722	2,451
P03	Ectoparasiticides, incl. scabicides, insecticides and repellents					1,396	1,416	1,492	1,511	2,254	2,283	2,396	2,432
P03A	Ectoparasiticides, incl. scabicides					1,396	1,416	1,492	1,511	2,254	2,283	2,396	2,432
P03AC	Pyrethrines, incl. synthetic compounds					1,388	1,416	1,492	1,511	2,241	2,283	2,396	2,432
P03AC04	Permethrin					1,388	1,416	1,492	1,511	2,241	2,283	2,396	2,432



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R	Respiratory system	40.49	42.40	44.40	43.08	29,911	31,759	32,526	29,034	53,422	56,864	57,650	51,012
R01	Nasal preparations	13.72	14.03	14.52	12.24	6,848	7,334	8,401	7,702	12,563	13,452	15,338	13,764
R01A	Decongestants and other nasal preparations for topical use	13.72	14.03	14.52	12.24	6,848	7,334	8,401	7,702	12,563	13,452	15,338	13,764
R01AA	Sympathomimetics, plain	10.24	10.74	11.11	9.17	4,542	4,834	5,799	5,243	8,502	9,059	10,751	9,445
R01AA05	Oxymetazoline	0.75	0.78	0.82	0.75	261	267	283	260	476	496	516	474
R01AA07	Xylometazoline	9.49	9.96	10.30	8.42	4,281	4,567	5,516	4,983	8,027	8,562	10,235	8,971
R01AB	Sympathomimetics, combinations excl. corticosteroids	0.82	0.80	0.83	0.64	539	539	612	492	973	961	1,097	892
R01AB06	Xylometazoline	0.82	0.80	0.83	0.64	539	539	612	492	973	961	1,097	892
R01AC	Antiallergic agents, excl. corticosteroids	0.25	0.35	0.33	0.22	232	313	301	246	412	552	533	422
R01AC01	Cromoglicic acid	0.16	0.20	0.19	0.03	121	142	132	21	221	259	242	38
R01AC02	Levocabastine	0.04	0.07	0.07	0.09	66	104	98	137	112	177	168	234
R01AC03	Azelastine	0.05	0.07	0.08	0.09	45	67	71	87	78	115	123	151
R01AD	Corticosteroids	1.51	1.88	2.01	2.03	1,213	1,507	1,565	1,624	2,098	2,621	2,727	2,824
R01AD01	Beclometasone	0.30	0.34	0.30	0.31	215	241	208	231	374	418	354	393
R01AD08	Fluticasone	0.53	0.61	0.63	0.60	530	605	608	621	920	1,056	1,064	1,086
R01AD09	Mometasone	0.47	0.61	0.73	0.71	279	355	418	403	470	623	735	708
R01AD11	Triamcinolone	0.21	0.33	0.36	0.40	188	306	331	369	334	524	574	638
R01AX	Other nasal preparations	0.89	0.26	0.23	0.18	321	139	124	98	578	259	229	181
R01AX10	Various	0.28	0.26	0.23	0.18	149	139	124	98	277	259	229	181

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R02	Throat preparations	3.48	3.68	3.28	2.51	7,135	7,917	7,531	5,683	12,683	14,069	13,285	9,969
R02A	Throat preparations	3.48	3.68	3.28	2.51	7,135	7,917	7,531	5,683	12,683	14,069	13,285	9,969
R02AA	Antiseptics	1.63	1.61	1.52	1.06	3,912	4,235	4,250	2,966	6,947	7,559	7,520	5,213
R02AA03	Dichlorobenzyl alcohol	1.58	1.57	1.51	1.05	3,408	3,567	3,636	2,622	6,039	6,362	6,387	4,597
R02AA05	Chlorhexidine	0.05	0.03	0.02	0.01	68	46	25	12	124	84	46	21
R02AA20	Various					436	623	588	332	784	1,113	1,087	594
R02AB	Antibiotics	1.23	1.38	1.18	1.06	2,172	2,440	2,216	2,050	3,863	4,343	3,897	3,588
R02AB30	Gramicidin	1.23	1.38	1.18	1.06	2,172	2,440	2,216	2,050	3,863	4,343	3,897	3,588
R02AX	Other throat preparations	0.63	0.70	0.58	0.38	1,052	1,241	1,065	667	1,873	2,167	1,869	1,168
R02AX01	Flurbiprofen	0.04	0.06	0.06	0.04	169	285	275	169	294	488	470	288
R02AX03	Benzydamine	0.59	0.64	0.52	0.35	883	956	790	498	1,579	1,679	1,399	881

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R05	Cough and cold preparations	3.82	3.73	3.36	2.43	7,154	7,434	6,827	5,120	12,573	13,130	11,974	8,955
R05C	Expectorants, excl. combinations with cough suppressants	2.17	2.04	1.90	1.38	2,708	2,587	2,465	1,812	4,765	4,580	4,346	3,182
R05CA	Expectorants	0.24	0.17	0.09	0.06	313	248	157	112	563	450	287	201
R05CA03	Guaifenesin	0.07	0.06	0.01		88	81	14		159	146	25	
R05CA10	Combinations	0.17	0.11	0.08	0.06	225	167	143	112	403	303	262	201
R05CB	Mucolytics	1.93	1.87	1.80	1.32	2,395	2,338	2,307	1,701	4,202	4,130	4,059	2,981
R05CB01	Acetylcysteine	0.68	0.67	0.68	0.50	727	731	744	543	1,281	1,281	1,302	950
R05CB02	Bromhexine	1.18	1.14	1.01	0.72	1,549	1,500	1,346	958	2,716	2,658	2,361	1,682
R05CB03	Carbocisteine	0.07	0.06	0.06	0.03	118	107	94	57	205	192	164	100
R05CB06	Ambroxol			0.06	0.06			123	142			231	249
R05D	Cough suppressants, excl. combinations with expectorants	0.95	0.92	0.81	0.54	1,673	1,658	1,454	977	2,966	2,995	2,579	1,730
R05DA	Opium alkaloids and derivatives	0.77	0.73	0.65	0.42	1,121	1,079	964	618	1,990	1,969	1,712	1,096
R05DA09	Dextromethorphan	0.77	0.73	0.65	0.42	1,121	1,079	964	618	1,990	1,969	1,712	1,096
R05DB	Other cough suppressants	0.18	0.19	0.16	0.12	552	579	490	359	976	1,026	867	634
R05DB05	Pentoxyverine	0.18	0.19	0.16	0.12	552	579	490	359	976	1,026	867	634
R05F	Cough suppressants and expectorants, combinations	0.70	0.77	0.66	0.52	2,135	2,480	2,305	1,837	3,756	4,349	4,024	3,205
R05FA	Opium derivatives and expectorants	0.23	0.21	0.22	0.19	558	513	544	461	998	918	972	824
R05FA02	Opium derivatives and expectorants	0.23	0.21	0.22	0.19	558	513	544	461	998	918	972	824
R05FB	Other cough suppressants and expectorants	0.47	0.56	0.43	0.33	1,577	1,967	1,761	1,376	2,758	3,431	3,052	2,381
R05FB02	Cough suppressants and expectorants	0.47	0.56	0.43	0.33	1,577	1,967	1,761	1,376	2,758	3,431	3,052	2,381
R05X	Other cold preparations					638	709	1,206	494	1,085	1,207	2,051	839

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
R06	Antihistamines for systemic use	19.47	20.95	23.24	25.90	8,774	9,074	9,767	10,530	15,604	16,213	17,053	18,323
R06A	Antihistamines for systemic use	19.47	20.95	23.24	25.90	8,774	9,074	9,767	10,530	15,604	16,213	17,053	18,323
R06AE	Piperazine derivatives	14.08	14.49	15.90	17.69	5,756	5,646	6,023	6,520	10,321	10,152	10,490	11,322
R06AE03	Cyclizine	0.07	0.05		0.00	139	93		14	245	164		25
R06AE05	Meclozine	0.14	0.14	0.19	0.09	334	319	439	233	582	556	765	414
R06AE07	Cetirizine	13.41	13.72	15.12	16.97	4,936	4,870	5,238	5,923	8,895	8,801	9,127	10,281
R06AE09	Levocetirizine	0.46	0.59	0.59	0.63	347	363	347	350	599	630	598	602
R06AX	Other antihistamines for systemic use	5.39	6.46	7.34	8.21	3,018	3,428	3,744	4,010	5,283	6,061	6,564	7,000
R06AX13	Loratadine	1.02	1.22	1.20	1.38	352	388	374	437	643	710	677	780
R06AX18	Acrivastine	0.05	0.05	0.08	0.08	85	90	144	144	153	163	260	260
R06AX22	Ebastine	2.21	2.59	2.87	3.26	1,259	1,390	1,455	1,566	2,083	2,391	2,474	2,650
R06AX26	Fexofenadine	1.39	1.58	2.14	2.27	894	1,009	1,194	1,216	1,663	1,804	2,131	2,146
R06AX27	Desloratadine	0.73	1.02	1.05	1.21	428	551	576	647	741	994	1,021	1,164

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
S	Sensory organs					13,681	14,573	15,225	14,437	23,171	24,598	25,658	24,254
S01	Ophthalmologicals					13,069	13,921	14,562	13,826	22,114	23,474	24,519	23,206
S01G	Decongestants and antiallergics					2,748	3,268	3,310	2,894	4,773	5,629	5,736	5,010
S01GA	Sympathomimetics used as decongestants					257	247	251	201	469	450	452	356
S01GA02	Tetryzoline					257	247	251	201	469	450	452	356
S01GX	Other antiallergics					2,491	3,021	3,059	2,693	4,305	5,179	5,284	4,653
S01GX01	Cromoglicic acid					2,100	2,506	2,601	2,286	3,629	4,298	4,474	3,938
S01GX02	Levocabastine					160	206	122	175	277	357	211	304
S01GX05	Lodoxamide					30	36	56	35	52	63	98	61
S01GX07	Azelastine					7	23	26		12	40	43	
S01GX08	Ketotifen					194	249	254	197	335	421	457	351
S01X	Other ophthalmologicals					10,320	10,653	11,252	10,932	17,340	17,845	18,783	18,196
S01XA	Other ophthalmologicals					10,320	10,653	11,252	10,932	17,340	17,845	18,783	18,196
S01XA02	Retinol					364	395	503	512	634	687	866	882
S01XA20	Artificial tears and other indifferent preparations					9,956	10,258	10,750	10,420	16,706	17,157	17,917	17,314
S02	Otologicals					613	652	663	611	1,058	1,124	1,139	1,048
S02A	Antiinfectives					379	431	460	498	655	744	790	852
S02AA	Antiinfectives					379	431	460	498	655	744	790	852
S02AA03	Boric acid					379	431	460	498	655	744	790	852
S02D	Other otologicals					234	221	203	114	403	380	350	196
S02DA	Analgesics and anesthetics					234	221	203	114	403	380	350	196
S02DA04	Cinchocaine					234	221	203	114	403	380	350	196

Table continued




ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2017	2018	2019	2020	2017	2018	2019	2020	2017	2018	2019	2020
V	Various					288	186	246	358	473	308	405	590
V03	All other therapeutic products					200	97	151	256	328	160	247	421
V03A	All other therapeutic products					200	97	151	256	328	160	247	421
V03AB	Antidotes					200	97	151	256	328	160	247	421
V03AB21	Potassium iodide					200	97	151	256	328	160	247	421
V07	All other non-therapeutic products					87	89	95	102	144	147	157	169
V07A	All other non-therapeutic products					87	89	95	102	144	147	157	169
V07AB	Solvents and diluting agents, incl. irrigating solutions					174	177	190	204	289	293	314	338



Figures on sales statistics


Figure 7.1. Consumption and sales of proton pump inhibitors (A02BC) in 2006–2020

DDD/1,000 inhabitants/day



- Esomeprazole (A02BC05)
- Rabeprazole (A02BC04)
- Lansoprazole (A02BC03)
- Pantoprazole (A02BC02)
- Omeprazole (A02BC01)

Wholesale price (VAT excluded) thousand euros



- Proton pump inhibitors (A02BC)
- Esomeprazole (A02BC05)
- Rabeprazole (A02BC04)
- - - Lansoprazole (A02BC03)
- Pantoprazole (A02BC02)
- Omeprazole (A02BC01)



Figure 7.2. Consumption of drugs for acid related disorders (A02) by hospital district in 2020

Whole country 72.93 DDD/1,000 inhabitants/day






Figure 7.3. Consumption and sales of insulins and analogues (A10A) in 2006–2020

DDD/1,000 inhabitants/day



- Insulins and analogues for injection, long-acting (A10AE)
- Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting (A10AD)
- Insulins and analogues for injection, intermediate-acting (A10AC)
- Insulins and analogues for injection, fast-acting (A10AB)


Wholesale price (VAT excluded) thousand euros




- Insulins and analogues (A10A)
- Insulins and analogues for injection, long-acting (A10AE)
- Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting (A10AD)
- Insulins and analogues for injection, intermediate-acting (A10AC)
- Insulins and analogues for injection, fast-acting (A10AB)

Figure 7.4. Consumption and sales of Blood glucose lowering drugs (A10B) in 2006–2020

DDD/1,000 inhabitants/day



Wholesale price (VAT excluded) thousand euros




- Sodium-glucose co-transporter 2 (SGLT2) inhibitors (A10BK)
- Glucagon-like peptide-1 (GLP-1) analogues (A10BJ)
- Dipeptidyl peptidase 4 (DPP-4) inhibitors (A10BH)
- Thiazolidinediones (A10BG)
- Combinations of oral blood glucose lowering drugs (A10BD)
- Sulfonylureas (A10BB)
- Biguanides (A10BA)

- Blood glucose lowering drugs, excl. Insulins (A10B)
- - - Sodium-glucose co-transporter 2 (SGLT2) inhibitors (A10BK)
- . . . Glucagon-like peptide-1 (GLP-1) analogues (A10BJ)
- . . . Dipeptidyl peptidase 4 (DPP-4) inhibitors (A10BH)
- Thiazolidinediones (A10BG)
- - - Combinations of oral blood glucose lowering drugs (A10BD)
- . . . Sulfonylureas (A10BB)
- . . . Biguanides (A10BA)




Figure 7.5. Consumption and sales of most common antihypertensives in 2006–2020

DDD/1,000 inhabitants/day



- Agents acting on the renin-angiotensin system (C09)
- Calcium channel blockers (C08)
- Beta blocking agents (C07)
- Diuretics (C03)

Wholesale price (VAT excluded) thousand euros




- Agents acting on the renin-angiotensin system (C09)
- - - Calcium channel blockers (C08)
- · - Beta blocking agents (C07)
- · · Diuretics (C03)




Figure 7.6. Consumption and sales of agents acting on renin-angiotensin system (C09) in 2006–2020

DDD/1,000 inhabitants/day



- Angiotensin II antagonists, combinations (C09D)
- Angiotensin II antagonists (C09C)
- ACE inhibitors, combinations (C09B)
- ACE inhibitors, plain (C09A)

Wholesale price (VAT excluded) thousand euros



- Angiotensin II antagonists, combinations (C09D)
- - - Angiotensin II antagonists (C09C)
- · - · - ACE inhibitors, combinations (C09B)
- · · ACE inhibitors, plain (C09A)



Figure 7.7. Consumption of agents acting on renin-angiotensin system (C09) by hospital district in 2020

Whole country 274.83 DDD/1,000 inhabitants/day








Figure 7.8. Consumption and sales of statins (C10AA) in 2006–2020

DDD/1,000 inhabitants/day



- Rosuvastatin (C10AA07)
- Atorvastatin (C10AA05)
- Fluvastatin (C10AA04)
- Pravastatin (C10AA03)
- Lovastatin (C10AA02)
- Simvastatin (C10AA01)

Wholesale price (VAT excluded) thousand euros



- Rosuvastatin (C10AA07)
- Atorvastatin (C10AA05)
- Fluvastatin (C10AA04)
- Pravastatin (C10AA03)
- Lovastatin (C10AA02)
- Simvastatin (C10AA01)



Figure 7.9. Consumption of lipid modifying agents reducers (C10) by hospital district in 2020

Whole country 147.73 DDD/1,000 inhabitants/day






Figure 7.10. Consumption of hormonal contraceptives in 2006–2020

DDD/1,000 inhabitants/day






Figure 7.11. Consumption of hormone replacement therapy drugs (G03C, G03F) among women aged over 45 by hospital district in 2020

Whole country 123.00 DDD/1,000 women aged over 45/day




Figure 7.12. Consumption of antibacterials (J01) in 2006–2020




Figure 7.13. Consumption of antibacterials (J01) by hospital district in 2020

Whole country 11.92 DDD/1,000 inhabitants/day





Figure 7.14. Consumption of analgesics (M01A, N02A and N02B) in 2006–2020

DDD/1,000 inhabitants/day



- Paracetamol (N02BE01)
- Acetylsalicylic acid (N02BA01)
- Opioids (N02A)
- Other antiinflammatory and antirheumatic agents, non-steroids (M01AX)
- Coxibs (M01AH)
- Fenamates (M01AG)
- Propionic acid derivatives (M01AE)
- Oxicams (M01AC)
- Acetic acid derivatives and related substances (M01AB)



Figure 7.15. Consumption of most common OTC analgesics in 2006–2020







Figure 7.16. Consumption of opioids (N02A, N07BC) in 2006–2020


DDD/1,000 inhabitants/day



- Tramadol (N02AX02)
- Opioids in combination with non-opioid analgesics (N02AJ)
- Buprenorphine (N02AE01, N07BC01, N07BC51)
- Dextropropoxyphene and methadone (N02AC04, N07BC02)
- Fentanyl (and pethidine) (N02AB)
- Natural opioid alkaloids (N02AA)

Figure 7.17. Consumption of most common hypnotics (N05C) in 2006–2020

DDD/1,000 inhabitants/day



- Melatonin (N05CH01)¹
- - - Zopiclone (N05CF01)
- Temazepam (N05CD07)
- Zolpidem (N05CF02)
- - - Nitrazepam (N05CD02)
- Midazolam (N05CD08)
- Triazolam (N05CD05)

1 Only products with marketing authorization.



Figure 7.18. Consumption of hypnotics (N05C) in outpatient care by hospital district in 2020

Whole country 47.83 DDD/1,000 inhabitants/day







Figure 7.19. Consumption of antidepressants (N06A) in 2006–2020

DDD/1,000 inhabitants/day



- Other antidepressants (N06AX)
- Monoamine oxidase type A inhibitors (N06AG)
- Selective serotonin reuptake inhibitors (N06AB)
- Non-selective monoamine reuptake inhibitors (N06AA)



Figure 7.20. Consumption of most common antidepressants (N06A) in 2006–2020






Figure 7.21. Consumption of antidepressants (N06A) in outpatient care by hospital district in 2020

Whole country 81.52 DDD/1,000 inhabitants/day





Figure 7.22. Consumption of inhaled drugs for obstructive airway diseases in 2006–2020


DDD/1,000 inhabitants/day



- Anticholinergics (R03BB)
- Glucocorticoids (R03BA)
- Adrenergics in combination with anticholinergics (R03AL)
- Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics (R03AK)
- Long-acting beta-2-adrenoreceptor agonists (R03AC12, R03AC13, R03AC18¹, R03AC19²)
- Short-acting beta-2-adrenoreceptor agonists (R03AC02, R03AC03)

1 From 2010.
2 From 2014.

Wholesale price (VAT excluded) thousand euros




- Anticholinergics (R03BB)
- ⋯ Glucocorticoids (R03BA)
- Adrenergics in combination with anticholinergics (R03AL)
- - - Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics (R03AK)
- Long-acting beta-2-adrenoreceptor agonists (R03AC12, R03AC13, R03AC18¹, R03AC19²)
- ⋯ Short-acting beta-2-adrenoreceptor agonists (R03AC02, R03AC03)

1 From 2010.
2 From 2014.




Figure 7.23. Consumption of drugs for obstructive airway diseases (R03) by hospital district in 2020

Whole country 83.83 DDD/1,000 inhabitants/day



Appendices





Appendix 1. Alterations to ATC classification, valid as of January 2021

Substance	Previous ATC code	New ATC code
Raltegravir	J05AX08	J05AJ01
Elvitegravir	J05AX11	J05AJ02
Dolutegravir	J05AX12	J05AJ03
Topotecan	L01XX17	L01CE01
Irinotecan	L01XX19	L01CE02
Etirinotecan pegol	L01XX56	L01CE03
Belotecan	L01XX68	L01CE04
Imatinib	L01XE01	L01EA01
Dasatinib	L01XE06	L01EA02
Nilotinib	L01XE08	L01EA03
Bosutinib	L01XE14	L01EA04
Ponatinib	L01XE24	L01EA05
Gefitinib	L01XE02	L01EB01
Erlotinib	L01XE03	L01EB02
Afatinib	L01XE13	L01EB03
Osimertinib	L01XE35	L01EB04
Rociletinib	L01XE37	L01EB05
Olmutinib	L01XE40	L01EB06
Dacomitinib	L01XE47	L01EB07
Icotinib	L01XE48	L01EB08
Vemurafenib	L01XE15	L01EC01
Dabrafenib	L01XE23	L01EC02
Encorafenib	L01XE46	L01EC03

Substance	Previous ATC code	New ATC code
Crizotinib	L01XE16	L01ED01
Ceritinib	L01XE28	L01ED02
Alectinib	L01XE36	L01ED03
Brigatinib	L01XE43	L01ED04
Lorlatinib	L01XE44	L01ED05
Trametinib	L01XE25	L01EE01
Cobimetinib	L01XE38	L01EE02
Binimetinib	L01XE41	L01EE03
Palbociclib	L01XE33	L01EF01
Ribociclib	L01XE42	L01EF02
Abemaciclib	L01XE50	L01EF03
Temsirolimus	L01XE09	L01EG01
Everolimus	L01XE10	L01EG02
Ridaforolimus	L01XE19	L01EG03
Lapatinib	L01XE07	L01EH01
Neratinib	L01XE45	L01EH02
Ruxolitinib	L01XE18	L01EJ01
Fedratinib	L01XE57	L01EJ02
Axitinib	L01XE17	L01EK01
Cediranib	L01XE32	L01EK02
Tivozanib	L01XE34	L01EK03
Ibrutinib	L01XE27	L01EL01
Acalabrutinib	L01XE51	L01EL02

Table continued



Table continued

Substance	Previous ATC code	New ATC code
Idelalisib	L01XX47	L01EM01
Copanlisib	L01XX61	L01EM02
Alpelisib	L01XX65	L01EM03
Sunitinib	L01XE04	L01EX01
Sorafenib	L01XE05	L01EX02
Pazopanib	L01XE11	L01EX03
Vandetanib	L01XE12	L01EX04
Regorafenib	L01XE21	L01EX05
Masitinib	L01XE22	L01EX06
Cabozantinib	L01XE26	L01EX07
Lenvatinib	L01XE29	L01EX08
Nintedanib	L01XE31	L01EX09
Midostaurin	L01XE39	L01EX10
Quizartinib	L01XE52	L01EX11
Larotrectinib	L01XE53	L01EX12
Gilteritinib	L01XE54	L01EX13
Entrectinib	L01XE56	L01EX14
Tretinoin	L01XX14	L01XF01
Alitretinoin	L01XX22	L01XF02
Bexarotene	L01XX25	L01XF03
Bortezomib	L01XX32	L01XG01
Carfilzomib	L01XX45	L01XG02
Ixazomib	L01XX50	L01XG03

Substance	Previous ATC code	New ATC code
Vorinostat	L01XX38	L01XH01
Romidepsin	L01XX39	L01XH02
Panobinostat	L01XX42	L01XH03
Belinostat	L01XX49	L01XH04
Entinostat	L01XX64	L01XH05
Vismodegib	L01XX43	L01XJ01
Sonidegib	L01XX48	L01XJ02
Glasdegib	L01XX63	L01XJ03
Olaparib	L01XX46	L01XK01
Niraparib	L01XX54	L01XK02
Rucaparib	L01XX55	L01XK03
Talazoparib	L01XX60	L01XK04



Appendix 2. Alterations to defined daily doses (DDD), valid as of January 2021

No DDD alterations 2021



Appendix 3. Deflators for converting expenditure items to 2020 money, 2000–2020

In the tables of the Finnish Statistics on Medicines, the euro amounts are presented in the current currency for each year. If necessary, the effects of changes in the money value may be eliminated by changing the euro amounts by means of a conversion factor appropriate to the monetary value on a given date (a so-called deflation coefficient). The coefficients below have been calculated from indices based on the situation on 31 December 2020.

Year	Consumer price index	Consumer health index/ health care	Year	Consumer price index	Consumer health index/ health care
2000	1.3148	1.3151	2011	1.0892	1.0894
2001	1.2822	1.2827	2012	1.0595	1.0596
2002	1.2621	1.2630	2013	1.0441	1.0444
2003	1.2512	1.2517	2014	1.0334	1.0335
2004	1.2489	1.2494	2015	1.0355	1.0357
2005	1.2380	1.2384	2016	1.0317	1.0319
2006	1.2168	1.2170	2017	1.0239	1.0244
2007	1.1871	1.1877	2018	1.0131	1.0133
2008	1.1408	1.1410	2019	1.0025	1.0030
2009	1.1406	1.1410	2020	1.0000	1.0000
2010	1.1269	1.1274			

Source: Statistics Finland.